GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 29, 2004, 18:02:07; Search time 102.067 Seconds

(without alignments)

3219.466 Million cell updates/sec

Title:

US-09-830-972-2

Perfect score: 5848

Sequence:

1 MEDIDQSSLVSSSTDSPPRP.....VKDAMAKIQAKIPGLKRKAD 1163

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched:

1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_29Jan04:*

- 1: geneseqp1980s:*
- 2: geneseqp1990s:*
- 3: geneseqp2000s:*
- 4: geneseqp2001s:*
- 5: geneseqp2002s:*
- 6: geneseqp2003as:*
- 7: geneseqp2003bs:*
- 8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

		ક				
Result		Query				
No.	Score	Match	Length	DB	ID	Description
1	5848	100.0	1163	- -	ABB81074	Abb81074 Rat neuro
2	5846	100.0	1163	3	AAY71310	Aay71310 Rat neuri
3	5840	99.9	1162	3	AAY71557	Aay71557 Rat Nogo
4	5823	99.6	1163	3	AAY71384	Aay71384 Alternati
5	4921	84.1	974	3	AAY71560	Aay71560 Rat Nogo
6	4403.5	75.3	1192	4	AAU04591	Aau04591 Human Nog
7	4403.5	75.3	1192	5	ABP68600	Abp68600 Human pan
8	4403.5	75.3	1192	6	ABR59667	Abr59667 Human Nog
9	4398.5	75.2	1192	3	AAY56967	Ab159007 Human MAG

10	4398.5	75.2	1192	4	AAB82349	Aab82349 Human NOG
11	4398.5	75.2	1192	5	ABG30938	Abg30938 Human Nog
12	4398.5	75.2	1192	5	ABB81078	Abb81078 Human neu
13	4276.5	73.1	1178	3	AAY71311	Aay71311 Human neu
14	4116	70.4	1246	4	AAU33228	Aau33228 Novel hum
15	4023	68.8	803	3	AAY71562	Aay71562 Rat Nogo
16	3714	63.5	737	3	AAY71386	Aay71386 Rat Nogo
17	3699.5	63.3	746	3	AAY71391	Aay71391 Rat Nogo
18	3651.5	62.4	736	3	AAY71398	Aay71398 Rat Nogo
19	3630.5	62.1	732	3	AAY71399	Aay71399 Rat Nogo
20	3494	59.7	695	3	AAY71387	Aay71387 Rat Nogo
21	3436	58.8	684	3	AAY71394	Aay71394 Rat Nogo
22	3385.5	57.9	983	6	ABU11573	Abu11573 Human MDD
23	3280.5	56.1	893	3	AAY95012	Aay95012 Human sec
24	2779	47.5	552	3	AAY71388	Aay71388 Rat Nogo
25	2500.5	42.8	642	2	AAW58383	Aaw58383 Human sec
26	2500.5	42.8	642	4	AAB90682	Aab90682 Human BG1
27	2432	41.6	502	3	AAY71396	Aay71396 Rat Nogo
28	2388	40.8	475	3	AAY71389	Aay71389 Rat Nogo
29	2291	39.2	457	3	AAY71392	Aay71392 Rat Nogo
30	1987	34.0	403	3	AAY71563	Aay71563 Rat Nogo
31	1868	31.9	417	3	AAY71393	Aay71393 Rat Nogo
32	1801	30.8	356	3	AAY71390	Aay71390 Rat Nogo
33	1795.5	30.7	374	3	AAY71397	Aay71397 Rat Nogo
34	1513	25.9	379	7	ADB85283	Adb85283 Rat fooce
35	1416	24.2	361	3	AAY71385	Aay71385 Alternati
36	1411.5	24.1	360	3	AAY71383	Aay71383 Rat neuri
37	1411.5	24.1	360	5	ABB81076	Abb81076 Rat neuro
38	1405.5	24.0	359	3	AAY71558	Aay71558 Rat Nogo
39	1191	20.4	373	3	AAY53624	Aay53624 A bone ma
40	1191	20.4	373	3	AAY56969	Aay56969 Human MAG
41	1191	20.4	373	3	AAB24242	Aab24242 Human Nog
42	1191	20.4	373	4	AAB82350	Aab82350 Human NOG
43	1191	20.4	373	5	AAM47954	Aam47954 Human RTN
44	1191	20.4	373	5	ABP68601	Abp68601 Human pan
45	1191	20.4	373	5	ABB81079	Abb81079 Human neu

ALIGNMENTS

```
RESULT 1
ABB81074
ID
     ABB81074 standard; protein; 1163 AA.
XX
AC
    ABB81074;
XX
DT
     05-NOV-2002 (first entry)
XX
DΕ
     Rat neurotransmitter receptor protein Nogo-A.
XX
KW
     Nerve regeneration; neuroprotection; neuronal degeneration; CNS; PNS;
KW
     central nervous system; peripheral nervous system; tranquillizer; Nogo;
KW
     vulnerary; cerebroprotective; anti-tumour; antidiabetic; anticonvulsant;
KW
     nootropic; antiparkinsonian; ophthalmological; analgesic; hepatotropic;
     osteopathic; vasotropic; nephrotropic; cytostatic; antigen; gene therapy;
KW
```

neurotransmitter receptor; rat; receptor.

KW

XX OS Rattus norvegicus. XX PN US2002072493-A1. XX PD 13-JUN-2002. XX PF28-JUN-2001; 2001US-00893348. XX PR 19-MAY-1998; 98IL-00124500. PR 21-JUL-1998; 98WO-US014715. 22-DEC-1998; PR 98US-00218277. PR 19-MAY-1999; 99US-00314161. XX PΑ (YEDA) YEDA RES & DEV CO LTD. XX Eisenbach-Schwartz M, Hauben E, Cohen IR, Beserman P, Mosonego A; PΙ PΙ Moalem G: XX DR WPI; 2002-607255/65. DR N-PSDB; ABN86600. XX PΤ Promoting nerve regeneration and preventing neuronal degeneration in the PTcentral/peripheral nervous system from injury/disease, comprises PTadministering nervous system-specific activated T cells/antigen, or PΤ analogs/peptides. XXPS Example 5; Page 44-47; 93pp; English. XX CC The invention relates to promoting nerve regeneration or conferring CC neuroprotection and preventing or inhibiting neuronal degeneration in the CC central/peripheral nervous system (NS). The method involves administering CC NS-specific activated T cells, NS-specific antigen, its analogue or its CC peptide, a nucleotide sequence the NS-specific antigen or its analogue or CC combinations. The method is useful for promoting nerve regeneration and CC preventing neuronal degeneration in central/peripheral nervous system CC from injury/disease, where the injury is spinal cord injury, blunt CC trauma, penetrating trauma, hemorrhagic stroke, ischaemic stroke or CC damages caused by surgery such as tumour excision. The disease is not an CC autoimmune disease or neoplasm. The disease results in a degenerative CC process occurring in either gray or white matter or both. The disease is CC diabetic neuropathy, senile dementia, Alzheimer's disease, Parkinson's CC disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea, CC amyotrophic lateral sclerosis, non-arteritic optic neuropathy, and CC vitamin deficiency, intervertebral disc herniation, prion diseases such as Creutzfeldt-Jakob disease, carpal tunnel syndrome, peripheral CC CC neuropathies associated with various diseases, including but not limited CC to uremia, porphyria, hypoglycemia, Sjorgren Larsson syndrome, acute CC sensory neuropathy, chronic ataxic neuropathy, biliary cirrhosis, primary CC amyloidosis, obstructive lung diseases, acromegaly, malabsorption CC syndromes, polycythemia vera, immunoglobulin (Ig)A- and IgG gamma-CC pathies, complications of various drugs (e.g., metronidazole) and toxins CC (e.g., alcohol or organophosphates), Charcot-Marie-Tooth disease, ataxia

telangectasia, Friedreich's ataxia, amyloid polyneuropathies,

adrenomyeloneuropathy, Giant axonal neuropathy, Refsum's disease, Fabry's

disease, or lipoproteinemia. The present sequence represents the rat

neurotransmitter receptor protein Nogo-A, an example of NS-specific

CC

CC

CC

CC

```
CC antigen
XX
SQ Sequence 1163 AA;
```

Query Match 100.0%; Score 5848; DB 5; Length 1163; Best Local Similarity Pred. No. 3.9e-297; 100.0%; Matches 1163; Conservative 0; Mismatches Indels 0; Gaps 1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60 Qy 1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEDDEDLEELEVLERK 60 Db 61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120 Qy 61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120 Db Qу 121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180 121 PAAAVLPSKLPEDDEPPARPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180 Db 181 AASEPVIPSSAEKIMDLMEOPGNTVSSGOEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240 Qу 181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240 Db 241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300 Qу 241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300 Db 301 AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA 360 Qу 301 AILVENTKEEVIVRSKDKEDLVCSAALHSPOESPVGKEDRVVSPEKTMDIFNEMOMSVVA 360 Db 361 PVREEYADFKPFEOAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEOKSLGKDSEGR 420 Qу 361 PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGR 420 Db 421 NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA 480 Qу 421 NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA 480 Db 481 QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL 540 Qу 481 QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL 540 Db 541 NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL 600 Qу 541 NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL 600 Db 601 LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF 660 Qy 601 LPSAGASVVOPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF 660 Db 661 NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE 720 Qу 661 NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE 720 Db 721 PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP 780 Qу

```
721 PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP 780
Db
        781 NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE 840
Qу
           781 NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE 840
Db
        841 IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK 900
Οv
           841 IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK 900
Db
        901 DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED 960
Qу
           901 DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED 960
Db
        961 RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS 1020
Qу
           961 RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS 1020
Db
       1021 VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL 1080
Qу
           1021 VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL 1080
Db
       1081 FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA 1140
Qу
           1081 FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA 1140
Db
       1141 NKSVKDAMAKIQAKIPGLKRKAD 1163
Qy
           1141 NKSVKDAMAKIQAKIPGLKRKAD 1163
Db
RESULT 2
AAY71310
    AAY71310 standard; protein; 1163 AA.
ΙD
XX
AC
    AAY71310;
XX
DT
    02-NOV-2000
              (first entry)
XX
    Rat neurite growth inhibitor Nogo A.
DE
XX
    Rat; neurite growth inhibitor; Nogo A; neural cell; myelin; CNS;
KW
    central nervous system; neoplastic disease; antiproliferative; glioma;
KW
    antisense gene therapy; neuroblastoma; menagioma; retinoblastoma;
KW
    degenerative nerve disease; Alzheimer's disease; Parkinson's disease;
KW
    hyperproliferative disorder; benign dysproliferative disorder; diagnosis;
KW
    psoriasis; tissue hypertrophy; neuronal regeneration; treatment;
KW
KW
    structural plasticity; screening.
XX
OS
    Rattus sp.
XX
                 Location/Qualifiers
FH
FT
    Inhibitory-site 1. .171
FT
                 /note= "Inhibits NIH 3T3 fibroblast spreading"
FT
    Modified-site
                 /note= "Casein kinase II site"
FT
```

```
FT
     Region
                      31. .58
                      /note= "Acidic region"
FT
FT
     Region
                      31. .57
FT
                      /note= "Region specifically described in claim 16"
FT
     Region
                      172. .259
FT
                      /note= "This region is not essential for inhibitory
FT
                      activity"
FT
     Modified-site
                      233
FT
                      /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                      242. .244
FT
                      /note= "Asn is N-glycosylated"
FT
     Modified-site
                      291
FT
                      /note= "Protein kinase C (PKC) site"
     Modified-site
FT
                      295
FT
                      /note= "Protein kinase C (PKC) site"
     Misc-difference 404
FT
FT
                      /note= "Encoded by TTG"
FT
     Modified-site
                      436
FT
                      /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                      468. .470
FT
                      /note= "Asn is N-glycosylated"
FT
     Modified-site
                      484
FT
                      /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                      488
FT
                      /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                      502
FT
                      /note= "Casein kinase II site"
FT
     Inhibitory-site 542. .722
FT
     Modified-site
                      576
FT
                      /note= "Casein kinase II site"
FT
     Peptide
                      623. .640
FT
                      /note= "used as immunogen to generate antibody AS 472"
FT
     Modified-site
                      626
FT
                      /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                      694. .696
FT
                      /note= "Asn is N-glycosylated"
FT
     Modified-site
                      715
FT
                      /note= "Casein kinase II site"
FT
     Peptide
                      762. .1163
FT
                      /note= "used as immunogen to generate antibody AS Bruna"
FT
     Modified-site
                      784
FT
                      /note= "Protein kinase C (PKC) site"
     Modified-site
FT
FT
                      /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                      850
FT
                      /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                      855
FT
                      /note= "Protein kinase C (PKC) site"
FT
     Modified-site
FT
                      /note= "Casein kinase II site"
FT
     Modified-site
                      868
FT
                      /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                      893
FT
                      /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                      912. .914
FT
                      /note= "Asn is N-glycosylated"
FT
     Modified-site
                      925. .927
```

```
FT
                      /note= "Asn is N-glycosylated"
FT
     Modified-site
FT
                      /note= "PKC and casein kinase II sites"
FT
     Modified-site
FT
                      /note= "PKC and casein kinase II sites"
FT
     Region
                     975. .1162
                      /note= "This region is not essential for inhibitory
FT
FT
                     activity"
FT
     Region
                     976. .1163
FT
                     /note= "C-terminal common region found in Nogo A, B and C
FT
                     isoforms"
FT
     Domain
                     988. .1023
FT
                     /label= Transmembrane domain
FT
                     /note= "C-terminal hydrophobic region specifically
FT
                     described in claim 16"
FT
     Modified-site
                     1024
FT
                     /note= "Protein kinase C (PKC) site"
     Modified-site
FT
                     1071. .1073
FT
                     /note= "Asn is N-glycosylated"
FT
     Modified-site
                     1073
FT
                     /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                     1089
FT
                     /note= "Protein kinase C (PKC) site"
FT
                     1090. .1125
     Domain
FT
                     /label= Transmembrane_domain
FT
                     /note= "C-terminal hydrophobic region specifically
FT
                     described in claim 16"
FT
                     1141. .1143
     Modified-site
FT
                     /note= "Asn is N-glycosylated"
FT
     Modified-site
                     1143
FT
                     /note= "Protein kinase C (PKC) site"
XX
     WO200031235-A2.
PN
XX
     02-JUN-2000.
PD
XX
PF
     05-NOV-1999;
                    99WO-US026160.
XX
PR
     06-NOV-1998;
                    98US-0107446P.
XX
PA
     (SCHW/) SCHWAB M E.
     (CHEN/) CHEN M S.
PA
XX
PΙ
     Schwab ME,
                Chen MS;
XX
     WPI; 2000-400052/34.
DR
DR
     N-PSDB; AAD01173.
XX
PT
     Nogo proteins and nucleic acids useful for treating neoplastic disorders
PT
     of the central nervous system and inducing regeneration of neurons.
XX
PS
     Claim 3; Fig 2A; 122pp; English.
XX
CC
     The present sequence is a rat Nogo A protein which is a potent neural
CC
     cell growth inhibitor and is free of all central nervous system (CNS)
CC
     myelin material with which it is natively associated. The protein was
CC
     derived from a cDNA generated by fusing RO18U37-3, R1-3U21 cDNAs isolated
```

CC from hexanucleotides-primed rat brain stem/spinal cord library, and Oli18 CC cDNA from an oligo d(T)-primed rat oligodendrocyte library. Nogo proteins CC and fragments displaying neurite growth inhibitory activity are used in CC the treatment of neoplastic disease of the CNS e.g. glioma, glioblastoma, CC medulloblastoma, craniopharyngioma, ependyoma, pinealoma, CC haemangioblastoma, acoustic neuroma, oligodendroglioma, menagioma, CC neuroblastoma or retinoblastoma and degenerative nerve diseases e.g. CC Alzheimer's and Parkinson's diseases. Therapeutics which promote Noqo CC activity can be used to treat or prevent hyperproliferative or benign CC dysproliferative disorders e.g. psoriasis and tissue hypertrophy. Ribozymes or antisense Nogo nucleic acids can be used to inhibit CC CC production of Nogo protein to induce regeneration of neurons or to CC promote structural plasticity of the CNS in disorders where neurite CC growth, regeneration or maintenance are deficient or desired. The animal CC models can be used in diagnostic and screening methods for predisposition CC to disorders and to screen for or test molecules which can treat or prevent disorders or diseases of the CNS. Note: The present sequence CC designated as SEQ ID NO: 2 is stated to be the same as the sequence shown CC in Fig. 13 (see AAY71384) of the specification. However, this sequence CC CC does not match the sequence given in Fig. 13. SEQ ID numbers 35-42 are CC referred in claim 32 and SEQ ID NO: 29 in disclosure of the CC specification. However, the specification does not include sequences for these SEQ ID numbers CC XX SO Sequence 1163 AA;

Query Match 100.0%; Score 5846; DB 3; Length 1163; Best Local Similarity 99.9%; Pred. No. 5e-297; Matches 1162; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
          Db
        1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
       61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
          61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Db
       121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
Qу
          Db
       121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
       181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
Qу
          Db
       181 AASEPVIPSSAEKIMDLMEQPGNTVSSGOEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
       241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300
Qу
          241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300
Db
       301 AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA 360
Qу
          Db
       301 AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA 360
       361 PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEOKSLGKDSEGR 420
Qу
          Db
       361 PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCIEDSLEQKSLGKDSEGR 420
```

QУ	421	NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA	480
Db	421		480
Qу	481	QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL	540
Db	481	QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL	540
QУ	541	NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL	600
Db	541	NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL	600
QУ	601	LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF	660
Db	601	LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF	660
Qу	661	NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE	720
Db	661	NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE	720
Qу	721	PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP	780
Db	721	PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP	780
QУ	781	NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE	840
Db	781		840
QУ	841	<pre>IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK</pre>	900
Db	841	IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK	900
QУ	901	DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED	960
Db	901		960
QУ	961	RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS	1020
Db	961	RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS	1020
QУ	1021	VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL	1080
Db	1021	VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL	1080
Qу	1081	FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA	1140
Db	1081	FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA	1140
Qу	1141	NKSVKDAMAKIQAKIPGLKRKAD 1163	
Db	1141	NKSVKDAMAKIQAKIPGLKRKAD 1163	

RESULT 3 AAY71557

ID AAY71557 standard; protein; 1162 AA.

XX AC AAY71557; XX DT02-NOV-2000 (first entry) XX DΕ Rat Nogo A truncated protein used in the construction of mutant Nogo-A. XX KW Rat; neurite growth inhibitor; Nogo A; neural cell; myelin; CNS; central nervous system; neoplastic disease; antiproliferative; glioma; KW KW antisense gene therapy; neuroblastoma; menagioma; retinoblastoma; KW degenerative nerve disease; Alzheimer's disease; Parkinson's disease; KW hyperproliferative disorder; benign dysproliferative disorder; diagnosis; KW psoriasis; tissue hypertrophy; neuronal regeneration; treatment; KW structural plasticity; screening; mutant; mutein. XX OS Rattus sp. XX PN W0200031235-A2. XX PD 02-JUN-2000. XX PF05-NOV-1999; 99WO-US026160. XX PR 06-NOV-1998; 98US-0107446P. XX PA (SCHW/) SCHWAB M E. PΑ (CHEN/) CHEN M S. XX PΙ Schwab ME, Chen MS; XX DR WPI; 2000-400052/34. XX PT Nogo proteins and nucleic acids useful for treating neoplastic disorders PTof the central nervous system and inducing regeneration of neurons. XX PS Example; Page; 122pp; English. XXCC The patent relates to neurite growth inhibitor Nogo which is free of all CC central nervous system (CNS) myelin material with which it is natively CC associated. Nogo proteins and fragments displaying neurite growth CC inhibitory activity are used in the treatment of neoplastic disease of the CNS e.g. glioma, glioblastoma, medulloblastoma, craniopharyngioma, CC CC ependyoma, pinealoma, haemangioblastoma, acoustic neuroma, CC oligodendroglioma, menagioma, neuroblastoma or retinoblastoma and CC degenerative nerve diseases e.g. Alzheimer's and Parkinson's diseases. CC Therapeutics which promote Nogo activity can be used to treat or prevent CC hyperproliferative or benign dysproliferative disorders e.g. psoriasis CCand tissue hypertrophy. Ribozymes or antisense Nogo nucleic acids can be CC used to inhibit production of Nogo protein to induce regeneration of CC neurons or to promote structural plasticity of the CNS in disorders where CC neurite growth, regeneration or maintenance are deficient or desired. The CCanimal models can be used in diagnostic and screening methods for CC predisposition to disorders and to screen for or test molecules which can

treat or prevent disorders or diseases of the CNS. The present sequence

tag/T7-tag/vector/Nogo-A sequence aa 1-1162. Nogo A deletion mutants were

is a truncated form of rat Nogo A protein shown in AAY71310, which is

used in the construction of mutant Nogo-A. Nogo-A is composed of His-

CC

CC

CC

CC

```
CC
     used for mapping the inhibitory sites of Nogo protein. Major inhibitory
CC
     region was identified in the Nogo A sequence from amino acids 172-974.
     particularly amino acids 542-722. In addition, N-terminal region 1-171
CC
     was found to be inhibitory to NIH 3T3 fibroblast spreading. Note: The
CC
CC
     present sequence is not given in the specification but is derived from
CC
     rat Nogo A sequence shown in AAY71310. SEQ ID numbers 35-42 are referred
CC
     in claim 32 and SEQ ID NO: 29 in disclosure of the specification.
CC
     However, the specification does not include sequences for these SEQ ID
CC
     numbers
XX
```

SQ Sequence 1162 AA;

Query Match 99.9%; Score 5840; DB 3; Length 1162; Best Local Similarity 99.9%; Pred. No. 1e-296; Matches 1161; Conservative 1; Mismatches 0; Indels Gaps 0: 1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60 Qy 1 MEDIDOSSLVSSSTDSPPRPPPAFKYOFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60 Db QУ 61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120 Db 61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120 121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180 Qу 121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180 Db 181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240 Qу 181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240 Db 241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300 Qу 241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300 Db 301 AILVENTKEEVIVRSKDKEDLVCSAALHSPOESPVGKEDRVVSPEKTMDIFNEMOMSVVA 360 Qy 301 AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA 360 Db 361 PVREEYADFKPFEOAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEOKSLGKDSEGR 420 QУ 361 PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCIEDSLEQKSLGKDSEGR 420 Db 421 NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA 480 Qу 421 NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA 480 Db 481 QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL 540 Qу Db 481 QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL 540 541 NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL 600 Qу 541 NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL 600 Db Qу 601 LPSAGASVVOPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF 660

```
601 LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF 660
Db
       661 NAAVOETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE 720
Qу
           661 NAAVOETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE 720
Db
       721 PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP 780
Qу
           721 PVDLFSDDSIPEVPOTOEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP 780
Db
       781 NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE 840
Qу
           781 NLHSTKDAASNDIPTLTKKEKISLOMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE 840
Db
       841 IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK 900
Qy
           841 IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK 900
Db
       901 DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED 960
Qу
           901 DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED 960
Db
       961 RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS 1020
Qу
           961 RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS 1020
Db
       1021 VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL 1080
Qу
           1021 VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL 1080
Db
       1081 FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHOVOIDHYLGLA 1140
Qу
           1081 FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA 1140
Db
       1141 NKSVKDAMAKIQAKIPGLKRKA 1162
Qу
           Db
       1141 NKSVKDAMAKIQAKIPGLKRKA 1162
RESULT 4
    AAY71384 standard; protein; 1163 AA.
XX
AC
    AAY71384;
XX
DT
    02-NOV-2000
              (first entry)
XX
DΕ
    Alternative version of rat neurite growth inhibitor Nogo A.
XX
KW
    Rat; neurite growth inhibitor; Nogo A; neural cell; myelin; CNS;
    central nervous system; neoplastic disease; antiproliferative; glioma;
KW
    antisense gene therapy; neuroblastoma; menagioma; retinoblastoma;
KW
    degenerative nerve disease; Alzheimer's disease; Parkinson's disease;
KW
    hyperproliferative disorder; benign dysproliferative disorder; diagnosis;
KW
    psoriasis; tissue hypertrophy; neuronal regeneration; treatment;
KW
```

KW

structural plasticity; screening.

```
XX
OS
     Rattus sp.
XX
                     Location/Qualifiers
FH
     Key
     Inhibitory-site 1. .171
FT
                      /note= "Inhibits NIH 3T3 fibroblast spreading"
FT
    Modified-site
FT
                      /note= "Casein kinase II site"
FT
                      31. .58
FT
     Region
                      /note= "Acidic region"
FT
                      172. .259
\Gamma T
     Region
                      /note= "This region is not essential for inhibitory
FT
                      activity"
FT
     Misc-difference 223
FT
                      /label= Unknown
FT
                      /note= "There is Leu at this position in the sequence
FT
                      shown in AAY71310"
FT
FT
     Modified-site
                      233
                      /note= "Protein kinase C (PKC) site"
FT
                      242. .244
FT
     Modified-site
                      /note= "Asn is N-glycosylated"
FT
    Modified-site
                      291
FT
                      /note= "Protein kinase C (PKC) site"
FT
FT
    Modified-site
                      295
                      /note= "Protein kinase C (PKC) site"
FT
     Misc-difference 404
FT
                      /note= "There is Ile at this position in the sequence
FT
                      shown in AAY71310"
FT
                      436
FT
     Modified-site
                      /note= "Protein kinase C (PKC) site"
FT
                      468. .470
FT
     Modified-site
                      /note= "Asn is N-glycosylated"
FT
     Misc-difference 469
FT
FT
                      /label= Unknown
                      /note= "There is Lys at this position in the sequence
FT
                      shown in AAY71310"
FT
     Modified-site
                      484
FT
                      /note= "Protein kinase C (PKC) site"
FT
     Modified-site
FT
                      /note= "Protein kinase C (PKC) site"
FT
FT
     Modified-site
                      502
                      /note= "Casein kinase II site"
FT
     Inhibitory-site 542. .722
FT
     Modified-site
                      576
FT
                      /note= "Casein kinase II site"
FT
FT
     Peptide
                      623. .640
                      /note= "used as immunogen to generate antibody AS 472"
FT
                      626
FT
     Modified-site
                      /note= "Protein kinase C (PKC) site"
FT
FT
     Misc-difference 661
                      /note= "There is Asn at this position in the sequence
FT
                      shown in AAY71310"
FT
FT
     Modified-site
                      694. .696
                      /note= "Asn is N-glycosylated"
FT
FT
     Modified-site
FT
                      /note= "Casein kinase II site"
FT
     Peptide
                      762. .1163
```

```
FT
                     /note= "used as immunogen to generate antibody AS Bruna"
FT
     Modified-site
FT
                     /note= "Protein kinase C (PKC) site"
FT
     Misc-difference 820
FT
                     /note= "There is Leu at this position in the sequence
FT
                     shown in AAY71310"
FT
     Modified-site
                     821
FT
                     /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                     850
FT
                     /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                     855
FT
                     /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                     /note= "Casein kinase II site"
FT
     Modified-site
FT
                     868
FT
                     /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                     893
                     /note= "Protein kinase C (PKC) site"
FT
FT
     Modified-site
                     912. .914
                     /note= "Asn is N-glycosylated"
FT
     Modified-site
FT
                     925. .927
                     /note= "Asn is N-glycosylated"
FT
FT
     Modified-site
                     954
                     /note= "PKC and casein kinase II sites"
FT
                     956
FT
     Modified-site
                     /note= "PKC and casein kinase II sites"
FT
     Region
                     975. .1162
FT
FT
                     /note= "This region is not essential for inhibitory
                     activity"
FT
                     976. .1163
FT
     Region
FT
                     /note= "C-terminal common region found in Nogo A, B and C
FT
                     isoforms"
FT
     Domain
                     988. .1023
                     /label= Transmembrane domain
FT
                     /note= "C-terminal hydrophobic region"
FT
FT
     Modified-site
                     1024
                     /note= "Protein kinase C (PKC) site"
FT
                     1071. .1073
FT
     Modified-site
                     /note= "Asn is N-glycosylated"
FT
     Modified-site
                     1073
FT
                     /note= "Protein kinase C (PKC) site"
FT
     Modified-site
                     1089
FT
                     /note= "Protein kinase C (PKC) site"
FT
                     1090. .1125
FT
     Domain
FT
                     /label= Transmembrane domain
                     /note= "C-terminal hydrophobic region"
FT
FT
     Modified-site
                     1141. .1143
                     /note= "Asn is N-glycosylated"
FT
FT
     Modified-site
                     /note= "Protein kinase C (PKC) site"
FT
XX
PN
     WO200031235-A2.
XX
     02-JUN-2000.
PD
XX
                    99WO-US026160.
PF
     05-NOV-1999;
```

XX

```
PR
    06-NOV-1998;
                  98US-0107446P.
XX
PA
    (SCHW/) SCHWAB M E.
PΑ
    (CHEN/) CHEN M S.
XX
PΙ
    Schwab ME, Chen MS;
XX
DR
    WPI; 2000-400052/34.
XX
    Nogo proteins and nucleic acids useful for treating neoplastic disorders
PT
PT
    of the central nervous system and inducing regeneration of neurons.
XX
PS
    Claim 3; Fig 13; 122pp; English.
XX
    The present sequence is an alternative version of rat Nogo A protein
CC
    which is a potent neural cell growth inhibitor and is free of all central
CC
    nervous system (CNS) myelin material with which it is natively
CC
CC
    associated. Nogo proteins and fragments displaying neurite growth
CC
    inhibitory activity are used in the treatment of neoplastic disease of
CC
    the CNS e.g. glioma, glioblastoma, medulloblastoma, craniopharyngioma,
    ependyoma, pinealoma, haemangioblastoma, acoustic neuroma,
CC
CC
    oligodendroglioma, menagioma, neuroblastoma or retinoblastoma and
CC
    degenerative nerve diseases e.g. Alzheimer's and Parkinson's diseases.
    Therapeutics which promote Nogo activity can be used to treat or prevent
CC
CC
    hyperproliferative or beniqn dysproliferative disorders e.g. psoriasis
    and tissue hypertrophy. Ribozymes or antisense Nogo nucleic acids can be
CC
CC
    used to inhibit production of Nogo protein to induce regeneration of
    neurons or to promote structural plasticity of the CNS in disorders where
CC
CC
    neurite growth, regeneration or maintenance are deficient or desired. The
CC
    animal models can be used in diagnostic and screening methods for
    predisposition to disorders and to screen for or test molecules which can
CC
    treat or prevent disorders or diseases of the CNS. Note: The present
CC
    sequence is an alternative version of the Nogo A sequence shown in Fig.
CC
    2A (see AAY71310). SEQ ID numbers 35-42 are referred in claim 32 and SEQ
CC
    ID NO: 29 in disclosure of the specification. However the specification
CC
    does not include sequences for these SEQ ID numbers
CC
XX
SO
    Sequence 1163 AA;
  Query Match
                        99.6%;
                               Score 5823; DB 3; Length 1163;
                        99.7%; Pred. No. 7.9e-296;
  Best Local Similarity
 Matches 1159; Conservative
                             0; Mismatches
                                               4;
                                                  Indels
                                                            0; Gaps
                                                                       0:
           1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEDLEELEVLERK 60
Qу
             1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Db
          61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Qу
             61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Db
         121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
Qу
             Db
         121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
         181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
Qу
```

Db	181	${\tt AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASXPSLSPLSTVSFKEHGYL}$	240
Qу	241	GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES	300
Db	241		300
Qу	301	AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA	360
Db	301	AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA	360
Qу	361	PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGR	420
Db	361	PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGR	420
Qу	421	NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA	480
Db	421	NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENXTDEKKIEERKA	480
Qу	481	QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL	540
Db	481	QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL	540
Qу	541	NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL	600
Db .	541	NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL	600
Qу	601	LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF	660
Db	601	LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF	660
Qy	661	NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE	720
Db	661	MAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE	720
Qу	721	PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP	780
Db	721	PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP	780
Qу	781	NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE	840
Db	781	NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLSSSKEDKIKESETFSDSSPIE	840
QУ	841	IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK	900
Db	841	IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK	900
Qу	901	DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED	960
Db	901	DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED	960
QУ	961	RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS	1020
Db	961	RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS	1020
Qу	1021	VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL	1080
Db	1021	VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL	1080

```
1081 FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA 1140
Qy
             1081 FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA 1140
Db
        1141 NKSVKDAMAKIQAKIPGLKRKAD 1163
Qy
             1141 NKSVKDAMAKIQAKIPGLKRKAD 1163
Db
RESULT 5
AAY71560
    AAY71560 standard; protein; 974 AA.
XX
AC
    AAY71560;
XX
    02-NOV-2000 (first entry)
DT
XX
    Rat Nogo A protein fragment used in the construction of mutant NiAext.
DE
XX
    Rat; neurite growth inhibitor; Nogo A; neural cell; myelin; CNS;
KW
    central nervous system; neoplastic disease; antiproliferative; glioma;
KW
    antisense gene therapy; neuroblastoma; menagioma; retinoblastoma;
KW
    degenerative nerve disease; Alzheimer's disease; Parkinson's disease;
KW
    hyperproliferative disorder; benign dysproliferative disorder; diagnosis;
KW
    psoriasis; tissue hypertrophy; neuronal regeneration; treatment;
KW
    structural plasticity; screening; mutant; mutein.
KW
XX
OS
    Rattus sp.
XX
    WO200031235-A2.
ΡN
XX
PD
    02-JUN-2000.
XX
     05-NOV-1999;
                   99WO-US026160.
PF
XX
     06-NOV-1998; 98US-0107446P.
PR
XX
PΑ
     (SCHW/) SCHWAB M E.
     (CHEN/) CHEN M S.
PΑ
XX
     Schwab ME, Chen MS;
PΙ
XX
DR
    WPI; 2000-400052/34.
XX
РΤ
    Nogo proteins and nucleic acids useful for treating neoplastic disorders
PT
     of the central nervous system and inducing regeneration of neurons.
XX
     Example; Page; 122pp; English.
PS
XX
     The patent relates to neurite growth inhibitor Nogo which is free of all
CC
     central nervous system (CNS) myelin material with which it is natively
CC
     associated. Nogo proteins and fragments displaying neurite growth
CC
     inhibitory activity are used in the treatment of neoplastic disease of
CC
     the CNS e.g. glioma, glioblastoma, medulloblastoma, craniopharyngioma,
CC
     ependyoma, pinealoma, haemangioblastoma, acoustic neuroma,
CC
     oligodendroglioma, menagioma, neuroblastoma or retinoblastoma and
CC
```

degenerative nerve diseases e.g. Alzheimer's and Parkinson's diseases. Therapeutics which promote Nogo activity can be used to treat or prevent hyperproliferative or benign dysproliferative disorders e.g. psoriasis and tissue hypertrophy. Ribozymes or antisense Nogo nucleic acids can be used to inhibit production of Nogo protein to induce regeneration of neurons or to promote structural plasticity of the CNS in disorders where neurite growth, regeneration or maintenance are deficient or desired. The animal models can be used in diagnostic and screening methods for predisposition to disorders and to screen for or test molecules which can treat or prevent disorders or diseases of the CNS. The present sequence is a fragment of rat Nogo A protein shown in AAY71310, which is used in the construction of mutant NiAext. The mutant is composed of His-tag/T7tag/vector/Nogo-A sequence aa 1-974/T7-tag. Nogo A deletion mutants were used for mapping the inhibitory sites of Nogo protein. Major inhibitory region was identified in the Nogo A sequence from amino acids 172-974, particularly amino acids 542-722. In addition, N-terminal region 1-171 was found to be inhibitory to NIH 3T3 fibroblast spreading. Note: The present sequence is not given in the specification but is derived from rat Nogo A sequence shown in AAY71310. SEQ ID numbers 35-42 are referred in claim 32 and SEQ ID NO: 29 in disclosure of the specification. However, the specification does not include sequences for these SEQ ID numbers

XX SQ Sequence 974 AA;

CC

CC CC

> Query Match 84.1%; Score 4921; DB 3; Length 974; Best Local Similarity 99.9%; Pred. No. 8.8e-249; Matches 973; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
          1 MEDIDOSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Db
       61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Qу
          61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Db
       121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
Qу
          121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
Db
       181 AASEPVIPSSAEKIMDLMEOPGNTVSSGOEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
Qу
          181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
Db
       241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300
Qу
          241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300
Db
       301 AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA 360
Qy
          301 AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA 360
Db
       361 PVREEYADFKPFEOAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGR 420
Qу
          361 PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCIEDSLEQKSLGKDSEGR 420
Db
```

```
421 NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA 480
Qу
          421 NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA 480
Db
       481 OIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL 540
QУ
           481 OIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL 540
Db
       541 NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL 600
Qy
           541 NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL 600
Db
        601 LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF 660
Qу
           601 LPSAGASVVOPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF 660
Db
        661 NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE 720
Qy
           661 NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE 720
Db
        721 PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP 780
Qу
           721 PVDLFSDDSIPEVPOTOEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP 780
Db
        781 NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE 840
Qу
           781 NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE 840
Db
        841 IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK 900
Qу
           841 IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK 900
Db
        901 DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED 960
Qу
           901 DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED 960
Db
        961 RSLSAVLSAELSKT 974
Qу
           961 RSLSAVLSAELSKT 974
Db
RESULT 6
AAU04591
TD
    AAU04591 standard; protein; 1192 AA.
XX
AC
    AAU04591;
XX
DT
    26-SEP-2001 (first entry)
XX
DE
    Human Nogo protein.
XX
    Human; Nogo receptor; axonal growth; immunogen; antibody; nogo protein;
KW
    cranial trauma; cerebral trauma; spinal cord injury; stroke;
KW
    demyelinating disease; multiple sclerosis; monophasis demyelination;
KW
    encephalomyelitis; multifocal leukoencephalopathy; panencephalitis;
ΚW
    Marchiafava-Bignami disease; pontine myelinolysis; adrenoleukodystrophy;
KW
    Pelizaeus-Merzbacher disease; Spongy degeneration; Alexander's disease;
KW
```

```
Canavan's disease; metachromatic leukodystrophy; viral infection;
KW
     Krabbe's disease.
KW
XX
     Homo sapiens.
OS
XX
                     Location/Qualifiers
FΗ
                     1054. .1119
FT
     Domain
                     /label= Lumenal extracellular domain
FT
                     /note= "This sequence is specifically claimed"
FT
                     1055. .1094
FT
     Peptide
                     /label= Pep1
FT
                     /note= "Receptor binding inhibitory peptide. This
FT
                     sequence is specifically claimed"
FT
                     1064. .1088
FT
     Peptide
                     /label= Pep2
FT
                      /note= "Receptor binding inhibitory peptide. This
FT
                      sequence is specifically claimed"
FT
                      1074. .1098
FT
     Peptide
                     /label= Pep3
FT
                      /note= "Receptor binding inhibitory peptide. This
FT
                      sequence is specifically claimed"
FT
                      1084. .1108
FT
     Peptide
                      /label= Pep4
FT
                      /note= "Receptor binding inhibitory peptide. This
FT
                      sequence is specifically claimed"
FT
                      1095. .1119
FT
     Peptide
                      /label= Pep5
FT
                      /note= "Receptor binding inhibitory peptide. This
FT
                      sequence is specifically claimed"
FT
XX
     WO200151520-A2.
PN
XX
     19-JUL-2001.
PD
XX
     12-JAN-2001; 2001WO-US001041.
PF
XX
     12-JAN-2000; 2000US-0175707P.
PR
     26-MAY-2000; 2000US-0207366P.
PR
     29-SEP-2000; 2000US-0236378P.
PR
XX
     (UYYA ) UNIV YALE.
PΑ
XX
     Strittmatter SM;
PΙ
XX
     WPI; 2001-442138/47.
DR
     N-PSDB; AAS09453.
DR
XX
     Novel Nogo receptor protein useful for identifying modulator of Nogo
PT
     protein or Nogo receptor protein, which is useful for treating central
PT
РΤ
     nervous system disorders.
XX
     Example 1; Page 101-104; 109pp; English.
PS
XX
     The sequence is the human Nogo protein, a 250kDa myelin-associated axon
CC
      growth inhibitor. The invention relates to the use of the nogo receptor,
CC
      nogo protein, their nucleic acids, vectors expressing them and antibodies
CC
      against them, to isolate agents which block nogo receptor mediated axonal
CC
```

```
growth. The agent is useful for treating a central nervous system
CC
       disorder which is a result of cranial or cerebral trauma, spinal cord
CC
       injury, stroke or a demyelinating disease selected from multiple
CC
       sclerosis, monophasis demyelination, encephalomyelitis, multifocal
CC
       leukoencephalopathy, panencephalitis, Marchiafava-Bignami disease,
CC
       pontine myelinolysis, adrenoleukodystrophy, Pelizaeus-Merzbacher disease,
CC
       Spongy degeneration, Alexander's disease, Canavan's disease,
CC
       metachromatic leukodystrophy, viral infection and Krabbe's disease
CC
XX
SQ
       Sequence 1192 AA;
                                        75.3%; Score 4403.5; DB 4;
                                                                                    Length 1192;
   Query Match
   Best Local Similarity
                                       75.9%; Pred. No. 1.3e-221;
                                                                                    Indels
                                                                                                                    20;
   Matches 909; Conservative 104; Mismatches 145;
                                                                                                  39; Gaps
                  1 MEDIDOSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qy
                     1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58
Db
                 61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
Qу
                      59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
Db
               116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166
Qу
                                                                                             119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178
Db
               167 RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS 225
Qу
                      179 RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS 237
Db
               226 LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY 285
Qy
                      :: | | | | | | | | | |
               238 LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY 297
Db
               286 SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVG----KED 339
Qу
                                 298 SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED 357
Db
               340 RVVSPEKTMDIFNEMOMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAA----RANV 395
Qу
                                 358 EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL 416
Db
                396 ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT 454
Qу
                      417 ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRSGAYITCAPFNPAATESIA 476
Db
                455 ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS 513
Qу
                        477 TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT 536
Db
                514 KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL 573
Qу
                             537 KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL 596
Db
                574 CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN 633
Qу
                      14114 | 14114 | 14114 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 | 1414 |
```

```
597 CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN 655
Db
       634 PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF 692
Qv
           656 PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF 715
Db
        693 SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS 752
Qу
           716 SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS 775
Db
       753 -ETVAOHK-EERLSASPOELGKPYLESFOPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF 809
Qу
            ::: ||:::||| || ||
       776 FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL 835
Db
       810 NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS 868
Qу
           836 STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS 895
Db
       869 DKSEIANIOSGADSLPCLELPCDLSFKNIYPK--DEVHVSDEFSENRSSVSKASISPSNV 926
Qу
                  896 HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV 955
Db
        927 SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK 986
Qу
              956 SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK 1015
Db
        987 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1046
Qу
           Db
       1016 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1075
       1047 YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1106
QУ
           1076 YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1135
Db
       1107 NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
           1136 NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1192
Dh
RESULT 7
ABP68600
    ABP68600 standard; protein; 1192 AA.
TD
XX
AC
    ABP68600;
XX
DT
    14-JAN-2003 (first entry)
XX
DΕ
    Human pancreatic cancer expressed protein SEQ ID NO 71.
XX
    Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;
KW
    cytostatic; tumour.
KW
XX
OS
    Homo sapiens.
XX
PN
    WO200260317-A2.
XX
```

PD

08-AUG-2002.

```
XX
    30-JAN-2002; 2002WO-US002781.
PF
XX
    30-JAN-2001; 2001US-0265305P.
PR
    31-JAN-2001; 2001US-0265682P.
PR
    09-FEB-2001; 2001US-0267568P.
PR
    21-MAR-2001; 2001US-0278651P.
PR
    28-APR-2001; 2001US-0287112P.
PR
    16-MAY-2001; 2001US-0291631P.
PR
    12-JUL-2001; 2001US-0305484P.
PR
    20-AUG-2001; 2001US-0313999P.
PR
    27-NOV-2001; 2001US-0333626P.
PR
XX
     (CORI-) CORIXA CORP.
PΑ
XX
                          Lodes MJ, Persing DH, Hepler WT, Jiang Y;
    Benson DR, Kalos MD,
PΙ
XX
    WPI; 2002-627435/67.
DR
DR
    N-PSDB; ABV94680.
XX
    New isolated polynucleotide and pancreatic tumor polypeptides, useful for
PT
     diagnosing, preventing and/or treating cancer, particularly pancreatic
PT
PT
     cancer.
XX
    Claim 2; SEQ ID NO 71; 300pp + Sequence Listing; English.
PS
XX
     The invention relates to an isolated polynucleotide (I) comprising: (a)
CC
     any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b)
CC
     complements of (a); (c) sequences consisting of at least 20 contiguous
CC
     residues of (a); (d) sequences that hybridize to (a), under moderately
CC
     stringent conditions; (e) sequences having at least 75% or 90% identity
CC
     to (a); or (f) degenerate variants of (a). Polypeptides (ABP68596-
CC
     ABP68637) encoded by (I) and oligonucleotide can be used to detect cancer
CC
     in a patient and compositions comprising polypeptides, polynucleotides,
CC
     antibodies, fusion proteins, T cell populations and antigen presenting
CC
     cells expressing the polypeptide are useful in treating pancreatic cancer
CC
     and stimulating an immune response. The polynucleotides can be used as
CC
     probes or primers for nucleic acid hybridisation, in the design and
CC
     preparation of ribozyme molecules for inhibiting expression of the tumour
CC
     polypeptides and proteins in the tumour cells, in vaccines and for gene
CC
     therapy. Note: The sequence data for this patent did not form part of the
CC
     printed specification, but was obtained in electronic format directly
CC
     from WIPO at ftp.wipo.int/pub/published pct sequences
CC
XX
SQ
     Sequence 1192 AA;
                                 Score 4403.5; DB 5; Length 1192;
                         75.3%;
  Query Match
                         75.9%; Pred. No. 1.3e-221;
  Best Local Similarity
                                                                          20;
  Matches 909; Conservative 104; Mismatches 145; Indels
                                                              39; Gaps
            1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
              1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58
Db
           61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
QУ
              59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
Db
```

Qy	116	APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKR	166
Db	119	APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR	178
Qy	167	RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS	225
Db	179	RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS	237
QУ	226	LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY	285
Db	238	LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY	297
QУ	286	SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVGKED	339
Db	298	SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED	357
QУ	340	RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANV	395
Db	358	EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL	416
QУ	396	ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT	454
Db	417	ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRSGAYITCAPFNPAATESIA	476
QУ	455	ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS	513
Db	477	TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT	536
Qy	514	KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL	573
Db	537	KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL	596
QУ	574	CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN	633
Db	597	CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN	655
Qy	634	PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF	692
Db	656	PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF	715
Qy	693	SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS	752
Db	716	SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS	775
QУ	753	-ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF	809
Db	776	FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL	835
Qу	810	NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS: :	868
Db	836	STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS	895
Qу	869	DKSEIANIQSGADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNV	926
Db	896	HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV	955

```
927 SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK 986
Qу
            956 SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK 1015
Db
        987 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1046
Qу
            1016 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1075
Db
        1047 YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1106
Qу
            1076 YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1135
Dh
        1107 NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
            1136 NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1192
Db
RESULT 8
ABR59667
    ABR59667 standard; protein; 1192 AA.
XX
AC
    ABR59667;
XX
DT
    22-JUL-2003 (first entry)
XX
DE
    Human NogoA protein.
XX
    Human; Nogo receptor; NgR; CTS domain; neuroprotective; gene therapy;
KW
    axonal growth; central nervous system; CNS; Nogo; spinal cord injury;
KW
    cranial trauma; cerebral trauma; spinal trauma; stroke; Krabbe's disease;
KW
    demyelinating disease; multiple sclerosis; monophasic demyelination;
KW
    encephalomyelitis; multifocal leukoencephalopathy; panencephalitis.
KW
XX
    Homo sapiens.
OS
XX
ΡN
    WO2003031462-A2.
XX
    17-APR-2003.
PD
XX
PF
    04-OCT-2002; 2002WO-US032007.
XX
    06-OCT-2001; 2001US-00972599.
PR
XX
     (UYYA ) UNIV YALE.
PΑ
XX
PΙ
    Strittmatter SM;
XX
    WPI; 2003-393433/37.
DR
    N-PSDB; ACC81048.
DR
XX
    New human Nogo receptor polypeptides and nucleic acids, useful for
PT
     decreasing inhibition of axonal growth by a central nervous system
PT
     neuron, or in treating central nervous system disease, disorder or
PT
PT
     injury, e.g. spinal cord injury.
XX
     Disclosure; Page 131-135; 148pp; English.
PS
XX
```

The invention relates to a novel nucleic acid encoding a polypeptide CC comprising amino acid residues 27-309 of a 473 amino acid sequence (P1, CC human Nogo receptor (NgR) NTLRRCT domain), or residues 27-309 of P1 with CC 1-20 conservative amino acid substitutions, and less than a complete CTS CC domain, provided that a partial CTS domain, if present, consists of no CC more than the first 39 consecutive residues. The nucleic acid of the CC invention has neuroprotective activity. The polynucleotide may have a use CC in gene therapy. The nucleic acid is useful for decreasing inhibition of CC axonal growth by a central nervous system (CNS) neuron. The NgR CC polypeptide or an agent inhibits the binding of Nogo to NgR or NgR-CC dependent signal transduction in the central nervous system neuron may be CC used in treating central nervous system disease, disorder or injury, e.g. CC spinal cord injury. Expression of an NgR protein may be associated with CC inhibition of axonal regeneration following cranial, cerebral or spinal CC trauma, stroke or a demyelinating disease, such as multiple sclerosis, CC monophasic demyelination, encephalomyelitis, multifocal CC leukoencephalopathy, panencephalitis, or Krabbe's disease. The present CC sequence is used in the exemplification of the invention CC XX

SQ Sequence 1192 AA;

75.3%; Score 4403.5; DB 6; Length 1192; Query Match 75.9%; Pred. No. 1.3e-221; Best Local Similarity Matches 909; Conservative 104; Mismatches 145; Indels 20; 39; Gaps 1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60 Qу 1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58 Db 61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115 QУ 59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118 Db 116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166 Qy 119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178 Db 167 RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS 225 Qv 179 RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS 237 Db 226 LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY 285 QУ ::||| |||||| 238 LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY 297 Db 286 SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVG----KED 339 Qу 298 SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED 357 Db 340 RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAA----RANV 395 Qу 358 EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL 416 Db 396 ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT 454 QУ 417 ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRSGAYITCAPFNPAATESIA 476 Db

```
455 ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS 513
Qу
           477 TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT 536
Db
       514 KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL 573
Qу
          537 KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL 596
Db
       574 CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN 633
Qу
                                             1:1:111
          597 CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN 655
Db
       634 PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF 692
Qу
          656 PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF 715
Db
       693 SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS 752
Qy
          716 SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS 775
Db
       753 -ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF 809
Qу
                                        776 FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL 835
Db
       810 NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS 868
Qу
          836 STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS 895
Db
       869 DKSEIANIQSGADSLPCLELPCDLSFKNIYPK--DEVHVSDEFSENRSSVSKASISPSNV 926
Qу
                 896 HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV 955
Db
       927 SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK 986
Qу
             956 SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK 1015
Db
       987 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1046
Qу
           1016 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1075
Db
       1047 YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1106
Qу
          1076 YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1135
Db
       1107 NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
QУ
           1136 NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1192
Db
RESULT 9
AAY56967
    AAY56967 standard; protein; 1192 AA.
ΙD
XX
    AAY56967;
АC
XX
    25-APR-2000
DΤ
             (first entry)
```

XX

```
Human MAGI polypeptide.
DE
XX
    MAGI protein; neuroendocrine-specific protein; neuropathy; human;
KW
    spinal injury; neuronal degeneration; neuromuscular disorder; cancer;
KW
    psychiatric disorder; developmental disorder; inflammatory disorder;
KW
    stroke; cytostatic; cerebroprotective; neuroprotective.
KW
XX
OS
    Homo sapiens.
XX
    WO200005364-A1.
PN
XX
    03-FEB-2000.
PD
XX
                  99WO-GB002360.
ΡF
    21-JUL-1999;
XX
                  98GB-00016024.
    22-JUL-1998;
PR
                  99GB-00016898.
    19-JUL-1999;
PR
XX
     (SMIK ) SMITHKLINE BEECHAM PLC.
PΑ
XX
ΡI
    Michalovich D, Prinjha RK;
XX
     WPI; 2000-182693/16.
DR
    N-PSDB; AAZ56886.
DR
XX
     Novel polypeptides related to neuroendocrine-specific proteins and
PT
     polynucleotides useful for diagnosis of various diseases and for
PT
     treatment of cancer and neurological disorders.
PT
XX
     Claim 2; Page 20-21; 35pp; English.
PS
XX
     The invention relates to human MAGI protein, which is similar to
CC
     neuroendocrine-specific protein. The MAGI protein can be expressed by
CC
     standard recombinant methodology. The MAGI polypeptides, polynucleotides
CC
     and antibodies are useful for treating diseases, including neuropathies,
CC
     spinal injury, neuronal degeneration, neuromuscular disorders,
CC
     psychiatric disorders and developmental disorders, cancer, stroke and
CC
     inflammatory disorders. The polynucleoitde is also useful for chromosome
CC
     localization and for tissue expression studies. The present sequence
CC
     represents the human MAGI protein
CC
XX
     Sequence 1192 AA;
SQ
                        75.2%; Score 4398.5; DB 3; Length 1192;
  Query Match
                        75.9%; Pred. No. 2.3e-221;
  Best Local Similarity
                                                                       20;
  Matches 908; Conservative 104; Mismatches 146; Indels
                                                            39; Gaps
            1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
              1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDLEELEVLERK 58
Db
           61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
Qу
              59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
Db
          116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE----PAAPPSTPAAPKR 166
 Qу
```

Db	119	APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAAAPPSTPAAPKR	178
QУ	167	RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS	225
Db	179	RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS	237
Qу	226	LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY	285
Db	238	LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY	297
QУ	286	SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVGKED	339
Db	298	SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED	357
QУ	340	RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANV	395
Db	358	EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL	416
Qу	396	ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT	454
Db	417	ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRPGAYITCAPFNPAATESIA	476
QУ	455	ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS	513
Db	477	TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT	536
Qу	514	KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL	573
Db	537	KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL	596
Qy		CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN	
Db		CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN	
Qу		PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF	
Db		PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF	
Qу		SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS	
Db		SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS	
QУ		-ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF	
Db		FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL	
. QУ		NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS : : : :	
Db		STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS	
QУ		DKSEIANIQSGADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNV	
Db		HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV	
QУ		SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK	
Db	956	SALATOAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK	1015

```
987 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1046
Qv
            1016 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1075
Db
        1047 YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1106
Qу
            1076 YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1135
Db
        1107 NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
            1136 NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1192
Db
RESULT 10
AAB82349
    AAB82349 standard; protein; 1192 AA.
XX
AC
    AAB82349;
XX
DT
    23-JUL-2001 (first entry)
XX
DE
    Human NOGO-A protein.
XX
    NOGO-A; human; chromosome 2p21; neuropathy; spinal injury; brain injury;
KW
    stroke; neuronal degeneration; Alzheimer's disease; Parkinson's disease;
KW
    neuromuscular disorder; psychiatric disorder; developmental disorder;
KW
    neuroprotective; nootropic; neuroleptic; antiparkinsonian;
KW
    cerebroprotective; neuroleptic; diagnosis; therapy.
KW
XX
OS
    Homo sapiens.
XX
PN
    WO200136631-A1.
XX
    25-MAY-2001.
PD
XX
    14-NOV-2000; 2000WO-GB004345.
PF
XX
    15-NOV-1999;
                  99GB-00026995.
PR
    24-JAN-2000; 2000GB-00001550.
PR
XX
     (SMIK ) SMITHKLINE BEECHAM PLC.
PA
XX
    Michalovich D, Prinjha R;
PΙ
XX
DR
     WPI: 2001-343822/36.
DR
    N-PSDB; AAF90324.
XX
     New polypeptide designated NOGO-C is a splice variant of the human NOGO
PT
     gene and may be useful in the treatment of neural disorders including
PT
     Alzheimer's and Parkinson's diseases.
PT
XX
     Disclosure; Page 26-27; 25pp; English.
PS
XX
     The present sequence is that of human NOGO-A. NOGO-A is a previously
CC
     known splice variant of the human NOGO gene on chromosome 2p21. The
CC
     invention relates to a novel splice variant, NOGO-C (see AAB82348). It
CC
```

producing such polypeptides by recombinant techniques. Also disclosed are CC methods for utilising NOGO-C polypeptides and polynucleotides in the CC treatment of diseases including neuropathies, spinal injury, brain CC injury, stroke, neuronal degeneration, for example Alzheimer's disease CCand Parkinson's disease, neuromuscular disorders, psychiatric disorders CC and developmental disorders. Also provided are methods for identifying CC agonists and agonists for use in treating conditions associated with NOGO CC-C imbalance, and diagnostic assays for detecting diseases associated CC with inappropriate NOGO-C activity or levels CC XX SO Sequence 1192 AA; 75.2%; Score 4398.5; DB 4; Length 1192; Query Match 75.9%; Pred. No. 2.3e-221; Best Local Similarity Matches 908; Conservative 104; Mismatches 146; Indels 20; 39; Gaps 1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60 Qу 1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58 Db 61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115 Qy 59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118 Db 116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166 Qy 119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178 Db 167 RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS 225 Qу 179 RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS 237 Db 226 LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY 285 Qу ::||| | ||||||| 238 LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY 297 Db 286 SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVG----KED 339 QУ 298 SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED 357 Db 340 RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAA----RANV 395 Qу 358 EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL 416 Db 396 ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT 454 Qy ||||||:|| ||||||: ||||| |:| |||||||:|| 417 ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRPGAYITCAPFNPAATESIA 476 Db 455 ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS 513 Qy 477 TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT 536 Db 514 KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL 573 Qу 537 KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL 596 Dh

provides NOGO-C polypeptides and polynucleotides, and methods for

CC

```
574 CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN 633
Qу
          597 CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN 655
Db
       634 PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF 692
Qу
          656 PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF 715
Db
       693 SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS 752
QУ
          716 SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS 775
Db
       753 -ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF 809
Qу
                                      ::: ||:||||| |||
           776 FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL 835
Db
       810 NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS 868
Qу
          836 STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS 895
Db
       869 DKSEIANIQSGADSLPCLELPCDLSFKNIYPK--DEVHVSDEFSENRSSVSKASISPSNV 926
Qy
                 896 HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV 955
Db
       927 SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK 986
Qу
             956 SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK 1015
Db
       987 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1046
Qу
          1016 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1075
Db
       1047 YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1106
Qу
          1076 YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1135
Db
       1107 NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qy
          1136 NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1192
Db
RESULT 11
ABG30938
```

ABG30938 standard; protein; 1192 AA. ID

AC ABG30938;

XX

DTXX

XX

KW

KW

KW

KW

KW

KW

ΧX

21-OCT-2002 (first entry)

DE Human NogoA protein.

> Human; Nogo; BACE; acute neuronal injury; spinal injury; head injury; stroke; peripheral nerve damage; neoplastic disorder; glioblastoma; neuroblastoma; hyperproliferative disorder; dysproliferative disorder; cirrhosis; psoriasis; keloid formation; fibrocystic condition; cancer; tissue hypertrophy; central nervous system; axon regeneration; NogoA; Nogo-associated disease; metastasis.

```
XX
OS
    Homo sapiens.
XX
     WO200257483-A2.
PN
XX
     25-JUL-2002.
PD
XX
     18-JAN-2002; 2002WO-GB000228.
PF
XX
     18-JAN-2001; 2001GB-00001312.
PR
XX
     (GLAX ) GLAXO GROUP LTD.
PΑ
     (SMIK ) SMITHKLINE BEECHAM PLC.
PΑ
XX
     Blackstock WP, Hale RS, Prinjha R, Rowley A;
PΙ
XX
     WPI: 2002-599722/64.
DR
     N-PSDB; ABK90134.
DR
XX
     Identifying modulators of Nogo or BACE activity for treating acute
PT
     neuronal injuries, neoplastic or dysproliferative disorders, comprises
PT
     providing and monitoring interaction between Nogo and BACE polypeptides.
PT
XX
     Disclosure; Page 59-62; 68pp; English.
PS
XX
     The present invention relates to a new method of identifying modulators
CC
     of Nogo function or BACE activity. The method involves providing Nogo and
CC
     BACE polypeptides capable of binding with each other, monitoring the
CC
     interaction between these polypeptides, and determining if the test agent
CC
     is a modulator of Nogo or BACE activity. The method is useful in treating
CC
     acute neuronal injuries, such as spinal or head injury, stroke,
CC
     peripheral nerve damage, and in neoplastic (e.g. glioblastomas,
CC
     neuroblastomas), hyperproliferative or dysproliferative disorders (e.g.
CC
     cirrhosis, psoriasis, keloid formation, fibrocystic conditions, tissue
CC
     hypertrophy) of the central nervous system. The BACE polypeptide is
CC
     useful in screening methods to identify agents that may act as modulators
CC
     of BACE activity and in particular agents that may be useful in treating
CC
     Nogo-associated diseases. The modulators of Nogo or BACE polypeptides,
CC
     and the polynucleotide encoding the BACE polypeptide are useful in
CC
     manufacturing a medicament for the treatment or prevention of disorders
CC
     responsive to the modulation of Nogo activity, in alleviating the
CC
     symptoms or improving the condition of a patient suffering from this
CC
     disorder, in axon regeneration, or in preventing metastasis or spreading
CC
     of a cancer. The polynucleotide may also be an essential component in
CC
     assays, a probe, in recombinant protein synthesis, and in gene therapy
CC
     techniques. The present amino acid sequence represents the human NogoA
CC
     protein of the invention
CC
XX
SQ
     Sequence 1192 AA;
                          75.2%; Score 4398.5; DB 5; Length 1192;
  Query Match
                          75.9%; Pred. No. 2.3e-221;
  Best Local Similarity
  Matches 908; Conservative 104; Mismatches 146; Indels
                                                                 39; Gaps
                                                                             20;
            1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
```

Db

Qу	61	PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAP	115
Db	59	PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP	118
Qу	116	APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKR	166
Db	119	APSPLSAAAVSPSKLPEDDEPPARPPPPPPPASVSPQAEPVWTPPAPAAPPSTPAAPKR	178
Qу	167	RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS	225
Db	179	RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS	237
Qу	226	LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY	285
Db	238	LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY	297
QУ	286	SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVGKED	339
Db	298	:: : : : : : :	357
QУ	340	RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANV	395
Db	358	EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL	416
QУ	396	ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT	454
Db	417	ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRPGAYITCAPFNPAATESIA	476
Qу	455	ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS	513
Db	477	TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT	536
QУ	514	KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL	573
Db	537	:	596
Qу	574	CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN	633
Db	597	CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN	655
Qу	634	PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF	692
Db	656	PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF	715
Qу	693	SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS	752
Db	716	: : : :	775
Qy	753	-ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF	809
Db	776	:::::: :	835
QУ	810	NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS	868
Db	836	: : : : :	895

```
869 DKSEIANIQSGADSLPCLELPCDLSFKNIYPK--DEVHVSDEFSENRSSVSKASISPSNV 926
Qy
             896 HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV 955
Db
        927 SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK 986
Qy
            956 SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK 1015
Db
        987 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1046
Qу
            1016 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1075
Db
       1047 YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1106
QУ
            1076 YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1135
Db
       1107 NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
            1136 NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1192
Db
RESULT 12
ABB81078
    ABB81078 standard; protein; 1192 AA.
ID
XX
AC
    ABB81078;
XX
    05-NOV-2002 (first entry)
DT
XX
    Human neurotransmitter receptor protein Nogo-A.
DΕ
XX
    Nerve regeneration; neuroprotection; neuronal degeneration; CNS; PNS;
KW
    central nervous system; peripheral nervous system; tranquillizer; Nogo;
KW
    vulnerary; cerebroprotective; anti-tumour; antidiabetic; anticonvulsant;
KW
    nootropic; antiparkinsonian; ophthalmological; analgesic; hepatotropic;
KW
    osteopathic; vasotropic; nephrotropic; cytostatic; antigen; gene therapy;
KW
    neurotransmitter receptor; human; receptor.
KW
XX
OS
    Homo sapiens.
XX
    US2002072493-A1.
PN
XX
PD
    13-JUN-2002.
XX
    28-JUN-2001; 2001US-00893348.
PF
XX
                 98IL-00124500.
PR
    19-MAY-1998;
    21-JUL-1998;
                 98WO-US014715.
PR
    22-DEC-1998;
                 98US-00218277.
PR
                 99US-00314161.
    19-MAY-1999;
PR
XX
    (YEDA ) YEDA RES & DEV CO LTD.
PΑ
XX
    Eisenbach-Schwartz M, Hauben E, Cohen IR, Beserman P, Mosonego A;
PΙ
    Moalem G:
PΙ
XX
    WPI; 2002-607255/65.
DR
```

DR N-PSDB; ABN86601.

XX PT

PT

PT

Promoting nerve regeneration and preventing neuronal degeneration in the central/peripheral nervous system from injury/disease, comprises administering nervous system-specific activated T cells/antigen, or analogs/peptides.

PT XX PS

Example; Page 53-56; 93pp; English.

XX CC

The invention relates to promoting nerve regeneration or conferring neuroprotection and preventing or inhibiting neuronal degeneration in the central/peripheral nervous system (NS). The method involves administering NS-specific activated T cells, NS-specific antigen, its analogue or its peptide, a nucleotide sequence the NS-specific antigen or its analogue or combinations. The method is useful for promoting nerve regeneration and preventing neuronal degeneration in central/peripheral nervous system from injury/disease, where the injury is spinal cord injury, blunt trauma, penetrating trauma, hemorrhagic stroke, ischaemic stroke or damages caused by surgery such as tumour excision. The disease is not an autoimmune disease or neoplasm. The disease results in a degenerative process occurring in either gray or white matter or both. The disease is diabetic neuropathy, senile dementia, Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, non-arteritic optic neuropathy, and vitamin deficiency, intervertebral disc herniation, prion diseases such as Creutzfeldt-Jakob disease, carpal tunnel syndrome, peripheral neuropathies associated with various diseases, including but not limited to uremia, porphyria, hypoglycemia, Sjorgren Larsson syndrome, acute sensory neuropathy, chronic ataxic neuropathy, biliary cirrhosis, primary amyloidosis, obstructive lung diseases, acromegaly, malabsorption syndromes, polycythemia vera, immunoglobulin (Ig)A- and IgG gammapathies, complications of various drugs (e.g., metronidazole) and toxins (e.g., alcohol or organophosphates), Charcot-Marie-Tooth disease, ataxia telangectasia, Friedreich's ataxia, amyloid polyneuropathies, adrenomyeloneuropathy, Giant axonal neuropathy, Refsum's disease, Fabry's disease, or lipoproteinemia. The present sequence represents the human neurotransmitter receptor protein Nogo-A, an example of NS-specific antigen

CC XX SQ

Sequence 1192 AA;

```
75.2%; Score 4398.5; DB 5; Length 1192;
 Query Match
                    75.9%; Pred. No. 2.3e-221;
 Best Local Similarity
 Matches 908; Conservative 104; Mismatches 146; Indels
                                                  39; Gaps
                                                           20;
         1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
           1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58
Db
        61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
Qу
           59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
Db
        116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166
QУ
                                                111111
               119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178
Db
```

QУ	167	RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS	225
Db	179	RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS	237
Qу	226	LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY	285
Db	238	LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY	297
Qу	286	SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVGKED	339
Db	298	SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED	357
Qу	340	RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANV	395
Db	358	EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL	416
Qу	396	ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT	454
Db	417	ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRPGAYITCAPFNPAATESIA	476
QУ	455	ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS	513
Db	477	TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT	536
Qу	514	KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL	573
Db	537	KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL	596
QУ	574	CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN	633
Db	597	CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN	655
Qу	634	PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF	692
Db	656	PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF	715
Qу	693	SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS	752
Db	716		775
Qу	753	-ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF	809
Db	776	FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL	835
Qу	810	NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS: :	868
Db	836	STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS	895
Qу	869	DKSEIANIQSGADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNV	926
Db	896	HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV	955
QУ	927	SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK	986
Db	956	SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK	1015
Qу	987	KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA	1046

```
1016 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1075
Db
        1047 YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1106
Qу
             1076 YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1135
Db
        1107 NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
             1136 NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1192
Dh
RESULT 13
AAY71311
    AAY71311 standard; protein; 1178 AA.
XX
AC
    AAY71311;
XX
DT
    02-NOV-2000 (first entry)
XX
    Human neurite growth inhibitor Nogo.
DE
XX
    Human; neurite growth inhibitor; Nogo; neural cell; myelin; CNS;
KW
    central nervous system; neoplastic disease; antiproliferative; glioma;
KW
    antisense qene therapy; neuroblastoma; menagioma; retinoblastoma;
KW
    degenerative nerve disease; Alzheimer's disease; Parkinson's disease;
KW
    hyperproliferative disorder; benign dysproliferative disorder; diagnosis;
KW
    psoriasis; tissue hypertrophy; neuronal regeneration; treatment;
KW
    structural plasticity; screening.
KW
XX
OS
    Homo sapiens.
XX
                    Location/Qualifiers
FH
    Key
    Misc-difference 187
FT
                    /label= Unknown
FT
    Misc-difference 188
FT
                    /label= Unknown
FT
FT
    Misc-difference 189
FT
                    /label= Unknown
    Misc-difference 190
FT
                    /label= Unknown
FT
    Misc-difference 221
FT
                    /label= Unknown
FT
FT
     Misc-difference 328
                    /label= Unknown
FT
FT
    Misc-difference 477
                    /label= Unknown
FT
                    977. .1012
FT
     Region
                    /note= "Region specifically described in claim 16"
FT
                    994. .1174
FT
     Region
                    /note= "Region specifically described in claim 16"
FT
                    1079. .1114
FT
     Region
                    /note= "Region specifically described in claim 16"
FT
XX
PN
     WO200031235-A2.
XX
     02-JUN-2000.
PD
```

```
XX
ΡF
    05-NOV-1999;
                   99WO-US026160.
XX
PR
    06-NOV-1998;
                   98US-0107446P.
XX
PΑ
    (SCHW/) SCHWAB M E.
PΑ
    (CHEN/) CHEN M S.
XX
ΡI
    Schwab ME,
                Chen MS;
XX
DR
    WPI; 2000-400052/34.
XX
PT
    Nogo proteins and nucleic acids useful for treating neoplastic disorders
    of the central nervous system and inducing regeneration of neurons.
PT
XX
    Claim 11; Fig 13; 122pp; English.
PS
XX
    The present sequence is a human Nogo protein which is a potent neural
CC
    cell growth inhibitor and is free of all central nervous system (CNS)
CC
    myelin material with which it is natively associated. The human Nogo
CC
    sequence was derived by aligning human expressed sequence tags (ESTs)
CC
    e.g. AA158636, AA333267, AA081783, AA167765, AA322918, AA092565, AA081525
CC
    and AA081840 with the rat Nogo sequence. Nogo proteins and fragments
CC
    displaying neurite growth inhibitory activity are used in the treatment
CC
    of neoplastic disease of the CNS e.g. glioma, glioblastoma,
CC
    medulloblastoma, craniopharyngioma, ependyoma, pinealoma,
CC
    haemangioblastoma, acoustic neuroma, oligodendroglioma, menagioma,
CC
    neuroblastoma or retinoblastoma and degenerative nerve diseases e.g.
CC
    Alzheimer's and Parkinson's diseases. Therapeutics which promote Nogo
CC
    activity can be used to treat or prevent hyperproliferative or benign
CC
    dysproliferative disorders e.g. psoriasis and tissue hypertrophy.
CC
    Ribozymes or antisense Nogo nucleic acids can be used to inhibit
CC
    production of Nogo protein to induce regeneration of neurons or to
CC
    promote structural plasticity of the CNS in disorders where neurite
CC
    growth, regeneration or maintenance are deficient or desired. The animal
CC
    models can be used in diagnostic and screening methods for predisposition
CC
CC
    to disorders and to screen for or test molecules which can treat or
    prevent disorders or diseases of the CNS. Note: SEQ ID numbers 35-42 are
CC
     referred in claim 32 and SEQ ID NO: 29 in disclosure of the
CC
     specification. However the specification does not include sequences for
CC
CC
     these SEQ ID numbers
XX
     Sequence 1178 AA;
SO
                                Score 4276.5; DB 3; Length 1178;
                         73.1%;
  Query Match
                         73.8%;
                                Pred. No. 5.5e-215;
  Best Local Similarity
                                                                          19;
  Matches 883; Conservative 104; Mismatches 158;
                                                    Indels
                                                              51;
           1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEEDEEEDDEDLEELEVLERK 60
Qy
             1 MEDLDQSPLVSSS-DSVPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58
Db
          61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
Qy
             59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
Db
         116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166
Qу
```

Db	119	APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR	178
QУ	167	RGSGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSL	226
Db	179	: : :	224
QУ	227	SPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYS	286
Db	225	SPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEYS	284
QУ	287	EMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVGKEDR	340
Db	285	EMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHXQQELPTALTKLVKEDE	344
QУ	341	VVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVE	396
Db	345	VVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNLE	403
Qу	397	SKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTTA	455
Db	404	SKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRSGAYITCAPFNPAATESIAT	463
QУ	456	NTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLSK	514
Db	464	NIFPLLEDPTSENXTDEKKIEEKKAQIVTEKNTSTKTSNPFFVAAQDSCTDYVTTDNLTK	523
Qy	515	VTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQLC	574
Db	524	VTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQLC	583
Qу	575	PSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENP	634
Db	584	PSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPENP	642
Qу	635	PPYEEAMNVALKALGTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSN	694
Db	643	PPYEEAMSVSLKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDFSD	702
Qу	695	YSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS-E	753
Db	703	YSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETSFE	762
Qy	754	TVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEFNT :: ::: : :	811
Db	763	SMIEYENKEKLSALPPEGGKPYLESFKLSLVNTKDTLLPDEVSTLSKKEKIPLQMEELST	822
Qy	812	AIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVSDK	870
Db	823	AVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVSHK	882
Qy	871	SEIANIQSGADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSA	928
Db	883	SEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDVSA	942
Qy	929	L-EPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKK	987

```
943 LGHTQAEIESIVKPKVLEKEAEKKLPSDTEKEDRSPSAIFSADLGKTSVVDLLYWRDIKK 1002
Db
         988 TGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAY 1047
Qу
             1003 TGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAY 1062
Db
        1048 LESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFN 1107
Qy
             Db
        1063 LESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFN 1122
        1108 GLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
             Db
        1123 GLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1178
RESULT 14
AAU33228
    AAU33228 standard; protein; 1246 AA.
ID
AC
    AAU33228;
XX
DT
    18-DEC-2001 (first entry)
XX
DE
    Novel human secreted protein #3719.
XX
    Human; vaccination; gene therapy; nutritional supplement;
KW
    stem cell proliferation; haematopoiesis; nerve tissue regeneration;
KW
    immune suppression; immune stimulation; anti-inflammatory; leukaemia.
KW
XX
OS
    Homo sapiens.
XX
    WO200179449-A2.
ΡN
XX
    25-OCT-2001.
PD
XX
    16-APR-2001; 2001WO-US008656.
ΡF
XX
PR
    18-APR-2000; 2000US-00552929.
PR
    26-JAN-2001; 2001US-00770160.
XX
PΑ
    (HYSE-) HYSEQ INC.
XX
PΙ
    Tang YT, Liu C, Drmanac RT;
XX
    WPI; 2001-611725/70.
DR
XX
PT
    Nucleic acids encoding a range of human polypeptides, useful in genetic
PT
    vaccination, testing and therapy.
XX
    Claim 20; Page 737; 765pp; English.
PS
XX
CC
    The invention relates to novel human secreted polypeptides. The
    polypeptides and antibodies to the polypeptides are useful for
CC
    determining the presence of or predisposition to a disease associated
CC
    with altered levels of polypeptide. The polypeptides are also useful for
CC
    identifying agents (agonists and antagonists) that bind to them. Cells
CC
     expressing the proteins are useful for identifying a therapeutic agent
CC
```

CC for use in treatment of a pathology related to aberrant expression or CC physiological interactions of the polypeptide. Vectors comprising the nucleic acids encoding the polypeptides and cells genetically engineered CC CC to express them are also useful for producing the proteins. The proteins CC are useful in genetic vaccination, testing and therapy, and can be used as nutritional supplements. They may be used to increase stem cell CC CC proliferation; to regulate haematopoiesis; and in bone, cartilage, tendon CC and/or nerve tissue growth or regeneration; immune suppression and/or CC stimulation; as anti-inflammatory agents; and in treatment of leukaemias. CC AAU29510-AAU33304 represent the amino acid sequences of novel human secreted proteins of the invention CC XX Sequence 1246 AA; SQ

Query Match 70.4%; Score 4116; DB 4; Length 1246; Best Local Similarity 72.0%; Pred. No. 1.4e-206; Matches 873; Conservative 112; Mismatches 171; 27: Indels Gaps 1 MEDIDOSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60 Qу 42 MEDLDOSPLVSSS-DSPPRPOPAFKYQFVREPEDEE-EEEEEEEEDEDLEELEVLERK 99 Db 61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115 Qу 100 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 159 Db 116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166 Qу 160 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 219 Db 167 RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS 225 QУ 220 RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS 278 Db 226 LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY 285 Qу ::||| |||||| 279 LSPLSAASFKEHEYLGNLSTVLPTEGTLOENVSEASKEVSEKAKTLLIDRDLTEFSELEY 338 Db 286 SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVG----KED 339 Qу 339 SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED 398 Db 340 RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAA----RANV 395 QУ 399 EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL 457 Db 396 ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT 454 Qу 458 ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRSGAYITCAPFNPAATESIA 517 Db 455 ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS 513 Qу 518 TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT 577 Db 514 KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVOTSEA1QESLYPTAQL 573 Qу 578 KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL 637 Db

```
574 CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN 633
Qу
           638 CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN 696
Db
        634 PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF 692
Qу
           697 PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF 756
Db
        693 SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS 752
Qу
          757 SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS 816
Db
        753 -ETVAOHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF 809
Qу
            ::: ||:|||| || ||
        817 FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL 876
Db
        810 NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS 868
Qу
           877 STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS 936
Db
        869 DKSEIANIOSGADSLPCLELPCDLSFKNIYPK--DEVHVSDEFSENRSSVSKASISPSNV 926
Qу
                  937 HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV 996
Db
        927 SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK 986
Qу
              997 SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK 1056
Db
        987 KTGVVFGAS-LFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFR 1045
Qу
           1057 KTGVVFGASAVFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFR 1116
Db
       1046 AY---LESEVAISEELVQKYSNSALGHV-NSTIKELRR---LFLVDDLVDSLK-FAVLMW 1097
Qу
                                          1
                        \square : : \square
                                              _|||||||
       1117 AISGNLESCLYLRELGSGRYSNSALGSMWNCTVKGNFRAPSFFSWMDLVDSLRSFAVLMW 1176
Db
       1098 VFTYVGALFNGLTLL-----ILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKI 1151
Qy
                            1 - 11
                                    1177 VFTYVGCL--GLMVLDTTGFWALNFISSSGSWLIYERHQAQIDHYLGLANKNVKDAMAKI 1234
Db
Qу
       1152 QAKIPGLKRKAD 1163
           11111111111:
       1235 QAKIPGLKRKAE 1246
Dh
RESULT 15
AAY71562
    AAY71562 standard; protein; 803 AA.
ID
XX
AC
    AAY71562;
XX
    02-NOV-2000 (first entry)
DT
XX
DE
    Rat Nogo A protein fragment used in the construction of mutant NiG.
XX
```

Rat; neurite growth inhibitor; Nogo A; neural cell; myelin; CNS;

KW

central nervous system; neoplastic disease; antiproliferative; glioma; KW antisense gene therapy; neuroblastoma; menagioma; retinoblastoma; KW KW degenerative nerve disease; Alzheimer's disease; Parkinson's disease; hyperproliferative disorder; benign dysproliferative disorder; diagnosis; KW psoriasis; tissue hypertrophy; neuronal regeneration; treatment; KW structural plasticity; screening; mutant; mutein. KW XX OS Rattus sp. XX WO200031235-A2. PNXX 02-JUN-2000. PDXX PF 05-NOV-1999; 99WO-US026160. XX 06-NOV-1998; 98US-0107446P. PR XX PΑ (SCHW/) SCHWAB M E. (CHEN/) CHEN M S. PAXX PΙ Schwab ME, Chen MS; XX WPI; 2000-400052/34. DR XX Nogo proteins and nucleic acids useful for treating neoplastic disorders PTof the central nervous system and inducing regeneration of neurons. PTXX PS Example; Page; 122pp; English. XX The patent relates to neurite growth inhibitor Nogo which is free of all CC central nervous system (CNS) myelin material with which it is natively CC associated. Nogo proteins and fragments displaying neurite growth CC CC inhibitory activity are used in the treatment of neoplastic disease of the CNS e.g. glioma, glioblastoma, medulloblastoma, craniopharyngioma, CC CC

ependyoma, pinealoma, haemangioblastoma, acoustic neuroma, oligodendroglioma, menagioma, neuroblastoma or retinoblastoma and degenerative nerve diseases e.g. Alzheimer's and Parkinson's diseases. Therapeutics which promote Nogo activity can be used to treat or prevent hyperproliferative or benign dysproliferative disorders e.g. psoriasis and tissue hypertrophy. Ribozymes or antisense Nogo nucleic acids can be used to inhibit production of Nogo protein to induce regeneration of neurons or to promote structural plasticity of the CNS in disorders where neurite growth, regeneration or maintenance are deficient or desired. The animal models can be used in diagnostic and screening methods for predisposition to disorders and to screen for or test molecules which can treat or prevent disorders or diseases of the CNS. The present sequence is a fragment of rat Nogo A protein shown in AAY71310, which is used in the construction of mutant NiG. The mutant is composed of His-tag/T7tag/Nogo-A sequence aa 172-974/His-tag. Nogo A deletion mutants were used for mapping the inhibitory sites of Nogo protein. Major inhibitory region was identified in the Nogo A sequence from amino acids 172-974, particularly amino acids 542-722. In addition, N-terminal region 1-171 was found to be inhibitory to NIH 3T3 fibroblast spreading. Note: The present sequence is not given in the specification but is derived from rat Nogo A sequence shown in AAY71310. SEQ ID numbers 35-42 are referred in claim 32 and SEQ ID NO: 29 in disclosure of the specification. However, the specification does not include sequences for these SEQ ID

CC

```
CC numbers
```

XX

SQ Sequence 803 AA;

	cal	68.8%; Score 4023; DB 3; Length 803; Similarity 99.9%; Pred. No. 6e-202; 2; Conservative 1; Mismatches 0; Indels 0; Gaps	0;
Qу	172	VDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLST	231
Db	1		60
Qу	232	VSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSS	291
Db	61		120
Qу	292	FKGSPKGESAILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIF	351
Db	121		180
QУ	352	NEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQK	411
Db	181		240
QУ	412	SLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTD	471
Db	241		300
Qу	472	EKKIEERKAQIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDL	531
Db	301		360
Qу	532	VQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDI	591
Db	361		420
QУ	592	VMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTK	651
Db	421	VMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTK	480
QУ	652	EGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAEL	711
Db	481		540
QУ	712	VEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELG	771
Db	541		600
Qу	772	KPYLESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESE	831
Db	601		660
QУ	832	TFSDSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCD	891
Db	661		720
Qy	892	LSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKK	951

Db		
Qу	952 LPSDTEKEDRSLSAVLSAELSKT 974	
Db		

Search completed: September 29, 2004, 18:13:54 Job time: 117.067 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 29, 2004, 18:09:33; Search time 28.8717 Seconds

(without alignments)

2079.581 Million cell updates/sec

Title: US-09-830-972-2

Perfect score: 5848

Sequence: 1 MEDIDQSSLVSSSTDSPPRP......VKDAMAKIQAKIPGLKRKAD 1163

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued_Patents_AA:*

1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep:*

2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep:*

3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep:*

4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep:*

5: /cgn2_6/ptodata/2/iaa/PCTUS_COMB.pep:*

6: /cgn2 6/ptodata/2/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

			8				
Re	esult No.	Score	Query Match	Length	DB	ID	Description
-	1 2 3 4 5 6 7 8	908 789.5 716.5 685 671 539.5 519 302.5 288	15.5 13.5 12.3 11.7 11.5 9.2 8.9 5.2 4.9	199 776 356 208 267 168 241 8991 2468	2 2 2 2 2 2 4 2 4	US-08-700-607-1 US-08-700-607-5 US-08-700-607-6 US-08-700-607-7 US-08-700-607-8 US-09-149-476-563 US-08-700-607-3 US-08-714-741-32 US-09-976-594-726	Sequence 1, Appli Sequence 5, Appli Sequence 6, Appli Sequence 7, Appli Sequence 8, Appli Sequence 563, App Sequence 3, Appli Sequence 32, Appl Sequence 726, App
	10 11	286 279.5	4.9 4.8	92 1786	4	US-09-149-476-411 US-08-973-462-8	Sequence 411, App Sequence 8, Appli

```
Sequence 5, Appli
                   1780 1 US-08-769-309A-5
12
    265.5
             4.5
                                                       Sequence 5, Appli
             4.5
                   1780 3
                            US-08-994-570-5
13
    265.5
                                                       Sequence 4463, Ap
                   2137 4
                            US-09-134-001C-4463
14
      265
             4.5
                                                       Sequence 4600, Ap
                     75 4 US-09-621-976-4600
15
     256.5
              4.4
                     75 4
                            US-09-621-976-4601
                                                       Sequence 4601, Ap
    256.5
              4.4
16
                   1596 4
                            US-08-978-277A-4
                                                       Sequence 4, Appli
17
     254.5
              4.4
                   1142 2
                                                       Sequence 7, Appli
              4.0
                            US-08-993-118-7
18
       233
                                                       Sequence 7, Appli
                            US-08-845-528C-7
19
              4.0
                   1142
       233
                                                       Sequence 7, Appli
                            US-09-066-281B-7
                   1142 4
              4.0
20
       233
                                                       Sequence 7, Appli
                            US-09-468-433C-7
       233
              4.0
                   1142 4
21
                                                        Sequence 2, Appli
                   1805 1
                            US-07-853-913-2
              4.0
22
     232.5
                                                        Sequence 98, Appl
                   3256 4
                            US-09-919-172-98
       230
              3.9
23
                                                        Sequence 22, Appl
                   3256 4
                            US-09-976-594-22
24
       230
              3.9
                                                        Sequence 2, Appli
                   1142 3
                            US-09-061-709-2
       228
              3.9
25
                                                        Sequence 2, Appli
              3.9
                   1142 4
                            US-09-899-651-2
       228
26
                                                        Sequence 26, Appl
                  1142 4
                            US-09-392-714-26
              3.9
27
       228
                   1270 4
                                                        Sequence 44, Appl
                            US-07-757-022B-44
28
       227
              3.9
                                                        Sequence 42, Appl
                   1311 4
                            US-07-757-022B-42
29
       227
              3.9
                                                        Sequence 142, App
                            US-07-757-022B-142
30
       227
              3.9
                   1313 4
                                                        Sequence 50, Appl
                    1314 4
                            US-07-757-022B-50
31
       227
              3.9
                   1320 4
                                                        Sequence 46, Appl
                            US-07-757-022B-46
32
       227
              3.9
                                                        Sequence 60, Appl
              3.9
                    1320 4
                            US-07-757-022B-60
33
       227
                                                        Sequence 48, Appl
                            US-07-757-022B-48
34
                   1354 4
              3.9
       227
                            US-07-757-022B-40
                                                        Sequence 40, Appl
       227
              3.9
                   1361 4
35
                                                        Sequence 52, Appl
                   1363 4
                            US-07-757-022B-52
       227
              3.9
36
                                                        Sequence 2, Appli
                            US-07-757-022B-2
                    1404 4
              3.9
37
       227
                                                        Sequence 62, Appl
                   1404 4
                            US-07-757-022B-62
38
       227
              3.9
                    688 3
                                                        Sequence 8, Appli
                            US-09-141-047-8
       225
              3.8
39
                    941 4
                                                        Sequence 14, Appl
     224.5
                             US-07-757-022B-14
              3.8
40
                                                        Sequence 84, Appl
              3.8 1022 4
                             US-07-757-022B-84
41
     224.5
                            US-07-757-022B-74
                                                        Sequence 74, Appl
              3.8 1038 4
42
     224.5
                                                        Sequence 58, Appl
                             US-07-757-022B-58
              3.8 1049 4
43
     224.5
                                                        Sequence 104, App
                    1140 4
                             US-07-757-022B-104
              3.8
44
     224.5
                                                        Sequence 2, Appli
                    1346 2
                            US-08-635-121-2
45
     224.5
              3.8
```

ALIGNMENTS

```
RESULT 1
US-08-700-607-1
; Sequence 1, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
     APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT:
                Goli, Surya K.
     APPLICANT: Hillman, Jennifer L.
     TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
    NUMBER OF SEQUENCES: 9
     CORRESPONDENCE ADDRESS:
       ADDRESSEE: Incyte Pharmaceuticals, Inc.
       STREET: 3174 Porter Drive
       CITY: Palo Alto
       STATE: CA
       COUNTRY: U.S.
       ZIP: 94304
```

```
COMPUTER READABLE FORM:
     MEDIUM TYPE: Diskette
     COMPUTER: IBM Compatible
     OPERATING SYSTEM: DOS
     SOFTWARE: FastSEQ Version 1.5
    CURRENT APPLICATION DATA:
     APPLICATION NUMBER: US/08/700,607
      FILING DATE: Filed Herewith
    ATTORNEY/AGENT INFORMATION:
     NAME: Billings, Lucy J.
      REGISTRATION NUMBER: 36,749
      REFERENCE/DOCKET NUMBER: PF-0114 US
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
  INFORMATION FOR SEQ ID NO:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 199 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: peptide
    IMMEDIATE SOURCE:
      LIBRARY:
      CLONE: Consensus
US-08-700-607-1
                       15.5%; Score 908; DB 2; Length 199;
 Query Match
                              Pred. No. 1.1e-50;
                       96.3%;
 Best Local Similarity
                                                                    0;
                             3; Mismatches
                                           4; Indels
                                                          0; Gaps
 Matches 184; Conservative
         973 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1032
Qy
            9 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 68
Db
        1033 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKF 1092
Qу
            69 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKF 128
Db
        1093 AVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQ 1152
Qу
            129 AVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQ 188
Db
        1153 AKIPGLKRKAD 1163
Qу
             1111111111:
         189 AKIPGLKRKAE 199
Db
RESULT 2
US-08-700-607-5
; Sequence 5, Application US/08700607
; Patent No. 5858708
   GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surya K.
     APPLICANT: Hillman, Jennifer L.
```

```
TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
   NUMBER OF SEQUENCES: 9
   CORRESPONDENCE ADDRESS:
     ADDRESSEE: Incyte Pharmaceuticals, Inc.
     STREET: 3174 Porter Drive
     CITY: Palo Alto
     STATE: CA
     COUNTRY: U.S.
     ZIP: 94304
   COMPUTER READABLE FORM:
    MEDIUM TYPE: Diskette
     COMPUTER: IBM Compatible
     OPERATING SYSTEM: DOS
;
     SOFTWARE: FastSEQ Version 1.5
;
   CURRENT APPLICATION DATA:
    APPLICATION NUMBER: US/08/700,607
     FILING DATE: Filed Herewith
   ATTORNEY/AGENT INFORMATION:
    NAME: Billings, Lucy J.
     REGISTRATION NUMBER: 36,749
     REFERENCE/DOCKET NUMBER: PF-0114 US
;
    TELECOMMUNICATION INFORMATION:
    TELEPHONE: 415-855-0555
     TELEFAX: 415-845-4166
  INFORMATION FOR SEQ ID NO: 5:
   SEQUENCE CHARACTERISTICS:
     LENGTH: 776 amino acids
;
     TYPE: amino acid
;
     STRANDEDNESS: single
;
     TOPOLOGY: linear
  MOLECULE TYPE: peptide
   IMMEDIATE SOURCE:
     LIBRARY: GenBank
     CLONE: 307307
US-08-700-607-5
 Query Match 13.5%; Score 789.5; DB 2; Length 776; Best Local Similarity 31.2%; Pred. No. 3.1e-42;
 Matches 243; Conservative 115; Mismatches 252; Indels 169; Gaps 28;
        487 TSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESELNEATGT 546
Qу
            65 SGPARQSP--VAMETASTGVAGVSSAMDHTFSTTSKDGEG-----SCYTSLI----S 110
Db
        547 KIAYETKVDLVQTSEAIQ-ESLYPTAQLCPSFEEAEATPSPVLPDI--VMEAPLNS---- 599
QУ
            111 DICYPPQEDSTYFTGILQKENGHVTISESP---EELGTPGPSLPDVPGIESRGLFSSDSG 167
         600 --LLPSAGASVVQPSVSPLEAPPPVSY------DSIKLEPENPPPYEEA------M 641
              168 IEMTPAESTEVNKILADPLDQMKAEAYKYIDITRPEEVKHQEQHHPELEDKDLDFKNKDT 227
         642 NVALKALGTKEGIKEPE-----SFNAAVQETEAPYISIACDLIKETKLSTE-PSP 690
QУ
         228 DISIK----PEGVREPDKPAPVEGKIIKDHLLEESTFAPYID---DLSEEQRRAPQITTP 280
Db
        691 DFSNYSEIAKFEKSVPEHAELVEDSSPESEPVDLF-SDDSIPEV----PQTQEEAVMLMK 745
Qy
```

```
:: :|| : : | | |::| | |::
               : | |
        281 VKITLTEIE-----PSVETTTQEKTPEKQDICLKPSPDTVPTVTVSEPEDDSPGSITPP 334
Db
        746 ESLTEVSETVAQHK----EERLSASPQELGKPYLESFQP----NLHSTKDAASND---- 792
Qу
            335 SSGTEPSAAESQGKGSISEDELITAIKEAKGLSYETAENPRPVGQLADRPEVKARSGPPT 394
Db
        793 IPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKI----- 827
Qy
           395 IPSPLDHEASSAESGDSEIELVSEDPM--AAEDALPSGYVSFGHVGGPPPSPASPSIQYS 452
Db
        828 ---KESETFSDSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEI----ANIQSG 879
Qу
             453 ILREEREAELDS---ELIIESCDASSASEESPKREQDSPPMKPSALDAIREETGVRAEER 509
Db
        880 ADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIV 939
QУ
           510 APSRRGLAEPG--SFLD-YPSTEPQPGPEL------PPGDGALEPETPM--- 549
Db
        940 KSKSLTKEAEKKLPSDTEKEDRSLSAVLSAE-----LSKTSVVDLLYWRD 984
QУ
                    | | | | :: | : : :
                                                550 -----LPRKPEEDSSSNOSPAATKGPGPLGPGAPPPLLFLNKQKAIDLLYWRD 597
Db
        985 IKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPF 1044
Qy
           598 IKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVLQAVQKTDEGHPF 657
Db
       1045 RAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGA 1104
Qу
           658 KAYLELEITLSQEQIQKYTDCLQFYVNSTLKELRRLFLVQDLVDSLKFAVLMWLLTYVGA 717
Db
       1105 LFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
           718 LFNGLTLLLMAVVSMFTLPVVYVKHQAQIDQYLGLVRTHINAVVAKIQAKIPGAKRHAE 776
Db
RESULT 3
US-08-700-607-6
; Sequence 6, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surya K.
APPLICANT: Hillman, Jennifer L.
    TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
    NUMBER OF SEQUENCES: 9
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Incyte Pharmaceuticals, Inc.
      STREET: 3174 Porter Drive
      CITY: Palo Alto
      STATE: CA
      COUNTRY: U.S.
      ZIP: 94304
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Diskette
      COMPUTER: IBM Compatible
```

```
OPERATING SYSTEM: DOS
     SOFTWARE: FastSEQ Version 1.5
    CURRENT APPLICATION DATA:
     APPLICATION NUMBER: US/08/700,607
     FILING DATE: Filed Herewith
    ATTORNEY/AGENT INFORMATION:
     NAME: Billings, Lucy J.
     REGISTRATION NUMBER: 36,749
     REFERENCE/DOCKET NUMBER: PF-0114 US
   TELECOMMUNICATION INFORMATION:
     TELEPHONE: 415-855-0555
     TELEFAX: 415-845-4166
  INFORMATION FOR SEQ ID NO: 6:
   SEQUENCE CHARACTERISTICS:
     LENGTH: 356 amino acids
     TYPE: amino acid
     STRANDEDNESS: single
     TOPOLOGY: linear
    MOLECULE TYPE: peptide
    IMMEDIATE SOURCE:
     LIBRARY: GenBank
     CLONE: 307309
US-08-700-607-6
                    12.3%; Score 716.5; DB 2; Length 356;
 Query Match
 Best Local Similarity 46.1%; Pred. No. 4.6e-38;
 Matches 164; Conservative 48; Mismatches 89; Indels 55; Gaps
        828 KESETFSDSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEI----ANIQSGADS 882
Qу
           36 EEREAELDS---ELIIESCDASSASEESPKREQDSPPMKPSALDAIREETGVRAEERAPS 92
Db
        883 LPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSK 942
Qу
                                     | |||||
             93 RRGLAEPG--SFLD-YPSTEPQPGPEL------PPGDGALEPETPM----- 129
Db
        943 SLTKEAEKKLPSDTEKEDRSLSAVLSAE-----LSKTSVVDLLYWRDIKK 987
Qу
                   |:| :|||||:
        130 -----LPRKPEEDSSSNQSPAATKGPGPLGPGAPPPLLFLNKQKAIDLLYWRDIKQ 180
Db
        988 TGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAY 1047
QУ
            181 TGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVLQAVQKTDEGHPFKAY 240
Db
       1048 LESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFN 1107
QУ
           241 LELEITLSQEQIQKYTDCLQFYVNSTLKELRRLFLVQDLVDSLKFAVLMWLLTYVGALFN 300
Db
       1108 GLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qy
            301 GLTLLLMAVVSMFTLPVVYVKHQAQIDQYLGLVRTHINAVVAKIQAKIPGAKRHAE 356
Db
RESULT 4
US-08-700-607-7
```

; Sequence 7, Application US/08700607 ; Patent No. 5858708

```
GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surya K.
    APPLICANT: Hillman, Jennifer L.
    TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
    NUMBER OF SEQUENCES: 9
    CORRESPONDENCE ADDRESS:
     ADDRESSEE: Incyte Pharmaceuticals, Inc.
     STREET: 3174 Porter Drive
     CITY: Palo Alto
     STATE: CA
     COUNTRY: U.S.
     ZIP: 94304
    COMPUTER READABLE FORM:
     MEDIUM TYPE: Diskette
     COMPUTER: IBM Compatible
     OPERATING SYSTEM: DOS
      SOFTWARE: FastSEQ Version 1.5
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/700,607
      FILING DATE: Filed Herewith
    ATTORNEY/AGENT INFORMATION:
     NAME: Billings, Lucy J.
      REGISTRATION NUMBER: 36,749
      REFERENCE/DOCKET NUMBER: PF-0114 US
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
  INFORMATION FOR SEQ ID NO:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 208 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: peptide
    IMMEDIATE SOURCE:
      LIBRARY: GenBank
      CLONE: 307311
US-08-700-607-7
                       11.7%; Score 685; DB 2; Length 208;
 Query Match
                      67.0%; Pred. No. 2.2e-36;
 Best Local Similarity
 Matches 128; Conservative 32; Mismatches 31; Indels
                                                                    0:
                                                         0; Gaps
         973 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1032
Qу
            18 KSQAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVL 77
Db
        1033 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKF 1092
Qу
            78 QAVQKTDEGHPFKAYLELEITLSQEQIQKYTDCLQFYVNSTLKELRRLFLVQDLVDSLKF 137
Db
        1093 AVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQ 1152
Qу
            138 AVLMWLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQIDQYLGLVRTHINAVVAKIQ 197
Dh
```

```
1153 AKIPGLKRKAD 1163
Qy
             11111 11 1:
Db
         198 AKIPGAKRHAE 208
RESULT 5
US-08-700-607-8
; Sequence 8, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surya K.
    APPLICANT: Hillman, Jennifer L.
    TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
    NUMBER OF SEQUENCES: 9
   CORRESPONDENCE ADDRESS:
      ADDRESSEE: Incyte Pharmaceuticals, Inc.
     STREET: 3174 Porter Drive
     CITY: Palo Alto
     STATE: CA
     COUNTRY: U.S.
     ZIP: 94304
    COMPUTER READABLE FORM:
     MEDIUM TYPE: Diskette
     COMPUTER: IBM Compatible
     OPERATING SYSTEM: DOS
     SOFTWARE: FastSEQ Version 1.5
   CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/700,607
      FILING DATE: Filed Herewith
   ATTORNEY/AGENT INFORMATION:
      NAME: Billings, Lucy J.
      REGISTRATION NUMBER: 36,749
      REFERENCE/DOCKET NUMBER: PF-0114 US
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
  INFORMATION FOR SEQ ID NO: 8:
   SEQUENCE CHARACTERISTICS:
      LENGTH: 267 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: peptide
    IMMEDIATE SOURCE:
      LIBRARY: GenBank
      CLONE: 281046
US-08-700-607-8
                        11.5%; Score 671; DB 2; Length 267;
  Query Match
  Best Local Similarity 66.3%; Pred. No. 2.5e-35;
  Matches 124; Conservative 33; Mismatches 30; Indels
                                                          0; Gaps
         973 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1032
QУ
```

9 KSQAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVL 68

Db

```
1033 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKF 1092
Qу
             69 QAVQKTDEGHPFKAYLELEITLSQEQIQKYTDCLQLYVNSTLKELRRLFLVQDLVDSLKF 128
        1093 AVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQ 1152
Qу
             : :||||
         129 AVLMWLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQVDQYLGLVRTHINTVVAKIQ 188
Db
        1153 AKIPGLK 1159
Qy
             11111:
        189 AKIPGAR 195
Db
RESULT 6
US-09-149-476-563
; Sequence 563, Application US/09149476
: Patent No. 6420526
; GENERAL INFORMATION:
  APPLICANT: Rosen et al.
  TITLE OF INVENTION: 186 Human Secreted proteins
  FILE REFERENCE: PZ002P1
  CURRENT APPLICATION NUMBER: US/09/149,476
  CURRENT FILING DATE: 1998-09-08
  EARLIER APPLICATION NUMBER: PCT/US98/04493
  EARLIER FILING DATE: 1998-03-06
  EARLIER APPLICATION NUMBER: 60/040,162
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,333
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/038,621
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,626
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,334
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,336
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,163
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/047,600
  EARLIER FILING DATE: 1997-05-23
  EARLIER APPLICATION NUMBER: 60/047,615
  EARLIER FILING DATE: 1997-05-23
   EARLIER APPLICATION NUMBER: 60/047,597
   EARLIER FILING DATE: 1997-05-23
   EARLIER APPLICATION NUMBER: 60/047,502
  EARLIER FILING DATE: 1997-05-23
   EARLIER APPLICATION NUMBER: 60/047,633
   EARLIER FILING DATE: 1997-05-23
  EARLIER APPLICATION NUMBER: 60/047,583
  EARLIER FILING DATE: 1997-05-23
  EARLIER APPLICATION NUMBER: 60/047,617
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,618
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,503
```

```
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,592
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,581
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,584
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,500
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,587
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,492
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,598
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,613
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,582
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,596
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,612
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,632
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,601
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/043,580
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,568
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,314
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,569
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,311
EARLIER FILING DATE: 1997-04-11
```

EARLIER APPLICATION NUMBER: 60/043,671

EARLIER APPLICATION NUMBER: 60/043,674

EARLIER APPLICATION NUMBER: 60/043,669

EARLIER APPLICATION NUMBER: 60/043,312

EARLIER APPLICATION NUMBER: 60/043,313

EARLIER APPLICATION NUMBER: 60/043,672

EARLIER APPLICATION NUMBER: 60/043,315

EARLIER APPLICATION NUMBER: 60/048,974

EARLIER APPLICATION NUMBER: 60/056,886

; EARLIER APPLICATION NUMBER: 60/056,877

EARLIER FILING DATE: 1997-04-11

EARLIER FILING DATE: 1997-06-06

; EARLIER FILING DATE: 1997-08-22

; EARLIER FILING DATE: 1997-08-22

```
; EARLIER APPLICATION NUMBER: 60/056,889
```

- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,893
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,630
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,878
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,662
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,872
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,882
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,637
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,903
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,888
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,879
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,880
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,894
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,911
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,636
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,874
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,910
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,864
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,631
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,845
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,892
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/057,761
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/047,595
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,599
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,588
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,585
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,586
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,590
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,594

```
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,589
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,593
; EARLIER FILING DATE: 1997-05-23
  EARLIER APPLICATION NUMBER: 60/047,614
  EARLIER FILING DATE: 1997-05-23
  EARLIER APPLICATION NUMBER: 60/043,578
  EARLIER FILING DATE: 1997-04-11
  EARLIER APPLICATION NUMBER: 60/043,576
  EARLIER FILING DATE: 1997-04-11
  EARLIER APPLICATION NUMBER: 60/047,501
  EARLIER FILING DATE: 1997-05-23
  EARLIER APPLICATION NUMBER: 60/043,670
  EARLIER FILING DATE: 1997-04-11
  EARLIER APPLICATION NUMBER: 60/056,632
  EARLIER FILING DATE: 1997-08-22
  EARLIER APPLICATION NUMBER: 60/056,664
  EARLIER FILING DATE: 1997-08-22
  EARLIER APPLICATION NUMBER: 60/056,876
  EARLIER FILING DATE: 1997-08-22
  EARLIER APPLICATION NUMBER: 60/056,881
  EARLIER FILING DATE: 1997-08-22
  EARLIER APPLICATION NUMBER: 60/056,909
  EARLIER FILING DATE: 1997-08-22
  EARLIER APPLICATION NUMBER: 60/056,875
  EARLIER FILING DATE: 1997-08-22
  EARLIER APPLICATION NUMBER: 60/056,862
  EARLIER FILING DATE: 1997-08-22
  EARLIER APPLICATION NUMBER: 60/056,887
  EARLIER FILING DATE: 1997-08-22
  EARLIER APPLICATION NUMBER: 60/056,908
  EARLIER FILING DATE: 1997-08-22
  EARLIER APPLICATION NUMBER: 60/048,964
  EARLIER FILING DATE: 1997-06-06
  EARLIER APPLICATION NUMBER: 60/057,650
  EARLIER FILING DATE: 1997-09-05
  EARLIER APPLICATION NUMBER: 60/056,884
  EARLIER FILING DATE: 1997-08-22
  EARLIER APPLICATION NUMBER: 60/057,669
  EARLIER FILING DATE: 1997-09-05
  EARLIER APPLICATION NUMBER: 60/049,610
  EARLIER FILING DATE: 1997-06-13
  EARLIER APPLICATION NUMBER: 60/061,060
  EARLIER FILING DATE: 1997-10-02
                         9.2%; Score 539.5; DB 4; Length 168;
  Query Match
  Best Local Similarity 59.3%; Pred. No. 3.2e-27;
          99; Conservative 36; Mismatches 31; Indels
         998 LLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEE 1057
Qу
             Db
           1 MLLSLAAFSVISVVSYLILALLSVTISFRIYKSVIQAVQKSEEGHPFKAYLDVDITLSSE 60
        1058 LVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALI 1117
Qу
                 61 AFHNYMNAAMVHINRALKLIIRLFLVEDLVDSLKLAVFMWLMTYVGAVFNGITLLILAEL 120
```

```
1118 SLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGL-KRKAD 1163
Qy
             Db
         121 LIFSVPIVYEKYKTQIDHYVGIARDOTKSIVEKIQAKLPGIAKKKAE 167
RESULT 7
US-08-700-607-3
; Sequence 3, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surya K.
    APPLICANT: Hillman, Jennifer L.
    TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
;
   NUMBER OF SEQUENCES: 9
   CORRESPONDENCE ADDRESS:
     ADDRESSEE: Incyte Pharmaceuticals, Inc.
     STREET: 3174 Porter Drive
     CITY: Palo Alto
     STATE: CA
     COUNTRY: U.S.
     ZIP: 94304
   COMPUTER READABLE FORM:
    MEDIUM TYPE: Diskette
     COMPUTER: IBM Compatible
     OPERATING SYSTEM: DOS
     SOFTWARE: FastSEQ Version 1.5
   CURRENT APPLICATION DATA:
;
    APPLICATION NUMBER: US/08/700,607
      FILING DATE: Filed Herewith
   ATTORNEY/AGENT INFORMATION:
     NAME: Billings, Lucy J.
      REGISTRATION NUMBER: 36,749
     REFERENCE/DOCKET NUMBER: PF-0114 US
   TELECOMMUNICATION INFORMATION:
     TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
ï
  INFORMATION FOR SEO ID NO: 3:
   SEQUENCE CHARACTERISTICS:
     LENGTH: 241 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: peptide
    IMMEDIATE SOURCE:
      LIBRARY: THP1NOB01
      CLONE: 31870
US-08-700-607-3
 Query Match 8.9%; Score 519; DB 2; Length 241; Best Local Similarity 59.4%; Pred. No. 1.1e-25;
 Matches 95; Conservative 33; Mismatches 32; Indels 0; Gaps
         972 SKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGV 1031
Qy
```

```
Db
          44 SSCAVHDLIXWRDVKKTGFVFGTTLIMLLSLAAFSVISVVSYLILALLSVTISFRIYKSV 103
Qγ
        1032 IOAIOKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLK 1091
             Db
         104 IQAVQKSEEGHPFKAYLDVDITLSSEAFHNYMNAAMVHINRALKLIIRLFLVEDLVDSLK 163
        1092 FAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQV 1131
Οv
              Dh
         164 LAVFMWLMTYVGAVFNGITLLILAELLIXSVPIVYXKYKV 203
RESULT 8
US-08-714-741-32
; Sequence 32, Application US/08714741
; Patent No. 6500613
  GENERAL INFORMATION:
    APPLICANT: Briles, David E.
    APPLICANT: McDaniel, Larry S.
;
    APPLICANT: Swiatlo, Edwin
    APPLICANT: Yother, Janet
    APPLICANT: Crain, Marilyn J.
    APPLICANT: Hollingshead, Susan
    APPLICANT: Tart, Rebecca
    APPLICANT: Brooks-Walter, Alexis
    TITLE OF INVENTION: PNEUMOCOCCAL GENES, PORTIONS THEREOF,
    TITLE OF INVENTION: EXPRESSION PRODUCTS THEREFROM, AND USES OF SUCH GENES,
   TITLE OF INVENTION: PORTIONS AND PRODUCTS
   NUMBER OF SEQUENCES: 47
   CORRESPONDENCE ADDRESS:
      ADDRESSEE: Curtis, Morris & Safford, P.C.
      STREET: 530 Fifth Avenue
      CITY: New York
;
      STATE: New York
      COUNTRY: U.S.
      ZIP: 10036
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/714,741
      FILING DATE: 16-SEP-1996
      CLASSIFICATION: 435
    ATTORNEY/AGENT INFORMATION:
      NAME: Frommer Esq., William S.
      REGISTRATION NUMBER: 25,506
      REFERENCE/DOCKET NUMBER: 454312-2460
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (212) 840-3333
      TELEFAX: (212) 840-0712
  INFORMATION FOR SEQ ID NO: 32:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 8991 amino acids
      TYPE: amino acid
     STRANDEDNESS: single
     TOPOLOGY: linear
```

; MOLECULE TYPE: amino acid US-08-714-741-32

В	est Local :	5.2%; Score 302.5; DB 4; Length 8991; Similarity 22.1%; Pred. No. 1.6e-09; 4; Conservative 125; Mismatches 439; Indels 297; Gaps	47;
Qу	18	PRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERKPAAGLSAAAVPPAAAAP	77
Db	7805	PKPAPAPQPAPAPKPEKTDDQQAEEDYARRSEEEYNRLPQQQPPKAEKP	7853
Qу	78	LLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLPPAAAVLPSKLPEDDEPP :	137
Db	7854	APAPKPEQPVPAEXPENPAPAPKPAXAPQPLKPEEPAEQP	7893
Qу	138	ARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALPAASEPVIPSSAEKIM	195
Db	7894	KPEKPEEPAGQPEPEKPDDQQAGEDYARRSGGEYNRFPQQQPPKAEKPAPAPK	7946
QУ	196	DLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYLGNLSAVSS	248
Db	7947	PEQPVPAPKTLLKKAKLAGAKSKAATKKAELEPELEKAEAELENLLSTLD	7996
Qу	249	SEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVEN	306
Db	7997	PEGKTQDELDKEAAEAELNKKVEALPNQVSELEEELSKLEDNLKDAETNNVEDYIKE	8053
QУ	307	TKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVAPVR	363
Db	8054	GLEEAIATKQAELEKTPKELDAALNELGPDGDEEETPPPEAPAE	8097
Qу	364	EEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGRN : : : : : :	421
Db	8098	QPKPE-KPAEETPAPAPKPEKSADQQAEEDYARRSEEEYNRLTQQQPPKAEKPAP	8151
QУ	422	EDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHT	465
Db	8152	APAPKPEQPAPA-PKSRGLATKKKLNLAEARIELLLKKLGLEPGLEKAGAGLGNLLSTLD	8210
QУ	466	SENKTDEKKIEERKAQIITEKTSPKTSNPFLVAVQDSEADYVTTDT	511
Db	8211	PEGKTQDELDKEAAEAELNKKVEALPNQVAELEEELSKLEDNLKDAETNHVEDYI	8265
Qу	512	LSKVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYET : :	552
Db	8266	KEGLEEAIATKQAELEKTPKELDAALNELGPDGDEEETPAPEAPAEQPKPEKPAEETPAP	8325
QУ	553	KVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAP : : : :	596
Db	8326	APKPEKSADQQAEEDYARRSEEEYNRLTQQQPPKAEKPAPAPAP-KPEQPAPAPKKKQ	8382
Qу	597	LNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAM	641
Db	8383	KVNLENLLSTLDPGGKTQDELDKGAAEAELNKKVEALPNPVXELEEELSPPEDN	8436
Qу	642	NVALKALGTKEGIKEPESFNAAVQETEAPYIS	673

```
Db
       8437 ---LKDAETNHVEDYIKEGLEEAIATKOAELEETPOEVDAALNDLVPDGGEEETPAP--- 8490
Qу
        674 IACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAE-----LVEDSSPESE 720
                | : |::|
Db
       8491 ----APQPDEPAPAPAPAPAPAPAPKPEKSADQQAEEDYARRSEGEYNRLTQQQPPKAE 8546
QУ
        721 -PVDLFSDDSIPEVPQTQEEAVML------MKESLTEVSETVAQHKEERLSASPQ 768
             : : : |
                                          ::::: | | :|: |:: |
Db
       8547 KPAPAPAPKPEQPAPAPNKEIARLQSDLKDAEENNVEDYIKEGLEQAITNKKAELATTQQ 8606
       769 ELGKPYLESFQPNLHSTKDAASNDIPTLTKKE-----KISLOMEEFNTAIYSNDDLL 820
Qу
             Db
       8607 NIDKTQKDLEDAELELEKVLATLDPEGKTQDELDKEAAEAELNEKVEALQNQVAELEEEL 8666
        821 SSKEDKIKESETFSDSSPI-EIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSG 879
0v
            | || :|::|| : | | ::|
                                           :|::||:|
       8667 SKLEDNLKDAETNNVEDYIKEGLEE------AIATKKAELEKTQKE----- 8706
Db
        880 ADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIV 939
Qy
                    8707 ------BAALNELGPDGD---EEETPAPAPQPEKPAEEPEN-PAPAPKPE---- 8747
Db
Qy
        940 KSKSLTKEAEKKLPSDTEKEDRSLS 964
            || ::||: :|:| |:
Db
       8748 -- KSADQQAEEDYARRSEEEYNRLT 8770
RESULT 9
US-09-976-594-726
; Sequence 726, Application US/09976594
; Patent No. 6673549
; GENERAL INFORMATION:
; APPLICANT: Furness, Michael
; APPLICANT: Buchbinder, Jenny
; TITLE OF INVENTION: GENES EXPRESSED IN C3A LIVER CELL CULTURES TREATED WITH
STEROIDS
; FILE REFERENCE: PA-0041 US
  CURRENT APPLICATION NUMBER: US/09/976.594
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/240,409
; PRIOR FILING DATE: 2000-10-12
; NUMBER OF SEQ ID NOS: 1143
  SOFTWARE: PERL Program
; SEQ ID NO 726
  LENGTH: 2468
   TYPE: PRT
  ORGANISM: Homo sapiens
  FEATURE:
   NAME/KEY: misc feature
   OTHER INFORMATION: Incyte ID No. 6673549 4295277CD1
US-09-976-594-726
 Query Match
                      4.9%; Score 288; DB 4; Length 2468;
 Best Local Similarity 20.2%; Pred. No. 2e-09;
 Matches 251; Conservative 166; Mismatches 441; Indels 386; Gaps 56;
Qy
        13 STDSPPR--PPPAFKYQFVTEPEDEEDEEE-----EED-----EED----EEEDDED 50
```

Db	625	: : : : ::: : : ATDVKPKAAKEKTVKKETKVKPEDKKEEKEKPKKEVAKKEDKTPIKKEEKPKKEEVKKEV	684
Qγ	51	LEELEVLERKPAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWER	110
Db	685	KKEIKKEEKKEPKKEVKKETPPKEVKKEEKKEVKKEEK	726
Qу	111	SPAAPAPSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRG	168
Db	727	: : : EPKKEIKKLPKDAKKSSTPLSEAKKPAALKPKVPKKEESVKKDSVAAGKPKEKGKI	782
Qу	169	SGSVDETLFALPAASEPVIPSSAEKIMDLME	199
Db		KVIKKEGKAAEAVAAAVGTGATTAAVMAAAGIAAIGPAKELEAERSLMSSPEDLTKDFEE	
Qу	200	QPGNTVSSGQEDFPSV-LLETAASLPSLSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLN	258
Db	843	:: : : : :: : LKAEEVDVTKDIKPQLELIEDEEKLKETEPVEAYVIQKEREVTKGPAESPDEG-ITTTEG	901
Qу	259	EASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENTK-EEVIVRSKD	317
Db	902	:::: : : : : :: :: :: EGECEQTPEELEPVEKQGVDDIEKFEDEGAGFEESSETGDYEEKAETEEAEEPEED	957
Qу	318	KEDLVC-SAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSV	358
Db	958	GEEHVCVSASKHSPTEDEESAKAEADAYIREKRESVASGDDRAEEDMDEAIEKG	1011
Qу	359	VAPVREEYADFKPFEQAWEVK-DTYEGSRDVLAARANVESKVDRKCLEDSLEQ	410
Db	1012	EAEQSEEEADEEDKAEDAREEEYEPEKMEAEDYVMAVVDKAAEAGGAEEQYGFLTT	1067
Qу	411	KSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFTSATESTT	454
Db	1068	PTKQLGAQSPGREPASSIHDETLPGGSESEATASDEENREDQPEEFTATSGYTQSTIEIS	1127
Qу	455	ANTFPLLEDHTSENKTDEKKIEERKAQIITEKTS-PKTSNPFLVAV : :	499
Db	1128	SEPTPMDEMSTPRDVMSDETNNEETESPSQEFVNITKYESSLYSQEYSKPADVTPLNGFS	1187
Qу	500	QDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDL: :	556
Db	1188	EGSKTDATDGKDYNASASTISPPSSMEEDKFSRSALRDAYCSEVKASTTLDIKDS	1242
Qу	557	VQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIV : : : :: :::	592
Db	1243	ISAVSSEKVSPSKSPSLSPSPPSPLEKTPLGERSVNFSLTPNEIKVSAEAEVAPVSPEVT	1302
QУ	593	MEAPLNSLLPSAGASVVQ :	610
Db	1303	QEVVEEHCASPEDKTLEVVSPSQSVTGSAGHTPYYQSPTDEKSSHLPTEVIEKPPAVPVS	1362
Qу	611	PSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALG	649
Db	1363	FEFSDAKDENERASVSPMDEPVPDSESPIEKVLSPLRSPPLIGSESAYESFLSADDKASG	1422
Qу	650	TKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPD-FSNYSEIAKF : : : : :	701

```
Db
       1423 -----RGAESPF-----EEKSGKQGSPDQVSPVSEMTSTSLYODKQ 1458
Qу
        702 EKSVPEHAELVEDSSPE-----SEPVDLFSDDSIPEVPQTQ-----EEAV 741
           | : | : | | | | | : | : : | | |
Db
       1459 EGKSTDFAPIKEDFGQEKKTDDVEAMSSQPALALDERKLGDVSPTQIDVSQFGSFKEDTK 1518
        742 MLMKE-----SLTEVSETVAQ----HKEERLSASPQELG-----KPYLESFQPNLHSTK 786
Qу
           1519 MSISEGTVSDKSATPVDEGVAEDTYSHMEGVASVSTASVATSSFPEPTTDDVSPSLH--- 1575
Db
       787 DAASNDIPTLTK-KEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEF 845
Qу
                Db
       1576 --AEVGSPHSTEVDDSLSVSVVQTPTT-FQETEMSPSKEECPR------ 1615
       846 PTFVSAKDDSPKLAKEYTDLE--VSDKSEIANIQSGADSLPCLELPCDLSFKN----- 896
Qу
           1616 PMSISPPDFSPKTAKSRTPVQDHRSEQSSM-SIEFGQES-PEQSLAMDFSRQSPDHPTVG 1673
       Qу
                                    Db
       1674 AGVLHITENGPTEVDYSPSDMQDSSLSHKIPPMEEPSYTQDNDLSELISVSQVEASPSTS 1733
Qу
       927 SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAE 970
           1734 SAHTP-SQIASPLQEDTLSDVAPPR-----DMSLYASLTSE 1768
Db
RESULT 10
US-09-149-476-411
; Sequence 411, Application US/09149476
; Patent No. 6420526
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
  TITLE OF INVENTION: 186 Human Secreted proteins
  FILE REFERENCE: PZ002P1
  CURRENT APPLICATION NUMBER: US/09/149,476
  CURRENT FILING DATE: 1998-09-08
  EARLIER APPLICATION NUMBER: PCT/US98/04493
  EARLIER FILING DATE: 1998-03-06
  EARLIER APPLICATION NUMBER: 60/040,162
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,333
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/038,621
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,626
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,334
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,336
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,163
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/047,600
  EARLIER FILING DATE: 1997-05-23
  EARLIER APPLICATION NUMBER: 60/047,615
```

; EARLIER FILING DATE: 1997-05-23

```
; EARLIER APPLICATION NUMBER: 60/047,597
```

- ; EARLIER FILING DATE: 1997-05-23
- EARLIER APPLICATION NUMBER: 60/047,502
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,633
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,583
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,617
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,618
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,503
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,592
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,581
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047.584
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,500
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,587
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,492
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,598
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,613
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,582
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,596
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,612
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,632
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,601
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/043,580
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,568
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,314
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,569
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,311
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,671
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,674
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,669
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,312

- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,313
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,672
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,315
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/048,974
- ; EARLIER FILING DATE: 1997-06-06
- ; EARLIER APPLICATION NUMBER: 60/056,886
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,877
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,889
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,893
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,630
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,878
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,662
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,872
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,882
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,637
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,903
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,888
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,879
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,880
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,894
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,911
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,636
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,874
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,910
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,864
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,631
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,845
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,892
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/057,761
- ; EARLIER FILING DATE: 1997-08-22

- ; EARLIER APPLICATION NUMBER: 60/047,595
- ; EARLIER FILING DATE: 1997-05-23
- EARLIER APPLICATION NUMBER: 60/047,599
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,588
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,585
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,586
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,590
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,594
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,589
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,593
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,614
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/043,578
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,576
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/047,501
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/043,670
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/056,632
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,664
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,876
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,881
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,909
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,875
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,862
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,887
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,908
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/048,964
- ; EARLIER FILING DATE: 1997-06-06
- ; EARLIER APPLICATION NUMBER: 60/057,650
- ; EARLIER FILING DATE: 1997-09-05
- ; EARLIER APPLICATION NUMBER: 60/056,884
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/057,669
- ; EARLIER FILING DATE: 1997-09-05
- ; EARLIER APPLICATION NUMBER: 60/049,610
- ; EARLIER FILING DATE: 1997-06-13
- ; EARLIER APPLICATION NUMBER: 60/061,060

```
; EARLIER FILING DATE: 1997-10-02
                       4.9%; Score 286; DB 4; Length 92;
 Query Match
 Best Local Similarity 56.0%; Pred. No. 2.2e-11;
 Matches 51; Conservative 21; Mismatches 19; Indels
       1064 NSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIP 1123
Qу
            Db
          2 NAAMVHINRALKLIIRLFLVEDLVDSLKLAVFMWLMTYVGAVFNGITLLILAELLIFSVP 61
       1124 VIYERHQVQIDHYLGLANKSVKDAMAKIQAK 1154
Qу
            ::||::: |||||:|:|
Db
         62 IVYEKYKTQIDHYVGIARDQTKSIVEKIPSK 92
RESULT 11
US-08-973-462-8
; Sequence 8, Application US/08973462B
; Patent No. 6191270
; GENERAL INFORMATION:
; APPLICANT: DRUILHE, PIERRE
 APPLICANT: DAUBERSIES, PIERRE
  TITLE OF INVENTION: MALARIAL PRE-ERYTHROCYTIC STAGE POLYPEPTIDE MOLECULES
  FILE REFERENCE: 0660-0125-0 PCT
  CURRENT APPLICATION NUMBER: US/08/973,462B
  CURRENT FILING DATE: 1998-02-06
  EARLIER APPLICATION NUMBER: PCT/FR96/00894
  EARLIER FILING DATE: 1996-06-12
  EARLIER APPLICATION NUMBER: FR 95/07007
  EARLIER FILING DATE: 1995-06-13
  NUMBER OF SEQ ID NOS: 29
 SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
  LENGTH: 1786
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Description of Artificial Sequence: Polypeptide
US-08-973-462-8
 Query Match
                       4.8%; Score 279.5; DB 3; Length 1786;
 Best Local Similarity 20.1%; Pred. No. 4.4e-09;
 Matches 261; Conservative 220; Mismatches 518; Indels 297; Gaps
                                                                 60;
         33 EDEEDEEEEDEEDDEDLEELEVLERKPAAGLSAAAVPPAAAAPLLDFSSDS-----VP 87
Qу
            Db
        225 EKVEESVEENDEESVEENVEE-NVEENDDG---SVASSVEESIASSVDESIDSSIEENVA 280
         88 P----APRGPLPAAPPAAPERQPSWERSPA----APAPSLPPAAAV-LPSKLPEDDE 135
QУ
            281 PTVEEIVAPSVVESVAPSVEESVEENVEESVAENVEESVAENVEESVAENVEESVAENVE 340
Db
        136 PPARP-----PPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALPAASEPVIPS 189
Qу
                 Db
        341 EIVAPTVEEIVAPTVEEIVAPSVVESVAPSVEESVEENVEESVAENV--EESVAENVEES 398
```

190 SAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASL--PSLSPLSTVSFKEHGYLGNLSAVS 247

Qy

Db	399	::::	449
Qу	248	SSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENT	307
Db	450	:: : : : : : SVEESVEENVEESVAENVEESVAENVEESVAENV	491
Qу	308	KEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVAPVREEYA	367
Db	492	:	535
Qу	368	DFKPFEQ-AWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGRN-EDAS	425
Db	536	APSVVESVAPSVEESVEENVEESVAE-NVEESVAEN-VEESVAENVEESVAENVEEIV	591
Qу	426	FPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKAQIITE	485
Db	592	APTVEEIVAPTVEEIVAPSVVESVAPSVEESVEENVEESVAENVEE	637
QУ	486	KTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESELNEATG	545
Db	638	: :: :: : : : : :	696
Qу	546	TKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSLL: : : :: : : :	601
Db	697	ENVE-ESVAENVEESVAENVEESVAENVEEIVAPTVEEIVAPTVEEIVAPSVVESVA	752
Qу	602	PSAGASVVQPSVSPLEAPPPVSYDSIKLE	630
Db	753	PSVEESVEENVEESVAENVEESVAENVEESVAPTVEEIVAPSVE	804
QУ		PENPPPYEEAMNVALKALGTKEGIKEPESFNAAVQETEAPYISIACDLIK	680
Db	805	:: : : :: :: :: :: ESVAPSVEESVAENVATNLSDNLLSNLLGGIETEEIKDSILNEIEEVKENVVTTILENVE	864
Qу	681	ETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESEPVDLF	725
Db	865	ETTAESVTTFSNILEEIQENTITNDTIEEKLEELHENVLSAALENTQSEEEKKEVIDV	922
QУ	726	SDDSIPEVPQTQEEAVMLMKESLTEVSETV	755
Db	923	:: : : :	982
Qγ	756	AQHKEERLSASPQELGKPYLESFQPNLHSTKDAASNDIPTLTKKEKISLQMEE	808
Db	983	: : :: ::	1042
Qу	809	FNTAIYSNDDLLSSKEDKIKESETFSDSSPI-EIIDEFPTFVS	850
Db	1043	: : :: : : : : :: LNENVVSSILDNIENMKEGLLNKLENISSTEGVQETVTEHVEQNVYVDVDVPAMKDQFLG	1102
QУ	851	AKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPKDEVHVSDEFS	910
Db	1103	::: : : :	1154
QУ	911	ENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLT-KEAEKKLPSDTEKEDR	961

```
Db
          1155 ENIVDVLEEEKEDLTDKMIDAVEESIEISSDSKEETESIKDKEKDVSLVVEEVODNDMDE 1214
  Qу
          962 SLSAVL----SAELSKTSV-VDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIA 1015
               1: 11
                      || || :| :: : |::| : |: :
  Db
          1215 SVEKVLELKNMEEELMKDAVEINDITSKLIEETQELNEVEADLIKDME-----K 1263
  Qу
          1016 LALLSVTISFRIYKGVIQA----IQK-SDEGHPFRAYLESEVA---ISEELVQKYSN--S 1065
               Db
          1264 LKELEKALS-EDSKEIIDAKDDTLEKVIEEEHDITTTLDEVVELKDVEEDKIEKVSDLKD 1322
         1066 ALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVI 1125
  Qу
                      :||:: | :::: |
          1323 LEEDILKEVKEIKE--LESEILEDYK------ELKTIETDIL 1356
  Db
  Qy
         1126 YERHQVQIDHYLGLANKS--VKDAMAKIQAKIPGLK 1159
                1: ::: | | :: : | : | :: | ::
 Db
          1357 EEKKEIEKDHFEKFEEEAEEIKDLEADILKEVSSLE 1392
 RESULT 12
US-08-769-309A-5
  ; Sequence 5, Application US/08769309A
  ; Patent No. 5741890
    GENERAL INFORMATION:
      APPLICANT: Scott, John D.,
      APPLICANT: Nauert, Brian J.,
      APPLICANT: Klauck, Theresa M.
      TITLE OF INVENTION: Protein Binding Domains of Gravin
      NUMBER OF SEQUENCES: 24
      CORRESPONDENCE ADDRESS:
        ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
        STREET: 6300 Sears Tower/233 South Wacker Drive
        CITY: Chicago
       STATE: Illinois
       COUNTRY: United States of America
       ZIP: 60606-6402
      COMPUTER READABLE FORM:
        MEDIUM TYPE: Floppy disk
        COMPUTER: IBM PC compatible
       OPERATING SYSTEM: PC-DOS/MS-DOS
       SOFTWARE: PatentIn Release #1.0, Version #1.30
     CURRENT APPLICATION DATA:
        APPLICATION NUMBER: US/08/769,309A
        FILING DATE:
        CLASSIFICATION: 435
     ATTORNEY/AGENT INFORMATION:
       NAME: No. 5741890and, Greta E.
        REGISTRATION NUMBER: 35,302
        REFERENCE/DOCKET NUMBER: 27866/33451
      TELECOMMUNICATION INFORMATION:
        TELEPHONE: 312-474-6300
        TELEFAX: 312-474-0448
        TELEX: 25-3856
    INFORMATION FOR SEQ ID NO: 5:
     SEQUENCE CHARACTERISTICS:
       LENGTH: 1780 amino acids
  ;
       TYPE: amino acid
```

; TOPOLOGY: linear ; MOLECULE TYPE: protein US-08-769-309A-5

	Query Ma Best Loc Matches	cal :	4.5%; Score 265.5; DB 1; Length 1780; Similarity 20.8%; Pred. No. 3.4e-08; 4; Conservative 146; Mismatches 486; Indels 371; Gaps	51
<u> </u>				
QΣ	7	11	SSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEED	47
Dk)	277	SKSAESPTSPVTSETGSTFK-KFFTQGWAGWRKKTSFRKPKEDEVEASEKKKEQEPEKVD	335
Qγ	7	48	DEDLEELEVLERKPAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQ	105
Db)	336	TEEDGKAEVASEKLTASEQAHPQEPAESAHEPRLSAEYEKVELPSEEQ	383
QΣ	7	106	PSWERSPAAPAPSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASP : : : : :	150
Db)	384	VSGSQGPSEEKPA-PLATEVFDEKIEVHQEEVVAEVHVSTVEERTEEQKTEVEETAGSVP	442
QΣ	7	151	LAEPAAPPSTPAAPKRRGSGSVDETLFALPAASEPVIPSSAEKIMDLMEQP	201
Db)	443		502
Qу	7	202	GNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYLGNLSAVSSSEGTI	253
Db)	503	: : : : : : : : : : : : :	557
Qу	,	254	EETLNEASKELPERATN-PFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENTKEEVI	312
Db)	558	: : : : : : : : EEQKGESSASSPEEPEEITCLEKGLAEVQQDGEAEEGATSDGEKKREGVTPWASFKKMVT	617
Qу	•	313	VRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVAPV	362
Db)	618	:: :: : :: : PKKRVRRPSESDKEDELDKVKSATLSSTESTASEMQEEMKGSVEEPK	664
Qу	,	363	REEYADFKPFEQAWEVKDTYEGS	385
Db)	665	PEEPKRKVDTSVSWEALICVGSSKKRARRRSSSDEEGGPKAMGGDHQKADEAGKDKETGT	724
Qу	,	386	RDVLAARANVESKVDRKCLEDSLEQKSLGKDS : : : : :	417
Db)	725	DGILAGSQEHDPGQGSSSPEQAGSPTEGEGVSTWESFKRLVTPRKKSKSKLEEKSEDS	782
Qу	,	418	-EGRNEDASFPSTPEPVKDSSRAYITCASFTSATEST	453
Db)	783	IAGSGVEHSTPDT-EPGKEESWVSIKKFIPGRRKKRPDGKQEQAPVEDAGPTGANEDDSD	841
Qу	,	454	TANTFPLLEDHTSENKTDEKKIEERKAQIITEKTSPKTSNPFLVAVQD	501
Db)	842	: :: :: : VPAVVPLSEYDAVEREKMEAQQAQKGAEQPEQKAATEVSKELSESQVHMMAAAVADGTRA	901
Qу	•	502	SEADYVTTDTLSKVTEAAVSNMPEG-	526
Db	•	902	: : : : : ATIIEERSPSWISASVTEPLEQVEAEAALLTEEVLEREVIAEEEPPTVTEPLPENR	957
Qv	•	527	LTPDLVOEA-CESELNEATGTKI-AYETKVDLVOTSEAIOESLYPTAO	572

```
Db
       958 EARGDTVVSEAELTPEAVTAAETAGPLGSEEGTEASAAEETTEMVSAVSQLTDSPDTTEE 1017
       573 L-----CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVS 623
Qу
                  1018 ATPVQEVEGGVPDIEEQERRTQEVLQAVAEKVKEESQLPGTG-----GPEDVLQPVQ 1069
Db
       624 YDSIKLEPENPPPYEEA-----MNVALK------ALGTKEGIKEPESFNAAVQE 666
Qу
             Db
      1070 ----RAEAERPEEQAEASGLKKETDVVLKVDAQEAKTEPFTQGKVVGQTTPESFEKAPQV 1125
       667 TEAPYISIACDLIKETKLSTEPSPD--FSNYSEIAKFEKSVPEHAELVEDSSPES--EPV 722
Qу
          1126 TES-----PDSVETPT 1166
Db
       723 DLFSDDSIP----EVPQTQEEAVMLMKESLTEVSETVAQH----KEERLSASPQELGKPY 774
Qу
          1167 DSETDGSTPVADFDAPGTTQ-----KDEIVEIHEENEVHLVPVRGTEAEAVPAQKERPP 1220
Dh
       775 LESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFS 834
Qу
                 11:
                       : |: :| : : : || : :|::::
           Db
      1221 APSSFVFQEETKE-----QSKMEDTLEHTDKEVSVETVSILSKTEGTQEADQYA 1269
       835 DSSPIEI-----IDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPC 885
Qy
             Db
      1270 DEKTKDVPFFEGLEGSIDTGITVSREKVTEVALKGEGTEEAECKKDDALELQSHAKSPPS 1329
       886 LELPCDLSF-----KNIYPKDEVHVSDEFSENRSS-----VSKASISPSNVSALEPQTE 934
QУ
            1330 ---PVEREMVVQVEREKTEAEPTHVNEEKLEHETAVTVSEEVSKQLLQTVNVPIIDGAKE 1386
Db
       935 MGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVVF-- 992
QУ
          1387 VSSLEGSPPPCLGQEEAVCTKIQVQSSEASFTLTAAAEEEKV--LGETANILETGETLEP 1444
Db
       993 -GASLFL 998
Qу
           Dh
      1445 AGAHLVL 1451
RESULT 13
US-08-994-570-5
; Sequence 5, Application US/08994570
; Patent No. 6090929
 GENERAL INFORMATION:
   APPLICANT: Scott, John D.,
   APPLICANT: Nauert, Brian J.,
   APPLICANT: Klauck, Theresa M.
   TITLE OF INVENTION: Protein Binding Domains of Gravin
   NUMBER OF SEQUENCES: 24
   CORRESPONDENCE ADDRESS:
     ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
     STREET: 6300 Sears Tower/233 South Wacker Drive
    CITY: Chicago
    STATE: Illinois
    COUNTRY: United States of America
    ZIP: 60606-6402
```

```
COMPUTER READABLE FORM:
     MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
     SOFTWARE: PatentIn Release #1.0, Version #1.30
    CURRENT APPLICATION DATA:
    APPLICATION NUMBER: US/08/994,570
     FILING DATE:
     CLASSIFICATION:
   ATTORNEY/AGENT INFORMATION:
     NAME: No. 6090929and, Greta E.
     REGISTRATION NUMBER: 35,302
     REFERENCE/DOCKET NUMBER: 27866/33451
    TELECOMMUNICATION INFORMATION:
     TELEPHONE: 312-474-6300
     TELEFAX: 312-474-0448
     TELEX: 25-3856
  INFORMATION FOR SEO ID NO: 5:
    SEQUENCE CHARACTERISTICS:
    LENGTH: 1780 amino acids
     TYPE: amino acid
     TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-994-570-5
 Query Match 4.5%; Score 265.5; DB 3; Length 1780; Best Local Similarity 20.8%; Pred. No. 3.4e-08;
 Matches 264; Conservative 146; Mismatches 486; Indels 371; Gaps 51;
        11 SSSTDSPPRPPPA----FKYQFVTE-----PEDE----EDEEEEEEDEEED 47
QУ
           277 SKSAESPTSPVTSETGSTFK-KFFTQGWAGWRKKTSFRKPKEDEVEASEKKKEQEPEKVD 335
Db
        48 DEDLEELEVLERKPAAGLSAAAVPPAAAA--PLLDFSSDSVPPAPRGPLPAAPPAAPERO 105
QУ
            Db
        336 TEEDGKAEVASEKLTASEQAHPQEPAESAHEPRLSAEYEKV-----ELPS-----EEO 383
        106 PSWERSPAAPAPSLPPAAAVLPSKLP-----EDDEPPARPPPPPPAGASP 150 | : |: |: |: |: |: |: |
QУ
Db
        384 VSGSQGPSEEKPA-PLATEVFDEKIEVHQEEVVAEVHVSTVEERTEEQKTEVEETAGSVP 442
Qу
        151 L-----AEP--AAPPSTPAAPKRRGSGSVDETLFALPAASEPVIPSSAEKIMDLMEOP 201
                 443 AEELVGMDAEPQEAEPAKELVKLKETCVSGEDPTQGADLSPDEKVLSKPPEGVVSEVEML 502
Db
        202 GNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYLG-----NLSAVSSSEGTI 253
Qу
           Db
        503 SSQERMKVQGSPLKKLFTSTGLKKLS-----GKKQKGKRGGGDEESGEHTOVPADSPDSO 557
        254 EETLNEASKELPERATN-PFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENTKEEVI 312
Οv
           Db
        558 EEQKGESSASSPEEPEEITCLEKGLAEVQQDGEAEEGATSDGEKKREGVTPWASFKKMVT 617
       313 VRSK-----DKE---DLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVAPV 362
Qу
            Db
        618 PKKRVRRPSESDKEDELDKVKSATLSSTEST-----ASEMQEEMKGSVEEPK 664
```

QУ	363	REEYADFKPFEQAWEVKDTYEGS	385
Db	665	:	724
Qy	386	RDVLAARANVESKVDRKCLEDSLEQKSLGKDS	417
Db	725	DGILAGSQEHDPGQGSSSPEQAGSPTEGEGVSTWESFKRLVTPRKKSKSKLEEKSEDS	782
Qy	418	-EGRNEDASFPSTPEPVKDSSRAYITCASFTSATEST	453
Db	783	: : : : IAGSGVEHSTPDT-EPGKEESWVSIKKFIPGRRKKRPDGKQEQAPVEDAGPTGANEDDSD	841
QУ	454	TANTFPLLEDHTSENKTDEKKIEERKAQIITEKTSPKTSNPFLVAVQD	501
Db	842	VPAVVPLSEYDAVEREKMEAQQAQKGAEQPEQKAATEVSKELSESQVHMMAAAVADGTRA	901
QУ	502		526
Db	902	ATIIEERSPSWISASVTEPLEQVEAEAALLTEEVLEREVIAEEEPPTVTEPLPENR	957
Qу	527	LTPDLVQEA-CESELNEATGTKI-AYETKVDLVQTSEAIQESLYPTAQ	572
Db	958	EARGDTVVSEAELTPEAVTAAETAGPLGSEEGTEASAAEETTEMVSAVSQLTDSPDTTEE	1017
Qу	573	LCPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVS	623
Db	1018	ATPVQEVEGGVPDIEEQERRTQEVLQAVAEKVKEESQLPGTGGPEDVLQPVQ	1069
Qу	624	YDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESFNAAVQE :	666
Db	1070	RAEAERPEEQAEASGLKKETDVVLKVDAQEAKTEPFTQGKVVGQTTPESFEKAPQV	1125
QУ	667	TEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESEPV	722
Db	1126	TESPDSVETPT	1166
Qy	723	DLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPY : : : : : :	774
Db	1167	DSETDGSTPVADFDAPGTTQKDEIVEIHEENEVHLVPVRGTEAEAVPAQKERPP	1220
QУ		LESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFS : : : : : : : : : : : : : : : : :	
Db		APSSFVFQEETKEQSKMEDTLEHTDKEVSVETVSILSKTEGTQEADQYA	
Qy	835	DSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPC ::	885
Db	1270	DEKTKDVPFFEGLEGSIDTGITVSREKVTEVALKGEGTEEAECKKDDALELQSHAKSPPS	
Qу		LELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTE : : :: : :: : :	
Db	1330	PVEREMVVQVEREKTEAEPTHVNEEKLEHETAVTVSEEVSKQLLQTVNVPIIDGAKE	1386
Qу		MGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVVF	
Db	1387	VSSLEGSPPPCLGQEEAVCTKIQVQSSEASFTLTAAAEEEKVLGETANILETGETLEP	1444
QУ	993	-GASLFL 998	

```
RESULT 14
US-09-134-001C-4463
; Sequence 4463, Application US/09134001C
; Patent No. 6380370
; GENERAL INFORMATION:
  APPLICANT: Lynn Doucette-Stamm et al
  TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO
STAPHYLOCOCCUS
  TITLE OF INVENTION: EPIDERMIDIS FOR DIAGNOSTICS AND THERAPEUTICS
  FILE REFERENCE: GTC-007
  CURRENT APPLICATION NUMBER: US/09/134,001C
  CURRENT FILING DATE: 1998-08-13
  PRIOR APPLICATION NUMBER: US 60/064,964
  PRIOR FILING DATE: 1997-11-08
; PRIOR APPLICATION NUMBER: US 60/055,779
; PRIOR FILING DATE: 1997-08-14
; NUMBER OF SEO ID NOS: 5674
; SEQ ID NO 4463
   LENGTH: 2137
   TYPE: PRT
   ORGANISM: Staphylococcus epidermidis
US-09-134-001C-4463
 Query Match
                       4.5%; Score 265; DB 4; Length 2137;
 Best Local Similarity 19.6%; Pred. No. 4.8e-08;
 Matches 172; Conservative 141; Mismatches 451; Indels 114; Gaps
        159 STPAAPKRRGSGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLE 218
Qу
                   | | | : |:
            11 :
                                     | | :| :| :| : |
Db
        990 STSTSTSDSASTSTSE-----SESDSASTSLSESTSTSVSDSTSTSTSDSASMSASESE 1043
Qу
        219 TAASLPSLSPLSTVSFKEHGYLGNLSAV---SSSEGTIEETLNEASKELPERATNPFVNR 275
            Db
        1044 SNSKSTSLSESTSTSLS----GSTSASTSDSASTSTSESESDSTSTSLSESTSTSLSGS 1098
Qy
        276 DLAEFSELEYSEMGSSFKGSPKGESAILVE-----NTKEEVIVRSKDKEDLVC 323
              1 1: 1 1:: 11 11 :: 1
        1099 TSASTSD---SASTSTSESDSTSESTSLSESLSTSVSDSTSASTSESASTSTSESESNSA 1155
Db
        324 SAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYE 383
Qу
                 1156 STSLSGSLSTSISDSTSTSTSDSASTSTSESESDSTSTSLSE-----STSTSLSDSTS 1208
Db
        384 GSRDVLAARANVESKVDRKCLEDSLEQK---SLGKDSEGRNEDASFPSTPEPVKDSSRAY 440
Qу
                1:: | | |
                               1209 TSTSESASTSTSES--DSTSESTSLSESTSTSVSDSTSASTSDSASTSTSVSDSESASTS 1266
Db
        441 ITCASFTSATESTTANTFPLLEDHTSE--NKTDEKKIEERKAQIITEKTSPKTSNPFLVA 498
Qy
            1:: || ::||::|| || || ||::: :| :|:::|| ||:::
       1267 ISESLSTSVSDSTSTSTSDSASTSTSESDSTSESTSLSESISTSVSDSTSASTSDSASTS 1326
Db
        499 VQDSEADYVTTD-----TLSKVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYE 551
Qy
              :||:| :|
```

```
Db
       1327 TSESESDSASTSLSGSTSTSLSDSTSTSTSDSASTSTSESDSERASTSLSGSTSTSLSDS 1386
Qу
        552 TKV---DLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASV 608
           1387 TSTSTSDSASTSTSVSDS-----NSASTSLSGSLSTSVSDSTSTSDSASAST 1435
Db
Qу
        609 VQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALK-ALGTKEGIKEPESFNAAVQET 667
             Db
       1436 --- SESDSERA-----STSLSGSTSTSISDSTSTSTSDSASTSTSVSESNSTSTSISES 1486
        668 EAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSD 727
Qу
                        Db
       1487 LSTSVS-----DSTSTSTSDSASTSTSVSDSDSASTSSSESV--STSDSESTSTSTS 1536
        728 DSI---PEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQE----LGKPYLESFQ 779
Qv
                Db
       1537 DSASTSTSVSESNSTSTSLSGSTSTSVSDSTSTSTSDSASASTSESDSDSASTSSSESVS 1596
       780 PNLH----STKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFS 834
Qv
            1597 TSVSDSTSASTSESASTSTSVSDSNSASTSLSESTSTSLSDSTSMSTSDSASTSTSESDS 1656
Db
        835 DSSPIEIID-----EFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADS 882
Qv
           1657 DSASTSLSDSTSTSVSESTSTSTSVSASNSTSTSLSDSRSTSLSDSTSTSTSESGSTS 1716
Db
        883 LPCLELPCDLSFKNIYPKDEVHVSDEFSENR--SSVSKASISPSNVSALEPQTEMGSIVK 940
Qу
              1 1: :: :|| | : |: |: || || :: :|
       1717 TS--ESDSDSASTSLSESTSTSISDSTSTSTSDSASTSMSVSDSNRASTSLSDSTSTSVS 1774
Db
Qу
       941 SKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVD 978
            Db
       1775 DSTSASTSESASTSTRESESTSASTSLS-ESTSTSVSD 1811
RESULT 15
US-09-621-976-4600
; Sequence 4600, Application US/09621976
; Patent No. 6639063
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Jobert, S.
; APPLICANT: Giordano, J.Y.
  TITLE OF INVENTION: ESTs and Encoded Human Proteins.
  FILE REFERENCE: GENSET.054PR2
  CURRENT APPLICATION NUMBER: US/09/621,976
  CURRENT FILING DATE: 2000-07-21
  NUMBER OF SEQ ID NOS: 19335
  SOFTWARE: Patent.pm
; SEQ ID NO 4600
  LENGTH: 75
   TYPE: PRT
  ORGANISM: Homo sapiens
  FEATURE:
  NAME/KEY: UNSURE
  LOCATION: 58
  OTHER INFORMATION: Xaa = His, Pro
```

```
LOCATION: 28
   OTHER INFORMATION: Xaa = Met, Val
   NAME/KEY: UNSURE
   LOCATION: 19
   OTHER INFORMATION: Xaa = Pro, Gln
   NAME/KEY: UNSURE
   LOCATION: 53
   OTHER INFORMATION: Xaa = Ser, Tyr
US-09-621-976-4600
 Query Match
                      4.4%; Score 256.5; DB 4; Length 75;
 Best Local Similarity 67.0%; Pred. No. 1.2e-09;
 Matches 59; Conservative 3; Mismatches 11; Indels 15; Gaps
          1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
           Db
          1 MEDLDQSPLVSSS-DSPPRXQPAFKYQFXREPEDEE-----EDLEELEVLERK 47
QУ
         61 PAAGLSAAAV--PPAAAAPLLDFSSDSV 86
           Db
         48 PAAGLXAAPVXTAPAAGAPLMDFGNDFV 75
```

Search completed: September 29, 2004, 18:20:58 Job time: 37.8717 secs

NAME/KEY: UNSURE

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 29, 2004, 18:05:43; Search time 28.465 Seconds

(without alignments)

3930.111 Million cell updates/sec

Title:

US-09-830-972-2

Perfect score: 5848

Sequence:

1 MEDIDQSSLVSSSTDSPPRP......VKDAMAKIQAKIPGLKRKAD 1163

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched:

283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters:

283366

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database:

PIR 78:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1 2 3 4 5	789.5 685 671 517 503.5 328.5	13.5 11.7 11.5 8.8 8.6 5.6	776 208 267 2484 2607 5327	2 2 2 2	A46583 I60904 A60021 T26216 T26215 T13564	neuroendocrine-spe neuroendocrine-spe tropomyosin-relate hypothetical prote hypothetical prote microtubule-associ
7 8 9 10 11 12 13	322 320 304.5 302.5 295.5 292 291.5	5.5 5.5 5.2 5.2 5.1 5.0 5.0	7962 222 873 1829 865 3507 2364	2 2 2 2 2 2 2	138346 T26213 A47283 T24583 A47282 T34513 A56577	elastic titin - hu hypothetical prote calphotin - fruit hypothetical prote calcium-binding pr hypothetical prote microtubule-associ

14	288.5	4 0	971	2	T19431
15	284	4.9		1	_
16	281	4.9	2464	2	QRMSP1
17	279.5	4.8	3488		T34418
18	279.3	4.8	1262	2	T22523
19		4.7	1621	2	A82255
	275.5	4.7	3924	2	537431
20	275	4.7	1299	2	T47182
21	273.5	4.7	1029	2	T30351
22	273.5	4.7	1274	2	T16251
23	273	4.7	1558	2	B71603
24	272.5	4.7	3534	2	Т42567
25	270	4.6	1230	2	T22458
26	269.5	4.6	2187	2	T30826
27	267	4.6	1684	2	JW0057
28	265.5	4.5	1828	2	A40115
29	263	4.5	1825	2	S13507
30	261.5	4.5	1087	1	QFMSH
31	261	4.5	606	2	A43427
32	261	4.5	2570	2	T17451
33	260	4.4	1804	2	T34518
34	259.5	4.4	1020	1	QFHUH
35	259	4.4	1510	2	T33100
36	258.5	4.4	1830	2	A37981
37	257	4.4	1224	2	T14007
38	256	4.4	2361	2	T25752
39	254.5	4.4	6642	2	T29757
40	254	4.3	1616	2	G64242
41	254	4.3	3381	2	T42389
42	253	4.3	3421	1	WZBEB6
43	252.5	4.3	5170	2	T15348
44	251	4.3	1824	1	ORHUMT
45	250.5	4.3	4377	2	A55575
				-	

hypothetical prote microtubule-associ hypothetical prote hypothetical prote hypothetical prote ankyrin 2, neurona hypothetical prote mucin-like protein hypothetical prote RESA-H3 antigen PF tegument protein 2 hypothetical prote nascent polypeptid gravin - human microtubule-associ microtubule-associ neurofilament trip neurofilament trip fimbriae-associate nestin - golden ha neurofilament trip hypothetical prote microtubule-associ microtubule-associ hypothetical prote protein UNC-89 - C cytadherence-acces. versican precursor 367K tegument prot hypothetical prote microtubule-associ ankyrin 3, long sp

ALIGNMENTS

RESULT 1 A46583

neuroendocrine-specific protein, splice form A - human

N; Contains: neuroendocrine-specific protein, splice form B

C; Species: Homo sapiens (man)

C;Date: 24-May-1996 #sequence_revision 24-May-1996 #text_change 05-Nov-1999

C; Accession: A46583; I60903

R; Roebroek, A.J.; van de Velde, H.J.; Van Bokhoven, A.; Broers, J.L.; Ramaekers, F.C.; Van de Ven, W.J.

J. Biol. Chem. 268, 13439-13447, 1993

A;Title: Cloning and expression of alternative transcripts of a novel neuroendocrine-specific gene and identification of its 135-kDa translational product.

A; Reference number: A46583; MUID: 93293865; PMID: 7685762

A; Accession: A46583

A; Status: preliminary; translated from GB/EMBL/DDBJ

A; Molecule type: mRNA A; Residues: 1-776 < ROE1>

A; Cross-references: GB:L10333; NID:g307306; PIDN:AAA59950.1; PID:g307307

A; Accession: I60903

```
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 421-776 < ROE2>
A;Cross-references: GB:L10334; NID:g307308; PIDN:AAA59951.1; PID:g307309
C; Genetics:
A; Gene: GDB: RTN1; NSP
A; Cross-references: GDB:203968; OMIM:600865
A; Map position: 14q21-14q22
 Query Match
                    13.5%; Score 789.5; DB 2; Length 776;
 Best Local Similarity 31.2%; Pred. No. 3.5e-25;
 Matches 243; Conservative 115; Mismatches 252; Indels 169; Gaps
                                                          28;
        487 TSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESELNEATGT 546
Qу
           Db
        65 SGPARQSP--VAMETASTGVAGVSSAMDHTFSTTSKDGEG-----SCYTSLI----S 110
        547 KIAYETKVDLVQTSEAIQ-ESLYPTAQLCPSFEEAEATPSPVLPDI--VMEAPLNS---- 599
Qу
           111 DICYPPQEDSTYFTGILQKENGHVTISESP---EELGTPGPSLPDVPGIESRGLFSSDSG 167
Db
       600 --LLPSAGASVVQPSVSPLEAPPPVSY------DSIKLEPENPPPYEEA------M 641
Qу
                 Db
       168 IEMTPAESTEVNKILADPLDQMKAEAYKYIDITRPEEVKHQEQHHPELEDKDLDFKNKDT 227
Qу
       642 NVALKALGTKEGIKEPE-----SFNAAVQETEAPYISIACDLIKETKLSTE-PSP 690
           228 DISIK----PEGVREPDKPAPVEGKIIKDHLLEESTFAPYID---DLSEEQRRAPQITTP 280
Db
       691 DFSNYSEIAKFEKSVPEHAELVEDSSPESEPVDLF-SDDSIPEV----PQTQEEAVMLMK 745
QУ
              281 VKITLTEIE-----PSVETTTQEKTPEKQDICLKPSPDTVPTVTVSEPEDDSPGSITPP 334
Db
       746 ESLTEVSETVAQHK----EERLSASPQELGKPYLESFQP----NLHSTKDAASND---- 792
Qу
           335 SSGTEPSAAESQGKGSISEDELITAIKEAKGLSYETAENPRPVGQLADRPEVKARSGPPT 394
Db
       793 IPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKI----- 827
Qу
               395 IPSPLDHEASSAESGDSEIELVSEDPM--AAEDALPSGYVSFGHVGGPPPSPASPSIQYS 452
Db
       828 ---KESETFSDSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEI----ANIQSG 879
Qу
             453 ILREEREAELDS---ELIIESCDASSASEESPKREQDSPPMKPSALDAIREETGVRAEER 509
Db
       880 ADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIV 939
Qу
          | ||||||
Db
       510 APSRRGLAEPG--SFLD-YPSTEPQPGPEL------PPGDGALEPETPM---- 549
       940 KSKSLTKEAEKKLPSDTEKEDRSLSAVLSAE-----LSKTSVVDLLYWRD 984
Qy
                   550 -----LPRKPEEDSSSNQSPAATKGPGPLGPGAPPPLLFLNKQKAIDLLYWRD 597
Db
QУ
       985 IKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPF 1044
          Dh
       598 IKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVLQAVQKTDEGHPF 657
```

```
Qу
        1045 RAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGA 1104
             Db
         658 KAYLELEITLSQEQIQKYTDCLQFYVNSTLKELRRLFLVQDLVDSLKFAVLMWLLTYVGA 717
Qу
        1105 LFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
             :
                                                  Db
         718 LFNGLTLLLMAVVSMFTLPVVYVKHQAQIDQYLGLVRTHINAVVAKIQAKIPGAKRHAE 776
RESULT 2
I60904
neuroendocrine-specific protein C - human
C; Species: Homo sapiens (man)
C;Date: 24-May-1996 #sequence_revision 24-May-1996 #text change 05-Nov-1999
C; Accession: I60904
R; Roebroek, A.J.; van de Velde, H.J.; Van Bokhoven, A.; Broers, J.L.; Ramaekers,
F.C.; Van de Ven, W.J.
J. Biol. Chem. 268, 13439-13447, 1993
A; Title: Cloning and expression of alternative transcripts of a novel
neuroendocrine-specific gene and identification of its 135-kDa translational
A; Reference number: A46583; MUID: 93293865; PMID: 7685762
A; Accession: I60904
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-208 < RES>
A; Cross-references: GB:L10335; NID:g307310; PIDN:AAA59952.1; PID:g307311
C; Genetics:
A; Gene: GDB: RTN1; NSP
A; Cross-references: GDB:203968; OMIM:600865
A; Map position: 14g21-14g22
  Query Match
                       11.7%; Score 685; DB 2; Length 208;
 Best Local Similarity 67.0%; Pred. No. 1e-21;
 Matches 128; Conservative 32; Mismatches 31; Indels
                                                         0; Gaps
                                                                    0;
         973 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1032
Qу
            Db
         18 KSQAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVL 77
        1033 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKF 1092
Qу
            78 QAVQKTDEGHPFKAYLELEITLSQEQIQKYTDCLQFYVNSTLKELRRLFLVQDLVDSLKF 137
Db
Qу
        1093 AVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQ 1152
            138 AVLMWLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQIDQYLGLVRTHINAVVAKIQ 197
Db
Qу
        1153 AKIPGLKRKAD 1163
            11111 11 1:
Db
        198 AKIPGAKRHAE 208
RESULT 3
A60021
tropomyosin-related protein, neuronal - rat
C; Species: Rattus norvegicus (Norway rat)
```

```
C;Date: 03-Mar-1993 #sequence revision 03-Mar-1993 #text change 05-Nov-1999
C; Accession: A60021
R; Wieczorek, D.F.; Hughes, S.R.
Brain Res. Mol. Brain Res. 10, 33-41, 1991
A; Title: Developmentally regulated cDNA expressed exclusively in neural tissue.
A; Reference number: A60021; MUID: 91278684; PMID: 1647480
A; Accession: A60021
A; Molecule type: mRNA
A; Residues: 1-267 <WIE>
A;Cross-references: EMBL:X52817; NID:g456549; PIDN:CAA37001.1; PID:g456550
C; Comment: This neuronal-specific mRNA was identified by hybridization to an
alpha-tropomyosin probe but does not show homology in amino acid sequence.
  Query Match
                         11.5%; Score 671; DB 2; Length 267;
  Best Local Similarity
                         66.3%; Pred. No. 5.6e-21;
  Matches 124; Conservative 33; Mismatches
                                               30; Indels
                                                              0; Gaps
                                                                         0;
          973 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1032
Qу
             Db
           9 KSQAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVL 68
         1033 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKF 1092
Qу
             11:11:11111:1111 1: :1:1 :111::
                                               Db
          69 QAVQKTDEGHPFKAYLELEITLSQEQIQKYTDCLQLYVNSTLKELRRLFLVQDLVDSLKF 128
        1093 AVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQ 1152
Qу
             Db
         129 AVLMWLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQVDQYLGLVRTHINTVVAKIQ 188
        1153 AKIPGLK 1159
Qу
             11111:
Db
         189 AKIPGAR 195
RESULT 4
T26216
hypothetical protein W06A7.3c - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text change 15-Oct-1999
C; Accession: T26216
R; Ainscough, R.
submitted to the EMBL Data Library, August 1996
A; Reference number: Z20173
A; Accession: T26216
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-2484 <WIL>
A; Cross-references: EMBL: Z78066; PIDN: CAB51467.1; GSPDB: GN00023; CESP: W06A7.3c
A; Experimental source: clone W06A7
C; Genetics:
A; Gene: CESP: W06A7.3c
A; Map position: 5
A; Introns: 1827/1; 1866/3; 1963/3; 1990/3; 2262/1; 2289/1; 2339/2; 2463/2
  Query Match
                         8.8%; Score 517; DB 2; Length 2484;
 Best Local Similarity
                        20.1%; Pred. No. 2.7e-13;
 Matches 262; Conservative 189; Mismatches 413; Indels 440; Gaps
```

Qу	28	FVTEPEDEEDEEEEEDEEEDDEDLEELEVL	- 57
Db	1437	FGTESSEESQKADGNQENQEEEDVVAELNFHPIRQWRDEDVISLQSLKSLVAEVGCITDV	1496
Qу	58	ERKPAAGLSAAAVPPAAAAPL-LDFSSDSVPPAPRGPLPAAPPAAPERQPSW	108
Db	1497	: : : : :: :	1 1554
Qу	109	KLP-EDDEPPARPPPPPPA	146
Db	1555	: : : :	1614
Qу	147	GASPLAEPAAPPSTPAAPKRRGSGSVDETLFALPAASEPVIPS-SAEKIMDLMEQPGNTV	205
Db	1615	: :: : :	1670
Qу		SSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELP	
Db	1671	:	1695
Qу	266	ERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENTKEEVIVRSKDKE	319
Db	1696	EKPTEDIGALSPLSPNTLAEYEEVPMMDMQS	1726
Qу	320	DLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQ-MSVVAPVREEYADFKPFEQAWEV	378
Db	1727	:::: :	1763
Qу	379	KDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDS	436
Db	1764	KDNESLEAPEIINEPIRRVLVETKIMGPGKSLNEDNDD	1801
Qу		SRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKAQIITEKTSPKTSNPFL : :	
Db	1802	: :	1824
Qу	497	VAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESELNEATGTKI ::	548
Db	1825	TSIDDPSIRRDSFSSISSFGDRQKFRTAIENIRQDLLP	1862
Qу	549	AYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASV ::: :: :: :: ::	608
Db	1863	-FQSSVSQYLRSSPNPSQQLLVTNLSMDSP-SDLSPNA	1898
Qу	609	VQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESFNAA	663
Db	1899	:::	1937
Qу	664	VQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPE	707
Db	1938	LDEFAAPPVHDPMQKSVFGSLGSDDMKPGSQDDGFVFIERNEANEATLKKNQKMSSH	1994
Qу	708	HAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTE	750
Db	1995	::: : : :: ::: :: HNDVIEKNYFNDNAPTAALLESPIAEEARKLVQDAVESASEYKKQAVDSGDEIGRELLDN	2054

```
751 VSETVAQHKE-----ERLSASPQELGKPYLESFQP 780
Qy
             1::11
                                                1 1:
Db
        2055 VEQKIEQVKEPIVDSLHKAYDGVGDFVHETVPNAVDDFVREAEKQLPESPVPEKIETPEP 2114
Qу
         781 --NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDK-----IKES 830
                                    | : ||:
              ::| | | ::: ::|
                                                   :11
Db
        2115 LVDIHDTVDKVHDEVDNFLRREP-----TPPFETDDVAPLSDDKPQFGNQTPEEDE 2165
         831 ETFSDSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGA----DSLPCL 886
Qу
                                      :: | |:
                   1: 1:1
                             : | : : :
        2166 TTFDRKGPLTIPEEVEKAAAAQNND---LDDFDPLVTSNTGAAFGAAVGAAAAVESLTEE 2222
Db
         887 ELPCDLSFKNI-----YPKDEVHVSDEFSENRSSVSKASISPSNVSA-----LEPQTEM 935
Qy
                   1::
                           111 :111
                                              : [] [:
        2223 EMFGHQKFETVPRPPTPPKD---ISDE-----DVKPSTVNLGPSHHHSHPSSPH 2268
Db
         936 GSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGAS 995
Qy
             11:1
                                      2269 HSILKHHG-----DAWIDFKTVPPCVLDVIYWRDAKKSAIVLSLA 2308
Db
Qу
         996 LFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAIS 1055
             Db
        2309 LLVLFVLAKYPLLTVVTYSLLLALGAAAGFRVFKKVEAQIKKTDSEHPFSEILAQDLTLP 2368
        1056 EELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILA 1115
QУ
            Db
        2369 QEKVHAQADVFVEHATCIANKLKKLVFVESPLESIKFGLVLWSLTYIASWFSGFTLAILG 2428
Qу
        1116 LISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLK 1159
            1: :||:| :|| :| :| : :|: | | |:| |:
Db
        2429 LLGVFSVPKVYESNQEAIDPHLATISGHLKNVQNIIDEKLPFLR 2472
RESULT 5
T26215
hypothetical protein W06A7.3a - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C; Date: 15-Oct-1999 #sequence revision 15-Oct-1999 #text change 15-Oct-1999
C; Accession: T26215
R; Ainscough, R.
submitted to the EMBL Data Library, August 1996
A; Reference number: Z20173
A; Accession: T26215
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-2607 <WIL>
A;Cross-references: EMBL:Z78066; PIDN:CAB01522.2; GSPDB:GN00023; CESP:W06A7.3a
A; Experimental source: clone W06A7
C; Genetics:
A; Gene: CESP: W06A7.3a
A; Map position: 5
A; Introns: 1827/1; 1866/3; 1963/3; 1990/3; 2262/1; 2289/1; 2412/1; 2462/2;
2586/2
 Query Match
                        8.6%; Score 503.5; DB 2; Length 2607;
 Best Local Similarity 20.8%; Pred. No. 1e-12;
 Matches 280; Conservative 181; Mismatches 481; Indels 407; Gaps
                                                                    52;
```

Qу	28	FVTEPEDEEDEEEEEDEEEDDEDLEELEVL	57
Db	1437	FGTESSEESQKADGNQENQEEEDVVAELNFHPIRQWRDEDVISLQSLKSLVAEVGCITDV	1496
Qу	58	ERKPAAGLSAAAVPPAAAAPL-LDFSSDSVPPAPRGPLPAAPPAAPERQPSW	108
Db	1497	: : : : :: :	1554
Qу	109	KLP-EDDEPPARPPPPPPA	146
Db	1555	: : : :	1614
QУ	147	GASPLAEPAAPPSTPAAPKRRGSGSVDETLFALPAASEPVIPS-SAEKIMDLMEQPGNTV	205
Db	1615	: :: : : QVQERIIPIEVEQAPTIPQRPPRAPKSELPKVAKPLDDSKSRVRFAPLNIKLGRTY	1670
Qу		SSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELP	
Db	1671	:	1695
Qу	266	ERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENTKEEVIVRSKDKE	319
Db	1696	: : : : : : EKPTEDIGALSPLSPNTLAEYEEVPMMDM-QSVPHSPQEKQEEIEALSEIIE	1746
Qу	320	DLVCSAALHSPQES-PVGKEDRVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQA	375
Db	1747	: : : : : : : : EPQAMKEVEKPVESAPEKDNESLEAPEIINEPIRRVLVETKIMGPGKSL	1795
Qу	376	WEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSE	418
Db	1796	: : : :: :: : : NEDNDDDDDGSECLDSIGDLSERTIQR-FNTSIDDPSIRRDSFSSISSFGDRQKFRTAIE	1854
Qу	419	GRNEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLE	462
Db	1855	: : : : :: :	1911
Qу	463	TEKTSPKTSNPF	495
Db		: : :: : : : : : KLQQEDRPSAEGSIDSSGFEKVDHEGLDEFAAPPVHDPMQKSVFGSLGSDDMKPGSQDDG	
Qу	496	LVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQ	533
Db	1972	:: : : : : : : : : FVFIERNEANEATLKKNQKMSSHHNDVIEKNYFNDNAPTAALLESPIAEEARKLVQDAVE	2031
Qу	534	EACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVL	588
Db	2032	: : :: : : : : : : SASEYKKQAVDSGDEIGRELLDNVEQKIEQVKEPIVDSLHKAYDGVGDFVH-ETVPNAV-	2089
Qу	589	PDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKAL	648
Db	2090		2106
Qу	649	GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEK	703
Db	2107	: : : :	2142

```
704 SVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLT---EVSETVAQHKE 760
                   QУ
       2143 -----TDDVAPLSDDKPQFGNQT-PE---EDETTFDRKGPLTIPEEVEKAAAAQNN 2189
Db
        761 ERLSASPQELGKPYLESFQPNLHSTKDA-----ASNDIPTLTKKEKISLQMEEFNTAI 813
                        QУ
       2190 D-----LDDFDPLVTSNTGAAFGAAVGAAAAVESLTEEEMFGHQ--KFETVP 2234
Db
        814 YSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDSP--KLAKEYTDLEVSDKS 871
                              :: |: : || : | : | : | : |:
Qу
                     :: :| |
        2235 RPPTPPKDISDEDVKPS-----TVNLGPSHHHSHPSSPHHSILKHHGDAWIDFKT 2284
Db
         872 EIANIQSG-----ADSLPCLE----LPCDLSFKNIYPKDEVH 904
                                       QУ
        2285 VPPCAQNAFSPGEIMFLLAFFVYLSCFASFFSKSLPLLDNLLSLVVYLSISLI----IH 2339
                 1:
Db
         905 VSDE----FSENRSSVSKASISPSNVSA-----LEPQTEMGSIVKSKSLTKEAEK 950
            | :::|| : :|
QУ
        2340 VKHHRKFRWNEEQATTMSKLGAVGRGLYALIAFIVNIVLRVGLNVALVVGVAVSAHEAYK 2399
Db
         951 KLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSV 1010
              Qу
        2400 LTKS-----SGVLRKKEVLDVIYWRDAKKSAIVLSLALLVLFVLAKYPLLTV 2446
Db
        1011 TAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHV 1070
                        Qу
              1 1
        2447 VTYSLLLALGAAAGFRVFKKVEAQIKKTDSEHPFSEILAQDLTLPQEKVHAQADVFVEHA 2506
Db
        1071 NSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQ 1130
                 :1::1 |: ::|:|| :::| ||: : |:| || || ||: :||:| :|| :|
 QУ
        2507 TCIANKLKKLVFVESPLESIKFGLVLWSLTYIASWFSGFTLAILGLLGVFSVPKVYESNQ 2566
 Db
        1131 VQIDHYLGLANKSVKDAMAKIQAKIPGLK 1159
 Qy
               11:1: :: :: ! :: !: !:
         2567 EAIDPHLATISGHLKNVQNIIDEKLPFLR 2595
 Db
 RESULT 6
 microtubule-associated protein homolog - fruit fly (Drosophila melanogaster)
 N; Alternate names: hypothetical protein EG: 49E4.1
 C; Species: Drosophila melanogaster
 C;Date: 13-Aug-1999 #sequence_revision 13-Aug-1999 #text_change 17-Nov-2000
 C; Accession: T13564
 R; Spanos, L.; Papagiannakis, G.; Siden-Kiamos, I.; Louis, C.
 submitted to the EMBL Data Library, April 1999
 A; Description: Sequencing the distal X chromosome of Drosophila melanogaster.
 A; Reference number: Z17689
 A; Accession: T13564
 A; Status: preliminary; translated from GB/EMBL/DDBJ
 A; Molecule type: DNA
 A; Residues: 1-5327 <SPA>
 A; Cross-references: EMBL: AL031128; PIDN: CAA20006.1
  C; Genetics:
 A; Cross-references: FlyBase: FBgn0025392
 A; Introns: 24/2; 52/3; 104/3; 179/1; 232/1; 1669/3; 2566/1; 4798/3; 5272/1
  A; Note: EG: 49E4.1
```

C; Superfamily: Drosophila 576K microtubule-associated protein homolog

	Boot Local S	5.6%; Score 328.5; DB 2; Length 5327; imilarity 22.7%; Pred. No. 4.1e-05; Conservative 176; Mismatches 453; Indels 238; Gaps	54;
Qу	2	EDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVL	57
Db	3196	:: : : : :	3253
Qу	58	ERKPAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAP	102
Db	3254	: :: : : : : PSKEASRPTSVAKSVKDEAEKSKEESSRDSVAEKSPLASKEASRPASVAESVQDEAEK	3311
Qу	103	ERQPSWERSPAAPAPSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLA-EPAA	156
Db	3312	: : : : :: :: :: :	3370
Qγ	157	PPSTPAAPKRRGSGSVDETLFALPAAS-EPVIPSS-AEKIMDLMEQPGNTVSSG	208
Db	3371	:: : : : : : : : :	3430
Qζ	209	QEDFPSVLLETAASLPSLSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEAS	261
Dk	3431	SVAEKSPLASKEASRPASVAESVKDDAEKSKEESRRESVAEKSPLASKEASRPASVAESV	3490
Qy	262	KELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENTKEEVIVRSKDKE	319
Dk	3491	: :: : : : : : : : : : : : : : : : : : : : : : : : :	3541
Q	320	DLVCSAALHSPQES-PVGKEDRVV-SPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWE : :: : : : :	377
D	3542	SVAEKSSLASKEASRPASVAESVKDEAEKSKEESRRESVAEKSPLASKEAS-RPASVAES	3600
Q:	378	VKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGRNE	422
DÌ	3601	VKDEAEKSKEVSRRESVAEKSPLPSKEASRPTSVAESVKDEADKSKEESRRESGAEKSPL	3660
Q:	•	DASFP-STPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTD-	
D.	3661	ASMEASRPTSVAESVKDETEKSKEESRRESVTEKS-PLPSKEASRPTSVAESVKDE	3715
Q	y 472	-EKKIEERKAQIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEG-	526
D	b 3716	AEKSKEESRRESVAEKSPLASKESSRPASVAESIKDEAEGTKQESRRESMPESG	3769
Q	y 527	LTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYP	569
D	b 3770	KAESIKGDQSSLASKETSRPDSVVESVKDETEKPEGSAIDKSQVASRPESVAVSAKD	3826
Q	•	TAQLCPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKL	
D	-	EKSPLHSRPESVADKSPDASKEASRSLSVAETASSPIEEGPRSIAD	
Ç	-	EPENPPPYEEAMNVALKALGTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPS ::: : : : : :: : : :	
Г	b 3873	LSLPLNLTGEAKG-KLP-TLSSPIDVAEGDFLEVKAESSPR	3911

```
690 PDFSNYSEIAKFEKSVPEH--AELVEDSSPESEPVDLF-----SDDSIPEV 733
Qу
                         | : |: |:| : | : |:::| | :::
                3912 P--AVLSKPAEFSQPDTGHTASTPVDEASPVLEEIEVVEQHTTSGVGATGATAETDLLDL 3969
Db
                  734 PQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQPNLHSTKDAASNDI 793
QУ
                           3970 TETKSETV--TKQSETTLFETLTSKVESKVEVLESSV-KQVEEKVQTSVKQAETTVTDSL 4026
Db
                  794 PTLTKKEKISLQMEE-----FNTAIYSNDDLLSSKEDKIKESETFSDSSP 838
Qу
                            4027 EQLTKKS--SEQLTEIKSVLDTNISNVTNLFSTAVETIEKKVQDVTEKVIEKAT----- 4078
Db
                  839 IEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIY 898
Qу
                           | : | | : : | : ::| : | | : : | | : : | | : : | | : : | | : : | | : : | | : : | : : | | : : | : : | : : | : : | : : | : : | : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : | : : |
                4079 -EHVSEHVT--TTGESSTETSQEKSSLDLGTFSELRETHITTVGSPEFTV-----TIC 4128
Db
                  899 PKDE--VH-VSDEFSENR----SSVSKAS-ISPSNVSALEPQTE-----MGSIVKS- 941
Qу
                           4129 ERDEPVLHDIKEEDEEHRFSPPSDVDKAAIIPPQPMRPLSPREEEVAKIVADVAKVLKSD 4188
Db
                 942 KSLT-----KEAEKKLPS--DTEKE-DRSLSAVLSAELS 972
Qу
                                             4189 KDITDIIPDFDERQLEEKLKSTADTEEESDKSTRDEKSLEIS 4230
Db
RESULT 7
I38346
elastic titin - human (fragment)
C; Species: Homo sapiens (man)
C; Date: 29-May-1998 #sequence revision 29-May-1998 #text change 21-Jul-2000
 C; Accession: I38346
 R; Labeit, S.; Kolmerer, B.
 Science 270, 293-296, 1995
A; Title: Titins: giant proteins in charge of muscle ultrastructure and
 elasticity.
 A; Reference number: A57430; MUID: 96026330; PMID: 7569978
 A; Accession: I38346
 A; Status: preliminary; translated from GB/EMBL/DDBJ
 A; Molecule type: mRNA
 A: Residues: 1-7962 < RES>
 A; Cross-references: EMBL: X90569; NID: g1017426; PIDN: CAA62189.1; PID: g1017427
 C; Genetics:
 A:Gene: GDB:TTN
 A; Cross-references: GDB:127867; OMIM:188840
 A; Map position: 2q31-2q31
    Query Match 5.5%; Score 322; DB 2; Length 7962; Best Local Similarity 21.7%; Pred. No. 0.00014;
     Matches 259; Conservative 146; Mismatches 416; Indels 370; Gaps
                     23 AFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVL-----ERKPAAGL 65
 QУ
                           6574 AFEEEVVTHVEEYLVEEEEEYIHEEEEFITEEEVVPVIPVKVPEVPRKPVPEEKKPVPVP 6633
 Db
                     66 SAAAVPPAAA-----APLLDFSSDSVPPA----PRGPLP-----AAP 98
  Qу
                                                              |:| : || |: |:|
                                   111
```

Db	6634	KKKEAPPAKVPEVPKKPEEKVPVLIPKKEKPPPAKVPEVPKKPVPEEKVPVPVPKKVEAP	6693
QУ	99	PA-APERQPSWERSPAAPAPSLPPA-AAVLPSKL-PEDDEPPARPPPPP	144
Db	6694	PAKVPEVPKKPVPEKKVPVPAPKKVEAPPAKVPEVPKKLIPEEKKPTPVPKKVEAPPPKV	6753
Qу	145	PAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNT	204
Db	6754	PKKREPVPVPVALPQEEEVLFEEEIVPE-EEVLPEEEE	6790
Qy	205	VSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNE : : : ! !	259
Db	6791	VLPEEEEVLPEEEEVLPEEEEIPPEEEEVPPEEEYVPEEEEFVPEEEVLPE	6841
QУ	260	ASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENTKEEVIV :: : : : : : : : :	313
Db	6842	VKPKVPVPAPVPEIKKKVTEKKVVIPKKEEAPPAKVPEVPKKVEEKRII	6890
QУ	314	RSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEM	354
Db	6891	LPKEEEVLPVEVT-EEPEEEPISEEEIPEEPPSIEEVEEVAPPRVPEVIKKAVPEAPTPV	6949
QУ	355	QMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESK : ::: : : : :	398
Db	6950	PKKVEAPPAKVSKKIPEEKVPVPVQKKEAPPAKVPEVPKKVPEKKVLVPKKEAVPPA	7006
QУ	399	VDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCA	444
Db	7007	KGRTVLEEKVSVAFRQEVVVKERLELEVVEAEVEEIPEEEEFHEVEEYFEEG	7058
ДÄ	445	SFTSATESTTANTFPLLEDHTSENKTDEKKIEERKAQIITEKTSPKT	491
Db	7059	EFHEVEEFIKLEQHRVEEEHRVEKVHRVIEVFEAEEVEVFEKPKAPPKGPEISEKIIPPK	7118
QУ	492	SNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLV	532
Db	7119	KPPTKVVPRKEPPAKVPEVPKKIVVEEKVRVPEEPRVPPTKVPEVLPPKEVVPEKKVPVP	7178
QУ	533	QEACESELNEATGTKIAYETKVDLVQTSEAIQESLYP	569
Db	7179	PAKKPEAPPPKVPEAP-KEVVPEKKVPVPPPKKPEVPPTKVPEVPKAAVPEKKVPEAIPP	7237
QУ	570	TAQLCPSFEEAEATPSPV-LPDIVMEAPLNSLLPSAGASVVQPSVSPLE : : : :: : : :: :: :: :: :	617
Db		KPESPPPEVFEEPEESPSAPPKKPEVPPVRVPEVPKEVVPEKKVPAAPPKKPEVTPVK	
Qу	618	APDSIKLEPENPPPYEE	639
Db	7296	VPEAPKEVVPEKKVPVPPPKKPEVPPTKVPEVPKVAVPEKKVPEAIPPKPESPPPEVFEE	7355
QУ	640	AMNVALKALGTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEP	688
Db	7356	PEEVALEE-PPAEVVEEPEPAAPPQVTVPPKNPVPEKKAPAVVAKKPELPPVK	7407
QУ	689	SPDFSNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESL	748
Db	7408	VPEVPKEVVP-EKKVPKVPEVPKEVV	7444

```
749 TEVSETVAQHKEERLSASPQELGKPYLESFQPNLHSTKDAASNDIPTLTKKEKISLQMEE 808
QУ
                 1: | : |: || || :| : | |
                                                    : |:|: : |
        7445 PEKKVAVPKKPEVPPAKVPEVPKKPVLEE-KPAVPVPERAESPPPEVYEEPEEIAPEEE- 7502
Db
        809 FNTAIYSNDDLLSSKEDK---IKESE-----TFSDSSPIEIIDEFPTFVSAKDDSPKLA 859
Qу
                     :: :|:| : | |
                                             1:11
                                                      | | | ::|
        7503 -----IAPEEEKPVPVAEEEEPEVPPPAVPEEPKKIIPEKKVPVIKKPEAPP-P 7550
Db
        860 KEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFK-NIYPKDEVHVSDEFSENRSSVSK 918
QУ
                 7551 KEPEPEKVIEKPKLKPRPPPPPPAPPKEDVKEKIFQLKAIPKKKV-----PENPQVPEK 7604
Db
         919 ASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLP--SDTEKEDRSLSAVL 967
Qу
              ::| | | | |
                                            ||: | : ||
        7605 VELTPLKVPGGE------KKVRKLLPERKPEPKEEVVLKSVL 7640
Db
RESULT 8
T26213
hypothetical protein W06A7.3b - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
C; Accession: T26213
R; Ainscough, R.
submitted to the EMBL Data Library, August 1996
A; Reference number: Z20173
A; Accession: T26213
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A: Residues: 1-222 <WIL>
A; Cross-references: EMBL: 278066; PIDN: CAB01523.1; GSPDB: GN00023; CESP: W06A7.3b
A; Experimental source: clone W06A7
C: Genetics:
A; Gene: CESP: W06A7.3b
A; Map position: 5
A; Introns: 27/1; 77/2; 201/2
                       5.5%; Score 320; DB 2; Length 222;
  Query Match
  Best Local Similarity 32.1%; Pred. No. 1e-06;
  Matches 59; Conservative 47; Mismatches 78; Indels 0; Gaps
                                                                    0;
         976 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 1035
Qу
            27 ILDVIYWRDAKKSAIVLSLALLVLFVLAKYPLLTVVTYSLLLALGAAAGFRVFKKVEAQI 86
Db
        1036 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVL 1095
Qу
                      :1:1 111
          87 KKTDSEHPFSEILAQDLTLPQEKVHAQADVFVEHATCIANKLKKLVFVESPLESIKFGLV 146
Db
        1096 MWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKI 1155
Qу
             147 LWSLTYIASWFSGFTLAILGLLGVFSVPKVYESNQEAIDPHLATISGHLKNVQNIIDEKL 206
Db
        1156 PGLK 1159
Qy
             1 1:
         207 PFLR 210
Db
```

```
RESULT 9
A47283
calphotin - fruit fly (Drosophila melanogaster)
C; Species: Drosophila melanogaster
C; Date: 21-Sep-1993 #sequence revision 25-Apr-1997 #text_change 21-Jul-2000
C; Accession: A47283
R; Ballinger, D.G.; Xue, N.; Harshman, K.D.
Proc. Natl. Acad. Sci. U.S.A. 90, 1536-1540, 1993
A; Title: A Drosophila photoreceptor cell-specific protein, calphotin, binds
calcium and contains a leucine zipper.
A; Reference number: A47283; MUID: 93165730; PMID: 8434015
A; Contents: photoreceptor cells
A; Accession: A47283
A; Status: preliminary
A; Molecule type: nucleic acid
A; Residues: 1-873 <BAL>
A; Cross-references: GB:L05080; NID:g157071; PIDN:AAA28420.1; PID:g157072
A; Note: sequence extracted from NCBI backbone (NCBIN:124958, NCBIP:124959)
C; Superfamily: collagen alpha 1(I) chain; fibrillar collagen carboxyl-terminal
homology; von Willebrand factor type C repeat homology
                     5.2%; Score 304.5; DB 2; Length 873;
 Query Match
 Best Local Similarity 21.9%; Pred. No. 3.1e-05;
 Matches 213; Conservative 126; Mismatches 362; Indels 273; Gaps
                                                               42;
         62 AAGLSAAAVPPAAAAPLLDFSSDSVPPAPR--GPLPAAP----PAAP----ERQPSWER 110
Qу
            11 SAPVAAPVTPSAVAAPVQVVSPAAVAVAPAVVAPAPAAPTAVTPVAPPPTLASVQPATVT 70
Db
        111 SPAAPAP----SLPPAAAVLPSKLPEDDEPPARPPPPPPP------AGASPLAEPAAPP 158
QУ
            71 VP-APAPIAAASVAPVASVAPPVVAAPTPPAASPVSTPPVAVAQIPVAVSAPVAPPVAAT 129
Db
        159 STPAAPKRRGSGSVDETLFALP--AASEP----VIPSSAEKIMDLMEQPGNT---VSSGQ 209
Qу
            130 PTPVAPI----PVAAPVIATPPVAASAPTPAAVTPVVSPVIATPPVVPANTTVPVAAPV 184
Db
        210 EDFPSVLLETAASL-PSLSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERA 268
Qу
              185 AAVPAAVPVVAPVLAPAVAPAVAPVVAETPAPPPVAEIPVA--TIPECVAPLIPEVSVVA 242
Db
        269 TNPFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENTKEEVIVRSKDKEDLVCSAALH 328
Qy
                                           243 TKPLA-----AAEPVVVAPPATETPVVAPAAA 269
Db
         329 SPQESPVGKEDRVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDV 388
QУ
            || | |:| ::::||||
         Db
         389 LAARANVESKVDRKCLEDSLEQKSL----GKDSEGRNEDASFPSTPEPVKDSSRAYITCA 444
Qу
               |:|| :| :| :| ::
         288 ---SASTEPPVAAATLTTAPETPALAPVVAESQVAANTVVATPPTPAPEPETIAPPVVAE 344
Db
         445 SFTSATESTTANTFPLLEDHTSENKTDEKKIEERKAQIITEKTSPKTSNPFLVAVQDSEA 504
QУ
```

```
345 TPEVASVAVAETTPPVVPPVAAES-----IPAPVVATTPVPATLAVTDPD- 389
Db
        505 DYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQ 564
QУ
                    390 ------P 420
Db
        565 ESLYP-TAQLCPSF--EEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAP-- 619
QУ
             | | |: |: || ||:| ::| |: :| : ||:| ||
        421 PVLPPVAAEPVPAVVAEETPETPAPASAPVTI-AALD--IPEVAPVIAAPSDAPAEAPSA 477
Db
        620 -- PPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESFNAAVQETEAPYISIACD 677
Qу
                                                 |:| || || :: :
                   11
        478 AAPIVS----TPPT------TASVPETTAPPAAVPTE 504
Db
        678 -----LIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAE--LVEDSSPESEPVDLFSD-DS 729
Qy
                505 PIDVSVLSEAAIETPVAPPVEVTTEVAVADVAPPEAAEDLIIEPVEPPAPIPDLLEQTTS 564
Db
        730 IPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQPNLHSTKDAA 789
Qу
            565 VPAVEAAESTSSPIPETSLPPPNEAVA---SPEVAVAPITAPEPIPEP-EPSLATPTEPI 620
Db
        790 SNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFV 849
Qу
                   :: |:: |:: | | | |
        621 PVEAPV------VIQEAVDAVEVPVTETSTSIPETTVEFPEAV 657
Db
        850 SAKDDSPKLAKEYTDLEV-SDKSEIANIQSGAD----SLPCLELPCDLSFKNIYPKDEVH 904
Qу
            : | |: |: |: ::||| || : |:|:
        658 AEKVLDPAI----TEAPVTTQEPDVANINDGAPATEITTPAVEI------VT 699
Db
        905 VSDEFSENRSSVSKASISPSNVSALE-PQTEM--GSIVKSKSLTKEAEKKLPSDTEKEDR 961
Qу
            : | {: : : | :: | |:| :: :| | | :: :
        700 AAAEVSDTAIPLIDPPV-PQEIAVAEIPETETKPAEVIVEQS-TIPIEAPVPEVSKYAEP 757
Db
        962 SLSAVLSAELSKTS 975
Qу
            :| :|[: |:
        758 VISEAPAAEVPITA 771
Db
RESULT 10
T24583
hypothetical protein T06D8.1 - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C; Date: 15-Oct-1999 #sequence revision 15-Oct-1999 #text_change 15-Oct-1999
C; Accession: T24583
R; Palmer, S.
submitted to the EMBL Data Library, April 1995
A; Reference number: Z19909
A:Accession: T24583
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-1829 <WIL>
A;Cross-references: EMBL:Z49130; PIDN:CAA88964.1; GSPDB:GN00020; CESP:T06D8.1
A; Experimental source: clone T06D8
C; Genetics:
A; Gene: CESP: T06D8.1
A; Map position: 2
```

A;Introns: 1391/3; 1432/3; 1470/3; 1505/1; 1520/1; 1616/1; 1644/1; 1687/3; 1742/1

Local S	Similarity 21.1%; Pred. No. 0.00011;	38
2	EDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEE	42
212	: :: :	271
43	DEEEDDEDLEELEVLERKPAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPP	99
272	GSGEDTTVVAVVELSGEQPASSSTSIPTELSKDDQVTEASGEETTTAAATE	322
100	AAPERQPSWERSPAAPAPSLPPAAAVLPSKLPEDDE-PPARPPPP	143
323	ASEETTTSAVTEGSGEETTVVAVVESSGEEPASSSTSIPTELSKDDQVTEASGEET	378
144	PPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALPAASEPVIPSSAEKIMD	196
379	TTAAATEASEETTTSAVTEGSGE-DTTVVAVVESSGEQPASSSTSIPTELSKDDQ	432
197	LMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEH	237
433	VTEASGEETTTAAATEASEETTTSAVTEGSGEDTTVVAVVESSGEQPASSSTSIPT	488
238	GYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPK	297
489	-ELSKDDQVTEASGEETTTAAATEASEETTTSAVTEGSGEETTV-VAVVESSGEEPAS	544
298	GESAILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDI ::	350
545	SSTSIPTELSKDDKVTEASGEETTTAAATDASSEETTTSAVTEGSGEETTVVAVVESSD-	603
604	-EEPASSSTSIPTELSKDDQVTEASGEETTTAAATEASEETTTSAVTEGSGEE	655
656	TTVVAVVESSGEEPASSSTSIPTELSKDDKVTEASGEETTTAAATDASSEETTTSAV	712
	TEGSGEETTVVAVVESSDEEPASSSTSIPTELSKDDQVTEASGEETTTAAATEASEETTT	
	ASEETTTSAVTEGSGEDTTVVAVVESSGEQPASSSTSIPTELS	
638	EEAMNVALKALGTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSE	697
	Local Shes 233 hes 233 2 212 43 272 100 323 144 379 197 433 238 489 298 545 351 604 411 656 471 713 530 773 578 829	Local Similarity 21.1%; Pred. No. 0.00011; hes 233; Conservative 157; Mismatches 469; Indels 245; Gaps 2 EDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEBDEEEEE : :: : ; 212 EETTVVAVVESSGEEPASSTSIPTELSKNDQVTFASGEETITAATEASEETTTSAVTE 43 DEEEDDEDLEELEVLERKPAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPP : : 272 GSGEDTTVVAVVELSGEQPAS-SSTSIPTELSKNDQVTFASGEETITAAATE 100 AAPERQPSWERSPAAPAPSLPPAAAVLPSKLPEDDE-PPARPPPP

```
872 -----KDDQVTEASGEETTT---AAATEASEETTTSAVTEGSGEETTV 911
Db
        698 IAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEV---PQTQEEAVMLMKESLTEVSET 754
Qу
            912 VAVVESSGEEPA----SSSTSIPTELSKDDQVTEASGEETTTAAATEASSEETTTSAVT 966
Db
        755 VAQHKEERLSASPQELGKPYLESFQP----- 791
Qу
                  : |:::::|
        967 EGSGEETTTSAVTEGSGEETTTSAVPEGENSTTEAPAFVTGSEIEIPSSEESSSTTTHDP 1026
Db
        792 DIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESET-FSDSSPIEIIDEFPTFVS 850
Qу
             1027 SIPVITPKPSVSSTIENVMSKTSSEE---AAEKKIIGEHQTGKDDDAGKEDEDNMPAFVT 1083
Db
        851 A-----KDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCD 891
Qу
                             :|:: |:|| :| :|
        1084 ANPAGTSTTESAENVTSTGEEDENIKMAKELGKQFAADLAKLA------ 1126
Db
        892 LSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKK 951
Qу
                   1127 -----AKDGVNLT-ETADAKDSGETAHVEDEQVSSTE--SSIGSEETTTTVNKETTEE 1176
Db
         952 LPSDTEKEDRSLSAVLSAELSKTS 975
Qу
               ::||::||
        1177 HHEASGEEDDAPAFVTGAPTDSTT 1200
Db
RESULT 11
A47282
calcium-binding protein calphotin - fruit fly (Drosophila melanogaster)
C:Species: Drosophila melanogaster
C; Date: 21-Sep-1993 #sequence revision 18-Nov-1994 #text change 21-Jul-2000
C; Accession: A47282
R; Martin, J.H.; Benzer, S.; Rudnicka, M.; Miller, C.A.
Proc. Natl. Acad. Sci. U.S.A. 90, 1531-1535, 1993
A; Title: Calphotin: a Drosophila photoreceptor cell calcium-binding protein.
A; Reference number: A47282; MUID: 93165729; PMID: 8094559
A; Accession: A47282
A; Status: preliminary
A; Molecule type: nucleic acid
A; Residues: 1-865 <MAR>
A; Cross-references: GB:L02111; NID:g157031; PIDN:AAA28405.1; PID:g157032
A; Experimental source: photoreceptor cells
A; Note: sequence extracted from NCBI backbone (NCBIN:124955, NCBIP:124956)
C; Genetics:
A; Gene: FlyBase:Cpn
A;Cross-references: FlyBase:FBgn0010218
C; Superfamily: collagen alpha 1(I) chain; fibrillar collagen carboxyl-terminal
homology; von Willebrand factor type C repeat homology
C; Keywords: calcium binding
                        5.1%; Score 295.5; DB 2; Length 865;
  Ouery Match
  Best Local Similarity 21.3%; Pred. No. 7.2e-05;
  Matches 217; Conservative 127; Mismatches 379; Indels 295; Gaps
                                                                  41;
          62 AAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPER----QPSWERSPAAPAP 117
QУ
```

Db	11	SAPVAAPVTPSAVAAPVQVVSPAAVAPAPAAPIAVTPVAPPPTLASVQPATVTIP-APAP	69
QУ	118	SLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTP	161
Db	70	: : : :	129
QУ	162	-AAPKRRGSGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQED	211
Db	130	VAAPVIATPPVAASAPTPAAVTPVISPVIASPPVVPANTTVPVAAPVAA	178
QУ	212	FPSVLLETAASL-PSLSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATN : : ::: : : : :	270
Db	179	VPAAVPVVAPVLAPAVAPAVAPVVAETPAPPPVAEIPVATIPECVAPLIPEVSVVATK	236
Qу	271	PFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENTKEEVIVRSKDKEDLVCSAALHSP	330
Db	237	PLAAAEPVVVAPPATETPVVAPAAASP	263
QУ	331	QESPVGKEDRVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLA	390
Db	264	HVSAVETAVVAPV	279
Qу	391	ARANVESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASF	446
Db	280	-SASTEPPVAAATLTTAPETPALAPVVAESQVAANTVVATPPTPAPEPETIAPPVVAETP	338
Qу	447	TSATESTTANTFPLLEDHTSENKTDEKKIEERKAQIITEKTSPKTSNPFLVAVQDSEADY ::: :: :: :: :: :: ::	506
Db	339	EVASVAVAETTPPVVPPVAAESIPAPVVATTPVPATLAVTDPD	381
Qу	507	VTTDTLSKVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQES	566
Db	382	VTASAVPELPPVIAPSPVPSAVAETPVDLAPPV	414
Qy	567	LYP-TAQLCPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAP	619
Db	415	LPPVAAEPVPAVVAEETPETPAPASAPVTI-AALDIPEVAPVIAAPSDAPAEAPSAAA	471
Qу	620	PPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESFNAAVQETEAPYISIACD	677
Db	472	PIVSTPPTTASVPETTAPPAAVPTEPI	498
Qу	678	LIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSD-DSIP :: : : : : : :	731
Db	499	DVSVLSEAAIETPVAPPVEVTTEVAVADVAPPEAAADLIIEPVEPPAPIPDLLEQTTSVP	558
Qy	732	EVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQPNLHSTKDAASN : : : : : : : : : :	791
Db	559	AVEAAESTSSPIPETSLPPPNEAVASPEVAVAPITAPEPIPEP-EPSLATPTEPIPV	614
Qу		DIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSA : :: :: : :	
Db	615	EAPVVIQEAVDAVEVPVTETSTSIPETTVEFPEAVAE	651
Qу	852	KDDSPKLAKEYTDLEV-SDKSEIANIQSGADSLPCLELPCDLSFKNIYP-	899
Db	652	: : : :	707

```
900 -KDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMG----- 936
Qу
               1: 1: 1 4 : :: : 1 : 1 1:
         708 VPQEIAVA-EIPETDTKPAEVIVEQSTIPIEAPVPEVSKYAEPVISEAPAAEVPITAGDN 766
Db
         937 ----SIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGV 990
QУ
                767 PDNTSVGISEVVPTIAEKPVEEVPTSEIPEQSSSPSDSVPVAKITPLL--RDLQTTDV 822
Db
RESULT 12
T34513
hypothetical protein ZK783.1 - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C; Date: 29-Oct-1999 #sequence revision 29-Oct-1999 #text change 29-Oct-1999
C; Accession: T34513
R; Favello, A.; Vaudin, M.
submitted to the EMBL Data Library, August 1994
A; Description: The sequence of C. elegans cosmid ZK783.
A; Reference number: Z21536
A; Accession: T34513
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-3507 <FAV>
A; Cross-references: EMBL: U13646; PIDN: AAC24418.1; GSPDB: GN00021; CESP: ZK783.1
A; Experimental source: strain Bristol N2; clone ZK783
C; Genetics:
A; Gene: CESP: ZK783.1
A; Map position: 3
A; Introns: 14/1; 48/2; 84/1; 196/3; 303/1; 381/1; 586/1; 605/1; 1175/3; 1207/1;
1409/2; 1450/1; 1760/1; 1898/1; 2153/1; 2628/1; 2681/1; 2899/1; 2946/1; 3088/3;
3184/1; 3283/1; 3346/3; 3365/3; 3484/3; 3504/1
                         5.0%; Score 292; DB 2; Length 3507;
  Query Match
                        20.6%; Pred. No. 0.00072;
  Best Local Similarity
  Matches 226; Conservative 146; Mismatches 491; Indels 236; Gaps
                                                                      37;
          11 SSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEEDEEEDDEDL--EELEVLERKPAAGLSAA 68
Qу
                      || ::|| :
                                       : | |
                                            1
                                                 2043 SSSSEAPLTSSPATTTEVITESSVKSTTPKEESSSEITVKLSSKSPEVTESSVKSSPSTP 2102
Db
          69 AVPPAAAAPLLDFSSDSVPPAPRGPLPAAPP----AAPERQPSWERSPA-----APAPSL 119
Qу
                 : : : | : : | : : |
                                             : | :|| |
        2103 STTSQSVTSTVPETSKSTVLSSEAPVTSTSPTEVHTSSETKPSLSASSTTGDTNSTTPST 2162
Db
         120 PPAAAVLPSKLPEDDEPPARPPPPPPAGASP-LAEP----AAPPSTPAAPKRRGSGSV 172
Qу
                          | | : || :::|
                                                | || || || :
                1:1 : 11
        2163 SSLASVKSTSAPEGTS--ASVAPVKLSSLSPDVSQPSTKTFDATESSTVQASETSSGTSV 2220
Db
         173 DET----LFALPAASEPVI-PSSAEKIMDLMEQPGNTVSSGQEDFP---SV 215
QУ
                             1
         2221 KSTSEPESHVTKLSITSSNPSSSVPVTSPKSTPTVPESTEQPTSTTPSGQSLTPMNSNSE 2280
Db
         216 LLETA---ASLPSLSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERAT--N 270
Qу
                                   1111 : 1
         2281 VLTTSEPHVLSSSLSPDVSQSSTTPNNLSESSTVETPKTSSEVSLNSEEPSTTEAPTTLS 2340
Db
```

Qу		PFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENTKEEVIVRSKD	
Db	2341	PDILSTTTNNLSQSSTVSTEDRSEISSENSEKPTSAPELVTSSVTHVASSSPDVPTESSE	2400
Qу	318	KEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVAPVREEYADFK :	370
Db	2401	PDDLTGSSTENIPEASSKQTISSTPTPDTTTASEEPTKSTSMSPDLSTTSNVLSESSTTP	2460
Qy	371	PFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTP : : : : : :	430
Db	2461	ESSSKSPVSSSTEGISVVTSTEFSKVPESTISSVLEEDLT-KTTP	2504
Qу	431	EPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEE : : : : : : :	477
Db	2505	SPILEETTTASETSEPLTEDSLTVSVRIHELTTSSENVPKESESTTTSSESSKPSQ	2560
QУ	478	RKAQIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLV	532
Db	2561	EPAGILTSTVVVPTSSVSLITASEIEAITSNTPFKQGRTPITTSPKSLVKSTTSPSTV	2618
QУ	533	QEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPD	590
Db	2619	TSSEPSESTKRTTVSTTVSTTTPTEETTTSESLILTAAPSKPTESTTESSEAPTTP-	2674
Qу	591	IVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGT	650
Db	2675		2692
Qу	651	KEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAE	710
Db	2693	::	2738
Qу	711	LVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKE-ERLSASPQE	769
Db	2739	NSSTSSPTSSEASVKLSSLFPESITSEAVTVSSRAPAEITMSSESHREISTVSSEPSE	2796
QУ	770	LGKPYLESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSS	822
Db	2797	: : : : : : : : : : : : : : : : :	2853
QУ	823	-KEDKIKESETFSDS-SPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGA	880
Db	2854	: : : : : III NRRQNITASSVPSNSTSPIILPSESLTTPQPPPTTTTTAKPATTSGK	2900
Qу	881	DSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVK	940
Db	2901	:: :: :	2929
Qу	941	SKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLL	1000
Db	2930	: :::	2976
Qу	1001	SLTVFSIVSVTAYIALALL 1019	
Db	2977	: GTTACSKKSTADCISLPSL 2995	

```
RESULT 13
A56577
microtubule-associated protein MAP 1B - rat (fragment)
C; Species: Rattus norvegicus (Norway rat)
C;Date: 21-Jul-1995 #sequence revision 21-Jul-1995 #text change 16-Feb-1997
C; Accession: A56577
R; Zauner, W.; Kratz, J.; Staunton, J.; Feick, P.; Wiche, G.
Eur. J. Cell Biol. 57, 66-74, 1992
A; Title: Identification of two distinct microtubule binding domains on
recombinant rat MAP 1B.
A; Reference number: A56577; MUID: 92347374; PMID: 1639092
A; Accession: A56577
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-2364 <ZAU>
A; Cross-references: GB: X60550
A: Experimental source: brain
A; Note: nucleotide sequence not given; conceptual translation not complete
C; Superfamily: microtubule-associated protein MAP1B
                                              5.0%; Score 291.5; DB 2; Length 2364;
    Query Match
    Best Local Similarity 20.0%; Pred. No. 0.00043;
    Matches 220; Conservative 167; Mismatches 456; Indels 255; Gaps 44;
                   30 TEPEDEEDEEEEEDEEEDDEDLEELEVLERKPAAGLSAAAVPPAAAAPLLDFSSDSVPPA 89
Qу
                         913 SEEEGEEEEDKAEDAREEDHEPDKTE-----AEDYVMAVVDKAAEAGVTEDQYDFL--- 963
Db
                   90 PRGPLPAAPPAAPERQPSWERSPAAPAPSLPPAAAVLPSKLPEDDEPPARPPPPPPAGAS 149
Qу
                                           | :| | :|| ||::: || |
                  964 ------GTPAKQ-----PGVQSPSREPASSIHDETLPGGSESEAT------AS 999
 Db
                  150 PLAEPAAPPSTPAAPKRRGSGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGN---TVS 206
 Qу
                                                       | | | | : : : | | |
                                      1000 DEENREDQPEEFTAT----SGYTQST---IEISSEPTPMDEMSTPRDVMTDETNNEETES 1052
 Db
                  207 SGQE----DFPSVLLETAASLP---SLSPLS----TVSFKEHGYLGNLSAVSSSEGTIE 254
 Qу
                                         1053 PSQEFVNITKYESSLYSQEYSKPVVASFNGLSDGSKTDATDGRDYNASASTISPPSSMEE 1112
 Db
                  255 ETLNEAS-----KELPERATNPFVNRDLAEF--SELEYSEMG--- 289
 Qу
                                                                       |:::: :| : |:
                                                                                                         1:1::1
                         : ::::
                 1113 DKFSKSALRDAYRPEETDVKTGAELDIKDVSDERLSPAKSPSLSPSPPSPIEKTPLGERS 1172
 Db
                  290 -----SSFKGSPKGESAILVENTKEEVIVR----SKDKEDL------VCSAALHSP 330
 Qу
                                     : | | : | | : : | | | : : | | | : : | | | : : | | | : | | : | | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | : | | :
                 1173 VNFSLTPNEIKASAEGEATAVVSPGVTQAVVEEHCASPEEKTLEVVSPSQSVTGSAGHTP 1232
 Db
                  331 -QESPVGKEDRVVSPEKTMDIFNEMQMSVVAPVREEYADFK-----PFEQAWEVKD 380
 Qy
                             :|| :: : | | : : | | | :: | | | :: | |
                 1233 YYQSPTDEKSSHLPTEVT-----ENAQAVPVSFEFTEAKDENERSSISPMDE--PVPD 1283
 Db
                   381 TYEGSRDVLAARANVESKVDRKCLED--SLEQKSLGKDS----EGRNEDASFPSTPEPVK 434
 Qу
                                                                  1284 SESPIEKVLSPLRSPPLIGSESAYEDFLSADDKALGRRSESPFEGKNGKQGFSDKESPVS 1343
 Db
                   435 DSSRAYITCASFTSATESTTANTFPLLEDHTSENKT------DEKKI----- 475
 Qу
```

```
:| : | | : | : | : |
       1344 D----LTSDLYQDKQEEKRAGFIPIKEDFSPEKKASDAEIMSSQSALALDERKLGGDGS 1398 ·
Db
       476 -----EERKAQIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAV-- 520
Qу
                     1399 PTQVDVSQFGSFKEDTKMSISEGTVSDKSATPVDEGAEDT---YSHMEGVASVSTASVAT 1455
Db
        521 SNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQES-LYPTAQLCP---S 576
QУ
           1456 SSFPEPTTDD-VSPSLHAEVGSPHSTEVDDSLSVSVVQTPTTFQETEMSPSKEECPRPMS 1514
        577 FEEAEATP------PSAGASVVQ 610
Qу
           ::| | : : |:| :||
                                                   1: || ::
       1515 ISPPDFSPKTAKSRTPVQDHRSEQSSMSIEFGQESPEHSLAMDFSRQSPDHPTVGAGMLH 1574
Db
        611 PSVSPLEAPPPVSYD-----SIKLEPENPPPYEEAMNVALKALGTKEGIKEPESFN 661
Qγ
            1575 ITEN---GPTEVDYSPSDIQDSSLSHKIPPTEEPSYTQDNDLS-ELISVSQVEASPSTSS 1630
Db
        662 AAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESEP 721
Qу
               1
       1631 AHTPS-----QIASPLQEDTLSDVVPPRDMSLYASLASEKVQSLEGEKL----SPKSDI 1680
Dh
        722 VDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYL-ESFQP 780
Qу
            1681 SPLTPRESSPTYSPGFSDSTSGAKES-TAAYQTSSSPPIDAAAAEPYGFRSSMLFDTMQH 1739
Db
        781 NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE 840
Qу
           :| ::| :: :|: :|: :|| |
       1740 HLALSRDLTTSSV----EKDNGGKTPGDFNYAYQKPESTTESPDEEDYDYE--SHEKTIQ 1793
Db
        841 IIDEFPTFVSAKDDSPK----LAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKN 896
Qу
             1794 AHDVGGYYYEKTERTIKSPCDSGYSYETIEKTTKTP----EDGGYS-----CEITEKT 1842
Db
        897 IYPKDEVHVSDEFSENRSSVSKAS-----ISPSNVSALEPQTEMGSIVKSKSL 944
Qу
              1843 TRTPEEGGYSYEISEKTTRTPEVSGYTYEKTERSRRLLDDISNGYDDTEDGGHTLGDCSY 1902
Db
        945 TKEAEKKLPSDTEKEDRS 962
Qу
           : | :|: | | | |
       1903 SYETTEKITSFPESESYS 1920
Db
RESULT 14
T19431
hypothetical protein C25A1.10 - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence revision 15-Oct-1999 #text change 21-Jan-2000
C:Accession: T19431
R; Mortimore, B.
submitted to the EMBL Data Library, October 1996
A; Reference number: Z19124
A; Accession: T19431
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-971 <WIL>
```

```
A;Cross-references: EMBL:Z81038; PIDN:CAB02755.1; GSPDB:GN00019; CESP:C25A1.10
A; Experimental source: clone C25A1
C; Genetics:
A; Gene: CESP: C25A1.10
A; Map position: 1
A; Introns: 38/3; 92/3; 201/3; 919/3
C; Superfamily: nucleolus-cytoplasm shuttle phosphoprotein
                    4.9%; Score 288.5; DB 2; Length 971;
 Query Match
 Best Local Similarity 20.6%; Pred. No. 0.00016;
 Matches 198; Conservative 127; Mismatches 391; Indels 247; Gaps 35;
         7 SSLVSSSTDSPPRPPPAFKYQFVTEP---EDEEDEEEEEDEEEDDEDLEELEVLERKPAA 63
QУ
           147 SSSDSDSDDEPPKKAPAVTTKVAPKPMAKKQDTSDSDSDSEDSDDGKSKKANPVKVTPVA 206
Db
        64 GLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAP-----ERQPSWE 109
Qу
           1::1 :
        207 NVLQKVVAKKAASSSSDSSDDEKKPAAK-PTPAKPTPKPVVKKAESSSDSSDDEKKPVAK 265
Db
        110 RSPAAPAPSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGS 169
Qу
            266 PAPAKATPK-PAAKKADSSSDSSDDEAPAK-KTPAKAAPKPVAKKAESSSDSSDDEKK-- 321
Db
        170 GSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPL 229
Qу
                  322 -----PAAK----PTPAKATPKPVAKKAESSSDSSDDEKKPVAKPAPAKATPKPV 367
Db
        230 STVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSE-- 287
Qν
               368 AK------KAESSSDSSDDEK-KPAAKPTPAKATPKPVAKKAESSSDSSDDEKK 414
Dh
        288 ---MGSSFKGSPKGESAILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSP 344
Qγ
                                 : | | | :: | |:| | :|
               :| | :||
        415 PVAKPTSAKATPK-----PAAKKAD---SSSDSSDDEAPAKKTPAKAAP 455
Db
        345 E---KTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRD-----VLAARANV 395
Qу
           456 KPASKKAESSSDSSDDEKPAAKSTPAKITPKPTAKKVASSSSDSSDDEKKPAAKPTPANA 515
Db
        396 ESKVDRKCLEDSL----EQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFTSAT 450
Qy
             516 TPKPVAKKAESSSDSSDDEKKPVAKPTSAK-----ATPKPAAKKADLSSDFSDDEAPA 568
Db
        451 ESTTANTFPLLEDHTSENKTDEKKIEERKAQIITEKTSPK-TSNPFLVAVQDSEADYVTT 509
Qу
            569 KKTPAKAAPKPASKKAESSSDSSDDEKPAAKSTPAKTTPKPTAKKAASSSSDSSDD--EK 626
 Db
        510 DTLSKVTEAAVSNMPEGLTPDLVQEACESELN----EATGTKIAYETKVDLVQTSEAI 563
 Qу
             627 KPVAKPTSAKATPKPAAKKADSSSDSSDDEAPAKKTPVKPTPVKIVAK-KVD--SSSDSS 683
 Db
         564 QESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVS 623
 QУ
            : [] : [] []
         684 DDEKKPT------KATPVKVTP------KSVTKKAAAS-----S 710
 Db
         624 YDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESFNAAVQETEAPYISIACDLIKETK 683
 Qу
```

```
1: 11 ::
                 : | | :: ||
         711 SDS--SDDEKKPVVKQTPNVV------PKKEKAASSSDDSS-----DDEKK 748
Db
         684 LSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVML 743
QУ
                                                    1: 1: : | | | | | |
         749 PTAKPTP------KATPKQSAKKADSSDDS-----SDDEAPA----- 779
Db
         744 MKESLTEVSETVAQHKEERLSASPQELGKPYLESFQPNLHSTKDAASNDIPTLTKKEKIS 803
Qу
                                                      780 ----KKTPAKSTPAKTAVKKEASS 799
Db
         804 LQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS--PKLAKE 861
Qу
                      800 -----SSDDSSDDEKTKKKSATTPAKSTPKTALKKAESSDSSDDDEDLPKPSKA 848
Db
         862 YTDL-EVSDKSEIANIQSGADSLPCLEL-PCDLSFKNIYPKDEVHVSDEFSENRSSVSKA 919
QУ
              849 VTPRPQRADSEESAETEESSSRTPALKAKPLATSTEKAVYENRKRKSSPF--RRVQMTKD 906
Db
         920 SIS 922
QУ
             1:1
         907 SVS 909
Db
RESULT 15
QRMSP1
microtubule-associated protein MAP1B - mouse
N; Alternate names: microtubule-associated protein MAP1(X); microtubule-
associated protein MAP1.2; microtubule-associated protein MAP5
C; Species: Mus musculus (house mouse)
C;Date: 30-Sep-1991 #sequence revision 30-Sep-1991 #text change 01-Sep-2000
C; Accession: S07549; S44387; A33645
R; Noble, M.; Lewis, S.A.; Cowan, N.J.
J. Cell Biol. 109, 3367-3376, 1989
A; Title: The microtubule binding domain of microtubule-associated protein MAP1B
contains a repeated sequence motif unrelated to that of MAP2 and tau.
A; Reference number: A33645; MUID: 90094539; PMID: 2480963
A; Accession: S07549
A; Molecule type: mRNA
A; Residues: 1-2464 < NOB>
A; Cross-references: EMBL: X51396; NID: g52999; PIDN: CAA35761.1; PID: g53000
R; Sanchez, C.; Padilla, R.; Paciucci, R.; Zabala, J.C.; Avila, J.
Arch. Biochem. Biophys. 310, 428-432, 1994
A; Title: Binding of heat-shock protein 70 (hsp70) to tubulin.
A; Reference number: S44387; MUID: 94234720; PMID: 8179328
A; Accession: S44387
A; Status: preliminary
A; Molecule type: protein
A; Residues: 653-663, 'IC' <SAN>
C; Superfamily: microtubule-associated protein MAP1B
C; Keywords: microtubule binding; phosphoprotein; tandem repeat
F;589-786/Domain: microtubule binding #status experimental <MTB>
F;589-592,639-642,649-652,655-658,660-663,668-671,674-677,679-682,683-686,687-
690,691-694,695-698,699-702,708-711,712-715,716-719,720-723,727-730,758-761,764-
767,783-786/Region: 4-residue repeats (K/R-K-E/D-X)
 F;1861-2064/Region: 17-residue repeats
```

```
F;91,116,351,888,1124,1153,1168,1208,1662,1877,1918,2003,2030,2054,2083/Binding
site: phosphate (Ser) (covalent) #status predicted
F;147,969,1336,1562,1563,1702,1708,1990,2057,2063,2419/Binding site: phosphate
(Thr) (covalent) #status predicted
F;1953/Binding site: phosphate (Tyr) (covalent) #status predicted
                   4.9%; Score 284; DB 1; Length 2464;
 Query Match
 Best Local Similarity 20.7%; Pred. No. 0.00093;
 Matches 233; Conservative 159; Mismatches 424; Indels 312; Gaps 51;
        31 EPEDEEDEEEEEDEEED-----DEDLEELE-----VLERKPAAG-----LSAAAVP 71
Qу
          1009 EAEQSEEEGEEEDKAEDAREEGYEPDKTEAEDYVMAVADKAAEAGVTEEQYGYLGTSAKQ 1068
Db
        72 PAAAAPLLDFSS----DSVPPAPRGPLPAAPPAAPERQP-----SWERSPAAPA 116
Qу
             1
       1069 PGIQSPSREPASSIHDETLPGGSESEATASDEENREDQPEEFTATSGYTQSTIEISSEPT 1128
Db
       117 P---SLPPAAAVLPSKLPEDDEPPARP------PPPPPAGASPLAEPA-- 155
Qу
          1129 PMDEMSTPRDVMSDETNNEETESPSQEFVNITKYESSLYSQEYSKPAVASFNGLSEGSKT 1188
Db
        156 ----APPSTPAAPKRRGSGSVDETLFALPA----ASEPVIPSSAEKIMDLMEQ 200
Qу
                 1189 DATDGKDYNASASTISPP----SSMEEDKFSKSALRDAYCSEEKELKASAE--LDIKDV 1241
Db
        201 PGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEA 260
Qу
             :1
                                                 11:1
       1242 SDERLS-----PAKSPSLSP------SPPSPIEKT---- 1265
Db
        261 SKELPERATNPFVNRDLAEFS----ELEYSEMGSSFKGSPKGESAILVEN--TKEEVIVR 314
Qу
             1266 --PLGERSVN-----FSLTPNEIKVSAEGEARSVSPGVTQAVVEEHCASPEEKTLE 1314
Db
        315 SKDKEDLVCSAALHSP-QESPVGKEDRVVSPEKTMDIFNEMQMSVVA-PVREEYADFK-- 370
Qу
                1315 VVSPSQSVTGSAGHTPYYQSP-----TDEKSSHLPTEVSENAQAVPVSFEFSEAKDE 1366
Db
        371 -----PFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLED--SLEQKSLGKDS---- 417
Qу
                1367 NERASLSPMDE--PVPDSESPVEKVLSPLRSPPLLGSESPYEDFLSADSKVLGRRSESPF 1424
Db
        418 EGRNEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKT----- 470
Qν
                1425 EGKNGKQGFPDRESPVSDLT----STGLYQDKQEEKSTGFIPIKEDFGPEKKTSDVETMS 1480
Db
        471 -----DEKKI------EERKAQIITEKTSPKTSNPFLVAVQDSEAD 505
Qу
                1481 SQSALALDERKLGGDVSPTQIDVSQFGSFKEDTKMSISEGTVSDKSATPVDEGV--AEDT 1538
Db
        506 YVTTDTLSKVTEAAV--SNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAI 563
Qу
           1539 YSHMEGVASVSTASVATSSFPEPTTDD-VSPSLHAEVGSPHSTEVDDSLSVSVVQTPTTF 1597
Db
        564 QES-LYPTAQLCP---SFEEAEATP------SPVLPDIVMEAPLNSLL-- 601
 QУ
           1598 QETEMSPSKEECPRPMSISPPDFSPKTAKSRTPVQDHRSEQSSMSIEFGQESPEHSFAMD 1657
 Db
```

QУ		PSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVA	
Db	1658	FSRQSPDHPTLGASVLHITENGPTEVDYSPCDIQDSSLSHKIPPTEEPSYTQDNDLS	1714
QΥ	645	LKALGTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKS : : : :: : :	704
Db	1715		1762
QУ	705	VPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKE : :	760
Db	1763	SEKVQSLEGEKLSPKSDISPLTPRESSPLYSPGFSDSTSAAKETAAAH	1810
QУ	761	ERLSASPQELGKPYLESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFN : :	810
Db	1811	-QASSSPPIDAATAEPYGFRSSMLFDTMQHHLALNRDLTTSSVEKDSGGKTPGDFN	1865
Qу	811	TAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLE	866
Db	1866	YAYQKPENAAGSPDEEDYDYESQEKTIRTHDVVRYYYEKTERTIKSPCDSGYSYETIE	1923
QУ	867	VSDKSEIANIQSGADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKAS : : : : : : : :	920
Db	1924	KTTKTPEDGGYTCEITEKTTRTPEEGGYSYEISEKTTRTPEVSGYTYEK	1972
Qy	921	ISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRS 962	
Db	1973	TERSRRLLDDISNGYDDTEDGGHTLGDCSYSYETTEKITSFPESESYS 2020	

Search completed: September 29, 2004, 18:15:50 Job time: 36.465 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

September 29, 2004, 18:16:15; Search time 124.84 Seconds Run on:

(without alignments)

2997.869 Million cell updates/sec

US-09-830-972-2 Title:

Perfect score: 5848

1 MEDIDQSSLVSSSTDSPPRP......VKDAMAKIQAKIPGLKRKAD 1163 Sequence:

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

1351062 seqs, 321799191 residues Searched:

Total number of hits satisfying chosen parameters: 1351062

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Published Applications AA: * Database :

1: /cgn2 6/ptodata/2/pubpaa/US07 PUBCOMB.pep:*

2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*

3: /cgn2 6/ptodata/2/pubpaa/US06 NEW_PUB.pep:*

/cgn2 6/ptodata/2/pubpaa/US06_PUBCOMB.pep:* 4:

/cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:* 5:

6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:*

7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*

8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*

9: /cgn2_6/ptodata/2/pubpaa/US09A PUBCOMB.pep:*

10: /cgn2 6/ptodata/2/pubpaa/US09B PUBCOMB.pep:*

11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*

12: /cgn2 6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*

13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*

14: /cgn2 6/ptodata/2/pubpaa/US10B PUBCOMB.pep:*

15: /cgn2 6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*

16: /cgn2 6/ptodata/2/pubpaa/US10 NEW_PUB.pep:*

/cgn2 6/ptodata/2/pubpaa/US60_NEW PUB.pep:* 17:

/cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:* 18:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

ક

Query Result

No. Score Match Length DB ID

Description

Sequence 18, Appl 1163 9 US-09-893-348-18 5848 100.0 1 Sequence 431, App 1163 12 US-10-267-502-431 90.7 2 5307 Sequence 6, Appli 1192 9 US-09-758-140-6 3 4403.5 75.3 Sequence 6, Appli 1192 9 US-09-972-599A-6 4 4403.5 75.3 Sequence 71, Appl 1192 14 US-10-060-036-71 5 4403.5 75.3 Sequence 2, Appli 1192 9 US-09-789-386-2 6 4398.5 75.2 Sequence 23, Appl 1192 9 US-09-893-348-23 4398.5 75.2 7 Sequence 429, App 1192 12 US-10-267-502-429 75.2 8 4398.5 Sequence 9, Appli 1192 16 US-10-327-213-9 75.2 9 4398.5 Sequence 9, Appli 1192 16 US-10-466-258-9 10 4398.5 75.2 Sequence 7, Appli 1192 12 US-10-408-967-7 4389.5 75.1 11 Sequence 164, App 14 US-10-205-194-164 25.9 379 12 1513 Sequence 20, Appl 360 9 US-09-893-348-20 24.1 13 1411.5 Sequence 6, Appli Sequence 6, Appli Sequence 24, Appl 373 9 US-09-789-386-6 20.4 1191 14 373 9 US-09-765-205-6 20.4 15 1191 373 9 US-09-893-348-24 20.4 16 1191 Sequence 8, Appli 373 12 US-10-408-967-8 20.4 17 1191 Sequence 72, Appl 14 US-10-060-036-72 20.4 373 18 1191 Sequence 4, Appli 16 US-10-466-258-4 20.2 373 19 1183 Sequence 21, Appl 199 9 US-09-893-348-21 15.8 925 20 Sequence 25, Appl 199 9 US-09-893-348-25 15.5 908 21 Sequence 1, Appli 199 12 US-10-660-946-1 15.5 908 22 Sequence 9, Appli 12 US-10-408-967-9 199 15.4 23 901 Sequence 467, App 199 12 US-09-978-360A-467 899 15.4 24 Sequence 4, Appli 289 9 US-09-789-386-4 15.2 888 25 Sequence 11, Appl 199 16 US-10-466-258-11 14.8 868 26 Sequence 93, Appl 14 US-10-205-219-93 777 801 13.7 27 Sequence 432, App 780 12 US-10-267-502-432 792 13.5 28 Sequence 5, Appli 776 12 US-10-660-946-5 29 789.5 13.5 Sequence 430, App 776 12 US-10-267-502-430 13.5 789.5 30 Sequence 6, Appli 12 US-10-660-946-6 356 31 716.5 12.3 Sequence 2892, Ap 15 US-10-108-260A-2892 12.1 593 32 706.5 Sequence 7, Appli 12 US-10-660-946-7 11.7 208 685 33 Sequence 8, Appli US-10-660-946-8 11.5 267 12 671 34 Sequence 127, App 14 US-10-205-194-127 267 671 11.5 35 Sequence 2330, Ap 12 US-10-276-774-2330 10.8 266 630 36 Sequence 20, Appl 9 US-09-729-674-20 10.7 236 625.5 37 Sequence 26, Appl 9 US-09-765-205-26 236 10.7 38 625.5 Sequence 2, Appli 236 12 US-10-408-967-2 625.5 10.7 39 Sequence 6222, Ap 14 US-10-106-698-6222 625.5 10.7 269 40 Sequence 563, App 10 US-09-809-391-563 168 539.5 9.2 41 Sequence 563, App 10 US-09-882-171-563 168 9.2 539.5 42 Sequence 563, App 12 US-10-164-861-563 168 9.2 539.5 43 Sequence 428, App 12 US-10-267-502-428 222 8.9 520 44 Sequence 3, Appli 12 US-10-660-946-3 241 8.9 519 45

ALIGNMENTS

RESULT 1 US-09-893-348-18

- ; Sequence 18, Application US/09893348
- ; Patent No. US20020072493A1
- ; GENERAL INFORMATION:
- ; APPLICANT: EISENBACH-SCHWARTZ, Michal

```
COHEN, Irun R.
  APPLICANT:
            BESERMAN, Pierre
  APPLICANT:
            MOSONEGO, Alon
  APPLICANT:
            MOALEM, Gila
  APPLICANT:
  TITLE OF INVENTION: ACTIVATED T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND
THEIR USES
  FILE REFERENCE: EIS-SCHWARTZ=2A
  CURRENT APPLICATION NUMBER: US/09/893,348
  CURRENT FILING DATE: 2001-06-28
  PRIOR APPLICATION NUMBER: US 09/314,161
  PRIOR FILING DATE: 1999-05-19
  PRIOR APPLICATION NUMBER: US 09/218,277
  PRIOR FILING DATE: 1998-12-22
  PRIOR APPLICATION NUMBER: PCT/US98/14715
  PRIOR FILING DATE: 1998-07-21
  PRIOR APPLICATION NUMBER: IL 124500
  PRIOR FILING DATE: 1998-05-19
  NUMBER OF SEQ ID NOS: 29
  SOFTWARE: PatentIn version 3.1
 SEQ ID NO 18
   LENGTH: 1163
   TYPE: PRT
   ORGANISM: Rattus norvegicus
US-09-893-348-18
                      100.0%; Score 5848; DB 9; Length 1163;
  Query Match
                     100.0%; Pred. No. 6.1e-287;
  Best Local Similarity
                                                                0:
                           0; Mismatches
                                          0;
                                             Indels
                                                         Gaps
  Matches 1163; Conservative
          1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
            1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Db
         61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Qу
            61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Db
        121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
Qу
            121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
Db
         181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
QУ
            181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
Db
         241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300
Qy
            241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300
Db
         301 AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA 360
 Qу
            301 AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA 360
 Db
         361 PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGR 420
 Qy
            361 PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGR 420
 Db
```

QУ		NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA	
Db		NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA	480
QУ	481	QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL	540
Db	481	QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL	540
QУ	541	NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL	600
Db	541	NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL	600
Qy	601	LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF	660
Db	601	LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF	660
Qу	661	NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE	720
Db	661	NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE	720
Qу	721	PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP	780
Db	721	PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP	780
Qy	781	NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE	840
Db	781	NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE	840
Qу	841	IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK	900
Db	841	IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK	900
QУ	901	DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED	960
Db	901	DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED	960
Qу	961	RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS	1020
Db	961	RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS	1020
QУ	1021	VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL	1080
Db	1021	VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL	1080
QУ	1081	FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA	. 1140
Db	1081	FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA	1140
QУ	1141	NKSVKDAMAKIQAKIPGLKRKAD 1163	
Db	1141		

RESULT 2

US-10-267-502-431

[;] Sequence 431, Application US/10267502; Publication No. US20040071700A1

```
; GENERAL INFORMATION:
  APPLICANT: Kim, Jaeseob
  APPLICANT: Galant, Ron
  TITLE OF INVENTION: Obesity Linked Genes
  FILE REFERENCE: LSD-07416
  CURRENT APPLICATION NUMBER: US/10/267,502
  CURRENT FILING DATE: 2003-01-27
  NUMBER OF SEQ ID NOS: 439
  SOFTWARE: PatentIn version 3.2
 SEQ ID NO 431
   LENGTH: 1163
   TYPE: PRT
   ORGANISM: Mus musculus
US-10-267-502-431
                    90.7%; Score 5307; DB 12;
                                          Length 1163;
 Query Match
                    91.1%; Pred. No. 1.3e-259;
 Best Local Similarity
                                                            7;
                       34; Mismatches
                                                 14;
                                                     Gaps
                                       56;
                                          Indels
 Matches 1066; Conservative
         1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qy
           1 MEDIDQSSLVSSSADSPPRPPPAFKYQFVTEPEDEEDEEDEE-EEEDDEDLEELEVLERK 59
Db
        61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Qу
           60 PAAGLSAVPVPP-AAAPLLDFSSDSVPPAPRGPLPAAPPTAPERQPSWERSPAASAPSLP 118
Db
        121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
Qy
           119 PAAAVLPSKLPEDDEPPAR--PPAPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 176
Db
        181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
Qу
           177 AASEPVIPSSAEKIMDLKEQPGNTVSSGQEDFPSVLFETAASLPSLSPLSTVSFKEHGYL 236
Db
        241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300
Qy
           237 GNLSAVASTEGTIEETLNEASRELPERATNPFVNRESAEFSVLEYSEMGSSFNGSPKGES 296
Db
        301 AILVENTKEEVIVRSKDKEDLVCSAALHSPQESP----VGKEDRVVSPEKTMDIFNEMQ 355
Qу
           | ||| |:||||||||
        297 AMLVENTKEEVIVRSKDKEDLVCSAALHNPQESPATLTKVVKEDGVMSPEKTMDIFNEMK 356
Db
        356 MSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGK 415
Qy
           357 MSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANMESKVDKKCFEDSLEQKSHGK 416
Db
        416 DSEGRNEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKI 475
Qу
           417 DSESRNENASFPSTPELVKDGSRAYITCDSFTSATESTAANIFPVLEDHTSENKTDEKKI 476
Db
        476 EERKAQIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEA 535
Qу
           477 EERKAQIITEKTSPKTSNPFLVAIHDSEADYVTTDNLSKVTEAVVATMPEGLTPDLVQEA 536
Db
        536 CESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEA 595
Qу
```

```
537 CESELNEATGTKIAYETKVDLVQTSEAIQESIYPTAQLCPSFEEAEATPSPVLPDIVMEA 596
Db
       596 PLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIK 655
Qу
          597 PLNSLLPSTGASVAQPSASPLEVPSPVSYDGIKLEPENPPPYEEAMSVALKTSDAKEEIK 656
Db
       656 EPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDS 715
Qу
          657 EPESFNAAAQEAEAPYISIACDLIKETKLSTEPSPGFSNYSEIAKFEKSVPDHCELVDDS 716
Db
       716 SPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHK-EERLSASPQELGKPY 774
Qy
          717 SPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVTQHKHKERLSASPQEVGKPY 776
Db
       775 LESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFS 834
Qу
          777 LESFQPNLHITKDAASNEIPTLTKKETISLQMEEFNTAIYSNDDLLSSKEDKMKESETFS 836
Db
       835 DSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSF 894
Qу
                             11111111111
       837 DSSPIEIIDEFPTFVSAKDDSP---KEYTDLEVSNKSEIANVQSGANSLPCSELPCDLSF 893
Db
       895 KNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPS 954
Qy
                                 11 1111 11111::11111 :
       894 KNTYPKDEAHVSDEFSKSRSSVSKVPLLLPNVSALESQIEMGNIVKPKVLTKEAEEKLPS 953
Db
       955 DTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVV-FGASLFLLLSLTVFSIVSVTAY 1013
Qу
          954 DTEKEDRSLTAVLSAELNKTSVVDLLYWRDIKKTGVVYFGASLFLLLSLTVFSIVSVTAY 1013
Db
       1014 IALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNST 1073
Qу
           1014 IALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNST 1073
Db
       1074 IKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQI 1133
Qу
           1074 IKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQAQI 1133
Db
       1134 DHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
           1134 DHYLGLANKSVKDAMAKIQAKIPGLKRKAE 1163
Db
```

US-09-758-140-6

- ; Sequence 6, Application US/09758140
- ; Patent No. US20020012965A1
- ; GENERAL INFORMATION:
- ; APPLICANT: Strittmatter, Stephen M.
- ; TITLE OF INVENTION: No. US20020012965Alo Receptor-Mediated Blockade of Axonal Growth
- ; FILE REFERENCE: 44574-5073-US
- ; CURRENT APPLICATION NUMBER: US/09/758,140
- ; CURRENT FILING DATE: 2001-01-12
- ; PRIOR APPLICATION NUMBER: US 60/175,707
- ; PRIOR FILING DATE: 2000-01-12
- ; PRIOR APPLICATION NUMBER: US 60/207,366

```
PRIOR FILING DATE: 2000-05-26
  PRIOR APPLICATION NUMBER: US 60/236,378
  PRIOR FILING DATE: 2000-09-29
  NUMBER OF SEQ ID NOS: 20
  SOFTWARE: PatentIn Ver. 2.1
 SEO ID NO 6
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-758-140-6
                    75.3%; Score 4403.5; DB 9;
                                            Length 1192;
 Query Match
                    75.9%; Pred. No. 5.9e-214;
 Best Local Similarity
 Matches 909; Conservative 104; Mismatches 145;
                                           Indels
                                                   39; Gaps
                                                            20;
         1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
           1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58
Dh
         61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
Qу
           59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
Db
        116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166
QУ
                                                11111111111
                119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178
Db
        167 RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS 225
QУ
           179 RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS 237
Db
        226 LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY 285
Qу
           ::||| |||||
        238 LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY 297
Db
        286 SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVG----KED 339
Qу
           298 SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED 357
Db
        340 RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAA----RANV 395
Qу
            358 EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL 416
Db
        396 ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT 454
Qу
           417 ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRSGAYITCAPFNPAATESIA 476
Db
        455 ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS 513
Qy
            477 TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT 536
Db
        514 KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL 573
Qу
               537 KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL 596
Db
        574 CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN 633
Qу
            181114:111141144144414111111 : 1818111:111 1444 - 1:1:111 1441
```

Db	597	CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN	655
Qу	634	PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF	692
Db	656		715
Qу	693	SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS	752
Db	716	SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS	775
QУ	753	-ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF	809
Db	776	FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL	835
Qу	810	NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS: :	868
Db	836	STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS	895
QУ	869	DKSEIANIQSGADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNV	926
Db	896	HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV	955
Qу	927	SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK	986
Db	956	SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK	1015
Qy	987	KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA	1046
Db	1016	KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA	1075
Qу	1047	YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF	1106
Db	1076	YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF	1135
QУ	1107	NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 11	63
Db	1136	NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 11	92

US-09-972-599A-6

- ; Sequence 6, Application US/09972599A
- ; Patent No. US20020077295A1
- ; GENERAL INFORMATION:
- ; APPLICANT: STRITTMATTER, STEPHEN M.
- ; TITLE OF INVENTION: NOGO-RECEPTOR-MEDIATED BLOCKADE OF AXONAL GROWTH
- ; FILE REFERENCE: C077 CIP US
- ; CURRENT APPLICATION NUMBER: US/09/972,599A
- ; CURRENT FILING DATE: 2001-10-06
- ; PRIOR APPLICATION NUMBER: PCT/US01/01041
- ; PRIOR FILING DATE: 2001-01-12
- ; PRIOR APPLICATION NUMBER: 09/758,140
- ; PRIOR FILING DATE: 2001-01-12
- ; PRIOR APPLICATION NUMBER: 60/236,378
- ; PRIOR FILING DATE: 2000-09-29
- ; PRIOR APPLICATION NUMBER: 60/207,366
- ; PRIOR FILING DATE: 2000-05-26

```
PRIOR APPLICATION NUMBER: 60/175,707
  PRIOR FILING DATE: 2000-01-12
  NUMBER OF SEQ ID NOS: 57
  SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO 6
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-972-599A-6
                    75.3%; Score 4403.5; DB 9; Length 1192;
 Query Match
                    75.9%; Pred. No. 5.9e-214;
 Best Local Similarity
 Matches 909; Conservative 104; Mismatches 145;
                                          Indels
                                                  39;
                                                      Gaps
                                                           20;
         1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
           1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58
Db
        61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
Qу
           59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
Db
       116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166
Qy
               119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178
Db
       167 RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS 225
Qу
           179 RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS 237
Db
        226 LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY 285
Qу
                                               ::||| ||||||
           11111 11111 111111 1 :1111:1 ::11111: 1:1
        238 LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY 297
Db
        286 SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVG----KED 339
QУ
           298 SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED 357
Db
        340 RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAA----RANV 395
Qу
            358 EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL 416
Db
        396 ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT 454
Qу
           417 ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRSGAYITCAPFNPAATESIA 476
Db
        455 ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS 513
Qy
            477 TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT 536
Db
        514 KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL 573
Qу
           537 KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL 596
Db
        574 CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN 633
Qу
           597 CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN 655
Db
```

```
634 PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF 692
Qу
           656 PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF 715
Db
        693 SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS 752
QУ
           716 SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS 775
Db
        753 -ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF 809
Qу
            ::: ||:|||| || ||
        776 FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL 835
Db
        810 NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS 868
Qу
           836 STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS 895
Db
        869 DKSEIANIQSGADSLPCLELPCDLSFKNIYPK--DEVHVSDEFSENRSSVSKASISPSNV 926
Qу
                   11 1111 111 111 111 11 ::: 11:11:1 1: 11 :: 1:1
        896 HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV 955
Db
        927 SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK 986
Qу
           956 SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK 1015
Db
        987 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1046
Οv
           1016 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1075
Db
       1047 YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1106
Qy
           1076 YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1135
Db
       1107 NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
            1136 NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1192
Db
RESULT 5
US-10-060-036-71
; Sequence 71, Application US/10060036
; Publication No. US20030073144A1
; GENERAL INFORMATION:
  APPLICANT: Benson, Darin R.
  APPLICANT: Kalos, Michael D.
  APPLICANT: Lodes, Michael J.
  APPLICANT: Persing, David H.
   APPLICANT: Hepler, William T.
   APPLICANT: Jiang, Yuqiu
   TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
   TITLE OF INVENTION: AND DIAGNOSIS OF PANCREATIC CANCER
   FILE REFERENCE: 210121.566
   CURRENT APPLICATION NUMBER: US/10/060,036
   CURRENT FILING DATE: 2002-01-30
```

NUMBER OF SEQ ID NOS: 4560

; SEQ ID NO 71

SOFTWARE: FastSEQ for Windows Version 4.0

```
TYPE: PRT
   ORGANISM: Homo sapiens
US-10-060-036-71
                    75.3%; Score 4403.5; DB 14; Length 1192;
 Query Match
                    75.9%; Pred. No. 5.9e-214;
 Best Local Similarity
 Matches 909; Conservative 104; Mismatches 145; Indels
                                                           20;
         1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
QУ
           1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58
Db
        61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
Qу
           59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
Db
       116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166
Qу
                                               1111111111111
               119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178
Db
        167 RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS 225
Qу
           179 RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS 237
Db
        226 LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY 285
Qу
           ::||| |||||
        238 LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY 297
Db
        286 SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVG----KED 339
QУ
                 298 SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED 357
Db
        340 RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAA----RANV 395
QУ
            358 EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL 416
Db
        396 ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT 454
Qу
           11111:11 11111 : 1111 11:1 1111111 : 11 1 11111 1 : 1111
        417 ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRSGAYITCAPFNPAATESIA 476
Db
        455 ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS 513
Qу
            477 TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT 536
Db
        514 KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL 573
Qу
               537 KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL 596
Db
        574 CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN 633
Qу
```

597 CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN 655

634 PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF 692

656 PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF 715

1:1:111 | | | |

LENGTH: 1192

Db

Qу

Db

QУ	693	SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS	752
Db		SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS	775
QУ		-ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF	809
Db		FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL	
QУ		NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS : : : : :	868
Db		21WA 12MDDRE 12VEWÖLVERLEIGEN 2017 1911 1911 1911 1911 1911 1911 1911 1	
ДУ		DKSEIANIQSGADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNV	
Db		SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK	
Qу Db			
Qy		KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA	
Db			
Qу	1047	YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF	1106
Db	1076		1135
Qу	1107	NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 11	63
Db	1136		92

US-09-789-386-2

- ; Sequence 2, Application US/09789386
- ; Patent No. US20020010324A1
- ; GENERAL INFORMATION:
- ; APPLICANT: MICHALOVICH, DAVID
- ; APPLICANT: PRINJHA, RABINDER KUMAR
- ; TITLE OF INVENTION: NOVEL COMPOUNDS
- ; FILE REFERENCE: GP-30165-C1
- ; CURRENT APPLICATION NUMBER: US/09/789,386
- ; CURRENT FILING DATE: 2001-02-21
- ; PRIOR APPLICATION NUMBER: U.K. 9916898.1
- ; PRIOR FILING DATE: 1999-07-19
- ; PRIOR APPLICATION NUMBER: U.K. 9816024.5
- ; PRIOR FILING DATE: 1998-07-22
- ; PRIOR APPLICATION NUMBER: US 09/359,208
- ; PRIOR FILING DATE: 1999-07-22
- ; NUMBER OF SEQ ID NOS: 6
- ; SOFTWARE: FastSEQ for Windows Version 3.0
- ; SEQ ID NO 2
- ; LENGTH: 1192
- ; TYPE: PRT
- ; ORGANISM: HOMO SAPIENS

US-09-789-386-2

75.2%; Score 4398.5; DB 9; Length 1192; Query Match 75.9%; Pred. No. 1e-213; Best Local Similarity Matches 908; Conservative 104; Mismatches 146; 20; Indels 39; Gaps 1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60 Qу 1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58 Db 61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115 Qу 59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118 Db 116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166 Qу 119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178 Db 167 RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS 225 Qу 179 RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS 237 Db 226 LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY 285 Qу ::||| |||||| 238 LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY 297 Db 286 SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVG----KED 339 Qу 298 SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED 357 Db 340 RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAA----RANV 395 Qу 358 EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL 416 Db 396 ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT 454 Qу 1111: 1111 417 ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRPGAYITCAPFNPAATESIA 476 Db 455 ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS 513 Qу 477 TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT 536 Db 514 KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL 573 Qу 537 KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL 596 Db 574 CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN 633 Qу 1:1:1111111 597 CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN 655 Db 634 PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF 692 Qу 656 PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF 715 Db 693 SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS 752 Qу 716 SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS 775 Db

```
753 -ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF 809
QУ
            776 FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL 835
Db
        810 NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS 868
Qу
           836 STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS 895
Db
        869 DKSEIANIQSGADSLPCLELPCDLSFKNIYPK--DEVHVSDEFSENRSSVSKASISPSNV 926
Qу
                   896 HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV 955
Db
        927 SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK 986
Qy
           956 SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK 1015
Db
        987 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1046
Qv
           1016 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1075
Db
       1047 YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1106
Qу
            1076 YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1135
Db
       1107 NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
            1136 NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1192
Db
RESULT 7
US-09-893-348-23
; Sequence 23, Application US/09893348
; Patent No. US20020072493A1
; GENERAL INFORMATION:
  APPLICANT: EISENBACH-SCHWARTZ, Michal
  APPLICANT: COHEN, Irun R.
  APPLICANT: BESERMAN, Pierre
  APPLICANT: MOSONEGO, Alon
  APPLICANT: MOALEM, Gila
  TITLE OF INVENTION: ACTIVATED T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND
THEIR USES
   FILE REFERENCE: EIS-SCHWARTZ=2A
   CURRENT APPLICATION NUMBER: US/09/893,348
   CURRENT FILING DATE: 2001-06-28
   PRIOR APPLICATION NUMBER: US 09/314,161
   PRIOR FILING DATE: 1999-05-19
   PRIOR APPLICATION NUMBER: US 09/218,277
   PRIOR FILING DATE: 1998-12-22
   PRIOR APPLICATION NUMBER: PCT/US98/14715
   PRIOR FILING DATE: 1998-07-21
   PRIOR APPLICATION NUMBER: IL 124500
   PRIOR FILING DATE: 1998-05-19
   NUMBER OF SEQ ID NOS: 29
   SOFTWARE: PatentIn version 3.1
; SEQ ID NO 23
   LENGTH: 1192
```

TYPE: PRT

; ORGANISM: Homo sapiens US-09-893-348-23

Score 4398.5; DB 9; Length 1192; Query Match 75.2%; Pred. No. 1e-213; Best Local Similarity 75.9%; 20; 39; Gaps Matches 908; Conservative 104; Mismatches 146; Indels 1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEEDEEEDDEDLEELEVLERK 60 Qу 1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58 Db 61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115 Qγ 59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118 Db 116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE------PAAPPSTPAAPKR 166 Qу 1111 11111111111111111 111111111111 119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAPPSTPAAPKR 178 Db 167 RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS 225 Qу 179 RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS 237 Db 226 LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY 285 Qу 11111 11111 111111 1 :111::1 ::11111: 1:1 ::||| ||||| 238 LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY 297 Db 286 SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVG----KED 339 Qу 298 SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED 357 Db 340 RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAA----RANV 395 Qy 358 EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL 416 Db 396 ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT 454 Qу 1111: 1 :1111 417 ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRPGAYITCAPFNPAATESIA 476 Db 455 ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS 513 QУ 477 TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT 536 Db 514 KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL 573 QУ 537 KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL 596 Db 574 CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN 633 Qy |:|:|4|| ||1|| 597 CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN 655 Db 634 PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF 692 QУ 656 PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF 715 Db 693 SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS 752 Qу

```
716 SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS 775
Db
        753 -ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF 809
Qу
            776 FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL 835
Db
        810 NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS 868
Qy
           836 STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS 895
Db
        869 DKSEIANIQSGADSLPCLELPCDLSFKNIYPK--DEVHVSDEFSENRSSVSKASISPSNV 926
Qу
                  896 HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV 955
Db
        927 SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK 986
Qу
           956 SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK 1015
Db
        987 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1046
Qу
           1016 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1075
Db
       1047 YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1106
Qу
           1076 YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1135
Db
       1107 NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
           1136 NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1192
Db
RESULT 8
US-10-267-502-429
; Sequence 429, Application US/10267502
; Publication No. US20040071700A1
; GENERAL INFORMATION:
  APPLICANT: Kim, Jaeseob
  APPLICANT: Galant, Ron
  TITLE OF INVENTION: Obesity Linked Genes
  FILE REFERENCE: LSD-07416
  CURRENT APPLICATION NUMBER: US/10/267,502
  CURRENT FILING DATE: 2003-01-27
  NUMBER OF SEQ ID NOS: 439
   SOFTWARE: PatentIn version 3.2
; SEQ ID NO 429
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-267-502-429
                     75.2%; Score 4398.5; DB 12; Length 1192;
  Query Match
  Best Local Similarity 75.9%; Pred. No. 1e-213;
  Matches 908; Conservative 104; Mismatches 146; Indels
                                                    39; Gaps
                                                             20;
          1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
            1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58
Db
```

Qy		PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAP	
Db		PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP	
QУ	116	APSLPPAAAVLPSKLPEDDEPPARPPPPPPPAGASPLAEPAAPPSTPAAPKR	166
Db	119	APSPLSAAAVSPSKLPEDDEPPARPPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR	178
QУ	167	RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS	225
Db	179	RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS	237
Qy	226	LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY	285
Db	238	LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY	297
Qу		SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVGKED	
Db	298	SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED	357
Qy	340	RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANV	395
Db	358	EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL	416
Qу	396	ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT	454
Db	417	ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRPGAYITCAPFNPAATESIA	476
QУ	455	ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS	513
Db	477	TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT	536
QУ		KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL	
Db	537	KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL	596
QУ	574	CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN	633
Db	597	CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN	655
Qу	634	PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF	692
Db	656	PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF	715
Qy	693	SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS : : : : :	752
Db	716	SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS	775
Qу	753	-ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF	809
Db	776	FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL	835
QУ	810	NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS	868
Db	836	5 STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS	895

```
869 DKSEIANIQSGADSLPCLELPCDLSFKNIYPK--DEVHVSDEFSENRSSVSKASISPSNV 926
Qу
                         896 HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV 955
Db
                927 SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK 986
QУ
                       956 SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK 1015
Db
                987 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1046
Qу
                        1016 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1075
Db
               1047 YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1106
Qу
                        1076 YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1135
Db
               1107 NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
                        1136 NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1192
Db
RESULT 9
US-10-327-213-9
 ; Sequence 9, Application US/10327213
 ; Publication No. US20040121341A1
 ; GENERAL INFORMATION:
     APPLICANT: FILBIN, MARIE T.
     APPLICANT: DOMENICONI, MARCO
     APPLICANT: CAO, ZIXUAN
     TITLE OF INVENTION: INHIBITORS OF MYELIN-ASSOCIATED GLYCOPROTEIN (MAG)
     TITLE OF INVENTION: ACTIVITY FOR REGULATING NEURAL GROWTH AND REGENERATION
     FILE REFERENCE: CUNY/003
     CURRENT APPLICATION NUMBER: US/10/327,213
      CURRENT FILING DATE: 2002-12-20
     NUMBER OF SEQ ID NOS: 43
      SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 9
       LENGTH: 1192
        TYPE: PRT
       ORGANISM: Homo sapiens
 US-10-327-213-9
                                             75.2%; Score 4398.5; DB 16; Length 1192;
    Query Match
                                             75.9%; Pred. No. 1e-213;
     Best Local Similarity
                                                                                                                                 20;
     Matches 908; Conservative 104; Mismatches 146; Indels
                                                                                                             39; Gaps
                     1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
 Qу
                         [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] [ : [] 
                     1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58
 Db
                    61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
 QУ
                          59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
  Db
                   116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166
  QУ
                                  119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178
  Db
```

	Qy Db		RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS	
	Qу		LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY	
	Db		LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY	
	Qу		SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVGKED	
	Db		SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED	
	Qу		RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANV	
	Db	358	EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL	416
	Qy		ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT	
	Db		ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRPGAYITCAPFNPAATESIA	
	Qy		ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS	
	Db	477	TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT	536
	Qу		KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL	
	Db	537	KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL	596
	Qу		CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN	
	Db	597	CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN	655
12	Qy		PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF	
	Db	656	PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF	715
	QУ		SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS	
	Db	716	SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS	775
	QУ		-ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF	
	Db	776	FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL	835
	Qу		NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS : : : :	
	Db	836	STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS	895
	QУ		DKSEIANIQSGADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNV	
	Db	896	HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV	955
	QУ		SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK	
	Db	956	SALATOAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK	1015

```
987 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1046
Qу
           1016 KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1075
Db
       1047 YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1106
QУ
           1076 YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1135
Db
       1107 NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
           1136 NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1192
Db
RESULT 10
US-10-466-258-9
; Sequence 9, Application US/10466258
; Publication No. US20040132096A1
; GENERAL INFORMATION:
  APPLICANT: GLAXO GROUP LIMITED
  TITLE OF INVENTION: ASSAY
  FILE REFERENCE: P80966 GCW
  CURRENT APPLICATION NUMBER: US/10/466,258
  CURRENT FILING DATE: 2003-07-15
  NUMBER OF SEQ ID NOS: 13
  SOFTWARE: PatentIn version 3.0
 SEO ID NO 9
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-466-258-9
                     75.2%; Score 4398.5; DB 16; Length 1192;
  Query Match
                           Pred. No. 1e-213;
                     75.9%;
  Best Local Similarity
                                                             20;
  Matches 908; Conservative 104; Mismatches 146;
                                            Indels
                                                   39; Gaps
          1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qy
           1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58
Db
         61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
Qу
           59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
Db
        116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166
Qу
                11111111111
        119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178
Db
        167 RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS 225
Qу
            179 RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS 237
Db
        226 LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY 285
 Qу
                                                ::||| |||||
                238 LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY 297
 Db
         286 SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVG----KED 339
 Qу
```

Db	298	SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED 357
Qу	340	RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANV 395
Db	358	::: : : : : : : EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL 416
QУ	396	ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT 454
Db	417	: : : :
QУ	455	ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS 513
Db	477	TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT 536
Qy	514	KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL 573
Db	537	KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL 596
Qу	574	CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN 633
Db	597	CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN 655
Qу	634	PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF 692
Db	656	PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF 715
Qу	693	SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS 752
Db	716	SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS 775
Qу	753	-ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF 809
Db		FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL 835
QУ		NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS 868
Db		STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS 895
Qу		DKSEIANIQSGADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNV 926
Db		HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV 955
Qу		SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK 986
Db		SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK 1015
QУ		KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1046
Db		KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA 1075
QУ		YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1106
Db		YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1135
QУ		NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Db	1136	NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1192

```
RESULT 11
US-10-408-967-7
; Sequence 7, Application US/10408967
; Publication No. US20040063161A1
; GENERAL INFORMATION:
  APPLICANT: Pharmacia & Upjohn Company
  APPLICANT: Yan, Rigiang
  APPLICANT: Lu, Yifeng
  TITLE OF INVENTION: Compositions and Methods of Treating Alzheimer's Disease
  FILE REFERENCE: 00925
  CURRENT APPLICATION NUMBER: US/10/408,967
  CURRENT FILING DATE: 2003-04-08
  NUMBER OF SEQ ID NOS: 9
  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-408-967-7
                      75.1%; Score 4389.5; DB 12; Length 1192;
  Query Match
                      75.8%; Pred. No. 3e-213;
  Best Local Similarity
 Matches 907; Conservative 104; Mismatches 147; Indels
                                                       39; Gaps
                                                                 20;
          1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
            1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58
Db
          61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
Qу
            59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
Db
         116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166
Qу
                                                     111111111111
                 119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178
Db
         167 RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS 225
Qу
            179 RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS 237
Db
         226 LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY 285
Qу
                                                   ::||| |||||
            1111 | 1111 | 11111 | 1111: | 11111: | 11111
         238 LSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEY 297
Db
         286 SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVG----KED 339
Qγ
             IIII
         298 SEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKED 357
Db
         340 RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAA----RANV 395
Qу
              358 EVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDS-DMLAAGGKIESNL 416
Db
         396 ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT 454
 QУ
             11111:11 11111 : 1111 1:1 1111111 :11
                                                 417 ESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRPGAYITCAPFNPAATESIA 476
 Db
```

Qу	455	ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS	513
Db	477	TNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLT	536
QУ	514	KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL	573
Db	537	KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL	596
QУ	574	CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN	633
Db	597	CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN	655
Qу	634	PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF	692
Db	656	PPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDF	715
Qу	693	SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS	752
Db	716	SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS	775
Qу	753	-ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF	809
Db	776	FESMIEYENKEKLSALPPEGGKPYLESFKLSLINTKDTLLPDEVSTLSKKEKIPLQMEEL	835
Qу	810	NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS: :	868
Db	836	STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS	895
QУ	869	DKSEIANIQSGADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNV	926
Db	896		955
QУ	927	SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK	986
Db	956	SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK	1015
QУ	987	KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA	1046
Db	1016	KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFPA	1075
Qу	1047	YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF	1106
Db	1076	YLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF	1135
Qу	1107	NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 11	63
Db	1136	NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 11	92

US-10-205-194-164

- ; Sequence 164, Application US/10205194
- ; Publication No. US20030134301A1
- ; GENERAL INFORMATION:
- ; APPLICANT: Warner-Lambert Company
- ; APPLICANT: Lee, Kevin

```
APPLICANT: Dixon, Alistair
 APPLICANT: Brooksbank, Robert
 APPLICANT: Pinnock, Robert
 TITLE OF INVENTION: Identification and Use of Molecules Implicated in Pain
  FILE REFERENCE: WL-A-018201
  CURRENT APPLICATION NUMBER: US/10/205,194
  CURRENT FILING DATE: 5200-07-24
  PRIOR APPLICATION NUMBER: GB 0118354.0
  PRIOR FILING DATE: 2001-07-27
  NUMBER OF SEQ ID NOS: 177
  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 164
  LENGTH: 379
  TYPE: PRT
  ORGANISM: Rattus norvegicus
  FEATURE:
  OTHER INFORMATION: Foocen-m2 reticulon
US-10-205-194-164
                    25.9%; Score 1513; DB 14; Length 379;
 Query Match
 Best Local Similarity 32.6%; Pred. No. 1.4e-68;
 Matches 379; Conservative 0; Mismatches 0; Indels 784; Gaps
         1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
           1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Db
        61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Qу
           61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Db
       121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
Qy
           121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
Db
       181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
Qу
           181 AASEPVIPSSA----- 191
Db
        241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300
Qу
        192 ------ 191
Db
        301 AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA 360
Qу
        192 ----- 191
Db
        361 PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGR 420
Qу
        192 ----- 191
Db
        421 NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA 480
Qу
        192 ----- 191
Db
        481 QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL 540
Qу
```

Db	192		191
QУ	541	NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL	600
Db	192		191
Qу	601	LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF	660
Db	192		191
Qу		NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE	
Db	192		191
QУ	721	PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP	780
Db	192		191
QУ	781	${\tt NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE}$	840
Db	192		191
QУ	841	IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK	900
Db	192		191
Qу	901	DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED	960
Db	192		191
Qу	961	RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS	1020
Db	192	VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS	236
Qу	1021	VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL	1080
Db	237	VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL	296
QУ	1081	FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA	1140
Db	297	FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA	356
QУ	1141	NKSVKDAMAKIQAKIPGLKRKAD 1163	
Db	357	NKSVKDAMAKIQAKIPGLKRKAD 379	

US-09-893-348-20

- ; Sequence 20, Application US/09893348
- ; Patent No. US20020072493A1
- ; GENERAL INFORMATION:
- ; APPLICANT: EISENBACH-SCHWARTZ, Michal
- ; APPLICANT: COHEN, Irun R. ; APPLICANT: BESERMAN, Pierre ; APPLICANT: MOSONEGO, Alon ; APPLICANT: MOALEM, Gila

```
; TITLE OF INVENTION: ACTIVATED T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND
THEIR USES
; FILE REFERENCE: EIS-SCHWARTZ=2A
  CURRENT APPLICATION NUMBER: US/09/893,348
  CURRENT FILING DATE: 2001-06-28
  PRIOR APPLICATION NUMBER: US 09/314,161
  PRIOR FILING DATE: 1999-05-19
  PRIOR APPLICATION NUMBER: US 09/218,277
  PRIOR FILING DATE: 1998-12-22
  PRIOR APPLICATION NUMBER: PCT/US98/14715
  PRIOR FILING DATE: 1998-07-21
  PRIOR APPLICATION NUMBER: IL 124500
  PRIOR FILING DATE: 1998-05-19
 NUMBER OF SEQ ID NOS: 29
  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 20
   LENGTH: 360
   TYPE: PRT
   ORGANISM: Rattus norvegicus
US-09-893-348-20
                   24.1%; Score 1411.5; DB 9; Length 360;
 Query Match
 Best Local Similarity 31.0%; Pred. No. 1.7e-63;
 Matches 360; Conservative 0; Mismatches 0; Indels 803; Gaps 1;
         1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
           1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Db
         61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Qу
           61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Db
        121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
QУ
           121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSV----- 172
Db
        181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
Qу
        173 ----- 172
Db
        241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300
QУ
        173 ----- 172
Db
        301 AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA 360
QУ
        173 ----- 172
Db
        361 PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGR 420
Qу
        173 ----- 172
Db
        421 NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA 480
 Qу
        173 ----- 172
 Db
```

QУ	481	QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL	540
Db	173		172
Qу	541	NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL	600
Db	173		172
Qу	601	LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF	660
Db	173		172
Qу		${\tt NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE}$	720
Db	173		172
QУ		PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP	780
Db	173		172
Qу		${\tt NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE}$	840
Db	173		172
Qу		IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK	900
Db	173		172
Qу		DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED	
Db	173		172
Qу	961	RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS	1020
Db	173	VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS	217
Qу	1021	VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL	1080
Db	218	VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL	277
Qу	1081	FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA	. 1140
Db	278	FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA	. 337
Qу	1141	NKSVKDAMAKIQAKIPGLKRKAD 1163	
Db	338	NKSVKDAMAKIQAKIPGLKRKAD 360	

US-09-789-386-6

- ; Sequence 6, Application US/09789386
- ; Patent No. US20020010324A1
- ; GENERAL INFORMATION:
- ; APPLICANT: MICHALOVICH, DAVID ; APPLICANT: PRINJHA, RABINDER KUMAR
- ; TITLE OF INVENTION: NOVEL COMPOUNDS

```
FILE REFERENCE: GP-30165-C1
  CURRENT APPLICATION NUMBER: US/09/789,386
  CURRENT FILING DATE: 2001-02-21
  PRIOR APPLICATION NUMBER: U.K. 9916898.1
  PRIOR FILING DATE: 1999-07-19
  PRIOR APPLICATION NUMBER: U.K. 9816024.5
  PRIOR FILING DATE: 1998-07-22
  PRIOR APPLICATION NUMBER: US 09/359,208
  PRIOR FILING DATE: 1999-07-22
  NUMBER OF SEQ ID NOS: 6
  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 6
  LENGTH: 373
  TYPE: PRT
  ORGANISM: HOMO SAPIENS
US-09-789-386-6
                   20.4%; Score 1191; DB 9; Length 373;
 Query Match
 Best Local Similarity 27.8%; Pred. No. 2.5e-52;
 Matches 327; Conservative 12; Mismatches 20; Indels 818; Gaps
                                                          7:
         1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
          1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58
Db
        61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
Qу
           59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
Db
       116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166
Qу
                                              119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178
Db
       167 RGSGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSL 226
Qу
           | | |
       179 RGSS----- 182
Db
       227 SPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYS 286
Qу
        183 ----- 182
Db
        287 EMGSSFKGSPKGESAILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEK 346
Qу
        183 ----- 182
Db
        347 TMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLED 406
Qу
        183 ----- 182
Db
        407 SLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTS 466
Qу
        183 ----- 182
Db
        467 ENKTDEKKIEERKAQIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEG 526
Qу
        183 ----- 182
Db
```

2у	527	LTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSP	586
Db	183		182
Qγ	587	VLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALK	646
Db	183		182
Qу		ALGTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVP	706
Db	183		182
Qу		EHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSAS	
Db	183		182
Qу	767	${\tt PQELGKPYLESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDK}$	826
Db	183		182
Qу	827	IKESETFSDSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCL	886
Db	183		182
Qу		ELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTK	
Db	183	GSV	185
Qу	947	EAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFS	1006
Db	186	VVDLLYWRDIKKTGVVFGASLFLLLSLTVFS	216
QУ	1007	IVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSA	1066
Db	217	IVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSA	276
QУ	1067	LGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIY	1126
Db	277	LGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSVPVIY	336
QУ	1127	ERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163	
Db	337	ERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 373	

US-09-765-205-6

- ; Sequence 6, Application US/09765205
- ; Patent No. US20020034800A1
- ; GENERAL INFORMATION:
- ; APPLICANT: Cao, Li
- ; TITLE OF INVENTION: BONE MARROW SECRETED PROTEINS AND POLYNUCLEOTIDES
- ; FILE REFERENCE: 1458.004/200130.449
- ; CURRENT APPLICATION NUMBER: US/09/765,205
- ; CURRENT FILING DATE: 2001-01-17
- ; PRIOR APPLICATION NUMBER: US/09/212,440
- ; PRIOR FILING DATE: 1998-12-16

```
; NUMBER OF SEQ ID NOS: 46
 SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 6
  LENGTH: 373
  TYPE: PRT
  ORGANISM: human
US-09-765-205-6
                  20.4%; Score 1191; DB 9; Length 373;
 Query Match
 Best Local Similarity 27.8%; Pred. No. 2.5e-52;
 Matches 327; Conservative 12; Mismatches 20; Indels 818; Gaps 7;
        1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
          1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDEDLEELEVLERK 58
Db
        61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
Qу
          59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
Db
       116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166
Qу
              ин ининишин і і
                                            119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178
Db
       167 RGSGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSL 226
Qу
       179 RGSS----- 182
Db
       227 SPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYS 286
Qу
       183 ----- 182
Db
       287 EMGSSFKGSPKGESAILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEK 346
Qу
       183 ------ 182
Db
       347 TMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLED 406
Qу
       183 ----- 182
Db
        407 SLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTS 466
Qу
Db
        467 ENKTDEKKIEERKAQIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEG 526
Qу
        183 ----- 182
Db
        527 LTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSP 586
Qу
        183 ----- 182
Db
        587 VLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALK 646
Qу
        183 ----- 182
 Db
        647 ALGTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVP 706
 QУ
```

Db	183		182
Ωу	707	EHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSAS	766
Db	183		182
Qу	767	PQELGKPYLESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDK	826
Db	183		182
Qу	827	IKESETFSDSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCL	886
Db	183		182
Qу		ELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTK	
Db	183	GSV	185
Qу	947	EAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFS	1006
Db	186	VVDLLYWRDIKKTGVVFGASLFLLLSLTVFS	216
Qу	1007	IVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSA	1066
Db	217	IVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSA	276
Qу		LGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIY	
Db	277	LGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSVPVIY	336
Qу	1127	ERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163 	
Db	337	ERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 373	

Search completed: September 29, 2004, 18:48:11 Job time: 131.84 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 29, 2004, 18:06:43; Search time 91.4948 Seconds

(without alignments)

4010.587 Million cell updates/sec

Title: US-09-830-972-2

Perfect score: 5848

Sequence: 1 MEDIDQSSLVSSSTDSPPRP......VKDAMAKIQAKIPGLKRKAD 1163

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SPTREMBL_25:*

1: sp_archea:*

2: sp_bacteria:*

3: sp fungi:*

4: sp_human:*

5: sp_invertebrate:*

6: sp_mammal:*

7: sp_mhc:*

8: sp_organelle:*

9: sp_phage:*

10: sp plant:*

11: sp_rodent:*

12: sp_virus:*

13: sp_vertebrate:*

14: sp_unclassified:*

15: sp_rvirus:*

16: sp_bacteriap:*

17: sp archeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result Query

ક

No. Score Match Length DB ID Description

1	5312.5	90.8	1162	11	Q8BGM9	Q8bgm9 mus musculu
2	5307	90.7	1163	11	Q8K3G8	Q8k3g8 mus musculu
3	4501.5	77.0	1046	11	Q8BGK7	Q8bgk7 mus musculu
4	3627.5	62.0	986	4	Q8IUA4	Q8iua4 homo sapien
5	3299.5	56.4	720	11	Q7TNB7	Q7tnb7 mus musculu
6	2926	50.0	639	11	Q8K290	Q8k290 mus musculu
7	2610	44.6	578	11	Q80W95	Q80w95 mus musculu
8	1416	24.2	375	11	Q8BHF5	Q8bhf5 mus musculu
9	1314.5	22.5	356	11	Q8BH78	Q8bh78 mus musculu
10	1304	22.3	357	11	Q8K3G7	Q8k3g7 mus musculu
11	1283.5	21.9	392	4	Q96B16	Q96b16 homo sapien
12	878	15.0	184	6	Q7YRW9	Q7yrw9 bos taurus
13	876	15.0	199	13	Q7T224	Q7t224 gallus gall
14	844	14.4	179	6	Q9GM33	Q9qm33 macaca fasc
15	792	13.5	780	11	Q8K4S4	Q8k4s4 mus musculu
16	788	13.5	780	11	Q8K0T0	Q8k0t0 mus musculu
17	762.5	13.0	760	13	Q90638	Q90638 gallus gall
18	737	12.6	214	13	Q7T222	Q7t222 carassius a
19	700	12.0	643	11	Q8CCU2	Q8ccu2 mus musculu
20	685	11.7	199	4	Q9BQ59	Q9bq59 homo sapien
21	671	11.5	267	11	Q63765	Q63765 rattus sp.
22	669	11.4	208	13	Q90637	Q90637 gallus gall
23	625.5	10.7	236	11	Q8VBU0	Q8vbu0 rattus norv
24	625.5	10.7	237	11	Q8C6D5	Q8c6d5 mus musculu
25	590.5	10.1	221	13	Q7ZUD6	Q7zud6 brachydanio
26	586	10.0	595	5	Q9VMV9	Q9vmv9 drosophila
27	532	9.1	224	5	Q9VMW1	Q9vmw1 drosophila
28	520	8.9	202	5	Q9VMW2	Q9vmw2 drosophila
29	520	8.9	222	5	Q9VMW4	Q9vmw4 drosophila
30	520	8.9	234	5	Q9VMW3	Q9vmw3 drosophila
31	517	8.8	2484	5	Q9U347	Q9u347 caenorhabdi
32	503.5	8.6	2607	5	Q23187	Q23187 caenorhabdi
33	377	6.4	2768	5	Q9VC00	Q9vc00 drosophila
34	347.5	5.9	10578	5	Q8ISF5	Q8isf5 caenorhabdi
35	344	5.9	107	13	Q7T223	Q7t223 carassius a
36	343.5	5.9	18519	5	Q8ISF6	Q8isf6 caenorhabdi
37	343.5	5.9	18534	5	Q8ISF7	Q8isf7 caenorhabdi
38	342.5	5.9	1417	3	Q871Y7	Q871y7 neurospora
39	335	5.7	5412	5	Q9W596	Q9w596 drosophila
40	331	5.7	4900	5	Q9N541	Q9n541 caenorhabdi
41	328.5	5.6	5327	5	076891	076891 drosophila
42	322	5.5	7962	4	Q10465	Q10465 homo sapien
43	320	5.5	222	5	Q23188	Q23188 caenorhabdi
44	317.5	5.4	17352	5	Q95YM2	Q95ym2 procambarus
45	313.5	5.4	1444	5	Q9VTN2	Q9vtn2 drosophila

ALIGNMENTS

```
RESULT 1
Q8BGM9
ID Q8BGM9 PRELIMINARY; PRT; 1162 AA.
AC Q8BGM9;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
```

```
DΕ
    RTN4
    RTN4.
GN
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
    NCBI TaxID=10090;
OX
RN
    [1]
    SEQUENCE FROM N.A.
RP
    STRAIN=129/SvcJ7, and 129SvcJ7;
RC
    Oertle T., van der Putten H., Schwab M.E.;
RA
    "Genomic Structure and Functional Characterization of the Promoter
RT
    Structures of Human and Mouse Nogo/Rtn-4.";
RT
    Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RΡ
    SEQUENCE FROM N.A.
    STRAIN=129/SvcJ7, and 129SvcJ7;
RC
    Oertle T., Schwab M.E.;
RA
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
    SEQUENCE FROM N.A.
RP
    STRAIN=129/SvcJ7;
RC
RA
    Van der Putten H.;
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
    SEQUENCE FROM N.A.
RP
RC
    STRAIN=129SvcJ7;
    Van der Putten H., Mir A.;
RA
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; AY102284; AAM73506.1; -.
DR
    EMBL; AY102286; AAM73511.1; -.
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    GO; GO:0007399; P:neurogenesis; IDA.
DR
    InterPro; IPR003388; Reticulon.
DR
DR
    Pfam; PF02453; Reticulon; 1.
    PROSITE; PS50845; RETICULON; 1.
DR
              1162 AA; 126613 MW; 855697FBEE11781F CRC64;
SO
    SEQUENCE
                       90.8%; Score 5312.5; DB 11; Length 1162;
  Query Match
  Best Local Similarity 91.0%; Pred. No. 9.1e-259;
                                                                      6;
  Matches 1064; Conservative 37; Mismatches
                                            55; Indels
           1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
             1 MEDIDQSSLVSSSADSPPRPPPAFKYQFVTEPEDEEDEEDEE-EEEDDEDLEELEVLERK 59
Db
          61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Qу
             60 PAAGLSAAPVPP-AAAPLLDFSSDSVPPAPRGPLPAAPPTAPERQPSWERSPAASAPSLP 118
Db
         121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
Qу
             119 PAAAVLPSKLPEDDEPPAR--PPAPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 176
Db
         181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
Qу
             177 AASEPVIPSSAEKIMDLKEQPGNTVSSGQEDFPSVLFETAASLPSLSPLSTVSFKEHGYL 236
Db
```

Qγ		GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES	
Db		GNLSAVASTEGTIEETLNEASRELPERATNPFVNRESAEFSVLEYSEMGSSFNGSPKGES	
QУ	301	AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQ :	355
Db	297	AMLVENTKEEVIVRSKDKEDLVCSAALHNPQESPATLTKVVKEDGVMSPEKTMDIFNEMK	356
Qу	356	MSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGK	415
Db	357	MSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANMESKVDKKCFEDSLEQKGHGK	416
Qy	416	DSEGRNEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKI	475
Db	417	DSESRNENASFPRTPELVKDGSRAYITCDSFSSATESTAANIFPVLEDHTSENKTDEKKI	476
Qy	476	EERKAQIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEA	535
Db	477	EERKAQIITEKTSPKTSNPFLVAIHDSEADYVTTDNLSKVTEAVVATMPEGLTPDLVQEA	536
Qу	536	CESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEA	595
Db	537	CESELNEATGTKIAYETKVDLVQTSEAIQESIYPTAQLCPSFEEAEATPSPVLPDIVMEA	596
Qy	596	PLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIK	655
Db	597	PLNSLLPSTGASVAQPSASPLEVPSPVSYDGIKLEPENPPPYEEAMSVALKTSDSKEEIK	656
Qу	656	EPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDS	715
Db	657	EPESFNAAAQEAEAPYISIACDLIKETKLSTEPSPEFSNYSEIAKFEKSVPDHCELVDDS	716
QУ	716	SPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHK-EERLSASPQELGKPY	774
Db	717	SPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVTQHKHKERLSASPQEVGKPY	776
QУ	775	LESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFS	834
Db	777		836
Qу	835	DSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSF	894
Db	837		893
QУ	895	KNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPS	954
Db	894	:: :	953
Qy	955	DTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYI	1014
Db	954	: : : : : : : : : :	1013
Qу	1015	ALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTI	1074
Db	1014		1073

```
1075 KELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQID 1134
Qу
            1074 KELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQAQID 1133
Db
       1135 HYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
QУ
            1134 HYLGLANKSVKDAMAKIQAKIPGLKRKAE 1162
Db
RESULT 2
08K3G8
                              PRT; 1163 AA.
              PRELIMINARY;
    Q8K3G8
TD
AC
    Q8K3G8;
    01-OCT-2002 (TrEMBLrel. 22, Created)
DT
    01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DΕ
    RTN4.
GN
    Mus musculus (Mouse).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
    [1]
    SEQUENCE FROM N.A.
RP
    STRAIN=BALB/c;
RC
    Jin W., Long M., Li R., Ju G.;
RA
    "Cloning and expression of the mouse Nogo-A protein.";
RT
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; AY114152; AAM77068.1; -.
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    GO; GO:0007399; P:neurogenesis; IDA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
              1163 AA; 126691 MW; 6B5F362799417EA4 CRC64;
SO
    SEQUENCE
                      90.7%; Score 5307; DB 11; Length 1163;
  Query Match
                      91.1%; Pred. No. 1.7e-258;
  Best Local Similarity
                                                                   7;
 Matches 1066; Conservative 34; Mismatches
                                           56; Indels
                                                       14; Gaps
          1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qy
            1 MEDIDQSSLVSSSADSPPRPPPAFKYQFVTEPEDEEDEEDEE-EEEDDEDLEELEVLERK 59
Db
          61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
QУ
                   60 PAAGLSAVPVPP-AAAPLLDFSSDSVPPAPRGPLPAAPPTAPERQPSWERSPAASAPSLP 118
Db
         121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
Qу
            119 PAAAVLPSKLPEDDEPPAR--PPAPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 176
Db
         181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
QУ
            177 AASEPVIPSSAEKIMDLKEQPGNTVSSGQEDFPSVLFETAASLPSLSPLSTVSFKEHGYL 236
Db
```

Qу		GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES : :	
Qу	301	AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQ	
Db	297	:	356
Qу	356	MSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGK	415
Db	357	MSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANMESKVDKKCFEDSLEQKSHGK	416
Qу		DSEGRNEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKI	475
Db	417	DSESRNENASFPSTPELVKDGSRAYITCDSFTSATESTAANIFPVLEDHTSENKTDEKKI	476
Qy	476	EERKAQIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEA	535
Db	477	EERKAQIITEKTSPKTSNPFLVAIHDSEADYVTTDNLSKVTEAVVATMPEGLTPDLVQEA	536
Qy		CESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEA	595
Db		CESELNEATGTKIAYETKVDLVQTSEAIQESIYPTAQLCPSFEEAEATPSPVLPDIVMEA	596
Qу		PLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIK	655
Db		PLNSLLPSTGASVAQPSASPLEVPSPVSYDGIKLEPENPPPYEEAMSVALKTSDAKEEIK	656
Qу		EPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDS	715
Db	657	EPESFNAAAQEAEAPYISIACDLIKETKLSTEPSPGFSNYSEIAKFEKSVPDHCELVDDS	716
Qу	716	SPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHK-EERLSASPQELGKPY	774
Db	717	SPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVTQHKHKERLSASPQEVGKPY	776
QУ	775	LESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFS	834
Db	777	LESFQPNLHITKDAASNEIPTLTKKETISLQMEEFNTAIYSNDDLLSSKEDKMKESETFS	836
QУ	835	DSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSF	894
Db	837	DSSPIEIIDEFPTFVSAKDDSPKEYTDLEVSNKSEIANVQSGANSLPCSELPCDLSF	893
Qу	895	KNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPS	954
Db	894	KNTYPKDEAHVSDEFSKSRSSVSKVPLLLPNVSALESQIEMGNIVKPKVLTKEAEEKLPS	953
Qу	955	DTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVV-FGASLFLLLSLTVFSIVSVTAY	1013
Db	954	DTEKEDRSLTAVLSAELNKTSVVDLLYWRDIKKTGVVYFGASLFLLLSLTVFSIVSVTAY	1013
Qy	1014	IALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNST	1073
Db	1014	IALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNST	1073
Qy	1074	IKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQI	1133

```
1074 IKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQAQI 1133
Db
        1134 DHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
             1134 DHYLGLANKSVKDAMAKIQAKIPGLKRKAE 1163
Db
RESULT 3
Q8BGK7
                                PRT; 1046 AA.
                PRELIMINARY;
ID
    Q8BGK7
AC
    08BGK7;
    01-MAR-2003 (TrEMBLrel. 23, Created)
DΤ
    01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DТ
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DE
   RTN4.
GN
    RTN4.
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
    [1]
    SEQUENCE FROM N.A.
RP
    STRAIN=129/SvcJ7, and 129SvcJ7;
RC
    Oertle T., van der Putten H., Schwab M.E.;
RA
    "Genomic Structure and Functional Characterization of the Promoter
RT
    Structures of Human and Mouse Nogo/Rtn-4.";
RT
    Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
    [2]
    SEQUENCE FROM N.A.
RP
    STRAIN=129/SvcJ7, and 129SvcJ7;
RC
    Oertle T., Schwab M.E.;
RA
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     SEQUENCE FROM N.A.
     STRAIN=129/SvcJ7;
RC
    Van der Putten H.;
RA
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
     SEQUENCE FROM N.A.
RP
     STRAIN=129SvcJ7;
RC
    Van der Putten H., Mir A.;
RA
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
     EMBL; AY102280; AAM73502.1; -.
DR
     EMBL; AY102286; AAM73507.1; -.
DR
DR
     MGD; MGI:1915835; Rtn4.
     GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
     GO; GO:0007399; P:neurogenesis; IDA.
DR
     InterPro; IPR003388; Reticulon.
DR
DR
     Pfam; PF02453; Reticulon; 1.
     PROSITE; PS50845; RETICULON; 1.
DR
     SEQUENCE 1046 AA; 114221 MW; 8CE2E2238ED51222 CRC64;
SO
                         77.0%; Score 4501.5; DB 11; Length 1046;
  Query Match
  Best Local Similarity
                         86.9%; Pred. No. 4.8e-218;
                                                                          4;
  Matches 910; Conservative 40; Mismatches 68; Indels
                                                             29; Gaps
```

Qγ	143	PPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALPAA	182
Db	3	: :	62
Qу	183	SEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYLGN	242
Db	63	SEPVIPSSAEKIMDLKEQPGNTVSSGQEDFPSVLFETAASLPSLSPLSTVSFKEHGYLGN	122
Qу	243	LSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGESAI	302
Db	123	LSAVASTEGTIEETLNEASRELPERATNPFVNRESAEFSVLEYSEMGSSFNGSPKGESAM	182
QУ	303	LVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMS	357
Db	183	LVENTKEEVIVRSKDKEDLVCSAALHNPQESPATLTKVVKEDGVMSPEKTMDIFNEMKMS	242
QУ	358	VVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDS	417
Db	243	VVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANMESKVDKKCFEDSLEQKGHGKDS	302
QУ	418	EGRNEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEE	477
Db	303	ESRNENASFPRTPELVKDGSRAYITCDSFSSATESTAANIFPVLEDHTSENKTDEKKIEE	362
QУ	478	RKAQIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACE	537
Db	363	RKAQIITEKTSPKTSNPFLVAIHDSEADYVTTDNLSKVTEAVVATMPEGLTPDLVQEACE	422
QУ	538	SELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPL	597
Db		SELNEATGTKIAYETKVDLVQTSEAIQESIYPTAQLCPSFEEAEATPSPVLPDIVMEAPL	482
Qу			657
Db	483	NSLLPSTGASVAQPSASPLEVPSPVSYDGIKLEPENPPPYEEAMSVALKTSDSKEEIKEP	542
Qу			717
Db		ESFNAAAQEAEAPYISIACDLIKETKLSTEPSPEFSNYSEIAKFEKSVPDHCELVDDSSP	
Qу		ESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHK-EERLSASPQELGKPYLE	
Db		ESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVTQHKHKERLSASPQEVGKPYLE	
Qу		SFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDS	
Db		SFQPNLHITKDAASNEIPTLTKKETISLQMEEFNTAIYSNDDLLSSKEDKMKESETFSDS	
QУ		SPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKN	
Db		SPIEIIDEFPTFVSAKDDSPKEYTDLEVSNKSEIANVQSGANSLPCSELPCDLSFKN	
QУ		IYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDT	
Db		TYPKDEAHVSDEFSKSRSSVSKVPLLLPNVSALESQIEMGNIVKPKVLTKEAEEKLPSDT	
Ov	957	EKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIAL	1016

```
840 EKEDRSLTAVLSAELNKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIAL 899
Db
        1017 ALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKE 1076
Qy
             900 ALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKE 959
Db
        1077 LRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHY 1136
QУ
             960 LRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQAQIDHY 1019
Db
        1137 LGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
             1020 LGLANKSVKDAMAKIQAKIPGLKRKAE 1046
Db
RESULT 4
Q8IUA4
    Q8IUA4
               PRELIMINARY;
                                PRT;
                                      986 AA.
ID
    Q8IUA4;
AC
    01-MAR-2003 (TrEMBLrel. 23, Created)
DΤ
    01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT
    01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DT
    RNT4 (RTN4).
DE
GN
    RTN4.
OS
    Homo sapiens (Human).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
    NCBI TaxID=9606;
OX
RN
    [1]
RP
    SEQUENCE FROM N.A.
    Oertle T., van der Putten H., Schwab M.E.;
RA
    "Genomic Structure and Functional Characterization of the Promoter
RT
RT
    Structures of Human and Mouse Nogo/Rtn-4.";
    Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
    [2]
    SEQUENCE FROM N.A.
RP
    Oertle T., Schwab M.E.;
RA
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
    [3]
    SEQUENCE FROM N.A.
RP
    Van der Putten H.;
RA
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
    SEQUENCE FROM N.A.
RP
RC
    TISSUE=Testis;
    MEDLINE=22376540; PubMed=12488097;
RX
    Oertle T., van der Putten H., Schwab M.E.;
RA
    "Genomic Structure and Functional Characterization of the Promoter
RT
    Structures of Human and Mouse Nogo/Rtn-4.";
RТ
    J. Mol. Biol. 325:299-323(2003).
RT.
    EMBL; AY102285; AAM64244.1; -.
DR
    EMBL; AY123245; AAM64249.1; -.
DR
    EMBL; AY123246; AAM64250.1; -.
DR
    EMBL; AY123247; AAM64251.1; -.
DR
    EMBL; AY123248; AAM64252.1; -.
DR
     EMBL; AY123249; AAM64253.1; -.
DR
```

```
DR
   EMBL; AY123250; AAM64254.1; -.
   GO; GO:0005783; C:endoplasmic reticulum; IEA.
DR
   InterPro; IPR003388; Reticulon.
DR
DR
   Pfam; PF02453; Reticulon; 1.
   PROSITE; PS50845; RETICULON; 1.
DR
            986 AA; 108449 MW; 0CDE8F647036415A CRC64;
SQ
   SEQUENCE
                    62.0%; Score 3627.5; DB 4; Length 986;
 Query Match
                    75.4%; Pred. No. 3.9e-174;
 Best Local Similarity
 Matches 745; Conservative 96; Mismatches 126;
                                                           13;
                                          Indels
                                                 21; Gaps
       195 MDLMEOPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYLGNLSAVSSSEGTIE 254
Qу
           1 MDLKEQPGNTISAGQEDFPSVLLETAASLPSLSPLSAASFKEHEYLGNLSTVLPTEGTLQ 60
Db
       255 ETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENTKEEVIVR 314
Qу
                        | ::|||||: |:|
        61 ENVSEASKEVSEKAKTLLIDRDLTEFSELEYSEMGSSFSVSPKAESAVIVANPREEIIVK 120
Db
       315 SKDKED-LVCSAALHSPQESPVG----KEDRVVSPEKTMDIFNEMQMSVVAPVREEYAD 368
Qy
                                :||:|: || : ||: ||
       121 NKDEEEKLVSNNILHNQQELPTALTKLVKEDEVVSSEKAKDSFNEKRVAVEAPMREEYAD 180
Db
       369 FKPFEQAWEVKDTYEGSRDVLAA----RANVESKVDRKCLEDSLEQKSLGKDSEGRNEDA 424
Qy
                                181 FKPFERVWEVKDSKEDS-DMLAAGGKIESNLESKVDKKCFADSLEQTNHEKDSESSNDDT 239
Db
       425 SFPSTPEPVKDSSRAYITCASFT-SATESTTANTFPLLEDHTSENKTDEKKIEERKAQII 483
Qy
                                   240 SFPSTPEGIKDRSGAYITCAPFNPAATESIATNIFPLLGDPTSENKTDEKKIEEKKAQIV 299
Dh
       484 TEK-TSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESELNE 542
Qу
           300 TEKNTSTKTSNPFLVAAQDSETDYVTTDNLTKVTEEVVANMPEGLTPDLVQEACESELNE 359
Db
        543 ATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSLLP 602
Qу
           360 VTGTKIAYETKMDLVQTSEVMQESLYPAAQLCPSFEESEATPSPVLPDIVMEAPLNSAVP 419
Db
        603 SAGASVVOPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKAL-GTKEGIKEPESFN 661
Qу
           111111:111 11111
                         420 SAGASVIQPSSSPLEA-SSVNYESIKHEPENPPPYEEAMSVSLKKVSGIKEEIKEPENIN 478
Db
        662 AAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESEP 721
Qу
           479 AALQETEAPYISIACDLIKETKLSAEPAPDFSDYSEMAKVEQPVPDHSELVEDSSPDSEP 538
Db
        722 VDLFSDDSIPEVPOTOEEAVMLMKESLTEVS-ETVAQHK-EERLSASPQELGKPYLESFQ 779
Qу
           539 VDLFSDDSIPDVPQKQDETVMLVKESLTETSFESMIEYENKEKLSALPPEGGKPYLESFK 598
Db
        780 PNLHSTKDA-ASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSP 838
Qу
                    599 LSLDNTKDTLLPDEVSTLSKKEKIPLQMEELSTAVYSNDDLFISKEAQIRETETFSDSSP 658
Db
        839 IEIIDEFPTFVSAKDDS-PKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNI 897
Qу
```

```
659 IEIIDEFPTLISSKTDSFSKLAREYTDLEVSHKSEIANAPDGAGSLPCTELPHDLSLKNI 718
Db
         898 YPK--DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSD 955
Qу
              719 QPKVEEKISFSDDFSKNGSATSKVLLLPPDVSALATQAEIESIVKPKVLVKEAEKKLPSD 778
Db
         956 TEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIA 1015
Qу
             779 TEKEDRSPSAIFSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIA 838
Db
        1016 LALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIK 1075
Qy
             839 LALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIK 898
Db
        1076 ELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDH 1135
Qу
             899 ELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDH 958
Db
        1136 YLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
             111111:1111111111111111111111111
         959 YLGLANKNVKDAMAKIQAKIPGLKRKAE 986
Db
RESULT 5
O7TNB7
                                       720 AA.
                                PRT:
                PRELIMINARY;
ID
    Q7TNB7
AC
    Q7TNB7;
    01-OCT-2003 (TrEMBLrel. 25, Created)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT
     01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
    Hypothetical protein.
DF.
    Mus musculus (Mouse).
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
    NCBI TaxID=10090;
OX
RN
     [1]
RP
     SEQUENCE FROM N.A.
     STRAIN=C57BL/6; TISSUE=Brain;
RC
     MEDLINE=22388257; PubMed=12477932;
RX
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA
     Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA
     Jones S.J., Marra M.A.;
RA
     "Generation and initial analysis of more than 15,000 full-length human
RT
```

```
RT
   and mouse cDNA sequences.";
   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
RN
   SEQUENCE FROM N.A.
RP
   STRAIN=C57BL/6; TISSUE=Brain;
RC
    Strausberg R.;
RA
    Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RL
   EMBL; BC056373; AAH56373.1; -.
DR
   Hypothetical protein.
KW
                  77435 MW; 80AB78728F16EAB2 CRC64;
   SEQUENCE
            720 AA;
SO
                    56.4%; Score 3299.5; DB 11; Length 720;
 Query Match
                    90.3%; Pred. No. 7.9e-158;
 Best Local Similarity
 Matches 654; Conservative
                                                           4;
                       22: Mismatches
                                      39;
                                          Indels
                                                9;
                                                     Gaps
         1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qy
           1 MEDIDQSSLVSSSADSPPRPPPAFKYQFVTEPEDEEDEEDEE-EEEDDEDLEELEVLERK 59
Db
        61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Qу
           60 PAAGLSAAPVPP-AAAPLLDFSSDSVPPAPRGPLPAAPPTAPERQPSWERSPAASAPSLP 118
Db
       121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
Qу
           119 PAAAVLPSKLPEDDEPPAR--PPAPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 176
Db
       181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
Qу
           177 AASEPVIPSSAEKIMDLKEQPGNTVSSGQEDFPSVLFETAASLPSLSPLSTVSFKEHGYL 236
Db
       241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300
Qу
           237 GNLSAVASTEGTIEETLNEASRELPERATNPFVNRESAEFSVLEYSEMGSSFNGSPKGES 296
Db
        301 AILVENTKEEVIVRSKDKEDLVCSAALHSPQESP----VGKEDRVVSPEKTMDIFNEMQ 355
Qу
                                         1:11111:111:111
        297 AMLVENTKEEVIVRSKDKEDLVCSAALHNPQESPATLTKVVKEDGVMSPEKTMDIFNEMK 356
Db
        356 MSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGK 415
Qу
           357 MSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANMESKVDKKCFEDSLEQKGHGK 416
Db
        416 DSEGRNEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKI 475
Qy
           417 DSESRNENASFPRTPELVKDGSRAYITCDSFSSATESTAANIFPVLEDHTSENKTDEKKI 476
Db
        476 EERKAQIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEA 535
Qу
           477 EERKAQIITEKTSPKTSNPFLVAIHDSEADYVTTDNLSKVTEAVVATMPEGLTPDLVQEA 536
Db
        536 CESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEA 595
Qу
           537 CESELNEATGTKIAYETKVDLVQTSEAIQESIYPTAQLCPSFEEAEATPSPVLPDIVMEA 596
Db
        596 PLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIK 655
Qу
```

```
597 PLNSLLPSTGASVAOPSASPLEVPSPVSYDGIKLEPENPPPYEEAMSVALKTSDSKEEIK 656
Db
         656 EPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDS 715
Qv
            657 EPESFNAAAQEAEAPYISIACDLIKETKLSTEPSPEFSNYSEIAKFEKSVPDHCELVDDS 716
Db
        716 SPES 719
Qу
            1111
        717 SPES 720
Db
RESULT 6
Q8K290
               PRELIMINARY;
                               PRT;
                                     639 AA.
ID
    Q8K290
AC
    Q8K290;
    01-OCT-2002 (TrEMBLrel. 22, Created)
DT
    01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DE
    Hypothetical protein.
GN
    RTN4.
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RA
    Strausberg R.;
RL
    Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; BC032192; AAH32192.1; -.
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
    GO; GO:0007399; P:neurogenesis; IDA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
KW
    Hypothetical protein.
              639 AA; 70312 MW; 309A19DA37603F11 CRC64;
SQ
    SEQUENCE
  Query Match 50.0%; Score 2926; DB 11; Length 639; Best Local Similarity 91.6%; Pred. No. 4e-139;
 Matches 588; Conservative 20; Mismatches
                                            30; Indels
                                                          4; Gaps
                                                                    2;
         523 MPEGLTPDLVOEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEA 582
Qу
            1 MPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESIYPTAQLCPSFEEAEA 60
Db
         583 TPSPVLPDIVMEAPLNSLLPSAGASVVOPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMN 642
Qу
            61 TPSPVLPDIVMEAPLNSLLPSTGASVAQPSASPLEVPSPVSYDGIKLEPENPPPYEEAMS 120
Db
         643 VALKALGTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFE 702
Qу
                    121 VALKTSDAKEEIKEPESFNAAAOEAEAPYISIACDLIKETKLSTEPSPEFSNYSEIAKFE 180
Db
         703 KSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHK-EE 761
QУ
            181 KSVPDHCELVDDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVTQHKHKE 240
Db
```

```
762 RLSASPQELGKPYLESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLS 821
Qу
            241 RLSASPQEVGKPYLESFQPNLHITKDAASNEIPTLTKKETISLQMEEFNTAIYSNDDLLS 300
Db
        822 SKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGAD 881
Qy
            Db
        301 SKEDKMKESETFSDSSPIEIIDEFPTFVSAKDDSP---KEYTDLEVSNKSEIANVQSGAN 357
Qу
        882 SLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKS 941
            111111 | 111:11
Db
        358 SLPCSELPCDLSFKNTYPKDEAHVSDEFSKSRSSVSKVPLLLPNVSALESQIEMGNIVKP 417
Qу
        942 KSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLS 1001
            418 KVLTKEAEEKLPSDTEKEDRSLTAVLSAELNKTSVVDLLYWRDIKKTGVVFGASLFLLLS 477
Db
Qу
       1002 LTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQK 1061
            Db
        478 LTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQK 537
       1062 YSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFS 1121
Qу
            538 YSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFS 597
Db
       1122 IPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
            Db
        598 IPVIYERHQAQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAE 639
RESULT 7
Q80W95
ID
    Q80W95
              PRELIMINARY;
                             PRT;
                                   578 AA.
AC
    Q80W95;
DT
    01-JUN-2003 (TrEMBLrel. 24, Created)
DТ
    01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE
    Nogo-A (Fragment).
GN
    NOGO-A.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
    [1]
    SEQUENCE FROM N.A.
RP
RA
    Tozaki H., Hirata T.;
    "The partial sequence of mouse nogo-A cDNA clone#4109.";
RT
RL
    Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; AB073672; BAC75974.1; -.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IEA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
FT
    NON TER
                1
                     7
    SEQUENCE
             578 AA; 63696 MW; 832670C171E4AC61 CRC64;
SQ
 Query Match
                     44.6%; Score 2610; DB 11; Length 578;
```

```
Best Local Similarity
                    90.7%; Pred. No. 2.7e-123;
  Matches 527; Conservative 18; Mismatches
                                           Indels
                                                            2:
                                                      Gaps
        584 PSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNV 643
Qу
           1 PSPVLPDIVMEAPLNSLLPSTGASVAQPSASPLEVPSPVSYDGIKLEPENPPPYEEAMSV 60
Db
Qy
        644 ALKALGTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEK 703
                Db
         61 ALKTSDAKEEIKEPESFNAAAQEAEAPYISIACDLIKETKLSTEPSPGFSNYSEIAKFEK 120
        704 SVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHK-EER 762
Qy
           Db
        121 SVPDHCELVDDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVTQHKHKER 180
        763 LSASPQELGKPYLESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSS 822
Qy
           181 LSASPQEVGKPYLESFQPNLHITKDAASNEIPTLTKKETISLQMEEFNTAIYSNDDLLSS 240
Db
        823 KEDKIKESETFSDSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADS 882
Qу
           241 KEDKMKESETFSDSSPIEIIDEFPTFVSAKDDSP---KEYTDLEVSNKSEIANVQSGANS 297
Db
        883 LPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSK 942
Qу
           298 LPCSELPCDLSFKNTYPKDEAHVSDEFSKSRSSVFKVPLLLPNVSALESQIEMGNIVKPK 357
Db
        943 SLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSL 1002
Qу
            Db
        358 VLTKEAEEKLPSDTEKEDRSLTAVLSAELNKTSVVDLLYWRDIKKTGVVFGASLFLLLSL 417
       1003 TVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKY 1062
Qу
           418 TVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKY 477
Db
       1063 SNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSI 1122
Qу
           478 SNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSI 537
Db
       1123 PVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
           538 PVIYERHQAQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAE 578
Db
RESULT 8
08BHF5
ID
   Q8BHF5
             PRELIMINARY;
                           PRT;
                                375 AA.
AC
   Q8BHF5;
   01-MAR-2003 (TrEMBLrel. 23, Created)
   01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT
   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
   RTN4.
DE
GN
   RTN4.
OS
   Mus musculus (Mouse).
   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
   Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
```

OX

NCBI TaxID=10090;

```
RN
     [1]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=129/SvcJ7, and 129SvcJ7;
RA
    Oertle T., van der Putten H., Schwab M.E.;
     "Genomic Structure and Functional Characterization of the Promoter
RT
RT
     Structures of Human and Mouse Nogo/Rtn-4.";
    Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
    SEQUENCE FROM N.A.
    STRAIN=129/SvcJ7, and 129SvcJ7;
RC
    Oertle T., Schwab M.E.;
RA
RL
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=129/SvcJ7;
RA
    Van der Putten H.;
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
    SEQUENCE FROM N.A.
    STRAIN=129SvcJ7;
RA
    Van der Putten H., Mir A.;
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; AY102282; AAM73504.1; -.
DR
DR
    EMBL; AY102286; AAM73509.1; -.
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    GO; GO:0007399; P:neurogenesis; IDA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
SO
    SEQUENCE 375 AA; 40300 MW; 23D9EB19BE671AE6 CRC64;
 Query Match
                      24.2%; Score 1416; DB 11; Length 375;
 Best Local Similarity 31.6%; Pred. No. 1.7e-63;
 Matches 367; Conservative 2; Mismatches 6; Indels 788; Gaps 4;
          1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEDDEDLEELEVLERK 60
Qу
            Db
          1 MEDIDQSSLVSSSADSPPRPPPAFKYQFVTEPEDEEDEEDEE-EEEDDEDLEELEVLERK 59
         61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Qу
            60 PAAGLSAAPVPP-AAAPLLDFSSDSVPPAPRGPLPAAPPTAPERQPSWERSPAASAPSLP 118
Db
        121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
QУ
            Db
        119 PAAAVLPSKLPEDDEPPAR--PPAPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 176
        181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
Qy
            Db
        177 AASEPVIPSSA----- 187
        241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300
Qу
        188 ----- 187
Db
Qу
       301 AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA 360
```

Db	. 1	188		187
Qу	3	361	PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGR	420
Db	1	188		187
Qу	4	121	NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA	480
Db	1	188		187
Qу	4	181	QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL	540
Db	1	188		187
Qу	5	541	NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL	600
Db	1	88		187
Qу			LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF	
Db	1	88		187
Qу			NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE	720
Db	1	.88		187
Qу	7	21	PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP	780
Db	1	88		187
Qу			NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE	840
Db	1	88		187
Qу			IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK	900
Db	1	88		187
QУ			DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED	
Db	1	88		187
Qу	9	61	RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS	1020
Db	1	88	VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS	232
Qу	10	21	VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL	1080
Db	2	33		292
QУ	10	81	FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA	1140
Db	2	93	FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQAQIDHYLGLA	352
Qy	11		NKSVKDAMAKIQAKIPGLKRKAD 1163 :	

```
RESULT 9
08BH78
TD
     Q8BH78
                 PRELIMINARY;
                                  PRT;
                                         356 AA.
AC
     Q8BH78;
DT
     01-MAR-2003 (TrEMBLrel. 23, Created)
DT
     01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT
     01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DΕ
     RTN4.
GN
     RTN4.
     Mus musculus (Mouse).
OS
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC.
OX
    NCBI TaxID=10090;
RN
     [1]
RP
     SEQUENCE FROM N.A.
     STRAIN=129/SvcJ7, and 129SvcJ7;
RC
RA
     Oertle T., van der Putten H., Schwab M.E.;
     "Genomic Structure and Functional Characterization of the Promoter
RT
RT
     Structures of Human and Mouse Nogo/Rtn-4.";
RL
     Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN
    [2]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=129/SvcJ7, and 129SvcJ7;
     Oertle T., Schwab M.E.;
RA
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
     [3]
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=129/SvcJ7;
RA
    Van der Putten H.;
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RΡ
    SEQUENCE FROM N.A.
RC
    STRAIN=129SvcJ7;
RA
    Van der Putten H., Mir A.;
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
DR
    EMBL; AY102281; AAM73503.1; -.
    EMBL; AY102286; AAM73508.1; -.
DR
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    GO; GO:0007399; P:neurogenesis; IDA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
SQ
    SEQUENCE 356 AA; 38403 MW; 4366C03BA9630B56 CRC64;
                         22.5%; Score 1314.5; DB 11; Length 356;
 Query Match
 Best Local Similarity 29.9%; Pred. No. 2e-58;
 Matches 348; Conservative
                                2; Mismatches
                                                 6; Indels 807; Gaps
           1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
QУ
             Db
           1 MEDIDQSSLVSSSADSPPRPPPAFKYQFVTEPEDEEDEEDEE-EEEDDEDLEELEVLERK 59
QУ
          61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
```

Db	60	PAAGLSAAPVPP-AAAPLLDFSSDSVPPAPRGPLPAAPPTAPERQPSWERSPAASAPSLP	118
Qу	121	PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP	180
Db	119		168
Qу	181	${\tt AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL}$	240
Db	169		168
Qу	241	GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES	300
Db	169		168
Qу	301	AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA	360
Db	169		168
Qу	361	PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGR	420
Db	169		168
Qу	421	${\tt NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA}$	480
Db	169		168
QУ	481	QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL	540
Db	169		168
ΟУ	541	${\tt NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL}$	600
Db	169		168
Qγ	601	LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF	660
Db	169		168
QУ	661	NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE	720
Db	169		168
QУ	721	PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP	780
Db	169		168
Qу	781	NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE	840
Db	169		168
Qy	841	IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK	900
Db	169		168
Οv	901	DEVHVSDEESENRSSVSKASTSPSNVSALEPOTEMCSTVKSKSITKEAEKKI DSDTEKED	960

```
Db
        961 RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS 1020
QУ
                        Db
        169 -----VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS 213
Qу
        1021 VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL 1080
            214 VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL 273
Db
       1081 FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA 1140
Qу
            Db
        274 FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHOAOIDHYLGLA 333
       1141 NKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
            Db
        334 NKSVKDAMAKIQAKIPGLKRKAE 356
RESULT 10
08K3G7
ID
    08K3G7
             PRELIMINARY; PRT;
                                   357 AA.
AC
    08K3G7;
DT
    01-OCT-2002 (TrEMBLrel. 22, Created)
DT
    01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DΕ
    Nogo-B.
    RTN4.
GN
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
    STRAIN=BALB/c;
RC
    Jin W., Li R., Long M., Shen J., Ju G.;
RA
    "Cloning and expression of the mouse Nogo-B protein.";
RT
RL
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; AY114153; AAM77069.1; -.
DR
    MGD; MGI:1915835; Rtn4.
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
DR
    GO; GO:0007399; P:neurogenesis; IDA.
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
DR
    PROSITE; PS50845; RETICULON; 1.
    SEQUENCE 357 AA; 38566 MW; 73BB3D17DFDBDF15 CRC64;
SQ
 Query Match
                      22.3%; Score 1304; DB 11; Length 357;
 Best Local Similarity 29.9%; Pred. No. 6.6e-58;
 Matches 348; Conservative 2; Mismatches 6; Indels 808; Gaps
                                                                 5;
QУ
          1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEEDEEEDLEELEVLERK 60
            Db
          1 MEDIDQSSLVSSSADSPPRPPPAFKYQFVTEPEDEEDEEDEE-EEEDDEDLEELEVLERK 59
QУ
         61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
```

Db	60	PAAGLSAAPVPP-AAAPLLDFSSDSVPPAPRGPLPAAPPTAPERQPSWERSPAASAPSLP	118
Qу	121	PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP	180
Db	119	PAAAVLPSKLPEDDEPPARPPAPAGASPLAEPAAPPSTPAAPKRRGSGSV	168
QУ	181	${\tt AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL}$	240
Db	169		168
Qy	241	GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES	300
Db	169		168
Qу	301	$\verb AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA $	360
Db	169		168
QУ	361	PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGR	420
Db	169		168
Qу	421	${\tt NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA}$	480
Db	169		168
Qу	481	QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL	540
Db	169		168
QУ	541	NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL	600
Db	169		168
Qу	601	LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF	660
Db	169		168
QУ	661	NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE	720
Db	169		168
Qy	721	PVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQP	780
Db	169		168
QУ	781	NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE	840
Db	169		168
QУ	841	IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK	900
Db	169		168
QУ	901	DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED	960
Dh	169		1.00

```
961 RSLSAVLSAELSKTSVVDLLYWRDIKKTGVV-FGASLFLLLSLTVFSIVSVTAYIALALL 1019
Qv .
                          Db
         169 ------VVDLLYWRDIKKTGVVYFGASLFLLLSLTVFSIVSVTAYIALALL 213
Qy
        1020 SVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRR 1079
             Db
         214 SVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRR 273
        1080 LFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGL 1139
Qу
             Db
         274 LFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHOAOIDHYLGL 333
        1140 ANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
            Db
         334 ANKSVKDAMAKIQAKIPGLKRKAE 357
RESULT 11
096B16
ID
    Q96B16
               PRELIMINARY; PRT;
                                      392 AA.
AC
    096B16;
DT
    01-DEC-2001 (TrEMBLrel. 19, Created)
DΤ
    01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
    01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DT
DΕ
    Hypothetical protein (RTN4).
    RTN4.
GN
OS
    Homo sapiens (Human).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
OX
    NCBI TaxID=9606;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RC
    TISSUE=Kidney;
    Strausberg R.;
RA
RL
    Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
RN
    [2]
RP
    SEQUENCE FROM N.A.
    Oertle T., van der Putten H., Schwab M.E.;
RA
RT
    "Genomic Structure and Functional Characterization of the Promoter
RT
    Structures of Human and Mouse Nogo/Rtn-4.";
RL
    Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN
    [3]
    SEQUENCE FROM N.A.
RP
    Oertle T., Schwab M.E.;
RA
RL
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN
    SEQUENCE FROM N.A.
RP
RA
    Van der Putten H.;
RL
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN
RP
    SEQUENCE FROM N.A.
RX
    MEDLINE=22376540; PubMed=12488097;
    Oertle T., van der Putten H., Schwab M.E.;
RA
    "Genomic Structure and Functional Characterization of the Promoter
RT
RT
    Structures of Human and Mouse Nogo/Rtn-4.";
RL
    J. Mol. Biol. 325:299-323(2003).
```

```
DR
   EMBL; BC016165; AAH16165.1; -.
DR
   EMBL; AY102285; AAM64242.1; -.
DR
   EMBL; AY102278; AAM64247.1; -.
   GO; GO:0005783; C:endoplasmic reticulum; IEA.
   InterPro; IPR003388; Reticulon.
DR
DR
   Pfam; PF02453; Reticulon; 1.
DR
   PROSITE; PS50845; RETICULON; 1.
KW
   Hypothetical protein.
   SEQUENCE 392 AA; 42274 MW; D7B2AA5E839E58AD CRC64;
SO
 Query Match
                  21.9%; Score 1283.5; DB 4; Length 392;
 Best Local Similarity 29.4%; Pred. No. 8.1e-57;
 Matches 346; Conservative 11; Mismatches 20; Indels 801; Gaps
                                                       7;
        1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
QУ
          1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDDLEELEVLERK 58
Db
Qу
        61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
          Db
        59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
Qу
       116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166
          119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178
Db
Qу
       167 RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS 225
          179 RGSSGSVDETLFALPAASEPVIRSSA----- 204
Db
Qy
       226 LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY 285
       205 ----- 204
Db
       286 SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPE 345
Qγ
       205 ----- 204
Db
Qу
       346 KTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLE 405
       205 ----- 204
Db
Qу
       406 DSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHT 465
       205 ----- 204
Db
Qу
       466 SENKTDEKKIEERKAQIITEKTSPKTSNPFLVAVODSEADYVTTDTLSKVTEAAVSNMPE 525
Db
       205 ----- 204
       526 GLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPS 585
Qу
Db
       205 ----- 204
       586 PVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVAL 645
Qу
Db
       205 ----- 204
```

```
QУ
        646 KALGTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSV 705
        205 ----- 204
Db
Qу
       706 PEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAOHKEERLSA 765
Db
       205 ----- 204
       766 SPQELGKPYLESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKED 825
QУ
       205 ----- 204
Db
Qy
        826 KIKESETFSDSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIOSGADSLPC 885
       205 ----- 204
Db
       886 LELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLT 945
Qy
       205 ----- 204
Db
QУ
       946 KEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVF 1005
                                 205 -----VVDLLYWRDIKKTGVVFGASLFLLLSLTVF 234
Db
Qу
       1006 SIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNS 1065
           Db
       235 SIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNS 294
       1066 ALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVI 1125
Qу
          295 ALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSVPVI 354
Db
       1126 YERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
           Db
       355 YERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 392
RESULT 12
Q7YRW9
         PRELIMINARY; PRT; 184 AA.
   O7YRW9
AC
   Q7YRW9;
    01-OCT-2003 (TrEMBLrel. 25, Created)
DT
DT
    01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
   RTN4w (Fragment).
DE
GN
   RTN4.
OS
    Bos taurus (Bovine).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
   Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;
OC
OC
   Bovidae; Bovinae; Bos.
OX
   NCBI TaxID=9913;
RN
    [1]
RΡ
   SEQUENCE FROM N.A.
RX
   MEDLINE=22715887; PubMed=12832288;
   Oertle T., Klinger M., Stuermer C.A., Schwab M.E.;
RA
```

"A reticular rhapsody: phylogenic evolution and nomenclature of the

RT

```
RT
    RTN/Nogo gene family.";
RL
    FASEB J. 17:1238-1247(2003).
DR
    EMBL; AY164744; AAP47319.1; -.
FT
    NON TER
               1
                      1
SO
    SEQUENCE
            184 AA; 20671 MW; DE990E03BBAF84A1 CRC64;
 Query Match
                       15.0%; Score 878; DB 6; Length 184;
 Best Local Similarity 96.2%; Pred. No. 6.9e-37;
 Matches 177; Conservative 3; Mismatches
                                           4; Indels
                                                         0;
                                                            Gaps
                                                                    0;
         980 LYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSD 1039
Qу
            Db
          1 LYWRDIKKTGVVFGXXLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIOAIOKSD 60
        1040 EGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVF 1099
Qу
            Db
         61 EGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVF 120
        1100 TYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLK 1159
Qу
            121 TYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLK 180
Db
        1160 RKAD 1163
Qу
            111:
Db
        181 RKAE 184
RESULT 13
Q7T224
    Q7T224
ID
              PRELIMINARY;
                              PRT;
                                    199 AA.
    Q7T224;
АC
    01-OCT-2003 (TrEMBLrel. 25, Created)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE
    RTN4-C.
    RTN4.
GN
    Gallus gallus (Chicken).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
    Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC
    Gallus.
OX
    NCBI TaxID=9031;
RN
    [1]
RP
    SEQUENCE FROM N.A.
    MEDLINE=22715887; PubMed=12832288;
RX
    Oertle T., Klinger M., Stuermer C.A., Schwab M.E.;
RA
RT
    "A reticular rhapsody: phylogenic evolution and nomenclature of the
    RTN/Nogo gene family.";
RT
    FASEB J. 17:1238-1247(2003).
RL
    EMBL; AY164737; AAP47312.1; -.
DR
    SEQUENCE 199 AA; 22293 MW; 07CF4E4EF2723251 CRC64;
SO
 Query Match
                      15.0%; Score 876; DB 13; Length 199;
 Best Local Similarity 90.6%; Pred. No. 9.7e-37;
 Matches 173; Conservative 10; Mismatches 8; Indels
                                                        0; Gaps
                                                                   0;
Qу
        973 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1032
```

```
Db
           9 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 68
Qу
        1033 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKF 1092
             Db
          69 QAIQKSDEGHPFRAYLESDVAVSEDLIQKYSSVVLGHINGTVKELRRLFLVDDLVDSLKF 128
        1093 AVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQ 1152
Qу
             Db
         129 AVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLVNKNVKDAMAKIQ 188
        1153 AKIPGLKRKAD 1163
Qy
             : !!!!!!!!
Db
         189 AKIPGLKRKTE 199
RESULT 14
Q9GM33
ID
    Q9GM33
               PRELIMINARY;
                               PRT:
                                      179 AA.
AC
    09GM33;
DТ
    01-MAR-2001 (TrEMBLrel. 16, Created)
    01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE
    Hypothetical protein.
OS
    Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae;
OC
OC
    Cercopithecinae; Macaca.
OX
    NCBI TaxID=9541;
RN
    [1]
    SEQUENCE FROM N.A.
RP
RC
    TISSUE=Brain;
RA
    Osada N., Hida M., Kusuda J., Tanuma R., Iseki K., Hirai M., Terao K.,
RA
    Suzuki Y., Sugano S., Hashimoto K.;
RT
    "Isolation of full-length cDNA clones from macaque brain cDNA
    libraries.";
RT
    Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RL
DR
    EMBL; AB049853; BAB16739.1; -.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IEA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
    PROSITE; PS50845; RETICULON; 1.
DR
    Hypothetical protein.
KW
SQ
    SEQUENCE 179 AA; 19949 MW; 5F8CD4383FEE9E02 CRC64;
 Query Match
                       14.4%; Score 844; DB 6; Length 179;
 Best Local Similarity
                              Pred. No. 3.4e-35;
                       95.5%;
 Matches 171; Conservative
                              6; Mismatches
                                              2; Indels
                                                          0; Gaps
                                                                     0;
Qу
         985 IKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPF 1044
            Db
           1 MKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYRGVIQAIQKSDEGHPF 60
Qу
        1045 RAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGA 1104
            Db
          61 RAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLRFAVLMWVFTYVGA 120
        1105 LFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
Qу
```

Db

```
RESULT 15
Q8K4S4
ID
    Q8K4S4
               PRELIMINARY; PRT;
                                      780 AA.
    Q8K4S4;
AC
DT
    01-OCT-2002 (TrEMBLrel. 22, Created)
DT
    01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE
    Reticulon 1A.
    RTN1 OR RTN-1A.
GN
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
    [1]
    SEQUENCE FROM N.A.
RP
RC
    STRAIN=ICR; TISSUE=Brain;
RA
    Hirata T., Nomura T., Takagi Y., Sato Y., Tomioka N., Fujisawa H.,
RA
    Osumi N.;
RT
    "Mosaic development of the olfactory cortex with Pax6-dependent and -
RT
    independent components.";
    Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases.
RL
DR
    EMBL; AB074899; BAB96551.1; -.
DR
    MGD; MGI:1933947; Rtn1.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    InterPro; IPR001951; Histone H4.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS00047; HISTONE H4; 1.
    PROSITE; PS50845; RETICULON; 1.
DR
    SEQUENCE 780 AA; 83504 MW; 545F5638C576A069 CRC64;
SO
                       13.5%; Score 792; DB 11; Length 780;
 Ouerv Match
 Best Local Similarity 32.5%; Pred. No. 1.1e-31;
 Matches 242; Conservative 105; Mismatches 260; Indels 138; Gaps
         517 EAAVSNMPEGLTPDLVQEACESELNEATG-----TKIAYETKVDLVQTSEAIQ-ESLY 568
Qу
            Db
         76 ETASTGM--AAVPDALDHSPSSTLKDGEGACYTSLISDVCYPPREDSAYFTGILOKENGH 133
         569 PTAQLCPSFEEAEATPSPVLPDIVMEAP---LNS-----LLPSAGASVVQPSVSPLEAPP 620
Qу
                 | :
Db
         134 ITTSESP--EEPE-TPGPSLPEVPGMEPQGLLSSDSGIEMTPAESTEVNKILADPLDQMK 190
Qу
         621 PVSYDSIKLE-----PENPPPYEEAMNVALKALGTK----EGIKEPESFNAAV---- 664
              :| | : : | ||:
                                                   11:: 1
                                                          1 1
         191 AEAYKYIDITRPQEAKGQEEQHPGLEDKDLDFKDKGTEVSTKAEGVRAPNQ-PAPVEGKL 249
Db
         665 -----QETEAPYISIACDLIKETKLSTEPSPDFSNYSEI----AKFEKSVPEHAELV 712
QУ
                   : | | | | | | ::::| :| :| :| :|
Db
         250 IKDHLFEESTFAPYIDELSD--EQHRVSLVTAPVKITLTEIEPPLMTATQETIPEKQDLC 307
         713 EDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHK----EERLSASP 767
Qy
```

Db	308	LKPSPDTVPTVTVSEPEDDSPGSVTPPSSGTEPSAAESQGKGSVSEDELIAAIK	361
Qу	768	QELGKPYLESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSS: : : :	822
Db	362	EAKGLSYETTESPRPVGQVADKPKTKTRSGLPTIPSPLDQEASS	405
QУ	823	KEDKIKESETFSDSSPIEIIDEFPTFVSAKDDSPKLAK-EYTDLEVSDKSEIAN	875
Db	406	AESGDSEIELVSE-DPMASEDALPSGYVSFGHVSGPPPSPASPSIQYSILREEREAEL	462
QУ	876	IQSGADSLPCLELPCDL-SFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVS	927
Db	463	DSELIIE-SCDASSASEESPKREQDSPPMKPGALDAIREETGSRATEERAPSHQG	516
QУ	928	ALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAE	970
Db	517	PVEPD-PMLSFAPAAALQSRPEPSSGDGASVPEPPRSQQQKPEEEAVSSSQSPTATEIPG	575
Qу	971	LSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALAL	1018
Db	576	PLGSGLMPPLPFFNKQKAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAA	635
Qу	1019	LSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELR	1078
Db	636	LSATISFRIYKSVLQAVQKTDEGHPFKAYLELEITLSQEQIQKYTDCLQLYVNSTLKELR	695
Qу	1079	RLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLG	1138
Db	696	RLFLVQDLVDSLKFAVLMWLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQVDQYLG	755
Qy	1139	LANKSVKDAMAKIQAKIPGLKRKAD 1163	
Db	756	: : : LVRTHINTVVAKIQAKIPGAKRHAE 780	

Search completed: September 29, 2004, 18:19:39 Job time: 98.4948 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 29, 2004, 18:04:48; Search time 16.6724 Seconds

(without alignments)

3632.211 Million cell updates/sec

Title: US-09-830-972-2

Perfect score: 5848

Sequence: 1 MEDIDQSSLVSSSTDSPPRP.....VKDAMAKIQAKIPGLKRKAD 1163

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: SwissProt 42:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	0				
Score	Query	Length	DB	ID	Description
5848	100.0	1163	1	RTN4 RAT	Q9jk11 rattus norv
4403.5	75.3	1192	1	RTN4 HUMAN	Q9nqc3 homo sapien
917	15.7	199	1	RTN4 MOUSE	Q99p72 mus musculu
801	13.7	777	1	RTN1 RAT	Q64548 rattus norv
789.5	13.5	776	1	RTN1 HUMAN	Q16799 homo sapien
625.5	10.7	236	1	RTN3 HUMAN	095197 homo sapien
625.5	10.7	237	1	RTN3 MOUSE	Q9es97 mus musculu
509	8.7	471	1	RTN2 MOUSE	070622 mus musculu
490	8.4	545	1	RTN2 HUMAN	075298 homo sapien
308.5	5.3	5147	1	PCLO HUMAN	Q9y6v0 homo sapien
300	5.1	5120	1	PCLO CHICK	Q9pu36 gallus gall
295.5	5.1	865	1	CPN_DROME	Q02910 drosophila
291.5	5.0	2459	1	MAPB RAT	P15205 rattus norv
288	4.9	2468	1	MAPB HUMAN	P46821 homo sapien
284	4.9	2464	1	MAPB MOUSE	P14873 mus musculu
282.5	4.8	2805	1	MAPA_HUMAN	P78559 homo sapien
279	4.8	5038	1	PCLO_MOUSE	Q9qyx7 mus musculu
	5848 4403.5 917 801 789.5 625.5 625.5 509 490 308.5 300 295.5 291.5 288 284 282.5	Score Match 5848 100.0 4403.5 75.3 917 15.7 801 13.7 789.5 13.5 625.5 10.7 625.5 10.7 509 8.7 490 8.4 308.5 5.3 300 5.1 295.5 5.1 291.5 5.0 288 4.9 284 4.9 282.5 4.8	Query Score Match Length 5848 100.0 1163 4403.5 75.3 1192 917 15.7 199 801 13.7 777 789.5 13.5 776 625.5 10.7 236 625.5 10.7 237 509 8.7 471 490 8.4 545 308.5 5.3 5147 300 5.1 5120 295.5 5.1 865 291.5 5.0 2459 288 4.9 2468 284 4.9 2464 282.5 4.8 2805	Query Score Match Length DB 5848 100.0 1163 1 4403.5 75.3 1192 1 917 15.7 199 1 801 13.7 777 1 789.5 13.5 776 1 625.5 10.7 236 1 625.5 10.7 237 1 509 8.7 471 1 490 8.4 545 1 308.5 5.3 5147 1 300 5.1 5120 1 295.5 5.1 865 1 291.5 5.0 2459 1 288 4.9 2468 1 284 4.9 2464 1 282.5 4.8 2805 1	Query Score Match Length DB ID 5848 100.0 1163 1 RTN4_RAT 4403.5 75.3 1192 1 RTN4_HUMAN 917 15.7 199 1 RTN4_MOUSE 801 13.7 777 1 RTN1_RAT 789.5 13.5 776 1 RTN1_HUMAN 625.5 10.7 236 1 RTN3_HUMAN 625.5 10.7 236 1 RTN3_HUMAN 625.5 10.7 237 1 RTN3_MOUSE 509 8.7 471 1 RTN2_MOUSE 490 8.4 545 1 RTN2_HUMAN 308.5 5.3 5147 1 PCLO_HUMAN 308.5 5.3 5147 1 PCLO_HUMAN 300 5.1 5120 1 PCLO_CHICK 295.5 5.1 865 1 CPN_DROME 291.5 5.0 2459 1 MAPB_RAT 288 4.9 2468 1 MAPB_HUMAN 284 4.9 2464 1 MAPB_MOUSE 282.5 4.8 2805 1 MAPA_HUMAN

18	277	4.7	3644	1	MINT_MOUSE	Q62504 mus musculu
19	275.5	4.7	3924	1	ANK2_HUMAN	Q01484 homo sapien
20	275	4.7	1972	1	P531_HUMAN	Q12888 homo sapien
21	272.5	4.7	3664	1	MINT_HUMAN	Q96t58 homo sapien
22	272	4.7	5085	1	PCLO_RAT	Q9jks6 rattus norv
23	267	4.6	1781	1	AK12_HUMAN	Q02952 homo sapien
24	265.5	4.5	1828	1	MAP2_MOUSE	P20357 mus musculu
25	261.5	4.5	1087	1	NFH_MOUSE	P19246 mus musculu
26	259.5	4.4	1026	1	NFH_HUMAN	P12036 homo sapien
27	259.5	4.4	2404	1	SON_MOUSE	Q9qx47 mus musculu
28	258.5	4.4	1861	1	MAP2_RAT	P15146 rattus norv
29	257.5	4.4	2715	1	MLL4_HUMAN	Q9umn6 homo sapien
30	256	4.4	1723	1	AIM1_HUMAN	Q9y4k1 homo sapien
31	255.5	4.4	1140	1	YM96_YEAST	Q04893 saccharomyc
32	254.5	4.4	6632	1	UN89_CAEEL	001761 caenorhabdi
33	254	4.3	1616	1	P200_MYCGE	Q49429 mycoplasma
34	254	4.3	3381	1	PGCV_BOVIN	P81282 bos taurus
35	253	4.3	3421	1	TEGU_HSVEB	P28955 equine herp
36	252.5	4.3	1411	1	TCOF_HUMAN	Q13428 homo sapien
37	252	4.3	2738	1	PGCV_RAT	Q9erb4 rattus norv
38	250.5	4.3	4377	1	ANK3_HUMAN	Q12955 homo sapien
39	248.5	4.2	1189	1	YJH6_YEAST	P47035 saccharomyc
40	248	4.2	1827	1	MAP2_HUMAN	P11137 homo sapien
41	245.5	4.2	1001	1	IF2_SYNY3	P72689 synechocyst
42	244	4.2	1338	1	ACIN_MOUSE	Q9jix8 mus musculu
43	241.5	4.1	8545	1	ANC1_CAEEL	Q9n4m4 caenorhabdi
44	238.5	4.1	831	1	NFH_RAT	P16884 rattus norv
45	238.5	4.1	1341	1	ACIN_HUMAN	Q9ukv3 homo sapien

ALIGNMENTS

```
RESULT 1
RTN4 RAT
                                   PRT; 1163 AA.
                    STANDARD;
ID
     RTN4 RAT
AC
     Q9JK11; Q9JK10; Q9R0D9; Q9WUE9; Q9WUF0;
     28-FEB-2003 (Rel. 41, Created)
DT
     28-FEB-2003 (Rel. 41, Last sequence update)
DT
     10-OCT-2003 (Rel. 42, Last annotation update)
DT
     Reticulon 4 (Neurite outgrowth inhibitor) (Nogo protein) (Foocen)
DE
DΕ
     (Glut4 vesicle 20 kDa protein).
GN
     RTN4 OR NOGO.
OS
     Rattus norvegicus (Rat).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OC
OX
     NCBI TaxID=10116;
RN
     [1]
     SEQUENCE FROM N.A. (ISOFORM 3), AND PARTIAL SEQUENCE.
RP
     STRAIN=Sprague-Dawley; TISSUE=Adipocyte;
RC
RX
     MEDLINE=99249816; PubMed=10231557;
     Morris N.J., Ross S.A., Neveu J.M., Lane W.S., Lienhard G.E.;
RA
     "Cloning and characterization of a 22 kDa protein from rat adipocytes:
RT
     a new member of the reticulon family.";
RT
     Biochim. Biophys. Acta 1450:68-76(1999).
RL
RN
     SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3).
RP
```

```
RX
    MEDLINE=20129258; PubMed=10667796;
RA
    Chen M.S., Huber A.B., Van der Haar M.E., Frank M., Schnell L.,
    Spillmann A.A., Christ F., Schwab M.E.;
RA
RT
    "Nogo-A is a myelin-associated neurite outgrowth inhibitor and an
RT
    antigen for monoclonal antibody IN-1.";
RL
    Nature 403:434-439(2000).
RN
    [3]
    SEQUENCE FROM N.A. (ISOFORMS 2 AND 4).
RΡ
    STRAIN=Wistar Kyoto; TISSUE=Vascular smooth muscle;
RC
RA
    Ito T., Schwartz S.M.;
RT
    "Cloning of a member of the reticulon gene family in rat: one of two
RT
    minor splice variants.";
    Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RL
RN
    [4]
RP
    FUNCTION.
    MEDLINE=22033691; PubMed=12037567;
RX
    GrandPre T., Li S., Strittmatter S.M.;
RA
    "Nogo-66 receptor antagonist peptide promotes axonal regeneration.";
RT
    Nature 417:547-551(2002).
RL
CC
    -!- FUNCTION: Potent neurite outgrowth inhibitor which may also help
        block the regeneration of the nervous central system in adults (By
CC
CC
        similarity).
CC
    -!- SUBUNIT: Binds to RTN4R. Interacts with Bcl-xl and Bcl-2 (By
CC
        similarity).
CC
    -!- SUBCELLULAR LOCATION: Integral membrane protein. Anchored to the
        membrane of the endoplasmic reticulum through 2 putative
CC
CC
        transmembrane domains (By similarity).
    -!- ALTERNATIVE PRODUCTS:
CC
CC
        Event=Alternative splicing; Named isoforms=4;
        Name=1; Synonyms=Nogo-A, NI-220-250;
CC
          IsoId=Q9JK11-1; Sequence=Displayed;
CC
        Name=2; Synonyms=Nogo-B, Foocen-M1;
CC
CC
          IsoId=Q9JK11-2; Sequence=VSP 005658;
        Name=3; Synonyms=Nogo-C, VP20;
CC
          IsoId=Q9JK11-3; Sequence=VSP 005656, VSP 005657;
CC
CC
        Name=4; Synonyms=Foocen-M2;
          IsoId=Q9JK11-4; Sequence=VSP 005659;
CC
    -!- TISSUE SPECIFICITY: Isoforms 1, 2 and 3 are present in optic
CC
        nerve, spinal cord and cerebral cortex. Isoforms 1 and 2 are
CC
CC
        present in dorsal root ganglion, sciatic nerve and PC12 cells
CC
        after longer exposure. Isoforms 2 and 3 are detected in kidney,
CC
        cartilage, skin, lung and spleen. Isoform 3 is expressed at high
        level in skeletal muscle. In adult animals isoform 1 is expressed
CC
        mainly in the nervous system.
CC
    -!- SIMILARITY: Contains 1 reticulon domain.
CC
     ______
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     ______
CC
DR
     EMBL; AF051335; AAF01564.1; -.
     EMBL; AJ242961; CAB71027.1; -.
DR
DR
     EMBL; AJ242962; CAB71028.1; -.
```

```
DR
    EMBL; AJ242963; CAB71029.1; -.
DR
    EMBL; AF132045; AAD31019.1; -.
DR
    EMBL; AF132046; AAD31020.1; -.
DR
    GO; GO:0030176; C:integral to endoplasmic reticulum membrane; IDA.
DR
    GO; GO:0005635; C:nuclear membrane; ISS.
    GO; GO:0005515; F:protein binding; ISS.
DR
    GO; GO:0019987; P:negative regulation of anti-apoptosis; ISS.
DR
    GO; GO:0030517; P:negative regulation of axon extension; ISS.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
    Endoplasmic reticulum; Alternative splicing; Transmembrane.
KW
                     989
                              CYTOPLASMIC (Potential).
    DOMAIN
                 1
FT
               990
                    1010
                              POTENTIAL.
    TRANSMEM
FT
              1011
                    1104
                              LUMENAL (Potential).
\mathbf{FT}
    DOMAIN
    TRANSMEM
              1105
                    1125
                              POTENTIAL.
FT
              1126
                              CYTOPLASMIC (Potential).
                    1163
FT
    DOMAIN
                              RETICULON.
    DOMAIN
               976
                    1163
FT
                              POLY-GLU.
    DOMAIN
                33
                      46
FT
                73
                      76
                              POLY-ALA.
FT
    DOMAIN
                              POLY-PRO.
FT
    DOMAIN
               140
                     145
FT
    VARSPLIC
                 1
                     964
                              Missing (in isoform 3).
FT
                              /FTId=VSP 005656.
               965
                     975
                              AVLSAELSKTS -> MDGQKKHWKDK (in isoform
FT
    VARSPLIC
FT
                              /FTId=VSP 005657.
FT
               173
                     975
                              Missing (in isoform 2).
FT
    VARSPLIC
                              /FTId=VSP 005658.
FT
                              Missing (in isoform 4).
FT
    VARSPLIC
               192
                     975
                              /FTId=VSP 005659.
FT
                              MISSING (IN REF. 3; AAD31020).
FT
    CONFLICT
              1130
                    1131
                                 8CB894B09E94F0B6 CRC64;
                      126386 MW;
    SEQUENCE
              1163 AA;
SQ
                       100.0%; Score 5848; DB 1; Length 1163;
 Ouery Match
                       100.0%; Pred. No. 3.9e-213;
 Best Local Similarity
                                                                      0;
                             0; Mismatches
                                              0; Indels
                                                           0; Gaps
 Matches 1163; Conservative
           1 MEDIDOSSLVSSSTDSPPRPPPAFKYOFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qy
             1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Db
          61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Qу
             61 PAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAAPAPSLP 120
Db
         121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
Qу
             121 PAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALP 180
Db
         181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
Qу
             181 AASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYL 240
Db
         241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300
Qу
             241 GNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGES 300
Db
```

Qу	301	AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA	360
Db	301	AILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSVVA	360
Qy	361	PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGR	420
Db	361	PVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDSEGR	420
Qу	421	NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA	480
Db	421	NEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKTDEKKIEERKA	480
QУ	481	QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL	540
Db	481	QIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESEL	540
Qy	541	NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL	600
Db	541	NEATGTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSL	600
Qу	601	LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF	660
Db	601	LPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESF	660
Qу	661	NAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESE	720
Db	661		720
Qy	721	~ ~ ~ ~ ~ ~	780
Db	721		780
Qу	781	NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE	840
Db	781	NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE	840
QУ	841	IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK	900
Db	841	IIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPK	900
Qу	901	DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED	960
Db	901	DEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKED	960
Qу	961	RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS	1020
Db	961	RSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLS	1020
Qу	1021	VTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRL	1080
Db	1021		1080
QУ	1081	FLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLA	1140
Db	1081		1140
QУ	1141	NKSVKDAMAKIQAKIPGLKRKAD 1163	

```
RESULT 2
RTN4 HUMAN
TD
     RTN4 HUMAN
                    STANDARD;
                                   PRT; 1192 AA.
     Q9NOC3; O94962; Q9BXG5; Q9H212; Q9H3I3; Q9UQ42; Q9Y293; Q9Y2Y7;
AC
AC
     Q9Y5U6;
     28-FEB-2003 (Rel. 41, Created)
DT
DT
     28-FEB-2003 (Rel. 41, Last sequence update)
DT
     15-MAR-2004 (Rel. 43, Last annotation update)
DΕ
     Reticulon 4 (Neurite outgrowth inhibitor) (Nogo protein) (Foocen)
DΕ
     (Neuroendocrine-specific protein) (NSP) (Neuroendocrine specific
DE
     protein C homolog) (RTN-x) (Reticulon 5) (My043 protein).
GN
     RTN4 OR NOGO OR ASY OR KIAA0886.
OS
     Homo sapiens (Human).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
OX
     NCBI TaxID=9606;
RN
     [1]
     SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3).
RP
     MEDLINE=20129242; PubMed=10667780;
RX
     Prinjha R., Moore S.E., Vinson M., Blake S., Morrow R., Christie G.,
RA
     Michalovich D., Simmons D.L., Walsh F.S.;
RA
RT
     "Inhibitor of neurite outgrowth in humans.";
RL
     Nature 403:383-384(2000).
RN
     [2]
RP
     SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).
RC
     TISSUE=Brain;
RX
     MEDLINE=21010696; PubMed=11126360;
RA
     Tagami S., Eguchi Y., Kinoshita M., Takeda M., Tsujimoto Y.;
RT
     "A novel protein, RTN-XS, interacts with both Bcl-XL and Bcl-2 on
     endoplasmic reticulum and reduces their anti-apoptotic activity.";
RT
     Oncogene 19:5736-5746(2000).
RL
RN
     SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3).
RP
     MEDLINE=20237542; PubMed=10773680;
RX
     Yang J., Yu L., Bi A.D., Zhao S.-Y.;
RA
     "Assignment of the human reticulon 4 gene (RTN4) to chromosome
RT
     2p14-->2p13 by radiation hybrid mapping.";
RT
     Cytogenet. Cell Genet. 88:101-102(2000).
RL
RN
     [4]
     SEQUENCE FROM N.A. (ISOFORM 4).
RP
RA
     Jin W.-L., Ju G.;
RT
     "Developmentally-regulated alternative splicing in a novel Nogo-A.";
RL
     Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases.
RN
RP
     SEQUENCE FROM N.A. (ISOFORMS 2 AND 3).
     TISSUE=Placenta, and Skeletal muscle;
RC
RA
     Ito T., Schwartz S.M.;
     "Cloning of a member of the reticulon gene family in human.";
RT
     Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 2).
RC
     TISSUE=Fibroblast;
RΑ
     Yutsudo M.;
```

```
"Isolation of a cell death-inducing gene.";
RT
     Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 3).
RC
     TISSUE=Pituitary;
     Song H., Peng Y., Zhou J., Huang Q., Dai M., Mao Y.M., Yu Y., Xu X.,
RA
RA
     Luo B., Hu R., Chen J.;
RT
     "Human neuroendocrine-specific protein C (NSP) homolog gene.";
RL
     Submitted (JUL-1998) to the EMBL/GenBank/DDBJ databases.
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 3).
RA
     Gu J.R., Wan D.F., Zhao X.T., Zhou X.M., Jiang H.Q., Zhang P.P.,
RA
     Qin W.X., Huang Y., Qiu X.K., Qian L.F., He L.P., Li H.N., Yu Y.,
RA
     Yu J., Han L.H.;
     "Novel human cDNA clone with function of inhibiting cancer cell
RT
RT
     growth.";
RL
     Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 1).
RC
     TISSUE=Brain:
     MEDLINE=99156230; PubMed=10048485;
RX
     Nagase T., Ishikawa K.-I., Suyama M., Kikuno R., Hirosawa M.,
RA
RA
     Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
     "Prediction of the coding sequences of unidentified human genes. XII.
RT
     The complete sequences of 100 new cDNA clones from brain which code
RT
     for large proteins in vitro.";
RT
     DNA Res. 5:355-364(1998).
RL
RN
     [10]
     SEQUENCE FROM N.A. (ISOFORMS 2 AND 3).
RP
     TISSUE=Brain, Ovary, Pancreas, Placenta, and Skeletal muscle;
RC
     MEDLINE=22388257; PubMed=12477932;
RX
RA
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
     "Generation and initial analysis of more than 15,000 full-length
RT
     human and mouse cDNA sequences.";
RT
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
RN
     [11]
RΡ
     SEQUENCE FROM N.A. (ISOFORM 3).
     MEDLINE=20499367; PubMed=11042152;
RX
     Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA
     Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA
     Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RA
```

```
RT
     "Cloning and functional analysis of cDNAs with open reading frames for
RT
     300 previously undefined genes expressed in CD34+ hematopoietic
RT
     stem/progenitor cells.";
RL
     Genome Res. 10:1546-1560(2000).
RN
RP
     SEQUENCE OF 482-1192 FROM N.A. (ISOFORM 1/4).
RC
     TISSUE=Brain;
RA
     Mao Y.M., Xie Y., Zheng Z.H.;
RL
     Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN
RP
     SEQUENCE OF 186-1192 FROM N.A. (ISOFORM 1).
RC
     TISSUE=Testis;
     Sha J.H., Zhou Z.M., Li J.M.;
RA
     Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     TOPOLOGY.
     TISSUE=Brain;
RC
     MEDLINE=20129259; PubMed=10667797;
RX
     GrandPre T., Nakamura F., Vartanian T., Strittmatter S.M.;
RA
     "Identification of the Nogo inhibitor of axon regeneration as a
RT
RT
     Reticulon protein.";
RL
     Nature 403:439-444(2000).
RN
     [15]
RP
     FUNCTION.
RC
     TISSUE=Brain;
     MEDLINE=21069055; PubMed=11201742;
RX
     Fournier A.E., Grandpre T., Strittmatter S.M.;
RA
     "Identification of a receptor mediating Nogo-66 inhibition of axonal
RT
RT
     regeneration.";
     Nature 409:341-346(2001).
RL
RN
     [16]
RP
     REVIEW.
     MEDLINE=21888956; PubMed=11891768;
RX
     Ng C.E.L., Tang B.L.;
RA
     "Nogos and the Nogo-66 receptor: factors inhibiting CNS neuron
RT
RT
     regeneration.";
RL
     J. Neurosci. Res. 67:559-565(2002).
     -!- FUNCTION: Potent neurite outgrowth inhibitor which may also help
CC
         block the regeneration of the nervous central system in adults.
CC
         Isoform 2 reduces the anti-apoptotic activity of Bcl-xl and Bcl-2.
CC
CC
         This is likely consecutive to their change in subcellular
CC
         location, from the mitochondria to the endoplasmic reticulum,
CC
         after binding and sequestration.
CC
     -!- SUBUNIT: Binds to RTN4R. Interacts with Bcl-xl and Bcl-2.
     -!- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic
CC
         reticulum. Anchored to the membrane of the endoplasmic reticulum
CC
         through 2 putative transmembrane domains.
CC
     -!- ALTERNATIVE PRODUCTS:
CC
         Event=Alternative splicing; Named isoforms=4;
CC
CC
         Name=1; Synonyms=RTN 4A, Nogo-A, RTN-xL;
CC
           IsoId=Q9NQC3-1; Sequence=Displayed;
         Name=2; Synonyms=RTN 4B, Nogo-B, RTN-xS, Foocen-M;
CC
           IsoId=Q9NQC3-2; Sequence=VSP 005655;
CC
CC
         Name=3; Synonyms=RTN 4C, Nogo-C, Foocen-S;
CC
           IsoId=Q9NQC3-3; Sequence=VSP 005652, VSP 005653;
CC
         Name=4;
CC
           IsoId=Q9NQC3-4; Sequence=VSP 005654;
```

```
-!- TISSUE SPECIFICITY: Isoform 1 is specifically expressed in brain
CC
        and testis and weakly in heart and skeletal muscle. Isoform 2 is
CC
        widely expressed excepted for the liver. Isoform 3 is expressed in
CC
        brain, skeletal muscle and adipocytes. Isoform 4 is testis-
CC
CC
        specific.
CC
    -!- SIMILARITY: Contains 1 reticulon domain.
CC
    -!- CAUTION: Ref.11 sequence differs from that shown due to
        frameshifts in positions 1149 and 1156.
CC
    _____
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
    or send an email to license@isb-sib.ch).
CC
DR
    EMBL; AJ251383; CAB99248.1; -.
    EMBL; AJ251384; CAB99249.1; -.
    EMBL; AJ251385; CAB99250.1; -.
DR
    EMBL; AB040462; BAB18927.1; -.
DR
    EMBL; AB040463; BAB18928.1; -.
DR
    EMBL; AF148537; AAG12176.1; -.
DR
DR
    EMBL; AF148538; AAG12177.1; -.
    EMBL; AF087901; AAG12205.1; -.
DR
    EMBL; AF320999; AAG40878.1; -.
DR
    EMBL; AF132047; AAD31021.1; -.
DR
    EMBL; AF132048; AAD31022.1; -.
DR
    EMBL; AB015639; BAA83712.1; -.
DR
    EMBL; AF077050; AAD27783.1; -.
DR
    EMBL; AF177332; AAG17976.1; -.
DR
    EMBL; AB020693; BAA74909.1; -.
DR
    EMBL; BC001035; AAH01035.1; -.
DR
DR
    EMBL; BC007109; AAH07109.1; -.
    EMBL; BC014366; AAH14366.1; -.
DR
                       75.3%; Score 4403.5; DB 1; Length 1192;
  Query Match
  Best Local Similarity 75.9%; Pred. No. 9.1e-159;
  Matches 909; Conservative 104; Mismatches 145; Indels 39; Gaps
                                                                   20;
           1 MEDIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERK 60
Qу
             1 MEDLDQSPLVSSS-DSPPRPQPAFKYQFVREPEDEE-EEEEEEEEDEDLEELEVLERK 58
Db
          61 PAAGLSAAAVP--PAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWERSPAA---P 115
Qу
             59 PAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVP 118
Db
         116 APSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAE-----PAAPPSTPAAPKR 166
QУ
            119 APSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKR 178
Db
         167 RG-SGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGNTVSSGQEDFPSVLLETAASLPS 225
QУ
             Db
         179 RGSSGSVDETLFALPAASEPVIRSSAEN-MDLKEQPGNTISAGQEDFPSVLLETAASLPS 237
         226 LSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATNPFVNRDLAEFSELEY 285
Qу
```

Db	238		297
Qу	286	SEMGSSFKGSPKGESAILVENTKEEVIVRSKDKED-LVCSAALHSPQESPVGKED	339
Db	298		357
Qу	340	RVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANV	395
Db	358	::: : : :	416
QУ	396	ESKVDRKCLEDSLEQKSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFT-SATESTT	454
Db	417	: : : :	476
Qу	455	ANTFPLLEDHTSENKTDEKKIEERKAQIITEK-TSPKTSNPFLVAVQDSEADYVTTDTLS	513
Db	477		536
Qу	514	KVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQESLYPTAQL	573
Db	537	KVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQL	596
QУ	574	CPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPEN	633
Db	597	CPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEA-SSVNYESIKHEPEN	655
Qу	634	PPPYEEAMNVALKAL-GTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDF	692
Db	656		715
Qу	693	SNYSEIAKFEKSVPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVS	752
Db	716	SDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETS	775
Qу	753	-ETVAQHK-EERLSASPQELGKPYLESFQPNLHSTKDA-ASNDIPTLTKKEKISLQMEEF	809
Db	776	FESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEEL	835
Qу	810	NTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDS-PKLAKEYTDLEVS : :	868
Db	836	STAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVS	895
Qу	869	DKSEIANIQSGADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNV	926
Db	896	HKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDV	955
Qу	927	SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIK	986
Db	956	SALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIK	1015
Qу	987	KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA	1046
Db	1016	KTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRA	1075
Qу	1047	YLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF	1106

```
Db
         1076 YLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALF 1135
         1107 NGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD 1163
QУ
              Db
         1136 NGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 1192
RESULT 3
RTN4 MOUSE
     RTN4 MOUSE
                                   PRT;
                                          199 AA.
ID
                    STANDARD;
     Q99P72; Q9CTE3;
AC
DT
     28-FEB-2003 (Rel. 41, Created)
     28-FEB-2003 (Rel. 41, Last sequence update)
DT
DT
     28-FEB-2003 (Rel. 41, Last annotation update)
     Reticulon 4 (Neurite outgrowth inhibitor) (Nogo protein).
DE
     RTN4 OR NOGO.
GN
OS
    Mus musculus (Mouse).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
     NCBI TaxID=10090;
RN
     [1]
RP
     SEQUENCE FROM N.A.
     STRAIN=3T3-L1; TISSUE=Adipocyte;
RC
     Coulson A.C., Craggs P.D., Morris N.J.;
RA
RT
     "Mouse vp20/RTN4C cDNA.";
     Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RL
RN
     SEQUENCE OF 170-199 FROM N.A.
RP
RC
     STRAIN=C57BL/6J; TISSUE=Embryo;
RX
    MEDLINE=21085660; PubMed=11217851;
RA
     Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
     Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA
     Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA
     Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA
     Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA
     Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA
     Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
RA
     Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA
RA
     Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA
     Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
     Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA
     Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA
     Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA
     Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA
     Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA
     Suzuki H., Toyo-oka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA
     Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
RA
RA
     Hayashizaki Y.;
     "Functional annotation of a full-length mouse cDNA collection.";
RT
RL
     Nature 409:685-690(2001).
     -!- FUNCTION: Potent neurite outgrowth inhibitor which may also help
CC
CC
         block the regeneration of the nervous central system in adults (By
CC
         similarity).
CC
     -!- SUBUNIT: Binds to RTN4R. Interacts with Bcl-xl and Bcl-2 (By
         similarity).
CC
CC
     -!- SUBCELLULAR LOCATION: Integral membrane protein. Anchored to the
```

membrane of the endoplasmic reticulum through 2 putative

CC

```
CC
        transmembrane domains (By similarity).
CC
    -!- ALTERNATIVE PRODUCTS:
CC
        Event=Alternative splicing; Named isoforms=1;
CC
          Comment=A number of isoforms may be produced;
CC
        Name=1;
CC
          IsoId=Q99P72-1; Sequence=Displayed;
CC
    -!- SIMILARITY: Contains 1 reticulon domain.
CC
    _____
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
    or send an email to license@isb-sib.ch).
CC
CC
DR
    EMBL; AF326337; AAK08076.1; -.
    EMBL; AK003859; -; NOT ANNOTATED CDS.
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
DR
    GO; GO:0030176; C:integral to endoplasmic reticulum membrane; ISS.
DR
    GO; GO:0005635; C:nuclear membrane; ISS.
    GO; GO:0005515; F:protein binding; ISS.
DR
    GO; GO:0019987; P:negative regulation of anti-apoptosis; ISS.
DR
    GO; GO:0030517; P:negative regulation of axon extension; ISS.
DR
DR
    GO; GO:0007399; P:neurogenesis; IDA.
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
    Endoplasmic reticulum; Alternative splicing; Transmembrane.
KW
    DOMAIN
               1 25
                              CYTOPLASMIC (Potential).
FT
    TRANSMEM
                26
                     50
FT
                              POTENTIAL.
                   137
                             LUMENAL (Potential).
FT
    DOMAIN
               51
              138
FT
    TRANSMEM
                   162
                              POTENTIAL.
               163
                     199
                              CYTOPLASMIC (Potential).
FT
    DOMAIN
FT
    DOMAIN
               12
                     199
                              RETICULON.
              199 AA; 22466 MW; 07BE5D580059ED9C CRC64;
SO
    SEQUENCE
 Query Match
                       15.7%; Score 917; DB 1; Length 199;
 Best Local Similarity 97.9%; Pred. No. 1.5e-28;
 Matches 187; Conservative 1; Mismatches 3; Indels
                                                           0; Gaps
                                                                      0;
         973 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1032
Qу
              9 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 68
Db
        1033 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKF 1092
Qу
             69 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKF 128
Db
QУ
        1093 AVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHOVOIDHYLGLANKSVKDAMAKIO 1152
             Db
         129 AVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQAQIDHYLGLANKSVKDAMAKIQ 188
Qу
        1153 AKIPGLKRKAD 1163
             111111111:
Db
         189 AKIPGLKRKAE 199
```

```
RESULT 4
RTN1 RAT
ID
    RTN1 RAT
                   STANDARD:
                                  PRT;
                                       777 AA.
    064548; 064547;
DT
    16-OCT-2001 (Rel. 40, Created)
    16-OCT-2001 (Rel. 40, Last sequence update)
DT
    10-OCT-2003 (Rel. 42, Last annotation update)
DT
DE
    Reticulon 1 (Neuroendocrine-specific protein) (S-rex).
GN
    RTN1 OR NSP.
OS
    Rattus norvegicus (Rat).
OC.
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX
    NCBI TaxID=10116;
RN
     [1]
RP
    SEQUENCE FROM N.A. (ISOFORMS RTN1-B AND RTN1-S).
RC
    STRAIN=Wistar; TISSUE=Brain cortex;
RX
    MEDLINE=96386034; PubMed=8793864;
RA
    Baka I.D., Ninkina N.N., Pinon L.G.P., Adu J., Davies A.M.,
    Georgiev G.P., Buchman V.L.;
RA
RT
    "Intracellular compartmentalization of two differentially spliced s-
RT
    rex/NSP mRNAs in neurons.";
    Mol. Cell. Neurosci. 7:289-303(1996).
RL
CC
    -!- FUNCTION: May be involved in neuroendocrine secretion or in
CC
        membrane trafficking in neuroendocrine cells.
CC
    -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane (By
CC
        similarity).
CC
    -!- ALTERNATIVE PRODUCTS:
CC
        Event=Alternative splicing; Named isoforms=2;
CC
        Name=RTN1-B; Synonyms=S-RexB;
CC
          IsoId=Q64548-1; Sequence=Displayed;
CC
        Name=RTN1-S; Synonyms=S-RexS;
CC
          IsoId=Q64548-2; Sequence=VSP 005647, VSP 005648;
    -!- TISSUE SPECIFICITY: EXPRESSED PREDOMINANTLY IN CENTRAL AND
CC
CC
        PERIPHERAL NERVOUS SYSTEM OF NEWBORN AND ADULT RATS. LOW LEVELS
CC
        HAVE BEEN ALSO DETECTED IN HEART, ADRENAL GLAND AND SPLEEN.
CC
        EXPRESSION OF ISOFORM RTN1-B IS RESTRICTED TO PARTICULAR NEURONAL
CC
        TYPES.
    -!- DEVELOPMENTAL STAGE: DETECTED ON EMBRYONIC DAY E10 IN THE
CC
        HINDBRAIN AND IN Ell IN THE FOREBRAIN. DURING THE NEXT 3 EMBRYONIC
CC
CC
        DAYS THE LEVELS OF S-REXS INCREASES AND REMAINS STABLE AT E13 IN
CC
        THE HINDBRAIN AND AT E14 IN THE FOREBRAIN. THE LEVELS OF S-REXB
CC
        DOES NOT CHANGE AS SIGNIFICANTLY DURING DEVELOPMENT OF THE
CC
        HINDBRAIN.
CC
    -!- SIMILARITY: Contains 1 reticulon domain.
CC
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
    the European Bioinformatics Institute. There are no restrictions on its
CC
CC
     use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
    or send an email to license@isb-sib.ch).
CC
CC
     DR
    EMBL: U17604; AAC53046.1; -.
    EMBL; U17603; AAC53045.1; -.
DR
```

```
DR
    InterPro; IPR003388; Reticulon.
    Pfam; PF02453; Reticulon: 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
    Endoplasmic reticulum; Alternative splicing; Transmembrane.
KW
FT
    TRANSMEM
             604
                  624
                           POTENTIAL.
FT
    TRANSMEM
             727
                   747
                           POTENTIAL.
FT
    DOMAIN
             590
                   777
                           RETICULON.
             610
FΤ
    DOMAIN
                   613
                           POLY-LEU.
FT
    VARSPLIC
             1
                   569
                           Missing (in isoform RTN1-S).
FT
                           /FTId=VSP 005647.
FT
   VARSPLIC 570 589
                           IPGPLGSDLVPPLPFFNKQK -> MQATADSTKMDCVWSNW
FT
                           KSQ (in isoform RTN1-S).
FT
                           /FTId=VSP 005648.
    SEQUENCE 777 AA; 83001 MW; AF7479C50F28D0AC CRC64;
SQ
 Query Match
                    13.7%; Score 801; DB 1; Length 777;
 Best Local Similarity 32.4%; Pred. No. 2e-23;
 Matches 258; Conservative 109; Mismatches 264; Indels 166; Gaps
        485 EKTSPKTSNPFLVAVQDSE-----ADYVTTDTL---SKVTEAAVSNMPEGL--TPD 530
QУ
           29 EEATPKGARP---AQQDGEPAWGSGAGAGVVSSRGLCSGPARSPPVAMETASTGVAAVPD 85
Db
        531 LVQEACESELNEATG-----TKIAYETKVDLVQTSEAIQ-ESLYPTAQLCPSFEEAEA 582
Qу
                 |: |
                            Db
        86 ALDHSSSPTLKDGEGACYTSLISDICYPPREDSAYFTGILQKENGHITTSESP---EELG 142
        583 TPSPVLPDIVMEAPLNSLLPSAGASVVQPS----VSPLEAPPPVSYDSIKLE----- 630
Qу
           Db
        143 TPGPSLPEVPGTEP-HGLLSSDSGIEMTPAESTEVNKILADP---LDQMKAEACKYIDIT 198
        631 -----PENPPPYEEAMNVALK----ALGTK-EGIKEPE-----SFNAAVQETE 668
Qу
                 199 RPQEAKGQEEQSPGLEDKDLDFKDKDSEVSTKPEGVHAPNOPSPVEGKLIKDNLFEESTF 258
Db
        669 APYISIACDLIKETKLSTEPSPDFSNYSEI----AKFEKSVPEHAELVEDSSPESEPVD 723
Qy
           259 APYIDELSD--EQHRMSLVTAPVKITLTEIGPPVMTATHETIPEKQDLCLKPSPDTVPTV 316
Db
       724 LFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHK----EERLSASPQELGKPYLESF 778
Qу
            317 TVSE-----PEDDSPGSVTPPSSGTEPSAAESQGKGSVSEDELIAAIKEAKGLSYETTE 370
Db
        779 QPN----LHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETF 833
Qy
           | | : :||:
                                           371 SPRPVGQAADRPKVKARSGLPTIPS------SLDQEASSAESGDSEIELV 414
Dh
        834 SDSSPIEIIDEFPT-----FVSAKDDSPKLAK-EYTDLEVSDKSEIANIOSGADSLPCL 886
QУ
           415 SE-DPMASEDALPSGYVSFGHVSGPPPSPASPSIQYSILREEREAEL-----DSELII 466
Db
        887 ELPCDL-SFKNIYPKDEVH------VSDEFSENRSSVSKASISPSNVSALEPQTEM--- 935
Qу
           467 E-SCDASSASEESPKREQDSPPMKPGVLDAIREETSSRATEERAPSHQGPVEPDPILSFT 525
Db
QУ
        936 -----GSIV----KSKSLTKEAE----KKLPSDTEKEDRSLSAVLSAEL-- 971
                      1: 1 11: 11 : 1: 11 : 1::1
```

```
Db
         526 PVTLOSRPEPSSGDGAPVPEPPKSOOOKPEEEAVSSSOSPAATE----IPGPLGSDLVP 580
Qγ
         972 ----SKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFR 1026
                     Db
         581 PLPFFNKQKAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFR 640
        1027 IYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDL 1086
Qy
             :|||:|||||
         641 IYKSVLQAVQKTDEGHPFKAYLELEITLSQEQIQKYTDCLQLYVNSTLKELRRLFLVQDL 700
Db
        1087 VDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKD 1146
Qу
             701 VDSLKFAVLMWLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQVDQYLGLVRTHINT 760
Db
        1147 AMAKIOAKIPGLKRKAD 1163
Qу
              Db
         761 VVAKIQAKIPGAKRHAE 777
RESULT 5
RTN1 HUMAN
ID
    RTN1 HUMAN
                  STANDARD:
                                 PRT:
                                       776 AA.
    Q16799; Q16800; Q16801;
AC
    16-OCT-2001 (Rel. 40, Created)
DT
DT
    16-OCT-2001 (Rel. 40, Last sequence update)
    10-OCT-2003 (Rel. 42, Last annotation update)
DT
    Reticulon 1 (Neuroendocrine-specific protein).
DE
    RTN1 OR NSP.
GN
OS
    Homo sapiens (Human).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
    NCBI TaxID=9606;
RN
    [1]
    SEQUENCE FROM N.A. (ISOFORMS RTN1-A; RTN1-B AND RTN1-C).
RP
RC
    TISSUE=Lung carcinoma;
RX
    MEDLINE=93293865; PubMed=7685762;
    Roebroek A.J.M., Van de Velde H.J.K., Van Bokhoven A., Broers J.L.V.,
RA
RA
    Ramaekers F.C.S., Van de Ven W.J.M.;
RT
    "Cloning and expression of alternative transcripts of a novel
RT
    neuroendocrine-specific gene and identification of its 135-kDa
RT
    translational product.";
    J. Biol. Chem. 268:13439-13447(1993).
RL
RN
    ALTERNATIVE SPLICING.
RP
    MEDLINE=96429995; PubMed=8833145;
RX
    Roebroek A.J.M., Ayoubi T.A.Y., Van de Velde H.J.K.,
RA
    Schoenmakers E.F.P.M., Pauli I.G.L., Van de Ven W.J.M.;
RA
RT
    "Genomic organization of the human NSP gene, prototype of a novel gene
RT
    family encoding reticulons.";
RL
    Genomics 32:191-199(1996).
RN
    [3]
RP
    TISSUE SPECIFICITY.
RX
    MEDLINE=98228245; PubMed=9560466;
RA
    Hens J., Nuydens R., Geerts H., Senden N.H., Van de Ven W.J.M.,
RA
    Roebroek A.J., van de Velde H.J.K., Ramaekers F.C., Broers J.L.;
RT
    "Neuronal differentiation is accompanied by NSP-C expression.";
RL
    Cell Tissue Res. 292:229-237(1998).
```

```
CC
     -!- FUNCTION: May be involved in neuroendocrine secretion or in
CC
        membrane trafficking in neuroendocrine cells.
CC
    -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane.
CC
    -!- ALTERNATIVE PRODUCTS:
CC
        Event=Alternative splicing; Named isoforms=3;
CC
        Name=RTN1-A; Synonyms=NSP-A;
CC
          IsoId=Q16799-1; Sequence=Displayed;
CC
        Name=RTN1-B; Synonyms=NSP-B;
CC
          IsoId=Q16799-2; Sequence=VSP 005644;
CC
        Name=RTN1-C; Synonyms=NSP-C;
CC
          IsoId=Q16799-3; Sequence=VSP 005645, VSP 005646;
CC
    -!- TISSUE SPECIFICITY: EXPRESSED IN NEURAL AND NEUROENDOCRINE TISSUES
CC
        AND CELL CULTURES DERIVED THEREFROM. EXPRESSION OF ISOFORM RTN1-C
CC
        IS STRONGLY CORRELATED WITH NEURONAL DIFFERENTIATION.
CC
    -!- PTM: Isoforms RTN1-A and RTN1-B are phosphorylated.
CC
    -!- SIMILARITY: Contains 1 reticulon domain.
    ______
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    ______
    EMBL; L10333; AAA59950.1; -.
DR
    EMBL; L10334; AAA59951.1; -.
DR
    EMBL; L10335; AAA59952.1; -.
DR
DR
    PIR; A46583; A46583.
DR
    PIR; 160904; 160904.
DR
    Genew; HGNC:10467; RTN1.
DR
    MIM; 600865; -.
    GO; GO:0030176; C:integral to endoplasmic reticulum membrane; TAS.
    GO; GO:0004871; F:signal transducer activity; NAS.
DR
    GO; GO:0030182; P:neuron differentiation; TAS.
DR
DR
    GO; GO:0007165; P:signal transduction; NAS.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
KW
    Endoplasmic reticulum; Alternative splicing; Transmembrane;
KW
    Phosphorylation.
FT
    TRANSMEM
                       623
                603
                                POTENTIAL.
                726
FT
    TRANSMEM
                      746
                                POTENTIAL.
                589
                      776
FT
    DOMAIN
                                RETICULON.
FT
               609
    DOMAIN
                    612
                                POLY-LEU.
FT
    VARSPLIC
                1
                     420
                                Missing (in isoform RTN1-B).
FT
                                /FTId=VSP 005644.
FT
    VARSPLIC 1
                      568
                                Missing (in isoform RTN1-C).
                                /FTId=VSP 005645.
FT
FT
    VARSPLIC
              569
                      588
                                GPGPLGPGAPPPLLFLNKQK -> MOATADSTKMDCVWSNW
FT
                                KSQ (in isoform RTN1-C).
FT
                                /FTId=VSP 005646.
    SEQUENCE 776 AA; 83617 MW; CA5B6232353096FE CRC64;
SO
 Query Match
                        13.5%; Score 789.5; DB 1; Length 776;
 Best Local Similarity 31.2%; Pred. No. 5.3e-23;
 Matches 243; Conservative 115; Mismatches 252; Indels 169; Gaps
                                                                        28;
```

Qу	487	TSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESELNEATGT: : : : : :	
Db	65	SGPARQSPVAMETASTGVAGVSSAMDHTFSTTSKDGEGSCYTSLIS	
Qу	547	KIAYETKVDLVQTSEAIQ-ESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNS	599
Db	111	DICYPPQEDSTYFTGILQKENGHVTISESPEELGTPGPSLPDVPGIESRGLFSSDSG	167
QУ	600	LLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAM : : : :: :: : ::	641
Db	168	IEMTPAESTEVNKILADPLDQMKAEAYKYIDITRPEEVKHQEQHHPELEDKDLDFKNKDT	227
QУ	642	NVALKALGTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTE-PSP:::: :: : : : : ::::	690
Db	228	DISIKPEGVREPDKPAPVEGKIIKDHLLEESTFAPYIDDLSEEQRRAPQITTP	280
QУ	691	DFSNYSEIAKFEKSVPEHAELVEDSSPESEPVDLF-SDDSIPEVPQTQEEAVMLMK :	745
Db	281	VKITLTEIEPSVETTTQEKTPEKQDICLKPSPDTVPTVTVSEPEDDSPGSITPP	334
QУ	746	ESLTEVSETVAQHKEERLSASPQELGKPYLESFQPNLHSTKDAASND	792
Db	335	SSGTEPSAAESQGKGSISEDELITAIKEAKGLSYETAENPRPVGQLADRPEVKARSGPPT	394
QУ	793	IPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKI	827
Db	395	IPSPLDHEASSAESGDSEIELVSEDPMAAEDALPSGYVSFGHVGGPPPSPASPSIQYS	452
Qу	828	KESETFSDSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSG	879
Db	453	ILREEREAELDSELIIESCDASSASEESPKREQDSPPMKPSALDAIREETGVRAEER	509
QУ	880	ADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMGSIV	939
Db	510	APSRRGLAEPGSFLD-YPSTEPQPGPELPPGDGALEPETPM	549
Qу		KSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRD	
Db	550	LPRKPEEDSSSNQSPAATKGPGPLGPGAPPPLLFLNKQKAIDLLYWRD	597
QУ	985	IKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPF	1044
Db	598	IKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVLQAVQKTDEGHPF	657
Qγ	1045	RAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGA : : : : : : :	1104
Db	658	KAYLELEITLSQEQIQKYTDCLQFYVNSTLKELRRLFLVQDLVDSLKFAVLMWLLTYVGA	717
QУ		LFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAKIPGLKRKAD J	
Db	718	LFNGLTLLLMAVVSMFTLPVVYVKHQAQIDQYLGLVRTHINAVVAKIQAKIPGAKRHAE 7	76

```
AC
     095197;
DT
     16-OCT-2001 (Rel. 40, Created)
DT
     16-OCT-2001 (Rel. 40, Last sequence update)
DT
     10-OCT-2003 (Rel. 42, Last annotation update)
DE
     Reticulon protein 3 (Neuroendocrine-specific protein-like 2) (NSP-like
DE
     protein II) (NSPLII).
GN
     RTN3 OR NSPL2.
OS
     Homo sapiens (Human).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
     NCBI TaxID=9606;
RN
RP
     SEQUENCE FROM N.A., AND TISSUE SPECIFICITY.
RC
     TISSUE=Retina;
RX
     MEDLINE=99265974; PubMed=10331947;
RA
     Moreira E.F., Jaworski C.J., Rodriguez I.R.;
RT
     "Cloning of a novel member of the reticulon gene family (RTN3): gene
RT
     structure and chromosomal localization to 11q13.";
RL
     Genomics 58:73-81(1999).
RN
     [2]
RP
     SEQUENCE FROM N.A.
RA
     Huang X., Zhou Y., Du G., Yuan J., Qiang B.;
     "Cloning and expression analysis of a cDNA encoding a novel
RT
RT
     neuroendocrine-specific protein-like protein 1: NSPL1.";
RL
     Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RN
     [3]
RP
     SEQUENCE FROM N.A.
RC
     TISSUE=Brain, Eye, and Lymph;
RX
     MEDLINE=22388257; PubMed=12477932;
RA
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
ŔĀ
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT
     "Generation and initial analysis of more than 15,000 full-length
RT
     human and mouse cDNA sequences.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
     -!- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic
CC
CC
         reticulum (Potential).
CC
     -!- TISSUE SPECIFICITY: WIDELY EXPRESSED WITH HIGHEST EXPRESSION IN
         BRAIN. THREE TIMES MORE ABUNDANT IN MACULA THAN IN PERIPHERAL
CC
CC
         RETINA.
CC
     -!- SIMILARITY: Contains 1 reticulon domain.
CC
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
```

```
between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    _____
    EMBL; AF059524; AAC99319.1; -.
DR
DR
    EMBL; AF059529; AAD20951.1; -.
    EMBL; AF059525; AAD20951.1; JOINED.
DR
    EMBL; AF059526; AAD20951.1; JOINED.
    EMBL; AF059527; AAD20951.1; JOINED.
DR
    EMBL; AF059528; AAD20951.1; JOINED.
DR
    EMBL; AF119297; AAD26810.1; -.
DR
DR
    EMBL; BC000634; AAH00634.1; -.
DR
    EMBL; BC010556; AAH10556.1; -.
    EMBL; BC011394; AAH11394.1; -.
DR
    EMBL; BC022993; AAH22993.1; -.
DR
    Genew; HGNC:10469; RTN3.
DR
    MIM; 604249; -.
DR
    GO; GO:0005615; C:extracellular space; TAS.
DR
    InterPro; IPR003388; Reticulon.
    Pfam; PF02453; Reticulon; 1.
DR
DR
    PROSITE; PS50845; RETICULON; 1.
KW
    Transmembrane; Endoplasmic reticulum.
                     88
FT
    TRANSMEM
              68
                             POTENTIAL.
                   197
236
FT
    TRANSMEM
              177
                             POTENTIAL.
FT
    DOMAIN
               48
                             RETICULON.
    SEQUENCE 236 AA; 25609 MW; DDC6A4544ABCDFB7 CRC64;
SO
 Query Match
                       10.7%; Score 625.5; DB 1; Length 236;
 Best Local Similarity 59.1%; Pred. No. 1.7e-17;
 Matches 114; Conservative 41; Mismatches 37; Indels 1; Gaps
Qγ
         972 SKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGV 1031
            44 SSCAVHDLIFWRDVKKTGFVFGTTLIMLLSLAAFSVISVVSYLILALLSVTISFRIYKSV 103
Db
        1032 IQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLK 1091
Qу
            Dh
        104 IQAVQKSEEGHPFKAYLDVDITLSSEAFHNYMNAAMVHINRALKLIIRLFLVEDLVDSLK 163
        1092 FAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKI 1151
Qу
             Db
        164 LAVFMWLMTYVGAVFNGITLLILAELLIFSVPIVYEKYKTQIDHYVGIARDQTKSIVEKI 223
Qy
        1152 QAKIPGL-KRKAD 1163
            |||:||: |:||:
Db
        224 QAKLPGIAKKKAE 236
RESULT 7
RTN3 MOUSE
    RTN3 MOUSE
                 STANDARD;
                              PRT; 237 AA.
AC
    Q9ES97;
DT
    16-OCT-2001 (Rel. 40, Created)
    16-OCT-2001 (Rel. 40, Last sequence update)
```

```
DT
     15-MAR-2004 (Rel. 43, Last annotation update)
DE
     Reticulon protein 3.
GN
     RTN3.
OS
     Mus musculus (Mouse).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
XO
     NCBI_TaxID=10090;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RA
     Huang X., Zhou Y., Qiang H., Yuan J., Qiang B.;
     "Cloning and expression profile of a novel mouse cDNA encoding a human
RT
RT
     RTN3 homolog.";
RL
     Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RN
     [2]
RP
     SEQUENCE FROM N.A.
RC
     TISSUE=Eye;
RX
     MEDLINE=22388257; PubMed=12477932;
RA
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RA
     "Generation and initial analysis of more than 15,000 full-length
RT
RT
     human and mouse cDNA sequences.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC
     -!- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic
CC
         reticulum (Potential).
CC
     -!- SIMILARITY: Contains 1 reticulon domain.
CC
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
     or send an email to license@isb-sib.ch).
CC
DR
     EMBL; AF195940; AAG31360.1; -.
DR
     EMBL; BC014697; AAH14697.1; -.
DR
    MGD; MGI:1339970; Rtn3.
DR
     InterPro; IPR003388; Reticulon.
DR
     Pfam; PF02453; Reticulon; 1.
DR
     PROSITE; PS50845; RETICULON; 1.
KW
     Transmembrane; Endoplasmic reticulum.
FT
     TRANSMEM
                  69
                         89
                                  POTENTIAL.
```

```
167
                      187
                                POTENTIAL.
FT
    DOMAIN
                 49
                      237
                                RETICULON.
SQ
    SEQUENCE
               237 AA; 25428 MW; EB60A0A7AC45F0DE CRC64;
  Query Match
                        10.7%; Score 625.5; DB 1; Length 237;
  Best Local Similarity
                        59.1%; Pred. No. 1.7e-17;
  Matches 114; Conservative 41; Mismatches
                                             37; Indels
                                                             1; Gaps
                                                                        1;
         972 SKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGV 1031
Qy
                Db
          45 SSCAVHDLIFWRDVKKTGFVFGTTLIMLLSLAAFSVISVVSYLILALLSVTISFRVYKSV 104
        1032 IQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLK 1091
Qy
             Db
         105 IQAVQKSEEGHPFKAYLDVDITLSSEAFHNYMNAAMVHVNKALKLIIRLFLVEDLVDSLK 164
        1092 FAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKI 1151
Qу
              Db
         165 LAVFMWLMTYVGAVFNGITLLILAELLVFSVPIVYEKYKTQIDHYVGIARDQTKSIVEKI 224
        1152 OAKIPGL-KRKAD 1163
Qу
             |||:||: |:||:
Db
         225 QAKLPGIAKKKAE 237
RESULT 8
RTN2 MOUSE
    RTN2 MOUSE
                  STANDARD:
                                PRT;
                                       471 AA.
AC
    070622; 070620;
    16-OCT-2001 (Rel. 40, Created)
DT
DT
    16-OCT-2001 (Rel. 40, Last sequence update)
DT
    15-MAR-2004 (Rel. 43, Last annotation update)
DE
    Reticulon protein 2 (Neuroendocrine-specific protein-like 1) (NSP-like
DE
    protein 1) (NSPLI).
    RTN2 OR NSPL1.
GN
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
RP
    SEQUENCE FROM N.A. (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY.
RC
    STRAIN=FVB/N, and 129/Sv; TISSUE=Cerebellum, and Skeletal muscle;
RX
    MEDLINE=98191726; PubMed=9530622;
    Geisler J.G., Stubbs L.J., Wasserman W.W., Mucenski M.L.;
RA
RT
    "Molecular cloning of a novel mouse gene with predominant muscle and
RT
    neural expression.";
RL
    Mamm. Genome 9:274-282(1998).
RN
RP
    SEQUENCE FROM N.A. (ISOFORM 1).
RC
    TISSUE=Retina;
    MEDLINE=22388257; PubMed=12477932;
RX
RA
    Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
    Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
    Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
    Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
    Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
    Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
```

FT

TRANSMEM

```
Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
RA
    Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
    Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
    Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
RA
    Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
    Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
    Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT
     "Generation and initial analysis of more than 15,000 full-length
RT
    human and mouse cDNA sequences.";
    Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
CC
    -!- SUBCELLULAR LOCATION: Membrane-bound. Endoplasmic reticulum
CC
         (Potential).
CC
    -!- ALTERNATIVE PRODUCTS:
CC
        Event=Alternative splicing; Named isoforms=2;
        Name=1; Synonyms=Brain;
CC
CC
          IsoId=070622-1; Sequence=Displayed;
CC
        Name=2; Synonyms=Muscle;
CC
          IsoId=070622-2; Sequence=VSP 005650, VSP 005651;
    -!- TISSUE SPECIFICITY: Expressed predominantly in neural and muscular
CC
CC
        tissues.
    -!- SIMILARITY: Contains 1 reticulon domain.
CC
CC
    CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    EMBL; AF038537; AAC14906.1; -.
DR
    EMBL; AF038537; AAC14907.1; -.
DR
    EMBL; AF038538; AAC14908.1; -.
DR
DR
    EMBL; AF038539; AAC14909.1; -.
DR
    EMBL; AF093624; AAD13195.1; -.
DR
    EMBL; BC031370; AAH31370.1; -.
DR
    MGD; MGI:107612; Rtn2.
DR
    InterPro; IPR003388; Reticulon.
    Pfam; PF02453; Reticulon; 1.
DR
DR
    PROSITE; PS50845; RETICULON; 1.
KW
    Endoplasmic reticulum; Alternative splicing; Transmembrane.
FT
    TRANSMEM
                295
                       315
                                 POTENTIAL.
                272
                       471
FT
    DOMAIN
                                 RETICULON.
FT
    VARSPLIC
                 1
                       267
                                 Missing (in isoform 2).
FT
                                 /FTId=VSP 005650.
FT
                268
                       271
                                 PLLL -> MGSK (in isoform 2).
    VARSPLIC
                                 /FTId=VSP 005651.
FT
SQ
               471 AA; 51346 MW; 9BBD8F372CF63AD3 CRC64;
    SEQUENCE
 Ouery Match
                          8.7%; Score 509; DB 1; Length 471;
 Best Local Similarity
                        28.6%; Pred. No. 1e-12;
 Matches 146; Conservative 84; Mismatches 175; Indels 106; Gaps
                                                                          13;
```

```
690 PDFSNYSEIAKFEKSVPEHAELVEDSSP--ESEPVDLFSDDSIPEVPOTOEEAVMLMKES 747
Qv
           6 PVFAHCKEAPSTASSTPDSTEGGNDDSDFRELHTAREFSED------ 46
Db
        748 LTEVSETVAOH-------KEERLSASPQELGKPYLESFQPNLHST 785
QУ
                                ::: |: |: |
            | || :|
        47 --EEEETTSQDWGTPRELTFSYIAFDGVVGSGGRRDSVVRRPRPQGRSVSEPRDPPQQSG 104
Db
        786 KDAASNDIPTLTKK-----EKISLQMEEFNTAIYSNDDLLSSKEDK 826
Qу
                                      |:: |:::: : |
Db
        105 LGDSLESIPSLSQSPEPGRRGDPDPVPPAERPLEELRLRLDQLGWVVRS----AGSGED- 159
        827 IKESETFSDSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCL 886
Qy
                160 ----SATSSSTPLE--NEEPDGLEASE-----AGEETNLEL----RLAO------SL 195
Db
        887 ELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKASISPSNVSALEPOTEMGSIVKSKSLTK 946
Qу
            196 HLQLEVLTPQLSPSSGTPQAHTPSPQRSQDSNS--GPDDEPLLNVVEEHWRLLEQEPITA 253
Db
        947 EAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFS 1006
QУ
           254 QC----LDSTDQSEFMLEPLL------LVADLLYWKDTRTSGAVFTGLMASLLCLLHFS 302
Db
       1007 IVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSA 1066
Qу
           303 IVSVAAHLALLGLCATISLRVYRKVLQAVHRGDGTNPFQAYLDMDLTLTREQTERLSQQI 362
Db
       1067 LGHVNSTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIY 1126
Qу
             363 ASHVVSTATQLRHFFLVEDLVDSLKLALLFYILTFVGAIFNGLTLVILGVVALFTVPLLY 422
Db
       1127 ERHOVOIDHYLGLANKSVKDAMAKIOAKIPG 1157
Qy
            423 RQHQAQIDQYVGLVTNQLSHIKAKIRAKIPG 453
Db
RESULT 9
RTN2 HUMAN
               STANDARD; PRT; 545 AA.
    RTN2 HUMAN
    075298; 060509;
DT
    16-OCT-2001 (Rel. 40, Created)
    16-OCT-2001 (Rel. 40, Last sequence update)
DT
    10-OCT-2003 (Rel. 42, Last annotation update)
DT
    Reticulon protein 2 (Neuroendocrine-specific protein-like 1) (NSP-like
DE
    protein 1) (NSPLI).
DΕ
    RTN2 OR NSPL1.
GN
    Homo sapiens (Human).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
OX
    NCBI_TaxID=9606;
RN
    [1]
    SEQUENCE FROM N.A., ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RΡ
RC
    TISSUE=Lung carcinoma;
    MEDLINE=98360096; PubMed=9693037;
RX
    Roebroek A.J.M., Contreras B., Pauli I.G.L., Van de Ven W.J.M.;
RA
```

"cDNA cloning, genomic organization, and expression of the human RTN2

RT

```
RT
    gene, a member of a gene family encoding reticulons.";
RL
    Genomics 51:98-106(1998).
RN
RP
    SEQUENCE OF 108-545 FROM N.A. (ISOFORM RTN2-B).
RC
    TISSUE=Brain:
    MEDLINE=98191726; PubMed=9530622;
RX
    Geisler J.G., Stubbs L.J., Wasserman W.W., Mucenski M.L.;
RA
    "Molecular cloning of a novel mouse gene with predominant muscle and
RT
RT
    neural expression.";
    Mamm. Genome 9:274-282(1998).
RL
    -!- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic
CC
        reticulum (Potential).
    -!- ALTERNATIVE PRODUCTS:
CC
CC
        Event=Alternative splicing; Named isoforms=2;
CC
        Name=RTN2-A;
CC
          IsoId=075298-1; Sequence=Displayed;
          Note=Isoform RTN2-C is produced by alternative initiation at
CC
CC
          Met-341 of isoform RTN2-A;
CC
        Name=RTN2-B;
CC
          IsoId=075298-2; Sequence=VSP 005649;
CC
        Event=Alternative initiation;
CC
          Comment=2 isoforms, RTN2-A (shown here) and RTN2-C, are produced
CC
          by alternative initiation at Met-1 and Met-341;
CC
    -!- TISSUE SPECIFICITY: ISOFORM RTN2-C IS HIGHLY EXPRESSED IN SKELETAL
CC
CC
    -!- SIMILARITY: Contains 1 reticulon domain.
CC . ------
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    EMBL; AF004222; AAC32542.1; -.
DR
DR
    EMBL; AF004223; AAC32543.1; -.
    EMBL; AF004224; AAC32544.1; -.
DR
DR
    EMBL; AF038540; AAC14910.1; -.
DR
    Genew; HGNC:10468; RTN2.
DR
    MIM; 603183; -.
DR
    GO; GO:0030176; C:integral to endoplasmic reticulum membrane; NAS.
DR
    GO; GO:0004871; F:signal transducer activity; NAS.
    GO; GO:0007165; P:signal transduction; NAS.
DR
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
    PROSITE; PS50845; RETICULON; 1.
    Endoplasmic reticulum; Alternative splicing; Transmembrane;
KW
    Alternative initiation.
FT
    CHAIN
                1
                      545
                               RETICULON PROTEIN 2, ISOFORM RTN2-A.
FT
    CHAIN
               341
                      545
                               RETICULON PROTEIN 2, ISOFORM RTN2-C.
FT
    INIT MET
               341
                     341
                               FOR ISOFORM RTN2-C.
FT
    TRANSMEM
               368
                     388
                               POTENTIAL.
FT
    TRANSMEM
               463
                     483
                               POTENTIAL.
FT
    DOMAIN
               345 545
                               RETICULON.
FT
    VARSPLIC
               272 344
                               Missing (in isoform RTN2-B).
FT
                               /FTId=VSP 005649.
```

```
Query Match
                     8.4%; Score 490; DB 1; Length 545;
 Best Local Similarity 28.3%; Pred. No. 6.3e-12;
 Matches 160; Conservative 76; Mismatches 202; Indels 128; Gaps 17;
Qy
        668 EAPYISIACDLIKETKLSTEPSPDFSNYSEI---AKFEKSVPEHAELVEDSSPESEPVDL 724
                      Db
         13 EAP----STASSTPDSTEGGNDDSDFRELHTAREFSEEDEEETTSQDWGTPRELTFSY 66
        725 FSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYL-ESFOPNLH 783
QУ
                  Db
         67 IAFDGVVGSGGRRDSTARRPRPQGRSVSEPRDQHPQPSLGDSLESI--PSLSQSPEPGRR 124
        784 STKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIEIID 843
Qy
              | | | : |:::
                                         125 GDPDTAP---PSERPLEDLRLRLDHLGWVARGT----GSGED-----SSTSSSTPLE--- 169
Db
        844 EFPTFVSAKDDSPKLAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKNIYPKDEV 903
Qу
                  1: | : | | | : |
        170 -----DEEP---QEPNRLETGEAGE-----EL--DLRLRLAOPSSPE 201
Db
        904 HVSDEFSENRSSVSKASISP----SNVSALEPOTE----- 934
Qу
            ::: | : : | | | | | | | | |
Db
        202 VLTPQLSPGSGTPQAGTPSPSRSRDSNSGPEEPLLEEEEKQWGPLEREPVRGQCLDSTDQ 261
        935 -----MGSIVK--SKSLTKEAEKKLP------ 954
Qу
                  :1: :: || | :1
Db
        262 LEFTVEPRLLGTAMEWLKTSLLLAVYKTVPILELSPPLWTAIGWVQRGPTPPTPVLRVLL 321
        955 DTEKEDRSLSAVLSAELSK---TSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVT 1011
Qy
             Db
        322 KWAKSPRS-SGVPSLSLGADMGSKVADLLYWKDTRTSGVVFTGLMVSLLCLLHFSIVSVA 380
       1012 AYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVN 1071
QУ
           381 AHLALLLLCGTISLRVYRKVLQAVHRGDGANPFQAYLDVDLTLTREQTERLSHQITSRVV 440
Db
       1072 STIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQV 1131
Qу
           Db
        441 SAATQLRHFFLVEDLVDSLKLALLFYILTFVGAIFNGLTLLILGVIGLFTIPLLYROHOA 500
       1132 QIDHYLGLANKSVKDAMAKIQAKIPG 1157
Qу
           Db
        501 QIDQYVGLVTNQLSHIKAKIRAKIPG 526
RESULT 10
PCLO HUMAN
    PCLO HUMAN STANDARD; PRT; 5147 AA.
ID
    Q9Y6V0; O43373; O60305; Q9BVC8; Q9UIV2; Q9Y6U9;
AC
    28-FEB-2003 (Rel. 41, Created)
DΤ
    28-FEB-2003 (Rel. 41, Last sequence update)
DT
    10-OCT-2003 (Rel. 42, Last annotation update)
DE
    Piccolo protein (Aczonin) (Fragments).
```

GN

OS

PCLO OR ACZ OR KIAA0559.

Homo sapiens (Human).

```
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
     NCBI TaxID=9606;
RN
RP
     SEQUENCE OF 1-759 FROM N.A.
RC
     TISSUE=Brain;
RX
     MEDLINE=99439764; PubMed=10508862;
RA
     Wang X., Kibschull M., Laue M.M., Lichte B., Petrasch-Parwez E.,
RA
     Kilimann M.W.;
RT
     "Aczonin, a 550-kd putative scaffolding protein of presynaptic active
RT
     zones, shares homology regions with rim and bassoon and binds
RT
     profilin.";
RL
     J. Cell Biol. 147:151-162(1999).
RN
RP
     SEQUENCE OF 552-4404 FROM N.A.
RA
     Kraemer J., Wollam C., Wohldmann P., McGrane B.;
RL
     Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN
RP
     SEQUENCE OF 3619-5147 FROM N.A. (ISOFORM 2).
RC
     TISSUE=Brain;
RX
     MEDLINE=98290545; PubMed=9628581;
RA
     Nagase T., Ishikawa K.-I., Miyajima N., Tanaka A., Kotani H.,
RA
     Nomura N., Ohara O.;
RT
     "Prediction of the coding sequences of unidentified human genes. IX.
RT
     The complete sequences of 100 new cDNA clones from brain which can
RT
     code for large proteins in vitro.";
RL
     DNA Res. 5:31-39(1998).
RN
     [4]
RP
     SEQUENCE OF 4405-4439 FROM N.A.
RC
     TISSUE=Placenta;
RX
     MEDLINE=22388257; PubMed=12477932;
RA
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
     "Generation and initial analysis of more than 15,000 full-length
RT
RT
     human and mouse cDNA sequences.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN
     [5]
RP
     SEQUENCE OF 4405-5147 FROM N.A.
RA
     Kalicki J., Elliott G.;
RL
     Submitted (FEB-1998) to the EMBL/GenBank/DDBJ databases.
CC
     -!- FUNCTION: May act as a scaffolding protein involved in the
CC
         organization of synaptic active zones and in synaptic vesicle
```

```
CC
        trafficking (By similarity).
CC
    -!- SUBUNIT: Interacts with Rabacl/Pral, RIMS2 and profilin (By
CC
        similarity).
CC
    -!- SUBCELLULAR LOCATION: Concentrated at the presynaptic side of
CC
        synaptic junctions (By similarity).
CC
    -!- ALTERNATIVE PRODUCTS:
CC
        Event=Alternative splicing; Named isoforms=2;
CC
          Comment=Additional isoforms seem to exist;
CC
        Name=1;
CC
          IsoId=Q9Y6V0-1; Sequence=Displayed;
CC
        Name=2;
CC
          IsoId=Q9Y6V0-2; Sequence=VSP 003923, VSP 003924, VSP 003925.
                                 VSP 003926, VSP 003927;
CC
          Note=No experimental confirmation available;
CC
CC
    -!- DOMAIN: C2 domain 1 is involved in binding calcium and
CC
        phospholipids. Calcium binds with low affinity but with high
CC
        specificity and induces a large conformational change.
CC
    -!- SIMILARITY: Contains 2 C2 domains.
CC
    -!- SIMILARITY: Contains 1 PDZ/DHR domain.
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
    or send an email to license@isb-sib.ch).
CC
     EMBL; Y19188; CAB60727.1; -.
DR
    EMBL; AC004903; AAD20936.1; -.
DR
DR
    EMBL; AC004886; AAD21789.1; -.
DR
    EMBL; AB011131; BAA25485.1; -.
DR
    EMBL; BC001304; AAH01304.1; -.
    EMBL; AC004082; AAB97937.1; -.
DR
DR
    PIR; T00634; T00634.
DR
    HSSP; P04410; 1A25.
DR
    Genew; HGNC:13406; PCLO.
DR
    MIM; 604918; -.
DR
    GO; GO:0005856; C:cytoskeleton; NAS.
    GO; GO:0045202; C:synaptic junction; ISS.
DR
DR
    GO; GO:0005509; F:calcium ion binding; ISS.
    GO; GO:0005544; F:calcium-dependent phospholipid binding; ISS.
DR
    GO; GO:0005522; F:profilin binding; ISS.
DR
DR
    GO; GO:0007010; P:cytoskeleton organization and biogenesis; ISS.
DR
    GO; GO:0016080; P:synaptic vesicle targeting; ISS.
DR
    InterPro; IPR000008; C2.
    InterPro; IPR001565; Synaptotagmin.
DR
    PRINTS; PR00360; C2DOMAIN.
DR
    PRINTS; PR00399; SYNAPTOTAGMN.
DR
DR
    SMART; SM00239; C2; 2.
    PROSITE; PS00499; C2 DOMAIN 1; 1.
DR
    PROSITE; PS50004; C2 DOMAIN 2; 2.
DR
KW
    Calcium/phospholipid-binding; Zinc; Metal-binding; Zinc-finger;
KW
    Repeat; Alternative splicing.
FT
    NON TER
                1
                        1
FT
    DOMAIN
                400
                      465
                                10 X 10 AA TANDEM APPROXIMATE REPEATS OF
FT
                                P-A-K-P-Q-P-Q-Q-P-X.
```

```
FT
    ZN FING
            499
                  523
                           C4-TYPE (POTENTIAL).
    ZN FING
                           C4-TYPE (POTENTIAL).
FT
             969
                  992
    NON CONS 1010 1011
FT
FT
    DOMAIN
             2300
                 2325
                          POLY-PRO.
FT
    DOMAIN
             4391
                  4442
                          PDZ.
FT
    DOMAIN
             4544
                  4633
                          C2 DOMAIN 1.
    DOMAIN
FT
             5031
                  5121
                          C2 DOMAIN 2.
FT
    VARSPLIC
             4404
                  4404
                           S -> SGNGLGIRIVGGKEIPGHSGEIGAYIAKILPGGSAE
FT
                           QTGKLMEG (in isoform 2).
FT
                           /FTId=VSP 003923.
    VARSPLIC
             4534
                  4534
FT
                           K -> KPTDGTKVVSHPITGEIQ (in isoform 2).
                           /FTId=VSP 003924.
FT
FT
    VARSPLIC
            4576
                  4576
                           G -> GQVMVVQNAS (in isoform 2).
                           /FTId=VSP 003925.
FT
FT
    VARSPLIC 4757
                  4761
                           TAHKS -> SKRRK (in isoform 2).
FT
                           /FTId=VSP 003926.
FT
   VARSPLIC 4762 5147
                           Missing (in isoform 2).
FT
                           /FTId=VSP 003927.
    SEQUENCE 5147 AA; 563537 MW; CD5D84990498CD3C CRC64;
SO
 Query Match 5.3%; Score 308.5; DB 1; Length 5147; Best Local Similarity 21.4%; Pred. No. 0.00076;
 Matches 264; Conservative 150; Mismatches 438; Indels 383; Gaps 63;
         3 DIDQSSLVSSSTDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDEDLEELEVLERKPA 62
Qу
           Db
        251 DIVRGESVKPSLPSPSKPP-----IQQPTPGKPPAQQPGHEKSQPG-----PAKPP 296
         63 AGLSAAAVP----PAAAAPLLDFSSDSVPPA-PRGPLPAAPPA-----A 101
Qу
          297 AQPSGLTKPLAQQPGTVKPPVQPPGTTKPPAQPLG--PAKPPAQOTGSEKPSSEOPGPKA 354
Db
        102 PERQPSWERSPA-APAPSLP----- 138
Qу
            : | ::|| | |: |
                                         355 LAQPPGVGKTPAQQPGPAKPPTQQVGTPKPLAQQPGLQSPAKAPGPTKTPAQTKPPSQQP 414
Db
        139 --- RPPPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDETLFALPAASEPVIPSSAEKIM 195
Qу
             415 GSTKPPPQQPGPAKP--SPQQPGSTKPPSQQPGS-----AKPSAQQ---PSPAKPSA 461
Db
       196 DLMEQPGNTVSSGQEDFPSVLLETAASLPS-----LSPL-STVSFKEH-GYLGNLSAVS 247
Qу
              Db
        462 QQFTKPVSQTGFGKPLQPPTVSPSAKQPPSQGLPKTICPLCNTTELLLHVPEKANFNTCT 521
        248 SSEGTI-----EETLNEASKEL------PERATNPFVNRDL 277
Qу
            522 ECQTTVCSLCGFNPNPHLTEAKEWLCLNCQMKRALGGDLAPVPSSPQPKLKTAPVTTTSA 581
Db
        278 AEFSELEYSEMGSSFKGSPKGESAILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGK 337
Qу
            Db
        582 VSKSSPQPQQTSPKKDAAPKQDLSKAPEPKKPPPLVKQPTLHGSPSAKAKQPPEADSLSK 641
        338 EDRVVSPEKTMDIFNEMOMSVVAPVREEYADFKPFEOAWEVKDTYEGSRDVLAARANVES 397
QУ
              Db
       642 P----APPKEPSVPSEQDK---APV----ADDKP-KQPKMVKPTTD---LVSSSSATTKP 686
Qy
       398 KVDRKCLEDSLEQKS---LGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFTSATESTT 454
```

```
: :: |:|: | || :: ||| | |
Db
        687 DIPSSKVOSOAEEKTTPPLKTDSAKPSQ--SFPPTGEKV-----TPFDSKAIPRP 734
Qу
        455 ANTFPLLE--DHTSENKTD-----EKKIEERKAQIITEKTSPK------ 490
           1: :: :||:| :|| :|| |
Db
        735 ASDSKIISHPGPSSESKGQKQVDPVQKKEEPKKAQ---TKMSPKPDAKPMPKGSPTPPGP 791
        491 --TSNPFLVAVODS----EADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESELNEAT 544
Qy
            Db
        792 RPTAGQTVPTPQQSPKPQEQSRRFSLNLGSITDAPKSQ-----PTTPQET-----VT 838
        545 GTKIAYETKVDLVQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSLLPSA 604
Qу
          | : : | | | : | : | : : | : : | : : | : : | : : |
Db
       839 GKLFGFGASI-FSQASNLISTAGQPG----PHSQSGPGAP-----MKQAPAPSOPPTS 886
Qу
        605 GASVVQPSVSPLEAPP-----PVSYD-----SIKLEP-----ENPPPYEE 639
           1 | :||| | :| : :|||| : :|||
       887 QG----PPKSTGQAPPAPAKSIPVKKETKAPAAEKLEPKAEQAPTVKRTETEKKPPPIKD 942
Db
       640 AMNVALK----ALGTK-----E 666
QУ
          | |:| :|| :
       943 SKSLTAEPQKAVLPTKLEKSPKPESTCPLCKTELNIGSKDPPNFNTCTECKNQVCNLCGF 1002
Db
       667 TEAPYISIAC-----DLIK-----ETKLSTEPSPDFSNYSEIAKFEKSVPEHA 709
Qу
            Db
       1003 NPTPHLTENCQTQRAISGQLGDIRKMPPAPSGPKASPMPVP----TESSSQKTAVPPQV 1057
QУ
       710 ELV----EDSSPESEPV-----DLFSDDSIPEV---PQTQEEAVMLMKESLTEVSETVA 756
          1058 KLVKKQEQEVKTEAEKVILEKVKETLSMEKIPPMVTTDQKQEES-KLEKDKASALQEKKP 1116
Db
       757 QHKEERLSASPQEL----GKPYLESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFNTA 812
Qу
            1117 LPEEKKLIPEEEKIRSEEKKPLLEEKKPTPEDKK-----LLPEAKTSAPEEQ---- 1163
Db
Qу
       813 IYSNDDLLSSK----EDKI-----KESETFSDSSPIEIIDEFPTFVSAKDDS- 855
              1164 ---KHDLLKSQVQIAEEKLEGRVAPKTVQEGKQPQTKMEGLP----SGTPQSLPKEDDKT 1216
Db
Qу
       856 -----PKLAKEYTDLEVSDKSEIANIO-----SGADSLPCLELPCD 891
                  Db
       1217 TKTIKEQPQPPCTAKPDQEKE-DDKSDTSSSQQPKSPQGLSDTGYSSDGISSSLGEIP-- 1273
       892 LSFKNIYPKDEVHV-----SDEFSENRSSVSK---ASISPSNVSALEPQTEMGSIVKSKS 943
Οv
             1274 ----SLIPTDEKDILKGLKKDSFSQESSPSSPSDLAKLESTVLSILEAQASTLADEKSEK 1329
Db
Qy
       944 LTK--EAEKKLPSDTEKEDRSLSAVLSAELSKTSV 976
           1: | : | | | : | : | : : :
Db
       1330 KTQPHEVSPEQPKDQEK-TQSLSETLEITISEEEI 1363
RESULT 11
PCLO CHICK
ID
   PCLO_CHICK STANDARD; PRT; 5120 AA.
AC
   Q9PU36;
   28-FEB-2003 (Rel. 41, Created)
DТ
```

```
DT
     28-FEB-2003 (Rel. 41, Last sequence update)
DT
     28-FEB-2003 (Rel. 41, Last annotation update)
DE
     Piccolo protein (Aczonin) (Fragment).
GN
     PCLO OR ACZ.
OS
     Gallus gallus (Chicken).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
     Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC
OC
     Gallus.
OX
    NCBI TaxID=9031;
RN
     [1]
RP
    SEQUENCE FROM N.A.
RC
    TISSUE=Brain;
RX
    MEDLINE=99439764; PubMed=10508862;
RA
    Wang X., Kibschull M., Laue M.M., Lichte B., Petrasch-Parwez E.,
RA
    Kilimann M.W.;
RT
     "Aczonin, a 550-kd putative scaffolding protein of presynaptic active
RT
     zones, shares homology regions with rim and bassoon and binds
RT
    profilin.";
RL
    J. Cell Biol. 147:151-162(1999).
CC
    -!- FUNCTION: May act as a scaffolding protein involved in the
        organization of synaptic active zones and in synaptic vesicle
CC
CC
        trafficking (By similarity).
CC
    -!- SUBUNIT: Interacts with Rabacl/Pra1 and profilin (By similarity).
CC
    -!- SUBCELLULAR LOCATION: Concentrated at the presynaptic side of
CC
        synaptic junctions (By similarity).
    -!- DOMAIN: C2 domain 1 is involved in binding calcium and
CC
CC
        phospholipids. Calcium binds with low affinity but with high
        specificity and induces a large conformational change.
CC
CC
    -!- SIMILARITY: Contains 2 C2 domains.
    -!- SIMILARITY: Contains 1 PDZ/DHR domain.
CC
CC
    ______
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
    modified and this statement is not removed. Usage by and for commercial
CC
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    DR
    EMBL; Y19187; CAB60725.1; -.
DR
    HSSP; P04410; 1A25.
DR
    GO; GO:0045202; C:synaptic junction; ISS.
    GO; GO:0005509; F:calcium ion binding; ISS.
DR
DR
    GO; GO:0005544; F:calcium-dependent phospholipid binding; ISS.
    GO; GO:0005522; F:profilin binding; ISS.
DR
    GO; GO:0007010; P:cytoskeleton organization and biogenesis; ISS.
DR
DR
    GO; GO:0016080; P:synaptic vesicle targeting; ISS.
DR
    InterPro; IPR000008; C2.
DR
    InterPro; IPR001478; PDZ.
    InterPro; IPR001565; Synaptotagmin.
DR
    InterPro; IPR008899; Znf piccolo.
DR
    Pfam; PF00168; C2; 2.
    Pfam; PF00595; PDZ; 1.
DR
DR
    Pfam; PF05715; Zf piccolo; 2.
DR
    PRINTS; PR00399; SYNAPTOTAGMN.
DR
   SMART; SM00239; C2; 2.
DR
    SMART; SM00228; PDZ; 1.
```

```
PROSITE; PS00499; C2 DOMAIN 1; 1.
DR
    PROSITE; PS50004; C2 DOMAIN 2; 2.
DR
DR
    PROSITE; PS50106; PDZ; 1.
    Calcium/phospholipid-binding; Zinc; Metal-binding; Zinc-finger;
KW
KW
    Repeat.
    NON_TER 1 1
DOMAIN 258 357
FT
FT
                        10 X 10 AA TANDEM APPROXIMATE REPEATS OF
FT
                          P-A-K-P-Q-P-Q-Q-P-X.
           368 392
836 859
                        C4-TYPE (POTENTIAL).
FT
    ZN FING
    ZN FING
FT
                         C4-TYPE (POTENTIAL).
FT
    DOMAIN
            2324 2343
                         POLY-PRO.
    DOMAIN
FT
           4414 4493
                         PDZ.
FT
    DOMAIN
           4627 4726
                         C2 DOMAIN 1.
    DOMAIN
FT
            5003 5094
                         C2 DOMAIN 2.
    SEQUENCE 5120 AA; 560751 MW; A658D9891B65B412 CRC64;
SQ
 Query Match
                    5.1%; Score 300; DB 1; Length 5120;
 Best Local Similarity 20.4%; Pred. No. 0.0016;
 Matches 258; Conservative 152; Mismatches 464; Indels 388; Gaps 56;
        14 TDSPPRPPPAFKYQFVTEPEDEEDEEE----EEDEEEDDEDLEELEVLERKPAAGLSAA 68
QУ
           Db
        90 SDSDAAHEEAGRKQKVTQKEQGKPEEQRGLAKHPSQQQSPKLVQQQGPVKPTPQQTESSK 149
        69 AVP-----PAAAAPLLDFSSDSV--PPAPRGP----LPAAPPAAPERQPSWE 109
Qу
          Db
       150 PVPQQQQPGEPKQGQKPGPSHP-GDSKAEQVKQPPQPRGPQKSQLQQSEPTKPGQQQTSA 208
       110 RSPAAPAPSLP--PAAAVLPSKLPEDDEP-----PAR----PAR-----P 140
Qу
           209 KTSAGPTKPLPQQPDSAKTSSQAPPPTKPSLQQSGSVKQPSQQPARQGGPVKPSAQQAGP 268
Db
       141 PPPPPAGASPLAEPAAPPSTPAAPKRRGSGSVDET--LFALPAASEPVIPSS--AEKIMD 196
Qу
          269 PKQQPGSEKPTAQQTGPAKQPPQP-GPGKTPLQQTGPVKQVPPQAGPTKPSSOTAGAAKS 327
Qy
       197 LMEQPGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYLGNLSAVSSSEGTIEET 256
           | :||| | |: | |: :
                                              | | | ::1
       328 LAQQPGLTKPPGQQPGPEKPLQQKQA-----STTQPVESTPKKT 366
Db
       257 L----NEASKELPERAT----LEYS 286
Qу
                367 FCPLCTTTELLLHTPEKANYNTCTQCHTVVCSLCGFNP--NPHITEIKEWLCLNCQMQRA 424
Db
       287 EMGSSFKGSPKGESAILVENTKEEVIVRSKDKEDLVCSAALHSPQESPVGKEDRVVSPE- 345
Qу
            425 LGGDLASGHGPGPQ-----LPPPKQKTPTPASTAKPSPQLQPGQKKDASPKPDP 473
Db
       346 -----KTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLAARANVESK 398
Qу
                1: : | ||:: :|: | | |:|
       474 SQQADSKKPVPQKKQPSMPGSPPVKSKQTHAEPSDTGQQI-DSTPKSDQVKPTQA---- 527
Db
       399 VDRKCLEDSLEQKSLGKD-----SEGRNEDASFPSTPEPVKDSSRAYITCASFTSA 449
Qу
          528 -----EEKQNQPSIQKPTMDTVPTSAAPGVKQDLADPQSP----STQQKVTDSPMPET 576
Db
       450 TESTTANTFPLLEDHTSENKTDEKKIEERKAQIITEKTSP-----KTSNPFLV 497
QУ
```

```
Db
       577 TK-----PPADTHPAGDKPDSKPL----PQVSRQKSDPKLASQSGAKSDAKTQKPSEP 625
Qу
       498 A-VQDSEADYVT----- 525
                               Db
       626 APVKDDPKKLQTKPAPKPDTKPAPKGPQAGTGPRPTSAQPAPQPQQPQKTPEQSRRFSLN 685
Qу
       526 --GLT-----PDLVQEACESEL-----NEA----TGTKIAYETKVDLVQTSEAIO 564
           686 LGGITDAPKPQPTTPQETVTGKLFGFGASIFSQASSLISTAGQPGSQTSGPAPPATKQPQ 745
Db
Qу
       565 ESLYPTAQLCPSFEEAEATPSP-VLPDIVMEAPLNS--LLPSAGASVVQPSVSPLEAPPP 621
            Db
       746 PPSQPPASQAPPKEAAQAQPPPKAAPTKKETKPLASEKLGPMASDSTLTTKGSDLEKKPS 805
       622 VSYDSIKLEPENPPPYE------EAMNVALKALGTKEGIKEPESFNAA----- 663
Qу
          Db
       806 LAKDSKHQTAEAKKPAELSEQEKASQPKVSCPLCKTGLNIGSKDPPNFNTCTECKKVVCN 865
       Qv
                             1: |
                  111 :: : 1
       866 LCGFNPMPHIVEVQE----WLCLNCQTQRAMSGQLGDMGKVPLPKLGPSQPVSKPPATPQ 921
Db
       681 -----ETKLSTEPSPDFSNYSEIAKFEKSVP--EHAEL-----VEDSS 716
Qy
                  Db
       922 KQPVPAVSHSPQKSSTPPTPAATKPKEEPSVPKEVPKLQQGKLEKTLSADKIQQGIQKED 981
Qy
       717 PESEPVDLF---SDDSIPEVPQTQEEAVMLMKESLTEVSETVAQH-KEERLSASPQELGK 772
          982 AKSKQGKLFKTPSADKIQRVSQKEDSRLQQTKLTKTPSSDKILHGVQKEDIKFQEAKLAK 1041
Db
       773 -----PYLESFQPNLHSTKDA---ASNDIPTLTKKEKISLQMEEFNTAIYSN---- 816
Qу
                 1042 IPSADKILHRLQKEDPKLQQMKMAKALSADKIQPEAQKEDVQLQEVRLSKAVSADKIQHG 1101
Db
       Qу
           1102 IQKDLNLQHVKIEKTSSVEKIQEAQKESKLQQDKLPKTLSEDKIPATVSSDHKKLLSKSE 1161
Db
       852 KDDSPKLAKEYTDLEVSDKSEIANIQSG--ADSLPCLELPCDLSFKNIYPKDEVHVSDE- 908
QУ
          1162 EDKKPELLEKSTPHPKDKKEQITAETTGHITEQKVEVEAPCD----KLHEKKQEDVKKED 1217
Db
       909 ----FSENRSSVSKA--SISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRS 962
Qу
             : | | | : | | | | | ::: | : | : | : | | | | | | |
Db
      1218 LTTGIPQMVSKPEKAEEEKTPVPVSRL-PRSDHVEAVREK-IEKEDDK---SDTSSSQQQ 1272
       963 LS 964
QУ
          - 1
Db
      1273 KS 1274
RESULT 12
CPN DROME
ID CPN DROME
            STANDARD; PRT; 865 AA.
   002910:
   01-OCT-1993 (Rel. 27, Created)
```

```
DT
     01-OCT-1993 (Rel. 27, Last sequence update)
DT
     10-OCT-2003 (Rel. 42, Last annotation update)
DΕ
     Calphotin.
GN
     CPN OR CAP.
OS
     Drosophila melanogaster (Fruit fly).
     Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC
OC
     Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC
     Ephydroidea; Drosophilidae; Drosophila.
OX
     NCBI TaxID=7227;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=Canton-S;
RX
     MEDLINE=93165729; PubMed=8094559;
     Martin J.H., Benzer S., Rudnicka M., Miller C.A.;
RT
     "Calphotin: a Drosophila photoreceptor cell calcium-binding protein.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 90:1531-1535(1993).
RN
     SEQUENCE FROM N.A.
RP
RC
     STRAIN=Canton-S;
RX
    MEDLINE=93165730; PubMed=8434015;
     Ballinger D.G., Xue N., Harshman K.D.;
RA
     "A Drosophila photoreceptor cell-specific protein, calphotin, binds
RT
    calcium and contains a leucine zipper.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 90:1536-1540(1993).
    -!- FUNCTION: Might function as a calcium-sequestering "sponge" to
CC
CC
        regulate the amount of free cytoplasmic calcium. It binds 0.3 mole
CC
        of Ca(2+) per mole of protein.
CC
    -!- SUBUNIT: Homodimer (Probable).
    -!- SUBCELLULAR LOCATION: Cytoplasmic; hypodense compartment.
CC
    -!- TISSUE SPECIFICITY: Soma and axons of photoreceptor cells of
CC
CC
        compound eyes and ocelli.
    -!- DEVELOPMENTAL STAGE: Expressed early in photoreceptor cell
CC
CC
        development.
CC
    -----
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    ______
DR
    EMBL; L02111; AAA28405.1; -.
DR
    EMBL; L05080; AAA28420.1; -.
DR
    PIR; A47282; A47282.
DR
    PIR; A47283; A47283.
    FlyBase; FBgn0010218; Cpn.
DR
    GO; GO:0005509; F:calcium ion binding; IDA.
DR
KW
    Calcium-binding.
FT
    CONFLICT
                       36
                               A -> AVAPAVVA (IN REF. 2).
FT
    CONFLICT
                43
                      43
                               I \rightarrow T (IN REF. 2).
FT
    CONFLICT
                64
                       64
                               I \rightarrow V (IN REF. 2).
               76
FT
    CONFLICT
                       76
                               T \rightarrow A (IN REF. 2).
    CONFLICT
FT
               100
                    100
                              P -> PP (IN REF. 2).
    CONFLICT 126 127
FT
                              VQ -> AP (IN REF. 2).
FT
                              I -> V (IN REF. 2).
    CONFLICT 154 154
FT
    CONFLICT
               160 160
                              S \rightarrow T (IN REF. 2).
```

```
CONFLICT 534 534 A -> E (IN REF. 2).
CONFLICT 699 699 I -> T (IN REF. 2).
CONFLICT 703 703 V -> L (IN REF. 2).
CONFLICT 721 721 D -> E (IN REF. 2).
FT
FT
FT
FT
    SEQUENCE 865 AA; 84781 MW; 2110417E0B0E7CFE CRC64;
SO
 Query Match
                    5.1%; Score 295.5; DB 1; Length 865;
 Best Local Similarity 21.3%; Pred. No. 0.00024;
 Matches 217; Conservative 127; Mismatches 379; Indels 295; Gaps 41;
Qу
         62 AAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPER----QPSWERSPAAPAP 117
           11 SAPVAAPVTPSAVAAPVQVVSPAAVAPAPAAPIAVTPVAPPPTLASVQPATVTIP-APAP 69
        118 ----SLPPAAAVLPSKLPEDDEPPARPPPPPPAGA------SPLAEPAAPPSTP----- 161
Qу
              Db
        70 IAAASVTPVASVAPPVVAAPTPPAASPVSTPVAVAQIPVAVSAPVAPPVAATPTPVVQIP 129
        162 -AAPKRRGSGSVDETLFALP--AASEP----VIPSSAEKIMDLMEQPGNT---VSSGQED 211
Qу
           130 VAAP-----VIATPPVAASAPTPAAVTPVISPVIASPPVVPANTTVPVAAPVAA 178
Db
        212 FPSVLLETAASL-PSLSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEASKELPERATN 270
Qу
           179 VPAAVPVVAPVLAPAVAPAVAPVVAETPAPPPVAEIPVA--TIPECVAPLIPEVSVVATK 236
Db
       271 PFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENTKEEVIVRSKDKEDLVCSAALHSP 330
Qy
                         237 PLA-----AAEPVVVAPPATETPVVAPAAASP 263
Db
        331 QESPVGKEDRVVSPEKTMDIFNEMQMSVVAPVREEYADFKPFEQAWEVKDTYEGSRDVLA 390
Qу
           1:1 ::::!!!!
Dh
       391 ARANVESKVDRKCLEDSLEQKSL----GKDSEGRNEDASFPSTPEPVKDSSRAYITCASF 446
Qу
            280 -SASTEPPVAAATLTTAPETPALAPVVAESQVAANTVVATPPTPAPEPETIAPPVVAETP 338
Db
       447 TSATESTTANTFPLLEDHTSENKTDEKKIEERKAQIITEKTSPKTSNPFLVAVQDSEADY 506
Qу
            1:: | |:: :|:
                                     339 EVASVAVAETTPPVVPPVAAES------IPAPVVATTPVPATLAVTDPD--- 381
Db
       507 VTTDTLSKVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQES 566
Qу
                 11:11:1:1:1
                                            382 -----VTASAVPELPPVIAPSPVPSA------VAETPVDLA-----PPV 414
Db
       567 LYP-TAQLCPSF--EEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAP--- 619
Qу
          1 1 1: 1: 11 11:1 :: 1 :: 1 :: 11:11
       415 LPPVAAEPVPAVVAEETPETPAPASAPVTI-AALD--IPEVAPVIAAPSDAPAEAPSAAA 471
       620 PPVSYDSIKLEPENPPPYEEAMNVALKALGTKEGIKEPESFNAAVQETEAPYISIACD-- 677
Qу
          472 PIVS-----TPPT------------TASVPETTAPPAAVPTEPI 498
Db
       678 ---LIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAE--LVEDSSPESEPVDLFSD-DSIP 731
QУ
            Db
       499 DVSVLSEAAIETPVAPPVEVTTEVAVADVAPPEAAADLIIEPVEPPAPIPDLLEQTTSVP 558
```

```
Qу
          732 EVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYLESFQPNLHSTKDAASN 791
                : : : : | | : | | | : : : |
                                                 :| | :|:| : :
Db
          559 AVEAAESTSSPIPETSLPPPNEAVA---SPEVAVAPITAPEPIPEP-EPSLATPTEPIPV 614
          792 DIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSA 851
Qу
             : |
                                      615 EAPV-----------VIQEAVDAVEVPVTETSTSIPETTVEFPEAVAE 651
Db
Qy
          852 KDDSPKLAKEYTDLEV-SDKSEIANIQSGAD----SLPCLEL-----PCDLSFKNIYP- 899
             Db
         652 KVLDPAI----TEAPVTTQEPDVANINDGAPATEITTPAVEIVTAAAEVSDIAIPVIDPP 707
Qу
         900 -KDEVHVSDEFSENRSSVSKASISPSNVSALEPQTEMG----- 936
                1: 1: 1 : :: : : : : : : : : :
         708 VPQEIAVA-EIPETDTKPAEVIVEQSTIPIEAPVPEVSKYAEPVISEAPAAEVPITAGDN 766
Db
Qу
         937 ----SIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAELSKTSVVDLLYWRDIKKTGV 990
                 767 PDNTSVGISEVVPTIAEKPVEEVPTSEIPEQSSSPSDSVPVAKITPLL--RDLQTTDV 822
Db
RESULT 13
MAPB RAT
ID
    MAPB RAT
                STANDARD;
                             PRT; 2459 AA.
AC
     P15205; Q62958; Q9ER21; Q9QW92;
DT
     01-APR-1990 (Rel. 14, Created)
    16-OCT-2001 (Rel. 40, Last sequence update)
DT
DT
    28-FEB-2003 (Rel. 41, Last annotation update)
    Microtubule-associated protein 1B (MAP 1B) (Neuraxin) [Contains: MAP1
DE
DΕ
    light chain LC1].
GN
    MAP1B.
OS
    Rattus norvegicus (Rat).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OC
OX
    NCBI TaxID=10116;
RN
    [1]
RP
    SEQUENCE OF 1-142 FROM N.A.
RC
    STRAIN=Sprague-Dawley; TISSUE=Testis;
RX
    MEDLINE=96257242; PubMed=8666295;
RA
    Liu D., Fischer I.;
    "Isolation and sequencing of the 5' end of the rat microtubule-
RT
    associated protein (MAP1B)-encoding cDNA.";
    Gene 172:307-308(1996).
RL
RN
    SEQUENCE OF 96-2459 FROM N.A., DOMAIN, AND INDUCTION.
RP
    STRAIN=Sprague-Dawley; TISSUE=Brain, and Glial tumor;
RC
RX
    MEDLINE=92347374; PubMed=1639092;
    Zauner W., Kratz J., Staunton J., Feick P., Wiche G.;
RA
    "Identification of two distinct microtubule binding domains on
RT
RT
    recombinant rat MAP 1B.";
    Eur. J. Cell Biol. 57:66-74(1992).
RL
RN
RP
    SEQUENCE OF 1541-2459 FROM N.A., AND TISSUE SPECIFICITY.
    TISSUE=Spinal cord;
RC
RX
    MEDLINE=90059871; PubMed=2555150;
RA
    Rienitz A., Grenningloh G., Hermans-Borgmeyer I., Kirsch J.,
```

```
Littauer U.Z., Prior P., Gundelfinger E.D., Schmitt B., Betz H.;
RA
     "Neuraxin, a novel putative structural protein of the rat central
RT
RT
     nervous system that is immunologically related to microtubule-
RT
     associated protein 5.";
RI_1
     EMBO J. 8:2879-2888(1989).
RN
RP
     DEVELOPMENTAL STAGE, AND PHOSPHORYLATION.
RX
     MEDLINE=97405699; PubMed=9260743;
RA
     Ma D., Nothias F., Boyne L.J., Fischer I.;
RT
     "Differential regulation of microtubule-associated protein 1B (MAP1B)
RТ
     in rat CNS and PNS during development.";
RL
     J. Neurosci. Res. 49:319-332(1997).
CC
     -!- FUNCTION: The function of brain MAPS is essentially unknown.
CC
         Phosphorylated MAP1B may play a role in the cytoskeletal changes
CC
         that accompany neurite extension. Possibly MAP1B Binds to at least
CC
         two tubulin subunits in the polymer, and this bridging of subunits
CC
         might be involved in nucleating microtubule polymerization and in
CC
         stabilizing microtubules.
CC
     -!- SUBUNIT: 3 different light chains, LC1, LC2 and LC3, can associate
CC
         with MAP1A and MAP1B proteins.
     -!- TISSUE SPECIFICITY: Nervous system (spinal cord, brain stem,
CC
         cerebellum and cerebrum). Not expressed in liver, spleen, kidney,
CC
CC
         heart or muscle.
CC
     -!- DEVELOPMENTAL STAGE: In cerebral cortex, spinal cord and sciatic
CC
         nerve levels are high early in development but decrease during
CC
         postnatal development and are low in adults. In dorsal root
CC
         ganglia levels remain high throughout development.
CC
     -!- INDUCTION: By nerve growth factor.
CC
     -!- DOMAIN: Has a highly basic region with many copies of the sequence
CC
         KKEE and KKEI/V, repeated but not at fixed intervals, which is
CC
         responsible for the binding of MAP1B to microtubules.
     -!- PTM: LC1 is coexpressed with MAP1B. It is a polypeptide generated
CC
CC
         from MAP1B by proteolytic processing. It is free to associate with
CC
        both MAP1A and MAP1B. It interacts with the amino-terminal region
CC
         of MAP1B (By similarity).
CC
    -!- PTM: Phosphorylated.
CC
    -!- SIMILARITY: TO MAP1A.
CC
     -!- CAUTION: A C-terminal fragment of this protein (residues 1597 to
CC
         2459) was originally described as neuraxin in Ref.3.
CC
     ______
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
CC
DR
    EMBL; U52950; AAB17068.1; -.
    EMBL; X60370; CAC16162.1; -.
DR
    EMBL; X16623; CAA34620.1; ALT SEQ.
DR
DR
    PIR; A56577; A56577.
DR
    InterPro; IPR000102; MAP1B neuraxin.
DR
    Pfam; PF00414; MAP1B neuraxin; 10.
DR
    PROSITE; PS00230; MAP1B NEURAXIN; 8.
```

Microtubule; Repeat; Phosphorylation.

? 2459 MAP1 LIGHT CHAIN LC1.

KW FT

CHAIN

```
FT
         REPEAT
                            1869
                                      1885
                                                           MAP1B 1.
 FT
         REPEAT
                            1886 1902
                                                          MAP1B 2.
         REPEAT
 FT
                            1903 1919
                                                          MAP1B 3.
        REPEAT 1920 1936
REPEAT 1937 1953
REPEAT 1954 1970
REPEAT 1988 2004
REPEAT 2005 2021
REPEAT 2022 2038
REPEAT 2039 2055
DOMAIN 559 1035
DOMAIN 588 786
         REPEAT
 FT
                                                          MAP1B 4.
 FT
                                                        MAP1B 5.
 FT
                                                        MAP1B 6.
                                                        MAP1B 7.
 FT
                                                        MAP1B 8.
 FT
                                                        MAP1B 9.
 FT
                                                        MAP1B 10.
 FΤ
                                                        GLU-RICH.
 FT
         DOMAIN
                           588 786
                                                        LYS-RICH (HIGHLY BASIC, CONTAINS MANY
 FT
                                                        KKEE AND KKEI/V REPEATS).
                                                     LYS-RICH.
M -> V (IN REF. 1).
                         2224 2312
FT
         DOMAIN
                          127
FT
         CONFLICT
                            127 127
140 140
FT
         CONFLICT
                                                        T \rightarrow S (IN REF. 1).
FΤ
         CONFLICT 2112 2112
                                                        R \rightarrow K (IN REF. 3).
         CONFLICT 2169 2169 L -> I (IN REF. 3).
FT
        SEQUENCE 2459 AA; 269497 MW; 2E3F6872DEDB8BA2 CRC64;
SO
   Query Match 5.0%; Score 291.5; DB 1; Length 2459; Best Local Similarity 20.0%; Pred. No. 0.0013;
   Matches 220; Conservative 167; Mismatches 456; Indels 255; Gaps 44;
                   30 TEPEDEEDEEEEEDEEEDDEDLEELEVLERKPAAGLSAAAVPPAAAAPLLDFSSDSVPPA 89
Qу
                        Db
              1008 SEEEGEEEEDKAEDAREEDHEPDKTE----AEDYVMAVVDKAAEAGVTEDQYDFL--- 1058
                   90 PRGPLPAAPPAAPERQPSWERSPAAPAPSLPPAAAVLPSKLPEDDEPPARPPPPPPAGAS 149
Qу
                                          Db
               1059 -----GTPAKQ-----PGVQSPSREPASSIHDETLPGGSESEAT-----AS 1094
               150 PLAEPAAPPSTPAAPKRRGSGSVDETLFALPAASEPVIPSSAEKIMDLMEQPGN---TVS 206
Qу
                                   Db
               1095 DEENREDQPEEFTAT----SGYTQST---IEISSEPTPMDEMSTPRDVMTDETNNEETES 1147
               207 SGQE----DFPSVLLETAASLP---SLSPLS----TVSFKEHGYLGNLSAVSSSEGTIE 254
Qy
                                      Db
               1148 PSQEFVNITKYESSLYSQEYSKPVVASFNGLSDGSKTDATDGRDYNASASTISPPSSMEE 1207
               255 ETLNEAS------KELPERATNPFVNRDLAEF--SELEYSEMG--- 289
Qу
                        : ::::
                                                                      Db
               1208 DKFSKSALRDAYRPEETDVKTGAELDIKDVSDERLSPAKSPSLSPSPPSPIEKTPLGERS 1267
               290 -----SSFKGSPKGESAILVENTKEEVIVR----SKDKEDL------VCSAALHSP 330
Qу
                                   : | | : | : : | | : : : | | : : | | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
               1268 VNFSLTPNEIKASAEGEATAVVSPGVTQAVVEEHCASPEEKTLEVVSPSQSVTGSAGHTP 1327
Db
                331 -QESPVGKEDRVVSPEKTMDIFNEMQMSVVAPVREEYADFK------PFEQAWEVKD 380
Qу
                          :|| :: : | | :: | | :: | | :: | |
               1328 YYQSPTDEKSSHLPTEVT-----ENAQAVPVSFEFTEAKDENERSSISPMDE--PVPD 1378
Db
Qy
                381 TYEGSRDVLAARANVESKVDRKCLED--SLEQKSLGKDS----EGRNEDASFPSTPEPVK 434
                      1379 SESPIEKVLSPLRSPPLIGSESAYEDFLSADDKALGRRSESPFEGKNGKQGFSDKESPVS 1438
Db
              435 DSSRAYITCASFTSATESTTANTFPLLEDHTSENKT-----DEKKI---- 475
Qу
```

```
Db
        1439 D----LTSDLYQDKQEEKRAGFIPIKEDFSPEKKASDAEIMSSQSALALDERKLGGDGS 1493
        476 -----EERKAQIITEKTSPKTSNPFLVAVQDSEADYVTTDTLSKVTEAAV-- 520
Qу
                     Db
       1494 PTQVDVSQFGSFKEDTKMSISEGTVSDKSATPVDEGAEDT---YSHMEGVASVSTASVAT 1550
        521 SNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAIQES-LYPTAQLCP---S 576
Qу
           1551 SSFPEPTTDD-VSPSLHAEVGSPHSTEVDDSLSVSVVQTPTTFQETEMSPSKEECPRPMS 1609
Db
Qу
        577 FEEAEATP------PSAGASVVQ 610
           ::| |:::|:|:|:::
Db
       1610 ISPPDFSPKTAKSRTPVQDHRSEQSSMSIEFGQESPEHSLAMDFSRQSPDHPTVGAGMLH 1669
        611 PSVSPLEAPPPVSYD-----SIKLEPENPPPYEEAMNVALKALGTKEGIKEPESFN 661
Qу
           Db
       1670 ITEN---GPTEVDYSPSDIQDSSLSHKIPPTEEPSYTQDNDLS-ELISVSQVEASPSTSS 1725
Qу
        662 AAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVEDSSPESEP 721
           Db
       1726 AHTPS-----QIASPLQEDTLSDVVPPRDMSLYASLASEKVQSLEGEKL----SPKSDI 1775
       722 VDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERLSASPQELGKPYL-ESFQP 780
Qу
            Db
       1776 SPLTPRESSPTYSPGFSDSTSGAKES-TAAYQTSSSPPIDAAAAEPYGFRSSMLFDTMQH 1834
Qу
       781 NLHSTKDAASNDIPTLTKKEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIE 840
           :| ::| :: :|: :|| : | ::: : | | |
Db
       1835 HLALSRDLTTSSV----EKDNGGKTPGDFNYAYQKPESTTESPDEEDYDYE--SHEKTIQ 1888
        841 IIDEFPTFVSAKDDSPK----LAKEYTDLEVSDKSEIANIQSGADSLPCLELPCDLSFKN 896
Qу
            1889 AHDVGGYYYEKTERTIKSPCDSGYSYETIEKTTKTP----EDGGYS-----CEITEKT 1937
Db
       897 IYPKDEVHVSDEFSENRSSVSKAS-----ISPSNVSALEPQTEMGSIVKSKSL 944
Qу
              1938 TRTPEEGGYSYEISEKTTRTPEVSGYTYEKTERSRRLLDDISNGYDDTEDGGHTLGDCSY 1997
Db
       945 TKEAEKKLPSDTEKEDRS 962
QУ
           : | : | : | | |
       1998 SYETTEKITSFPESESYS 2015
RESULT 14
MAPB HUMAN
   MAPB HUMAN STANDARD; PRT; 2468 AA.
AC
    P46821;
    01-NOV-1995 (Rel. 32, Created)
   01-NOV-1995 (Rel. 32, Last sequence update)
16-OCT-2001 (Rel. 40, Last annotation update)
   Microtubule-associated protein 1B (MAP 1B) [Contains: MAP1 light chain
DE
DΕ
   LC1].
   MAP1B.
GN
   Homo sapiens (Human).
OS
   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
```

```
OX
     NCBI TaxID=9606;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RC
     TISSUE=Fetal brain;
RX
     MEDLINE=95104835; PubMed=7806212;
RA
     Lien L.L., Feener C., Fischbach N., Kunkel L.M.;
RT
     "Cloning of human microtubule-associated protein 1B and the
RT
     identification of a related gene on chromosome 15.";
     Genomics 22:273-280(1994).
RL
     -!- FUNCTION: The function of brain MAPS is essentially unknown.
CC
CC
         Phosphorylated MAP1B may play a role in the cytoskeletal changes
CC
         that accompany neurite extension. Possibly MAP1B Binds to at least
         two tubulin subunits in the polymer, and this bridging of subunits
CC
CC
         might be involved in nucleating microtubule polymerization and in
CC
         stabilizing microtubules.
     -!- SUBUNIT: 3 different light chains, LC1, LC2 and LC3, can associate
CC
CC
         with MAPIA and MAPIB proteins.
     -!- DOMAIN: Has a highly basic region with many copies of the sequence
CC
CC
         KKEE and KKEI/V, repeated but not at fixed intervals, which is
CC
         responsible for the binding of MAP1B to microtubules.
     -!- PTM: LC1 is coexpressed with MAP1B. It is a polypeptide generated
CC
CC
         from MAP1B by proteolytic processing. It is free to associate with
CC
         both MAP1A and MAP1B. It interacts with the amino-terminal region
CC
         of MAP1B (By similarity).
CC
     -!- SIMILARITY: TO MAP1A.
CC
     ______
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
     or send an email to license@isb-sib.ch).
CC
     ______
     EMBL; L06237; AAA18904.1; -.
DR
    Genew; HGNC:6836; MAP1B.
DR
    MIM; 157129; -.
    GO; GO:0005875; C:microtubule associated complex; TAS.
DR
DR
    InterPro; IPR000102; MAP1B neuraxin.
DR
    Pfam; PF00414; MAP1B neuraxin; 10.
    PROSITE; PS00230; MAP1B NEURAXIN; 6.
DR
    Microtubule; Repeat; Phosphorylation.
KW
FT
    CHAIN
                 ?
                    2468
                               MAP1 LIGHT CHAIN LC1.
FT
    REPEAT
               1878 1894
                               MAP1B 1.
FT
    REPEAT
               1895 1911
                               MAP1B 2.
FT
    REPEAT
              1912 1928
                               MAP1B 3.
FT
    REPEAT
              1929 1945
                               MAP1B 4.
FT
              1946 1962
    REPEAT
                               MAP1B 5.
FT
              1963 1979
    REPEAT
                               MAP1B 6.
FT
              1997 2013
    REPEAT
                               MAP1B 7.
FT
               2014 2030
    REPEAT
                               MAP1B 8.
FT
    REPEAT
               2031 2047
                               MAP1B 9.
FT
    REPEAT
              2048
                     2064
                               MAP1B 10.
FT
    DOMAIN
              589 790
                               LYS-RICH (HIGHLY BASIC, CONTAINS MANY
FT
                               KKEE AND KKEI/V REPEATS).
    SEQUENCE 2468 AA; 270618 MW; 540839CBDF09D461 CRC64;
SO
```

	Query M Best Lo	cal	4.9%; Score 288; DB 1; Length 2468; Similarity 20.2%; Pred. No. 0.0017; 1; Conservative 166; Mismatches 441; Indels 386; Gaps	
	Qу		STDSPPRPPPAFKYQFVTEPEDEEDEEEEEDEEEDDED	
	Db	625	ATDVKPKAAKEKTVKKETKVKPEDKKEEKEKPKKEVAKKEDKTPIKKEEKPKKEEVKKEV	684
	Qу	51	LEELEVLERKPAAGLSAAAVPPAAAAPLLDFSSDSVPPAPRGPLPAAPPAAPERQPSWER : :: : : : : :: :	
	Db	685	KKEIKKEEKKEPKKEVKKETPPKEVKKEEKKEVKKEEK	726
	Qу	111	SPAAPAPSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPAAPPSTPAAPKRRG	168
	Db	727	: : : EPKKEIKKLPKDAKKSSTPLSEAKKPAALKPKVPKKEESVKKDSVAAGKPKEKGKI	782
	Qу	169	SGSVDETLFALPAASEPVIPSSAEKIMDLME	199
	Db	783	:	842
	Qу	200	QPGNTVSSGQEDFPSV-LLETAASLPSLSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLN	258
	Db	843	:: : : : :: : LKAEEVDVTKDIKPQLELIEDEEKLKETEPVEAYVIQKEREVTKGPAESPDEG-ITTTEG	901
	Qу	259	EASKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENTK-EEVIVRSKD	317
	Db	902	:::: : : : : : : : EGECEQTPEELEPVEKQGVDDIEKFEDEGAGFEESSETGDYEEKAETEEAEEPEED	957
	Qу	318	KEDLVC-SAALHSPQESPVGKEDRVVSPEKTMDIFNEMQMSV	358
	Db	958	: :	1011
	Qу	359	VAPVREEYADFKPFEQAWEVK-DTYEGSRDVLAARANVESKVDRKCLEDSLEQ	410
	Db 1	1012	EAEQSEEEADEEDKAEDAREEEYEPEKMEAEDYVMAVVDKAAEAGGAEEQYGFLTT	1067
	Qу	411	KSLGKDSEGRNEDASFPSTPEPVKDSSRAYITCASFTSATESTT	454
	Db 1	1068	: : : : : : :	1127
	Qу	455	ANTFPLLEDHTSENKTDEKKIEERKAQIITEKTS-PKTSNPFLVAV	499
	Db 1	128	: : : : : :	1187
	Qу	500	QDSEADYVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDL	556
1	Db 1	188	: : : : : : : : : :	1242
(Qу	557	VQTSEAIQESLYPTAQLCPSFEEAEATPSPVLPDIV	592
1	Db 1	.243	: : : : : : : : :: :: :: :: :	1302
Ç	ДĀ	593	MEAPLNSLLPSAGASVVQ	610
I	Ob 1	303	: : :: QEVVEEHCASPEDKTLEVVSPSQSVTGSAGHTPYYQSPTDEKSSHLPTEVIEKPPAVPVS	1362
Ç	Σλ	611	PSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVALKALG	649

```
Db
        1363 FEFSDAKDENERASVSPMDEPVPDSESPIEKVLSPLRSPPLIGSESAYESFLSADDKASG 1422
         650 TKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPD-FSNYSEIA-----KF 701
 Qу
                        1423 -----RGAESPF-----EEKSGKQGSPDQVSPVSEMTSTSLYQDKQ 1458
 Db
         702 EKSVPEHAELVEDSSPE-----SEPVDLFSDDSIPEVPQTQ-----EEAV 741
 Qv
            1459 EGKSTDFAPIKEDFGQEKKTDDVEAMSSQPALALDERKLGDVSPTQIDVSQFGSFKEDTK 1518
Db
         742 MLMKE-----SLTEVSETVAQ----HKEERLSASPQELG----KPYLESFQPNLHSTK 786
QУ
            1:1
                    1519 MSISEGTVSDKSATPVDEGVAEDTYSHMEGVASVSTASVATSSFPEPTTDDVSPSLH--- 1575
Db
         787 DAASNDIPTLTK-KEKISLQMEEFNTAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEF 845
Qу
             1 | 1 |: :: :: : :: :: :: :: :: :: ::
        1576 -- AEVGSPHSTEVDDSLSVSVVQTPTT-FQETEMSPSKEECPR----- 1615
Db
         846 PTFVSAKDDSPKLAKEYTDLE--VSDKSEIANIQSGADSLPCLELPCDLSFKN----- 896
Qу
            1616 PMSISPPDFSPKTAKSRTPVQDHRSEQSSM-SIEFGQES-PEQSLAMDFSRQSPDHPTVG 1673
Db
        897 -------97PKDE-VHVSDEFSENRSSVSKASISPSNV 926
QУ
                                    1674 AGVLHITENGPTEVDYSPSDMQDSSLSHKIPPMEEPSYTQDNDLSELISVSQVEASPSTS 1733
Db
        927 SALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRSLSAVLSAE 970
Qy
            Db
        1734 SAHTP-SQIASPLQEDTLSDVAPPR-----DMSLYASLTSE 1768
RESULT 15
MAPB MOUSE
ID
    MAPB MOUSE STANDARD; PRT; 2464 AA.
AC
    P14873;
    01-APR-1990 (Rel. 14, Created)
DT
    01-APR-1990 (Rel. 14, Last sequence update)
DT
DT
    28-FEB-2003 (Rel. 41, Last annotation update)
    Microtubule-associated protein 1B (MAP 1B) (MAP1.2) (MAP1(X))
DE
DE
    [Contains: MAP1 light chain LC1].
GN
    MAP1B OR MTAP1B OR MTAP5.
os
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A., AND DOMAIN.
RC
    STRAIN=Swiss Webster; TISSUE=Brain;
    MEDLINE=90094539; PubMed=2480963;
RX
    Noble M., Lewis S.A., Cowan N.J.;
RT
    "The microtubule binding domain of microtubule-associated protein
    MAP1B contains a repeated sequence motif unrelated to that of MAP2
RT
RT
    and tau.";
RL
    J. Cell Biol. 109:3367-3376(1989).
    -!- FUNCTION: The function of brain MAPS is essentially unknown.
CC
       Phosphorylated MAP1B may play a role in the cytoskeletal changes
CC
```

```
CC
         that accompany neurite extension. Possibly MAP1B Binds to at least
CC
         two tubulin subunits in the polymer, and this bridging of subunits
CC
        might be involved in nucleating microtubule polymerization and in
CC
        stabilizing microtubules.
CC
     -!- SUBUNIT: 3 different light chains, LC1, LC2 and LC3, can associate
CC
        with MAP1A and MAP1B proteins.
     -!- DOMAIN: Has a highly basic region with many copies of the sequence
CC
CC
        KKEE and KKEI/V, repeated but not at fixed intervals, which is
CC
        responsible for the binding of MAP1B to microtubules.
     -!- PTM: LC1 is coexpressed with MAP1B. It is a polypeptide generated
CC
        from MAP1B by proteolytic processing. It is free to associate with
CC
        both MAP1A and MAP1B. It interacts with the amino-terminal region
CC
CC
        of MAP1B.
CC
     -!- SIMILARITY: TO MAP1A.
     ______
CC
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
CC
     the European Bioinformatics Institute. There are no restrictions on its
     use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
     or send an email to license@isb-sib.ch).
     ______
CC
     EMBL; X51396; CAA35761.1; -.
DR
DR
    PIR; S07549; QRMSP1.
DR
    MGD; MGI:1306778; Mtaplb.
    GO; GO:0016358; P:dendrite morphogenesis; IMP.
DR
    GO; GO:0001578; P:microtubule bundling; IMP.
DR
DR
    InterPro; IPR000102; MAP1B neuraxin.
DR
    Pfam; PF00414; MAP1B neuraxin; 10.
    PROSITE; PS00230; MAP1B NEURAXIN; 7.
DR
    Microtubule; Repeat; Phosphorylation.
ΚW
FT
    CHAIN
                ?
                    2464
                              MAP1 LIGHT CHAIN LC1.
FT
    REPEAT
              1874
                    1890
                              MAP1B 1.
FT
    REPEAT
              1891
                   1907
                              MAP1B 2.
FT
    REPEAT
              1908
                   1924
                              MAP1B 3.
FT
    REPEAT
              1925
                    1941
                              MAP1B 4.
FT
              1942
    REPEAT
                    1958
                             MAP1B 5.
FT
    REPEAT
              1959 1975
                             MAP1B 6.
FT
    REPEAT
             1993 2009
                             MAP1B 7.
FT
    REPEAT
             2010 2026
                              MAP1B 8.
FT
    REPEAT
              2027
                    2043
                              MAP1B 9.
FT
             2044 2060
    REPEAT
                              MAP1B 10.
FT
    DOMAIN
              589
                    787
                              LYS-RICH (HIGHLY BASIC, CONTAINS MANY
FT
                              KKEE AND KKEI/V REPEATS).
    SEQUENCE 2464 AA; 270408 MW; FBD3DD99CFDBDA87 CRC64;
SO
 Query Match
                       4.9%;
                              Score 284; DB 1; Length 2464;
 Best Local Similarity 20.7%; Pred. No. 0.0025;
 Matches 233; Conservative 159; Mismatches 424; Indels 312; Gaps
Qу
          31 EPEDEEDEEEEEDEEED-----DEDLEELE-----VLERKPAAG-----LSAAAVP 71
            1009 EAEQSEEEGEEDKAEDAREEGYEPDKTEAEDYVMAVADKAAEAGVTEEQYGYLGTSAKQ 1068
Db
         72 PAAAAPLLDFSS----DSVPPAPRGPLPAAPPAAPERQP-----SWERSPAAPA 116
Qy
```

Db	1069	PGIQSPSREPASSIHDETLPGGSESEATASDEENREDQPEEFTATSGYTQSTIEISSEPT	1128
QУ	117	PSLPPAAAVLPSKLPEDDEPPARPPPPPPAGASPLAEPA	155
Db	1129	: : :: PMDEMSTPRDVMSDETNNEETESPSQEFVNITKYESSLYSQEYSKPAVASFNGLSEGSKT	1188
Qу	156	APPSTPAAPKRRGSGSVDETLFALPAASEPVIPSSAEKIMDLMEQ	200
Db	1189	: :: : : : : : : : DATDGKDYNASASTISPPSSMEEDKFSKSALRDAYCSEEKELKASAELDIKDV	1241
Qу	201	PGNTVSSGQEDFPSVLLETAASLPSLSPLSTVSFKEHGYLGNLSAVSSSEGTIEETLNEA :	260
Db	1242	SDERLSPAKSPSLSPSPPSPIEKT	1265
Qу	261	SKELPERATNPFVNRDLAEFSELEYSEMGSSFKGSPKGESAILVENTKEEVIVR	314
Db	1266	PLGERSVNFSLTPNEIKVSAEGEARSVSPGVTQAVVEEHCASPEEKTLE	1314
QУ	315	SKDKEDLVCSAALHSP-QESPVGKEDRVVSPEKTMDIFNEMQMSVVA-PVREEYADFK	370
Db	1315	VVSPSQSVTGSAGHTPYYQSPTDEKSSHLPTEVSENAQAVPVSFEFSEAKDE	1366
QУ	371	PFEQAWEVKDTYEGSRDVLAARANVESKVDRKCLEDSLEQKSLGKDS	417
Db	1367	NERASLSPMDEPVPDSESPVEKVLSPLRSPPLLGSESPYEDFLSADSKVLGRRSESPF	1424
QУ		EGRNEDASFPSTPEPVKDSSRAYITCASFTSATESTTANTFPLLEDHTSENKT	
Db		EGKNGKQGFPDRESPVSDLTSTGLYQDKQEEKSTGFIPIKEDFGPEKKTSDVETMS	
QУ		DEKKIEERKAQIITEKTSPKTSNPFLVAVQDSEAD	
Db		SQSALALDERKLGGDVSPTQIDVSQFGSFKEDTKMSISEGTVSDKSATPVDEGVAEDT	
Qy		YVTTDTLSKVTEAAVSNMPEGLTPDLVQEACESELNEATGTKIAYETKVDLVQTSEAI ::: : : : : :	,
Db		YSHMEGVASVSTASVATSSFPEPTTDD-VSPSLHAEVGSPHSTEVDDSLSVSVVQTPTTF	
ДУ		QES-LYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSLL	
Db	1598	QETEMSPSKEECPRPMSISPPDFSPKTAKSRTPVQDHRSEQSSMSIEFGQESPEHSFAMD	
Qγ		PSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPPYEEAMNVA	
Db		FSRQSPDHPTLGASVLHITENGPTEVDYSPCDIQDSSLSHKIPPTEEPSYTQDNDLS	
Ой		LKALGTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKS : : : :: : ::	
Db		-ELISVSQVEASPSTSSAHTPSQIASPLQEDTLSDVVPPREMSLYASLA	
Qy Db		VPEHAELVEDSSPESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKE	
		SEKVQSLEGEKLSPKSDISPLTPRESSPLYSPGFSDSTSAAKETAAAH	
ДУ		ERLSASPQELGKPYLESFQPNLHSTKDAASNDIPTLTKKEKISLQMEEFN	
Db	1811 -	-QASSSPPIDAATAEPYGFRSSMLFDTMQHHLALNRDLTTSSVEKDSGGKTPGDFN	1865

QУ	811	TAIYSNDDLLSSKEDKIKESETFSDSSPIEIIDEFPTFVSAKDDSPKLAKEYTDLE 866
Db	1866	YAYQKPENAAGSPDEEDYDYESQEKTIRTHDVVRYYYEKTERTIKSPCDSGYSYETIE 1923
QУ	867	VSDKSEIANIQSGADSLPCLELPCDLSFKNIYPKDEVHVSDEFSENRSSVSKAS 920 : : : ::: : : :
Db	1924	KTTKTPEDGGYTCEITEKTTRTPEEGGYSYEISEKTTRTPEVSGYTYEK 1972
Qу	921	ISPSNVSALEPQTEMGSIVKSKSLTKEAEKKLPSDTEKEDRS 962
Db	1973	: :: : : : : TERSRRLLDDISNGYDDTEDGGHTLGDCSYSYETTEKITSFPESESYS 2020

Search completed: September 29, 2004, 18:14:37 Job time: 27.6724 secs